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The prevalence of obesity is increasing at a rapid rate internationally, paralleled with an increase in 
the number of people with type 2 diabetes.        Whilst the cornerstone of management of both 
conditions is lifestyle change, dietary interventions tend to result in only minimal weightless which is 
frequently regained over the subsequent years.  Medical therapies for weight loss are only moderately 
more effective, whilst those used in the management of diabetes control hyperglycaemia rather than 
addressing the underlying pathophysiology.  Bariatric surgery has therefore emerged as an apparently 
effective technique for both conditions, particular when occurring in association.  Whilst high quality 
short term follow up studies now support bariatric surgery as the most effective treatment option 
available, there is a lack of longer term outcome studies to support its durability and safety.  In chapter 
1 of this thesis, I provide a summary of the current view of the pathophysiology of both obesity and 
type 2 diabetes, along with a review of non-surgical and surgical interventions.  Lastly, I provide an 
overview of the research exploring the mechanisms by which bariatric surgery may induce these 
effects. 
In this thesis I report findings from a long term follow up study involving 118 participants following 
Roux-en-Y Gastric bypass surgery.  The mean duration of follow up was 10.2 years, with the mean 
body weight loss 29.6% (38.5kg) at last follow up.    28% of participants with type 2 diabetes prior to 
surgery remained with type 2 diabetes at follow up, whilst 72% had improved glucose tolerance.  
Significant reductions in blood pressure and lipid markers were observed, as well as a reduced 
likelihood of depression, gout, and sleep apnoea after surgery.  Quality of life was better when 
compared against non-surgical BMI matched controls.   Furthermore, I report that the variable 
definitions of both diabetes at baseline and glycaemic outcomes used in the bariatric literature, results 
in significantly different published outcomes, and is an impediment to comparative analysis. 
In addition, I report the findings of two studies exploring further the mechanisms underlying the 
effects of bariatric surgery on durable weight loss and glucose homeostasis.  In the first study, I 
demonstrate that whilst the acute hormonal stress response to RYGB surgery is short lived, an ongoing 
inflammatory response, still evident six days after surgery, should be considered when assessing 
changes in glucose homeostasis within this period.  In the second study, I begin a line of research 
exploring the association between altered gut peptide physiology after bariatric surgery and longer 
term weight outcomes.  These mechanistic studies are performed to both optimise outcomes 
following RYGB surgery, and to better understand the pathophysiology of obesity and type 2 diabetes. 













1.1 Overview of obesity and type 2 diabetes 
1.2 Non-surgical management of obesity and type 2 diabetes 
1.3 Bariatric surgery for the management of obesity and type 2 diabetes 
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1.1 Overview of obesity and type 2 diabetes 
 
1.1.1 Rising prevalence and cost of obesity and type 2 diabetes 
The prevalence of both type 2 diabetes and obesity has risen significantly over the past five 
decades, and is projected to rise further in the coming years.  Obesity is a strong risk factor for 
the development of type 2 diabetes, and therefore the prevalence of type 2 diabetes is closely 
related to that population’s obesity prevalence.1 
 
A recent population study revealed that approximately 35% of the adult population of the 
United States are obese (BMI  30 kg/m2), and, perhaps more surprisingly, that the average 
weight of the same population now lies someway above the “healthy” range BMI (Average BMI 
= 28 kg/m2, NR = 19-25 kg/m2).2  The picture in New Zealand is no less concerning; the ‘Health 
of New Zealand adults” survey of 2012 demonstrated that 28.4% of New Zealand adults are 
obese, whilst 63.8% are overweight or obese (BMI >25 kg/m2).3 Of particular concern is the 
marked disparity in prevalence rates between ethnic groups within New Zealand.  The rates in 
Caucasians approximate to the national averages; however, the rates of obesity and 
overweight in Maori (44.4 and 75.3% respectively) and Polynesians (62.1 and 84.8% 
respectively) are extreme.  Furthermore, the issue is evident in childhood where 27% of Maori 
and 19% of Pacific Islander children in New Zealand are obese.  The likelihood of obesity in New 
Zealand is positively associated with neighbourhood deprivation, and varies significantly across 
the nation (Figure 1-1). 
 
The International Diabetes Federation (IDF) has published regular reports on the prevalence of 
diabetes since 2000.  The latest publication from 2011 drew upon 133 studies assessing 
prevalence in 91 countries.4  Prevalence rates for the remaining 125 countries were estimated 
by extrapolating the prevalence in a country considered comparable with respect to ethnic, 
geographical, and socio-economic similarities.  8.3% of the world population had type 2 
diabetes in 2011, although there are significant regional differences. (Figure 1-2)  Prevalence 
rates in excess of 20% were reported in  
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Figure 1-1   Estimated prevalence of a) obesity and b) type 2 diabetes by New Zealand district health 
board (reproduced from “Obesity and diabetes in New Zealand: Parliamentary library research paper,  
October 2014) 
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4 countries (Nauru, Kiribati, Marshall Islands, and Kuwait), whilst 3 regions (Middle East and 
North Africa, Western Pacific, and Central and South America) had prevalence rates in excess 
of 10%.  Recent research suggests that the prevalence of type 2 diabetes in the United states 
has increased by 75% over the 20 year period from 1988–1994 to 2005–2010, and that an 
increased prevalence was evident in each age group.5  Other countries have seen a similar 
steep rise in the prevalence of diabetes perhaps illustrated most dramatically by studies 
conducted in China over the past 30 years.  The prevalence of type 2 diabetes was calculated 
at just 1% in 1980, but had increased to 5.5% in 2001, and 11.6% in 2013.6,7,8  
 
 
Figure 1-2  Prevalence of type 2 diabetes by region, expressed as millions of cases with percentage 














The 2013/2014 New Zealand health survey showed that 198,000 adults (5.5%) in New Zealand 
had diabetes, with men more likely to have diabetes than women (6.3% in males, 4.8% in 
females).  Pacific (9%), Maori (7%), and Asian (6%) adults were all more likely to have diabetes 
than the national average.  Furthermore, the prevalence of diabetes increased with age in each 
ethnic group, such that the prevalence of diabetes in New Zealand adults over the age of 75 
years exceeded 15%.  As with obesity, the prevalence varies widely throughout the nation.  It 
should be noted that adults with type 2 diabetes are frequently unaware of their diagnosis, or 
chose not to accept it.  Illustrating this, the New Zealand Ministry of Health virtual diabetes 
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registry reported a 21% higher prevalence of type 2 diabetes; 241,381 New Zealand Adults 
were recorded as having type 2 diabetes in 2013 on the basis of laboratory testing.  Given the 
asymptomatic nature of early dysglycaemia, it is likely the true prevalence is higher still.    
 
Based on trajectories calculated by comparing prevalence data across the previous 10 years, 
the IDF predicts significant increases in diabetes prevalence in all world regions over the next 
30-40 years (Figure 1-2).  The world prevalence is predicted to increase from 8.3% to 9.9%, 
although given the significant increases in population forecast in each region, this amounts to 
an absolute additional 181 million people with type 2 diabetes worldwide (187% increase from 
366 million cases in 2011).  An American study projected a US prevalence of 33% by 2050 if 
prevalence rates continue to increase at the current rate, but suggested true prevalence rates 
may be closer to 20% given improvements in pre-diabetes management.10 Whilst diabetes 
control appears to have improved during the same time period, only 1 in 5 patients with 
diabetes achieves target concentrations of HbA1c, blood pressure, and lipid concentrations.11 
 
The financial burden placed on New Zealand’s health resulting from obesity and type 2 diabetes 
is significant.  A 2006 study estimated that the annual health care cost attributable to increased 
BMI (overweight or obesity) alone was NZ$686 million, representing 4.5% of the health 
budget.12  The cost is greater still once lost productivity as a direct consequence of increased 
BMI is factored in, and may be as high as NZ$849 million.13  Although there is considerable 
overlap, type 2 diabetes also presents significant health care costs.  A PricewaterhouseCoopers 
study to calculate current and projected health care costs attributable to type 2 diabetes 
reported an annual cost of NZ$600 million in 2008, and a projected increase to NZ$1.8 billion 
by 2022.14 
 
It is clear therefore that strategies to reduce the prevalence of type 2 diabetes and obesity are 
of paramount importance.  Whilst the greatest gains may be made by preventing the 
development of these conditions, effective interventions to treat existing disease are needed.  
The following chapters present the pathophysiology of obesity and type 2 diabetes, and non-
surgical interventions for both conditions.  Finally, bariatric surgery as an intervention for each 
condition is discussed, along with notes on the mechanism of action. 
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1.1.2 Pathophysiology of obesity 
Obesity is the consequence of a net positive energy imbalance, where intake (ingested calories) 
exceeds expenditure (basal metabolic rate, thermic effect of food, physical activity) over a 
prolonged period of time. Body weight is maintained within surprisingly narrow thresholds 
throughout life in healthy individuals, with changes in adiposity the predominant contributor 
to changes in body weight.  The average adult male will gain 0.25 to 0.5kg of body weight per 
year, equating to a difference as little as 10 kilocalories per day of energy intake versus 
expenditure.15  This precise balance is maintained over long periods of time despite significant 
fluctuations in daily intake and expenditure, and has been calculated to equate to an imbalance 
in cumulative intake and expenditure of 0.17% over 10 years.16  In this section I will discuss the 
current model of human energy homeostasis and factors that are believed to underlie the 
increasing prevalence of obesity. 
 
1.1.2.1 Human adipose tissue 
Fundamental to any effective physiological system regulating energy homeostasis are 
mechanisms by which body habitus can be communicated to cerebral centres, so that adaptive 
responses to weight loss or gain can be enacted.  As adiposity is the predominate determinant 
of obesity, it stood to reason that cerebral “awareness” of fat is required for this physiological 
model to be plausible.  This concept was first proposed by Kennedy over 60 years ago, who 
suggested a ‘lipostatic model’ whereby metabolites would circulate in proportion to 
adiposity.17,18  In this section, I will discuss adipose tissue as a functional endocrine unit, and the 
role of the major adipose hormones Leptin and adiponectin. 
  
Adipose tissue constitutes approximately 28% and 40% of total body weight in adult males and 
females respectively in a population characterised by a high proportion of obesity and 
overweight.19   Adipose tissue is composed of two forms; white and brown adipose tissue 
(WAT/BAT), although recent evidence suggests a third form known as beige adipose tissue.20  
The predominant role of BAT is to generate heat via thermogenesis.   BAT contains abundant 
mitochondria which uniquely express uncoupling protein (UCP-1).  Numerous factors have 
been shown to regulate BAT activity including thyroid hormones, FGF21, cardiac derived 
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natriuretic peptides, and insulin, although neuronal mediators are predominant.21 ,22 ,23 ,24 ,25  
Sympathetic activation, via adrenergic receptor subtype ADRB3, is the primary neuronal 
regulator of  BAT, and allows thermogenesis to associate with ambient external temperature.  
Brain derived natriuretic factor (BDNF) and bone morphogenetic proteins (BMP7/8b) both 
increase BAT activity, either through activation of existing tissue or through ‘browning’ white 
adipose tissue.26,27  Whilst the role of BAT thermogenesis appears primarily to relate to body 
temperature maintenance, it is clear that this system can be utilised to expend surplus energy 
under some circumstances.25   
 
Mature adipocytes constitute 30-70% of WAT, with the remainder being progenitor cells.28  A 
single cytoplasmic lipid droplet constitutes over 90% of the white adipocyte volume.  The major 
role of WAT is to store triglyceride for release (lipolysis) and utilisation as energy, particularly 
during periods of reduced dietary energy intake.  Whilst the exact mechanisms remain to be 
elucidated, it is apparent that the sympathetic nervous system is the major stimulator of WAT 
lipolysis.29  Along with provision of thermal insulation, WAT has a number of other endocrine 
and secretory roles.30 WAT is a primary site for fat soluble vitamin storage, and also expresses 
1-hydroxylase which converts 25-hydroxycholecalciferol to 1,25-hydroxycholecalciferol. 31  
The presence of 11-hydroxysteroid allows the conversion of cortisone to cortisol.32  A large 
number of proteins, often referred to as adipokines, are secreted by WAT including Adipsin, 
tumour-necrosis factors, interleukin-6, plasminogen activating factors, lipoprotein lipase, 
resistin, leptin, and adiponectin; the last of these hormones is discussed below.   
 
1.1.2.1.1 Leptin 
Arguably the most important WAT secreted hormone is leptin, identified over twenty years ago 
through study of the hyper obese ob/ob mouse.33,34   Leptin consists of 166 amino acids and is 
encoded by the OB gene located on chromosome 7.35,36   Whilst WAT is the major site of leptin 
production, synthesis also occurs in BAT, heart, placenta, stomach, and ovaries.37  The leptin 
receptor (LEP-R or OB-R), encoded by the OBR gene on chromosome 1, is expressed 
predominantly in the hypothalamus and cerebellum, but also within the vasculature and 
stomach.3738,39,   Serum leptin concentrations are proportionate to adipose tissue volume, and 
therefore concentrations correlate positively with body fat content in humans.40   Leptin freely 
crosses the blood-brain barrier and cerebral spinal leptin concentrations also correlate with 
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body fat content.41 Leptin acts centrally via the hypothalamic LEP-R, which in turn stimulates 
the release of numerous anorexigenic peptides that reduce adiposity by decreasing appetite 
and increasing thermogenesis (see below).42   
 
Whilst low leptin concentrations are observed in a small subgroup of obese individuals, human 
OB mutations are rare. 43    However, individuals who harbour heterozygous frame shift 
mutations in the OB gene have lower leptin concentrations and an increased prevalence of 
obesity than controls.44  Furthermore, leptin treatment in these individuals results in reduced 
appetite and consequent weight loss.44   Thus, it may be hypothesized that leptin treatment in 
obese individuals may also support weight loss.  Contrary to this assumption however, is the 
finding that leptin concentrations generally remain elevated in obese individuals. 45 , 46  
Furthermore, recombinant leptin therapy does not promote weight loss in obese individuals 
despite clear increases in serum leptin concentrations.47,48,49   
 
The concept of leptin resistance was therefore postulated as an explanation for these apparent 
contradictory findings, and supported by documentation of the development of resistance in 
rat models exposed to long term leptin infusion.50   Over eating leads to rapid rises in leptin 
concentrations, and early research focused on the possible effect this may have on 
hypothalamic leptin receptor expression.51   Although leptin deficiency appears to increase 
hypothalamic leptin receptor expression in ob/ob mice, it is not clear that a similar decrease in 
expression occurs in states of elevated leptin concentrations.52  Whilst the same group showed 
decreases in leptin receptor mRNA concentrations in the hypothalamic areas of obese mice 
treated with leptin, other groups have found no differences in leptin receptor expression 
between healthy and obese humans.52,53    
 
Obesity related leptin resistance may better be explained by alterations in movement across 
the blood brain barrier with differing body weight.   The peripheral administration of leptin to 
diet induced obese mice leads to longer term leptin resistance.  This is rapidly overcome once 
leptin is centrally infused, as evident by weight loss.54  Furthermore, the ratio of cerebrospinal 
and plasma leptin concentrations in humans is lower in obese subjects when compared to 
normal weight individuals.55  Both of these findings support a defect in central transfer of leptin 
underlying the apparent leptin resistance seen in obesity, as opposed to ‘true’ resistance at the 
target cellular level.  In addition, blood brain barrier leptin transport defects appear to be 
acquired consistent with the notion of leptin resistance relating to obesity rather than being 
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causal; the study of rat models has documented the onset of apparent leptin transport 
dysfunction only after significant weight gain.56 
1.1.2.1.2 Adiponectin 
Adiponectin production is specific to WAT, and accounts for 0.01 to 0.05% of the total plasma 
protein content.57  However, and in direct contrast to leptin, the serum level of adiponectin 
paradoxically decreases with increasing body fat.58  Furthermore, adiponectin concentrations 
increase during caloric restriction, possibly as a result of increased bone marrow adipose tissue 
secretion.59  The mechanism underlying this phenomenon remains to be elucidated, and a 
recent meta-analysis did not support an association between adiponectin concentrations and 
body mass index.60   However, it is possible that visceral fat mass may be associated with 
adiponectin concentrations.61  It is interesting to note however that women have significantly 
higher circulating adiponectin concentrations than men, suggesting a modulating role of sex 
hormones. 62   To support this, concentrations of adiponectin vary with differing body fat 
distributions, such that higher adiponectin concentrations are seen with increased lower 
extremity and truncal obesity.63   Adiponectin concentrations rise following weight loss as a 
consequence of any intervention.64,65 
 
Adiponectin acts via adiponectin receptors 1 and 2 (ADIPOR/2) and T-cadherin.57    The functions 
of adiponectin demonstrated thus far include promotion of beta cell function and survival, and 
thereafter, the enhancement of peripheral insulin sensitivity, and anti-inflammatory 
effects.66,67,68  Higher adiponectin concentrations appear to protect against the development of 
diabetes, and conversely, hypoadiponectinaemia is independently associated with the risk of 
diabetes and the metabolic syndrome. 69 , 70 , 71   Adiponectin predominantly enhances insulin 
sensitivity by decreasing hepatic glucose output via AMP-activated protein kinase pathways, 
although an additional effect on peripheral skeletal muscle can not be discounted.72 
 
1.1.2.2 The hypothalamus in human energy homeostasis 
Experiments in rodents established conclusively that the hypothalamus was fundamentally 
involved in energy homeostasis.   Drawing on previous observations, Hetherington and Ranson 
observed a significant increase in adiposity following electrolytic hypothalamic ablation in rats 
in their seminal work published 75 years ago.73   The identification of leptin as a messenger that 
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could convey information about adiposity to the hypothalamus, lead to the rapid 
characterisation of the neural circuits that modulate energy homeostasis.  Further evidence for 
the critical role of each of these neurotransmitters has been obtained through the study of 
human monogenic syndromes that result in obesity.74  Leptin acts by activating arcuate nucleus 
proopiomelanocortin (POMC) and cocaine and amphetamine-regulated transcript (CART) 
neurons, whilst anabolic neuropeptide Y (NPY) and Agouti-related peptide (AgRP) neurons are 
suppressed by leptin.75 POMC/CART neurons project to the lateral hypothalamic area, where 
they inhibit the release of melanocortin-stimulating hormone (MSH) and orexins A and B, and 
the paraventricular nucleus, where they stimulate the release of thyrotroph releasing hormone 
(TRH), corticotroph releasing hormone (CRH) and oxytocin.75 NPY/ArGP neurons also project to 
the lateral hypothalamic are and paraventricular nucleus, but have opposing effects on post 
neuron peptide release.  MSH and orexin A and B are orexigenic (increase appetite) peptides, 
whilst TSH and CRH have predominantly anorexigenic effects.   
The melanocortin system, now known to be critical to functional energy homeostasis, is defined 
as neurons expressing either POMC or AgRP, or melanocortin receptors with affinity for 
neuropeptides released by these neurons. 76  POMC is a polypeptide precursor with eight 
potential cleavage sites that are targets for cleavage enzymes.77  The presence or absence of 
these enzymes in each tissue expressing POMC dictates local concentrations of post cleavage 
peptides.  In the hypothalamus POMC is predominantly cleaved to MSH and MSH which 
interact with melanocortin receptor 3 and 4 (MC3-R/MC4-R).78  Humans with loss of function 
mutations in the MC4-R receptor present in childhood with severe obesity, and this monogenic 
disorder has been shown to be present in up to 6% of severely obese children. 79   Whilst 
homozygotes are more severely affected than heterozygotes, penetrance also varies, and 
mutations resulting in a degree of retained post receptor signally capacity are less severely 
affected. 80 
It is likely that multiple other peptides are involved in the hypothalamic regulation of energy 
homeostasis.  Insulin receptor dysfunction mice develop diet sensitive obesity associated with 
increases in adiposity, leptin, and insulin concentrations.81  Insulin receptors are present within 
the arcuate nucleus POMC neurons in separate populations from those that express the leptin 
receptor.82  It therefore appears that both leptin and insulin function as lipostatic hormones, 
indicating energy repletion to the hypothalamus.83  Endocannabinoids appear to play a role in 
regulating feeding behaviour through interactions in the paraventricular nucleus, possibly by 
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increasing the release of TRH and CRH, and augmenting the effect of ghrelin. 84  
Endocannabinoid receptor agonists have been shown to increase food intake, whilst 
antagonists result in weight loss in over weight adults as demonstrated in recent randomised 
controlled trials.85 , 86  The peroxisome proliferator activated receptor  (PPAR) is a nuclear 
receptor for which a high affinity ligand has not yet been identified; it has been suggested that 
the receptor may instead act as sensor of ambient fatty acid concentration.87  The receptor is 
expressed in WAT and also within the hypothalamus, and central antagonism of this receptor 
results in negative energy balance in high-fat diet rodents.88   This in keeping with clinical 
experience of using PPAR agonists (thiazolidinediones, see 1.2.2) for the management of type 
2 diabetes where weight gain is an undesired side effect of therapy.  Further research is 
required to define the role of the central PPAR receptor in human energy homeostasis.  Other 
potential peptide regulators of hypothalamic energy homeostasis are the subject of current 
research as possible therapeutic targets.89 
 
1.1.2.3 Gut peptide physiology and role in energy homeostasis 
Along with the adipocyte derived hormones leptin and adiponectin described above, a large 
number of additional hormones produced in the gastrointestinal tract have a role in energy 
homeostasis and are discussed below.  Whilst leptin is predominantly involved in conveying 
information related to the longer term regulation of energy balance, gastrointestinal peptides, 
frequently released in direct response and proportion to ingested food, play key roles in the 
short term regulation of food intake.90 
 
1.1.2.3.1 Ghrelin 
Ghrelin, a 28 amino acid protein manufactured and secreted from mucosal oxyntic glands 
located in the gastric fundus, and to a lesser extent the proximal intestine and pancreatic islets, 
is the only known endogenous stimulant of appetite in humans.91  Two major isoforms can be 
identified in the circulation; acylated ghrelin (AG) and des-acylated ghrelin (dAG).  Acylation 
occurs during post translational modification, and involves the covalent linkage of medium-
chain fatty acid groups.  Ghrelin O-Acyltransferase (GOAT) has recently been identified as the 
enzyme required for acylation to occur, and may have other physiological effects independent 
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of this role.92  dAG results either from lack of acylation at this post translational stage, or later 
enzymatic removal of the acyl group.  dAG is the major circulatory isoform, present at greater 
than 4 times the concentration of AG.93   Acylation is required for ghrelin to bind to the growth 
hormone secretagogue receptor (GHSR) expressed in the hypothalamus and brainstem, 
through which most of its biological effects are mediated.     
AG is likely to act as a meal initiator by modulating feelings of hunger.91  In healthy individuals, 
ghrelin concentrations are highest in the fasting state, before falling to nadir concentrations at 
one to two hours after commencement of the meal.94  Thus, suppression of AG after meals in 
healthy individuals is likely to be important in indirectly promoting appropriate satiety.  Fasting 
concentrations are often two fold higher than minimal daily concentrations, although a single 
measurement of AG during the post-breakfast trough (90 minutes following commencement 
of the meal) correlates well with the total 24 hour mean AG level.94  Administration of 
intravenous AG to achieve circulatory concentrations equivalent the fasting state increase food 
intake by up to 30% in both healthy and obese individuals.95,96  
Circulating total ghrelin concentrations are decreased in simple obesity, but the normal 
suppressive effect of food consumption on ghrelin concentrations is attenuated in obese 
persons suggesting a blunting of the normal flux of ghrelin with food intake and starvation.97,98  
This finding along with the previously confirmed orexigenic effects of AG, has led to a number 
of attempts to favourably modulate the weight associated effects of ghrelin through 
pharmaceutical means.  Antagonists against the GHSR receptor have been developed by a 
number of pharmaceutical companies but, with the exception of some but not all early phase 
rodent studies, have not yet demonstrated a favourable weight effect in humans. 99 , 100  
Therapies which neutralize circulating AG are also under active investigation but, again, have 
encountered difficulties.  A vaccine involving antibodies directed against circulating AG has 
been developed, and early rodent studies demonstrated weight loss in recipient animals 
associated with increasing antibody titres. 101   However, similar work in humans has not 
replicated these findings, and concerns about the permanency of antibodies against AG, and 
consequent long term adverse metabolic effects, may limit further work in this area.99  Finally, 
inhibition of GOAT, and thus reduced acylation of ghrelin, is an attractive method by which to 
selectively modify the physiological effects of circulating ghrelin.  Recent work has 
demonstrated that the administration of synthetic peptide coenzyme A conjugate (GO-CoA-
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Tat) to rodents reduces feed seeking behaviour even in the fasted state.102  Human studies are 
required to further investigate the potential of this therapeutic strategy. 
Recently, the physiological effects of dAG have been clarified in more detail, with many authors 
now stating that dAG should be considered a separate hormone rather than a simple metabolic 
by-product of AG.103,104  This is on the basis of numerous recent studies supporting a GHSR 
independent role of ghrelin, along with its ability to either antagonise or agonise the effects of 
AG.  dAG appears to induce insulin secretion in rodent cell lines, and its continued ability to do 
this despite the co-administration of a GHSR antagonist, suggests that it does so via a separate 
receptor.105  Additionally, dAG appears to improve pancreatic beta cell survival and protect 
against chemically induced (Streptozotocin) beta cell damage in rodent pancreases. 106  
Furthermore, obesity associated with insulin resistance has been shown in some studies to be 
associated with a higher AG/dAG ratio than seen in obesity associated with insulin resistance 
and in healthy individuals.107,108  Using modern assays that better discriminate the relative 
contribution of AG and dAG to total ghrelin concentrations, some studies suggest that the 
lower total fasting ghrelin concentrations seen in simple obesity are a consequence of 
decreased dAG, and that AG remains similar to concentrations in healthy individuals.103  This 
interpretation is however contradictory to other studies in the field and requires clarification.  
Nonetheless, dAG analogs have been developed and are currently under investigation in the 
management of diabetes.109 
1.1.2.3.2 Polypeptide YY 
Polypeptide YY (PYY) is a 36 amino acid peptide, closely related to pancreatic peptide, and 
secreted by endocrine L cells in the ileum, colon, and rectum, which co-secrete glicentin, GLP-
1, and GLP-1.110  Its major role appears to be as an anorexigenic hormone, although it likely to 
play a role in glucose homeostasis.  PYY is secreted in response to the presence of nutrients in 
the intestinal lumen, and is elevated 30-60 minutes after eating.  The release of PYY is 
proportional to the caloric content of the ingested meal, and concentrations remain elevated 
for up to six hours.110,111  Higher concentrations of PYY are released in response to a fat rich 
meal, when compared with carbohydrate or protein.112  It is a substrate for dipeptidyl peptidase 
4 inhibitor which cleaves PYY to PYY3-36.
113
  Thus PYY1-36 is the major form in the fasting state, 
whilst PYY3-36 is the major form in the post prandial state.  PYY3-36 crosses the blood brain 
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barrier and binds to receptors in the arcuate nucleus, which results in a reduction in 
neuropeptide Y expression.114,115   
PYYs role as a satiety signal is evident by the finding that peripheral administration of PYY to 
healthy normal weight humans results in a 30% reduction in food intake, as a consequence of 
a reduction in hunger.115  A similar effect is seen following the infusion of PYY in obese 
individuals. 116    Furthermore, concentrations of PYY are lower in fasting state in obese 
individuals, and a blunted PYY response to meals is seen.116  In addition to reducing food intake, 
PYY administration delays gastric emptying, reduces intestinal motility, and decreases 
pancreatic secretions.  It is thus an attractive target for pharmacological obesity treatments, 
although research in this area is ongoing.  
1.1.2.3.3 Amylin 
Amylin, or Islet Amyloid Polypeptide (AIP), is produced by the beta cells of the endocrine 
pancreas and complements the action of insulin by regulating gastric motility and acid 
secretion, satiety, and glucagon homeostasis. 117 , 118   Amylin is secreted in response to a 
carbohydrate load within the same granules that contain insulin and c-peptide, at a molar ratio 
of approximately 1:100 with respect to insulin.119  Fasting amylin concentrations are increased 
in obesity associated with normal insulin sensitivity, whilst insulin resistance is associated with 
a reduced fasting amylin level.  The amylin response to a glucose load is increased in obesity 
and insulin resistance, but is significantly reduced or absent in type 1 diabetes or late type 2 
diabetes in parallel with insulin deficiency.120  Amylin binds to the amylin receptor complex 
(ACR) composed of a G protein-coupled receptor and a receptor modifying protein, which is 
expressed in the brain, liver, muscle and throughout the gastrointestinal tract.121 
Exogenous supraphysiological amylin reduces rat food intake rapidly, whilst a reduction in meal 
size is evident in humans.122,123  Administration of an injectable amylin anolog (Pramlintide) at 
supraphysiological doses to obese human participants with type 2 diabetes resulted in modest 
weight loss of 0.5-1.5kg over a 12 month period of study.124  Activation of the area postrema 
by amylin appears to be fundamental for this effect.117  Additionally, there is evidence for a 
minor role of amylin on weight maintenance in rodents at physiological concentrations, as 
amylin gene knockout mice are up to 29% heavier than controls.125  Administration of amylin 
antagonists to rodents stimulates increased meals sizes, whilst a similar effect is achieved by 
selective ablation of the rodent area postrema.126,117  Future research into the therapeutic use 
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of amylin as an anti-obesity agent will need to consider that obesity may reflect a state of 
relative amylin resistance.  Hyperinsulinaemia, and thus hyperamylinaemia, commonly seen in 
association with obesity has been reported to result in down regulation of amylin receptors.119 
Amylin decreases gastric motility through activation of receptors located in the gastric fundus 
and the higher centres.119   Whilst the mechanism is unclear, this effect appears to be 
appropriately blocked during hypoglycaemia.127  The major nuclei regulating gastric motility are 
located within the brainstem, and amylin receptors are readily identifiable within these tissues.  
Gastric-brainstem nervous connections are mediated via the vagus nerve.  The selective 
ablation of these brainstem nuclei in rodents, or vagotomy, results in a loss of the amylin 
induced reduction of gastric motility.128,129  Injection of an amylin analogue in rodents reduced 
gastric emptying, whilst administration of an amylin analogue (Pramlintide) to humans with 
type 1 or type 2 diabetes had a similar effect.130,131 
Amylin inhibits glucagon secretion, although likely plays a lesser role in the regulation of 
glucagon than insulin.  The physiological effects of glucagon are discussed in detail below, and 
primarily involve effects on the liver (increased glycogenolysis and gluconeogenesis) and 
increased lipolysis.132  Thus, the amylin response to ingestion of a meal is important in reducing 
unnecessary endogenous glucose production otherwise mediated by glucagon.  The literature 
around the use of amylin to modulate glucagon physiology is discussed below. 
1.1.2.3.4 Cholecystokinin (CKK) 
CKK is released from duodenal mucosal cells in response to ingested fat and protein, and is 
involved in exocrine pancreas and gallbladder function.133  Two distinct receptors have been 
identified (CCKA and CCKB) and CCK appears to mediate its cerebral affects via CCKA which is 
expressed within the hypothalamus.134 Infusion of CCK in humans reduces caloric intake by 
reducing portion size and duration of eating.135   Consequently, CCKA receptor antagonists 
increase caloric intake and reduce satiety.136 CCK concentrations rise rapidly during a meal 
suggesting its primary role may be as an indicator of satiety.  However, CCK has not been shown 
to be a useful therapeutic target as reduced food intake appears to be compensated by 
increased meal frequency.137   
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1.1.2.3.5 Glucagon like peptide 1 (GLP-1), glucose dependent insulinotropic peptide (GIP), 
and oxyntomodulin (OXM) 
GLP-1, GLP, and OXM are products of post-translational processing of the preproglucagon 
gene, which is expressed in the brain, pancreas, and intestine.  Bayliss and Starling first 
proposed the existence of intestinal hormones influencing glucose homeostasis in 1902, and 
subsequent experiments demonstrated that the administration of duodenal extracts to 
patients with diabetes occasionally ameliorated glycosuria.138 ,139    The term “incretin” was 
coined in the early 1930s for a proposed hormone produced by the upper gastrointestinal tract 
in response to ingested food that induced hypoglycaemia, whilst the phrase “incretin effect” 
came to be applied to observation that ingested glucose provoked a more rapid release of 
insulin than intravenous administration.140,141   However, a series of negative experiments to 
further test this hypothesis in 1940 resulted in an absence of research in this area over the next 
few decades, until the identification of confirmed gastrointestinal hormones in the 1970s.142 
GIP predominantly affects glucose homeostasis, whilst GLP-1 and OXM have additional roles in 
appetite regulation.  GLP-1 is produced in two forms by intestinal L cells, GLP-1(7-37) and GLP-
1(7-36) amide , both of which are rapidly degraded in the circulation by dipeptidyl peptidase 4 
(DPP4) to GLP-1(9-37) and GLP-1(9-36)amide respectively.
143  These two metabolites account for 80% 
of plasma immunoreactive GLP-1 but are physiologically inactive with respect to insulin 
secretion.144  OXM is released in tandem to GLP-1 from intestinal L cells.  GIP, secreted by 
intestinal K cells, is also degraded by DPP4 to GIP(3-42) which accounts for 60% of plasma GIP.
145  
The GIP receptor (GIPR) and GLP-1 receptor (GLP-1R) are G protein receptor complexes 
expressed widely in humans.  GLP-1 and OXM both exert their physiological effects via the GLP-
1R although there remains some debate as to whether a second, as yet unidentified, receptor 
mediating some of GLP-1s effects exists.143  Additionally, it remains possible that OXM has a 
unique receptor, with studies showing similar physiological effects of GLP-1 and OXM at equal 
concentrations, despite the GLP-1R having a clearly greater affinity for GLP-1.146 
GLP-1 and OXM concentrations are low in the fasting state, and rapidly increase after a meal.  
The rise in GLP-1 is detectable at approximately 10 minutes after ingestion, and there is a wide 
body of evidence to suggest that the presence of nutrients in the intestinal lumen rather than 
a neuronal signal is the stimulus for GLP-1 and GIP release.147,148  The mechanisms underlying 
how L cells “sense” nutrients are not established, although the increase in GLP-1 associates 
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with the size and calorie content of the ingested meal.149,150  The peripheral administration of 
GLP-1 results in anorexigenic effects through a number of pathways.  Hypothalamic GLP1-R 
receptors convey satiety and reduce food intake via the arcuate and paraventricular nuclei.151  
Delayed gastric emptying and a reduction in gastric acid secretion is also evident.  Obesity 
appears to be associated with a blunted GLP-1 response to a meal, such that circulating AUC 
GLP-1 concentrations are lower after a meal in obese compared to lean humans, and this is 
corrected somewhat by weight loss.152  However, unlike leptin, sensitivity to GLP-1 appears to 
be conserved in obesity, with peripheral administration exerting anorexigenic effects.153  OXM 
also reduces food intake in rodents and humans following peripheral and central (rodents) 
administration, although the role of OXM in energy regulation remains to be fully investigated.   
The peripheral administration of OXM to normal weight humans resulted in an immediate 
reduction in calorie intake of approximately 20%, possibly in part by reducing ghrelin 
secretion.134   The therapeutic use of GLP-1 mimetics as weight loss agents is now widespread 
following the publication of a large number of randomised trials illustrating efficacy.154  Long 
acting OXM analogs are currently under development and are an attractive target for weight 
loss therapy.155   
With respect to glucose homeostasis, the important roles of GLP-1 and GIP both in health and 
in the pathophysiology of type 2 diabetes, are well established.143  Both hormones stimulate 
glucose dependent insulin release, and both increase beta cell insulin synthesis. 156   The 
demonstration that in patients with type 2 diabetes, post prandial hyperglucagonaemia is 
suppressed by intravenous but not oral glucose raised the possibility that glucagonotropic 
peptides released from the gastrointestinal tract were at play.157  Indeed, the administration of 
GIP appears to increase glucagon concentrations during an intravenous glucose infusion to 
those seen during oral glucose administration, and increases glucagon release in the fasting 
state.158,159 
 
1.1.2.4 An integrated model of energy homeostasis 
Thus, current knowledge on mechanisms underlying human energy homeostasis allow for the 
construction of a model whereby short and long term determinants of energy status can be 
differentiated.  Lipostatic hormones including leptin and insulin convey information on whole 
body adiposity to the hypothalamus allowing awareness of long term energy stores and 
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requirements.  The hypothalamus regulates both energy intake and energy expenditure, 
drawing upon additional indicators regarding health, etc.  Short term regulators of energy 
intake derive predominantly from the gastrointestinal tract and regulate appetite, satiety, 
glucose homeostasis, and digestion.  This group includes ghrelin, PYY, Amylin, GLP-1, GIP, and 
CCK with effects mediated via interactions with the hypothalamus or 
gastrointestinal/pancreatic structures. 
 
1.1.2.5 The aetiology of obesity 
The current model explaining the recent dramatic rise in the prevalence of obesity considers 
that genetic, environmental, and lifestyle factors all contribute, in the context of a permissive 
physiological state that evolved primarily to counteract energy insufficiency.160  In simplified 
terms, obesity results from the persistent consumption of a higher number of calories in 
comparison to those that are expended. 
Dietary intake has increased significantly over the past few decades, and particularly the 
proportion of calories obtained from fat.  Fat provided 15% of total daily calories in the average 
British diet in 1890, but had increased to 42% one hundred years later.161  Fat contains nine 
calories per gram intake, whilst protein and carbohydrate provide only 4 calories per gram.162   
Food portions have increased in size, especially when food consumed out of the home is 
considered.163  A significant number of studies in adults and children have demonstrated an 
association between dietary fat and adiposity. 164 , 165 , 166   However, recent studies have 
suggested that apportioning all the blame on dietary fat may be unjustified.  Two studies from 
Finland and American in the early 1990s failed to show clear associations between body weight 
and dietary fat intake, despite evident relationships between energy intake and body 
weight.167,168  Consideration of dietary fat added very little beyond energy intake as a predictor 
of body weight in the Nurses’ Health Study.169  Multiple studies in American children have not 
only suggested that dietary fat intake is falling (from approximately 37% to 33% between 1973 
and 1993), but that caloric intake did not increase enough over this period despite to account 
for the accelerating prevalence of childhood obesity.170   It is worth noting, however, that 
dietary recording via diet diaries has limitations and may particularly under report fat intake.171  
Attention has therefore turned to the role of increasing carbohydrate intake as an alternative 
dietary explanation for the rise in obesity.  Australian data suggests that energy intake in adults 
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increased by 4% (350 Kj/day) between 1983 and 1995 and that this increase could be attributed 
to an increase in carbohydrate.172  This finding was supported by studies in American (NHANES 
data) and European populations, and that carbohydrate intake was a useful additional 
predictor of body weight in association with overall energy intake.173,174  An increase in energy 
intake of this degree would equate to weight gain of approximately 1kg per year if energy 
expenditure was not increased.  
An increase in the prevalence of urban as opposed to rural living has likely reduced energy 
expenditure in many individuals; whilst urban work is frequently rather sedentary, those living 
in rural areas are more likely to expend calories through manual labour.175,176  American data 
in 2000 suggested that less than 30% of the population were achieving the recommended 
weekly concentrations of physical activity, whilst 40% had sedentary lifestyle.177   Canadian 
children have a significantly lower risk of obesity through participation in organised and 
unorganised sport, whilst increasing television and computer use are positively associated with 
obesity.178  Over 60% of American children watch more than two hours of television daily, whilst 
25% watch a staggering four hours or more.179   Resting energy expenditure, as the major 
contributor to total energy expenditure, is definitively measured only through the use of 
laborious double label water techniques, suitable only for research settings.  Population resting 
energy expenditure is instead calculated using models that make a large number of 
assumptions and frequently extrapolate from other ethnic populations.180  Further research is 
required to better approximate resting energy expenditure so that the contribution of this to 
whole body energy balance can be accounted for in studies. 
 
1.1.2.6 Summary 
Human energy homeostasis is tightly regulated and involves input from adipose tissue and the 
gut to hypothalamic centres mediating food intake.  The recent significant increase in obesity 
in most populations places a huge cost burden on medical services, and is explained by multiple 
drivers, which includes both decreases in physical activity and changes in energy intake, of 
which an increase in carbohydrate predominant caloric intake may prove to be the most 
important. 
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1.1.3 Pathophysiology of type 2 diabetes 
Diabetes mellitus is defined as occasional or persistent plasma glucose concentrations above 
accepted normal range thresholds.  These thresholds are established on the basis of clear 
causal relationships with end organ microvascular complications, although do differ 
internationally (Table 1-1).  Diabetes may be the result of an autoimmune beta cell ileitis (type 
1), may occur in the presence of monogenic disorders disrupting normal glucose homeostasis, 
may develop during and remain isolated to pregnancy, or may occur as an effect of secondary 
medical disorders.   Type 2 diabetes mellitus describes a process where dysglycaemia has 
developed as a consequence of an inadequate beta cell response to insulin resistance, which is 
itself generally the result of excess weight adiposity.  Type 2 diabetes is the focus of the 
discussion below.  
 









WHO/ADA 47 7.0 11.1 11.1 
NZSSD 50 7.0 N/A 11.1 
Prediabetes 
WHO N/A 6.1 and < 7.0 7.8 and <11.1 N/A 
ADA 39 to 47 5.6 to 6.9 7.8 to 11.0 N/A 
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1.1.3.1 Identification of insulin as the major regulator of glucose homeostasis  
Total pancreatectomy was shown to result in the rapid fatal development of severe diabetes 
(characterised at that time by glycosuria) in dogs over 120 years ago.181  Investigators therefore 
reasonably assumed that a product of the pancreas was integral in preventing glycosuria; this 
concept was further developed to isolate the source of this product to the endocrine Islets of 
Langerhans.  In 1900, Opie described hyaline degeneration within the islets of Langerhans 
during autopsy studies of patients with diabetes. 182   The following year, Ssobolew 
demonstrated the importance of these islets in glucose homeostasis though experimental 
ligation of the pancreatic ducts in a number of mammalian species.  This resulted in destruction 
of the exocrine enzyme secreting components of the pancreas, leaving the endocrine tissue 
intact; these animals would remain without glycosuria for some weeks after the procedure. 183   
However, none of these investigators or others were able to successfully extract the product 
responsible for correcting glycosuria prior to the animal’s death. 
Frederick Banting (1891 to 1941), based at the University of Toronto, is credited as the primary 
driver behind the discovery of insulin.184  His introduction to the field was somewhat fortuitous 
and occurred following his review of a case report published in the November 1920 edition of 
Surgery, Gynaecology, and Obstetrics.  This report described the post mortem finding of a 
pancreatic stone completely obstructing the pancreatic duct as the cause of fatal 
pancreatitis.185  The author was surprised to note that the majority of the endocrine cells had 
survived intact, and drew comparisons with the earlier work of Ssobolew.   Banting was clearly 
fascinated by this finding, and designed his now famous study: “Ligate pancreatic ducts of dogs.  
Wait six to eight weeks for degeneration.  Remove the residue and extract”.186   
Banting convinced colleagues to support the experiment and, with the assistance of Charles 
Best initiated proceedings in 1921.184  Professor John MacLeod advised on experimental design 
to ensure the studies could produce a scientifically sound conclusion.  The technique was 
successful and administration of the resultant extract did reduce glycosuria in 
pancreatectomized dogs.  The name Insulin (Insula, Latin for Island), which was first suggested 
by De Meyer, was subsequently universally accepted.187   Additional purification was followed 
by the first use of this extract diabetic humans, with rapid improvements in glycosuria and 
ketosis.  For their work, Banting and MacLeod received the Noble prize in 1923. 
 




Insulin is the primary hormonal regulator of carbohydrate metabolism and plays a predominant 
role in glucose homeostasis. 188   Insulin secretion is biphasic comprised of a first phase 
characterised by rapid glucose dependent release of preformed mature insulin, and a second 
phase characterised by the predominantly non-glucose dependent synthesis and release of 
additional insulin.189  The first phase is initiated within 1 minute of a glucose bolus, peaks at 
between 3 and 5 minutes, and lasts approximately 10 minutes.190  The second phase of insulin 
secretion is also initiated rapidly after a glucose bolus or non-nutrient stimuli, but is not 
measurable until approximately 10 minutes.  Unlike first phase secretion, second phase 
secretion persists for the duration of hyperglycaemia.  An increase in ambient glucose 
concentrations is the stimuli for “first phase” insulin release.  Glucose enters the beta cell via 
the GLUT 2 transporter and is phosphorylated to glucose-6-phosphate (G6P) by glucokinase, a 
process which generates ATP.191  Glucokinase therefore acts as a “sensor” of plasma glucose 
concentrations, and provides a mechanism by which insulin secretion can be appropriately 
matched to glucose requirements.  The consequent increase in intracellular ATP concentrations 
drives the closure of transmembrane K+-ATP-dependent channels resulting in membrane 
depolarization, which results in activation of transmembrance voltage dependent calcium 
channels.192  Thus, an increase in beta cell glucose concentrations, results in increased beta cell 
calcium concentrations which promotes the movement of insulin containing secretory granules 
to the membrane for exocytosis.    
“Second phase” insulin release is stimulated by both nutrient (glucose, fructose, mammose, 
galactose) and non-nutrient (neural, hormonal, amino acids) triggers.188   An awareness of, or 
consumption of food triggers second phase insulin secretion via cholinergic vagal nerve 
stimulation, through the activation of beta cell phospholipase C and protein kinase C.  This so 
called “cephalic insulin response” will not occur under normal circumstances in the fasting state 
or in the context of hypoglycaemia, and is critical in post-prandial glucose homeostasis.193  In 
contrast adrenergic stimuli generally inhibit insulin secretion.  Catecholamine release during 
exercise or stress, prompts a reduction in basal insulin output, mediated via alpha 2 
adrenoreceptors.194  Multiple gastrointestinal hormones including GLP1 (discussed in chapter 
1-x) and cholecystokinin enhance insulin secretion, and are themselves released at least in part 
by nutrient dependent mechanisms.195,196,197 Somatostatin inhibits insulin release, although can 
provoke hypoglycaemia in therapeutic circumstances through inhibition of additional 
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hormones that favour an increase in plasma glucose.198   Leptin also inhibits the release of 
insulin by provoking activation of the K+-ATP-dependent channel, thereby preventing 
membrane depolarisation, via a leptin receptor expressed on the beta cell membrane. 199  
Arginine increases the intracellular movement of potassium and thereby enhances membrane 
depolarization and insulin release; like the cephalic insulin response, arginine mediated insulin 
release only occurs at normal or elevated concentrations of plasma glucose.200 
The insulin receptor (IR) is encoded by the INSR gene on chromosome 11, and is activated by 
insulin, and the insulin like growth factor proteins (IGF1 and IGF2).  IR is a dimeric protein 
complex comprised of two extracellular alpha subunits and two beta subunits that span the cell 
membrane.  The subunits are linked by disulphide bonds.  Activation of the receptor through 
insulin binding to the extracellular alpha subunits, results in a conformational alteration in the 
intracellular beta subunits.  ATP binding may then occur, facilitating phosphorylation of the 
beta unit conferring tyrosine kinase activity, which mediates the intracellular actions of insulin 
via phosphorylation of insulin responsive substrates (IRS).  IRS phosphorylation enhances the 
affinity of IRS to bind other signalling molecules, and allows activation of intracellular molecular 
cascades.201  4 IRS are known to exist along with a related protein (Gab1, Grb2-associated 
binder-1) differing with respect to target hormones and tissue distribution.201,202  IRS1 and IRS2 
share wide tissue distribution although it has been suggested that IRS1 is the predominant 
mediator of insulin action in skeletal muscle, whilst IRS2 is predominantly active at the liver.201 
Insulin acts widely throughout human tissues, but predominantly acts at the skeletal muscle 
and adipose tissue to promote glucose uptake and at the liver to facilitate a number of 
physiological processes.  Glucose uptake into skeletal muscle and adipose tissue, via GLUT4, is 
insulin dependent.  Under experimental conditions of intravenously infused glucose and 
induced hyperinsulinaemia, this uptake accounts for up to 80% of whole body insulin 
dependent glucose uptake.203  In the post prandial phase, insulin promoted the synthesis of 
glycogen in skeletal muscle and lipogenesis in adipose tissue.188  Skeletal muscle glycolysis 
during rigorous physical activity provides anaerobic energy, whilst free fatty acids (and 
consequently ketone) bodies can be released from adipose tissue to provide energy to other 
non-glucose dependent organs.  The effect of insulin on skeletal muscle protein metabolism 
varies depending on the dose of provided insulin; insulin deficiency promoted protein 
catabolism and the release of amino acids, whilst the presence of insulin suppresses this 
process.  At higher doses however, insulin has an anabolic effect on muscle. 204    Insulin’s 
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primary role in regulating hepatic aspects of glucose homeostasis is to directly and indirectly 
inhibit hepatic glucose production.   Indeed, hepatic glucose production may account for up to 
80% of endogenous glucose production in the fasted state.205  Insulin acts directly to inhibit 
both hepatic gluconeogenesis and glycogenolysis (whilst promoting glycogen synthesis), and 
indirectly by reducing the production of gluconeogenic precursors (circulating lipids, glycerol, 
and protein) by other tissues, and also by inhibiting pancreatic glucagon secretion.206  Studies 
in dogs suggest that the direct hepatic action of insulin may predominate, but it remains 
unclear whether this is true in humans.207  Insulin enhances the production of nitric oxide, 
which is the predominant factor regulating vascular endothelial relaxation in large arteries.208  
Glucose uptake in the brain is independent of insulin; nonetheless, insulin plays a major role in 
regulating a number of cerebral functions.209  Insulin has been shown to mediate some aspects 
of both cognition and feeding behaviour, in that increasing cerebral insulin concentrations 
reduce food intake.210  Furthermore, insulin plays an integral role in maintenance and function 
of the brain endothelial cells that form the blood brain barrier; altered transport across the 
blood brain barrier in states of hyperglycaemia has been attributed to alterations in insulin’s 
ability to perform these functions.209   Insulin has documented effects in a number of other 
tissues including the pancreas, pituitary, kidneys, and bones. 
 
1.1.3.3 The role of insulin resistance in type 2 diabetes 
The development of the insulin radioimmunoassay by Yalow in 1960 allowed insulin 
concentrations in patients presenting with maturity onset diabetes to be assessed accurately 
for the first time.211   Unlike those with type 1 diabetes, these patients were found to have 
normal or elevated concentrations of insulin, and secreted insulin in response to food intake.  
However, insulin therapy did not correct the hyperglycaemia suggesting the concept of insulin 
resistance, although early investigators considered the possibility of this phenomenon being 
the result of an absence of insulin sensitiser.212  Insulin resistance has since been defined by 
many authors as a reduction in the ability of insulin to induce both glucose disposal and reduce 
endogenous glucose production in target tissues.213  The theory that insulin resistance was 
significantly increased in patients with type 2 diabetes was further supported by work in the 
1960s and 1970s in a number of pioneering experiments in humans214,215  As skeletal muscle is 
the major site of glucose disposal in healthy individuals, development of tools to assess insulin 
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physiology in these tissues have been of prime importance.  De Fronzo and colleagues 
developed the euglycaemic hyperinsulinaemic clamp over 30 years ago and subsequently 
confirmed reduced glucose disposal in people with type 2 diabetes.216,217  The euglycaemic 
hyperinsulinaemic clamp remains the gold standard assessment of insulin resistance. 
The mechanisms underlying insulin resistance remain poorly understood however but include 
inflammation, mitochondrial dysfunction, hyperinsulinaemia, hepatic fat content, lipotoxicity, 
and endoplasmic reticulum stress, many of which are associated with obesity.218,219   Additional 
factors such as aging, genetic predisposition, and pregnancy play a role, whilst insulin resistance 
is a feature of many medical disorders, mediated by one or more of the above mechanisms.    
However, an association between lipids and insulin resistance is clear, and predominantly 
relates to the intracellular accumulation of lipid in tissues whose function is modified by the 
action of insulin. Hepatocyte ectopic lipid accumulation is the result of either increased hepatic 
uptake of lipids, or decreased export.  Lipoprotein lipase (LPL) has been shown to be a key 
regulator of hepatic lipid import, through the study of LPL over expression or knockout rodent 
models. 220 , 221   In healthy adult humans, muscle insulin resistance is predicted by 
intramyocellular diacylglycerol content rather than ambient plasma fatty acid 
concentrations.222,223  It appears that diacylglycerol (DAG) accumulation is the key lipid driving 
insulin resistance at both the liver and muscle. DAG promotes insulin resistance through 
activation of members of the protein kinase C family, which in turn alter post receptor 
signalling.218   The primary role that DAG plays in lipid accumulation mediated insulin resistance 
is evidenced by the observation that mice that overexpress diacylglycerol acyltransferase 
(DGAT, converting DAG to triglycerides) have marked intramyocellular triglyceride 
accumulation, but do not exhibit increased muscle insulin resistance.224   
Insulin resistance appears to be an early feature of type 2 diabetes and is evident almost 
universally in patients with earlier forms of dysglycaemia (impaired glucose tolerance/impaired 
fasting glucose/prediabetes).225  Indeed, glucose disposal during a clamp study, as a surrogate 
of insulin resistance may be reduced by 50% or more in those with type 2 diabetes when 
compared with control.226,227  However, insulin stimulated glucose uptake is reduced in patients 
with impaired glucose tolerance and type 2 diabetes to a similar degree.227  Furthermore, there 
is little if any relationship between fasting glucose and insulin resistance in patients with 
impaired glucose tolerance or type 2 diabetes.227  It is therefore apparent that insulin resistance 
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alone cannot explain the development of hyperglycaemia, and that this must be accompanied 
by inappropriate insulin production.  
1.1.3.4 Increasing importance of beta cell dysfunction in the pathogenesis of type 2 
diabetes 
Confirmation that insulin secretion is under the control of a feedback loop allowing a 
connection with ambient plasma glucose concentrations, was provided in seminal studies by 
Kahn and colleagues. 228   Using a minimal model approach, they described a hyperbolic 
relationship between insulin sensitivity and beta cell function in healthy young humans with 
normal glucose tolerance, such that for any reduction in insulin sensitivity, a proportionate 
increase in beta cell insulin secretion would occur.  The exact mechanisms by which target 
tissue indicates insulin requirements however remains to be elucidated.  Hyperglycaemia, in 
the context of type 2 diabetes, therefore implies the presence of beta cell dysfunction. Further 
studies have confirmed this dysfunction by demonstrating a reduced insulin response to 
intravenous glucose, and changes in the pulsatile and oscillatory nature of insulin 
secretion.229,230   Furthermore, the insulin response to non-glucose dependent stimuli (arginine, 
gastrointestinal hormones, sulphonylurea therapy) is diminished in patients with established 
type 2 diabetes.231  It is therefore clear that both insulin resistance and beta cell dysfunction 
are the hallmarks of type 2 diabetes.    
However, beta cell dysfunction is apparent long before the onset of type 2 diabetes in patients 
at risk of dysglycaemia, even when glucose tolerance remains normal.231  First degree relatives 
of persons with type 2 diabetes, who are themselves obese and have evidence of insulin 
resistance, have a poorer beta cell response than would be predicted by concurrent 
measurements of insulin sensitivity, even when glucose tolerance appears normal.232    An 
impaired beta cell response is also evident in obese individuals with impaired glucose 
tolerance.233  Furthermore, individuals known to be at  higher risk of future development of 
type 2 diabetes (women with polycystic ovary syndrome or previous gestational diabetes) also 
have poorer beta cell responses than would be predicted based on the hyperbolic relationship 
to insulin sensitivity. 234 , 235   Insulin resistance is present under certain conditions, but a 
continuum of deteriorating beta cell function from adequate to insufficient, characterises the 
progress from normal glucose tolerance to prediabetes to type 2 diabetes.231   
 




1.1.3.5 Genetic and environmental factors underlying insulin resistance and beta cell 
dysfunction 
The first gene to be clearly associated with the development of type 2 diabetes was PPAR 
(peroxisome proliferator-activated receptor-), with a specific substitution (Pro12AIa) 
conferring a 4.35 fold increased likelihood for the presence of type 2 diabetes in Japanese 
Americans.236  Subsequent research has identified over 50 single nucleotide polymorphisms 
(SNP) that associate with the development of type 2 diabetes.  237  , 238    Whilst the exact 
mechanism associating each SNP with type 2 diabetes has not been defined, the majority 
appear to impact on beta cell function.238 
However, the presence of susceptible single nuclear polymorphisms explains less than 10% of 
type 2 diabetes heritability, although polygenic factors likely explain a significant proportion of 
the remainder.237  Indeed, genetic risk scores, aimed at predicting the presence of type 2 
diabetes on the basis of present SNPs, do not perform any better than calculations based on 
traditional metabolic risk factors.239  Furthermore, the rapidly increasing prevalence of type 2 
diabetes in most societies indicates factors beyond genetics are likely to be important 
predictors of the development of type 2 diabetes.   Environmental factors are therefore clearly 
of high importance in the pathophysiology of this condition, and the interaction between genes 
and the environment may assume even greater importance.   
Ageing alone reduces glucose tolerance; both increasing insulin resistance and decreasing beta 
cell function contribute. 240   Physical activity and exercise share complex roles in the 
pathogenesis of type 2 diabetes.  Long term aerobic exercise improves insulin sensitivity such 
that reduced insulin release is required to maintain normal glucose tolerance. 241 , 242 , 243  
However, high intensity exercise for 10 to 15 minutes results in a rise in glucose concentrations 
(albeit in persons with type 1 diabetes).244   Furthermore, numerous studies have recently 
identified the benefits of short duration (10 seconds) high intensity exercise in reducing post 
exercise hypoglycaemia which may be mediated by increased catecholamine concentrations.245  
Multiple studies have now shown that physical exercise is an important and effective 
intervention in patients with type 2 diabetes and results in improved glucose control.246,247  An 
imbalance between energy intake and expenditure is clearly associated with glucose 
intolerance, but it is apparent that specific dietary constituents also play a role.248  A reduction 
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in the insulin response to carbohydrate ingestion with increasing age is an important factor 
underlying age related changes in glucose tolerance.249  Dietary fat has been shown to directly 
impact upon insulin resistance and beta cell dysfunction, as well as being a primary modulator 
in the development of obesity.248  However, multiple randomised controlled trials of specific 
macronutrient diets in the management of established type 2 diabetes have failed to clearly 
show superiority over other macronutrient diets.250  Medical conditions or treatments such as 
disorders of cortisol excess can impact glucose tolerance.  Finally, it is likely that exposure to a 
number of naturally occurring and synthetic environmental chemicals impact both on glucose 
tolerance and increase the risk of obesity.251,252  However, after accounting for each of the 
above mentioned genetic and environmental risk factors, it is clear that a considerable amount 
of the risk underlying the development of glucose intolerance remains; it is likely that the 
majority of this residual can be attributed to obesity and body fat distribution (see 1.1.4). 
 
1.1.3.6 The gastrointestinal tract in the pathogenesis of type 2 diabetes 
Numerous gastrointestinal processes that either facilitate nutrient digestion or convey 
information regarding food intake to the brain are evident in healthy humans, and dysfunction 
of these processes is apparent once glucose intolerance has developed.  Hormones that also 
regulate weight are reviewed in section 1.1.2.3 
   
1.1.3.6.1 Glucagon 
Pancreatic glucagon, secreted by islet alpha cells, has perhaps received less attention than 
other pathophysiological factors, but clearly has a role in type 2 diabetes.  Glucagon, a 
polypeptide containing 29 amino acids, is produced by the cleavage of proglucagon by 
proprotein convertase 2, a process which produces similar hormones elsewhere in the 
gastrointestinal tract (see GLP-1, 1.1.2.3.5).253  Alpha cells appear to be scattered throughout 
the islets and junctional cell communication is required to regulate the secretion of glucagon, 
such that glucagon secretion is many fold higher in isolated alpha cells than those within intact 
islets.254   
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Glucagon secretion is stimulated by hypoglycaemia, cholecystokinin, amino acids, and 
activation of the autonomic nervous system, along with glucose-dependent insulinotropic 
peptide (GIP)254,255   Insulin, somatostatin, leptin, amylin, GLP-1, and increased zinc secretion 
from beta cells all have inhibitory effects on glucagon secretion.254,256,257  Of these regulatory 
factors it has been argued that an absence of insulin and zinc are of most importance; 
hypoglycaemia directly is likely to be of minor physiological relevance.254  Whilst insulin induces 
glucagon suppression through hyperpolarisation of the alpha cell membrane, the mechanism 
via which GLP-1 induces a similar response remains unclear.  GLP-1 receptor expression on the 
alpha cell is variably reported in the literature but is likely to be low; it is possible that GLP-1 
may instead mediate its effect on glucagon via somatostatin, receptors for which are widely 
expressed on alpha cells.255 The major target for glucagon is the liver where it binds to the 
glucagon receptor expressed in high numbers on hepatocytes.  Glucagon increases hepatic 
glucose output both through increasing glycogenolysis and gluconeogenesis, whilst also 
inhibiting glycogenesis and glycolysis. 258   
 Hyperglucagonaemia as an early feature of type 2 diabetes was recognised over forty years 
ago, although the exact role of this pathophysiological feature remains to be fully elucidated.259  
The alpha cell does not respond normally to physiological stimuli in the context of type 2 
diabetes.  There is a blunted alpha cell response to hyperglycaemia when a reduction in 
glucagon secretion is required.  Furthermore, the ingestion of a protein rich meal invokes an 
exaggerated glucagon response.260,261  The alpha cell to beta cell ratio appears to be increased 
in type 2 diabetes as a result of beta cell apoptosis, but the total alpha cell mass appears 
unchanged. 262   It is possible that alpha cell resistance to insulin, in parallel with insulin 
resistance in other tissues, is a significant contributor to these changes in alpha cell function.  
Obese individuals with either prediabetes or type 2 diabetes have impaired alpha cell responses 
to oral glucose ingestion, even when hyperinsulinaemia is present. 263  In addition, insulin 
receptor knockout mice have significantly higher glucagon concentrations than normal 
controls.264    
Furthermore, it is clear that glucagon plays a significant role in glycaemic dysfunction under 
these circumstances.  The clear association between insulin action at the alpha cell and 
glucagon release is evident in patients with uncontrolled type 1 diabetes.  Near total insulin 
deficiency is associated with very high glucagon concentrations, whilst inhibition of glucagon 
secretion in this context significantly reduced the hyperglycaemia and ketogenesis that would 
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otherwise be expected.265,266   Further studies using somatostatin to either inhibit glucagon 
release or inhibit insulin release, with physiological replacement of glucagon, indicate that 
glucagon action may account for up to 50% of total hepatic glucose production in the fasting 
state. 267 , 268   Recent work using glucagon receptor knockout mice showed that fasting 
hyperglycaemia does not develop even after streptozotocin induced complete insulin 
deficiency, illustrative of the fundamental role glucagon plays in fasting hyperglycaemia.269,270  
As noted previously, in type 2 diabetes glucagon suppression in response to ingestion of a meal 
is blunted, and therefore, in the context of inappropriate hyperglucagonaemia, hepatic glucose 
production continues in the post prandial state. It is therefore apparent that 
hyperglucagonaemia, most likely directly the result of impaired alpha cell sensitivity to insulin, 
is a significant factor underlying both fasting and post prandial hyperglycaemia in type 2 
diabetes. 
Thus, reduction of glucagon action would appear to be an attractive strategy for the 
development of pharmaceutical agents for glucose control in diabetes.132  Concerns regarding 
hepatic accumulation of lipids and glycogen as an adverse consequence of glucagon regulating 
therapy have been alleviated to some extent by studies in glucagon receptor knock out mouse 
models where these concerns did not materialise.271  Three classes of pharmaceutical agents 
that effect glucagon action are currently in use; GLP-1 mimetics and dipeptidyl peptidase 4 
inhibitors, and the amylin mimetic Pramlintide and are discussed later (see chapter 1.2.2 ) 
 
1.1.3.7 Inflammation in diabetes 
Both type 2 diabetes and obesity are closely associated with systemic inflammation, and 
markers including c-reactive protein (CRP) and interleukin-6 are related to insulin sensitivity 
and beta cell function (see chapter 1.1.4)   However, inflammation at the level of the beta cell 
is likely to be a significant contributor to beta cell dysfunction.272   Whilst glucose is the primary 
beta cell stimulus regulating insulin secretion, persistently elevated glucose concentrations 
prompts beta cell apoptosis in humans (glucotoxicity).  High concentrations of free fatty acids 
(lipotoxicity) have more recently been shown to have similar deleterious effect.273,274 Apoptosis 
is mediated by the actions of interleukin-1 (IL-1), a cytokine produced by the beta cell itself 
which induces apoptosis by activating the transcription factor nuclear factor- (NF-).275  The 
specific role of this cytokine was confirmed by the finding that the addition of a naturally 
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occurring IL-1 receptor antagonist to cultured human islets exposed to hyperglycaemia 
reduced beta cell apoptosis.275  A randomised trial of recombinant IL-1 receptor antagonist 
(Anakinra) has shown early and durable benefits with respect to overall glucose control and 
beta cell function in a cohort of overweight recruits with sub-optimally controlled type 2 
diabetes.276,277  It is therefore likely that inflammation at the beta cell, and mediated in part by 
nutrient exposure is a primary driver behind the reduced beta cell mass evident in type 2 
diabetes.  This illustrates an interesting overlap between the accepted aetiological models of 
type 1 and type 2 diabetes. 
 
1.1.3.8 Summary 
Type 2 diabetes is a heterogeneous disorder characterised by the presence of insulin resistance 
and beta cell dysfunction.  Environmental factors are the predominant drivers of both 
pathophysiological hallmarks, although genetic susceptibility (particularly with respect to beta 
cell function) plays a role.  Research into the gastrointestinal and inflammatory factors involved 
in the pathophysiology of type 2 diabetes is in its infancy but is likely to lead to novel 
therapeutic strategies. 
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1.1.4 Linking obesity and type 2 diabetes 
As noted above, obesity is the predominant modifiable risk factor for the development of type 
2 diabetes, and the prevalence of type 2 diabetes has increased in proportion to the population 
increase in the prevalence of obesity.  Interactions between the increased adipocyte tissue 
mass, and the secretion and action of insulin provide a mechanism to link these disorders.278 
 
1.1.4.1 Obesity and Insulin resistance  
Adipocytes produce a wide range of hormones and peptides, many of which have the potential 
to affect systemic insulin sensitivity.  Retinol-binding protein-4 (RBH4) enhances hepatic 
glucose production by increasing the expression of gluconeogenic enzymes within hepatocytes, 
but also increases muscle insulin resistance.279  A number of cytokines have been implicated in 
the link between obesity and insulin resistance; tumour necrosis factor- (TNF-) and 
interleukin-6 (IL-6) both circulate at higher concentrations in obesity, and up regulate 
intracellular pathways in target tissues that promotes insulin resistance.280   
The release of non-esterified fatty acids (NEFA) from adipocytes through lipolysis is likely to be 
a significant contributor to the development of insulin resistance. 281   In humans, insulin 
resistance and improved glucose tolerance are seen rapidly after a rise or fall respectively in 
NEFA concentrations.282,283  Whilst it appears that post receptor insulin signalling is negatively 
affected by NEFA, the exact mechanisms underlying this association remain to be clarified. 
In contrast to the above deleterious effects, adipose tissue also produces adiponectin (see 
1.1.2.1.2) which acts as an insulin sensitiser and reduces hepatic glucose output.  Thus 
adiposity, has both positive and negative effects on glucose homeostasis and this appears to 
be dependent on the site and volume of adipose accumulation.  It has long been known that 
central adiposity, both in overweight and lean individuals, tends to result in more marked 
insulin resistance than weight matched individuals with a more peripheral distribution of 
adiposity.284  Intra-abdominal adipose tissue is less sensitive to the suppressive effects of insulin 
than peripheral subcutaneous adipose tissue, resulting in greater lipolysis and consequently a 
higher output of NEFA.285  Because the output of the intra-abdominal adipose tissue drains into 
the portal circulation, this results in an increased likelihood of hepatic insulin resistance.    
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Furthermore, whilst central adipocytes secrete a greater concentration of adiponectin per unit 
than peripheral adipocytes, the peripheral total adipocyte mass is significantly greater than the 
central unit.285,286  Therefore, the insulin sensitising effect of adiponectin may be greater in 
those with peripheral adiposity. 
 
1.1.4.2 Obesity and the beta cell 
As discussed above (see 1.1.3.4) beta cell dysfunction is by definition present once glucose 
intolerance is evident, long before the onset of type 2 diabetes.  Whilst a reduction in total beta 
cell mass is evident, it has also been suggested that each beta cell is on average functioning at 
approximately 25% of its capacity once type 2 diabetes is present.  This is evident both with 
respect to an impaired insulin release in response to a glucose stimulus, and to other 
secretagogues such as GLP-1.  The exact mechanisms underlying this impairment remain 
unclear but it is likely that individuals are genetically predisposed to beta cell maladaptation.  
Thus, beta cell dysfunction may be indirectly related to obesity in the sense that beta cells 
cannot overcome obesity driven insulin resistance. 
However, as with insulin resistance, an increase in circulating NEFA, proportional to total body 
adipocyte mass, may also adversely and directly affect beta cell function.  Whilst the infusion 
of fatty acids enhances rodent insulin secretion in the acute phase, impairment of both insulin 
synthesis and secretion is seen with chronic exposure. 287 , 288   Similar effects are seen in 
humans.289  Thus, the increased concentrations of NEFA observed in obesity may provide a 
mechanism to link this state to both insulin resistance directly and beta cell dysfunction directly 
and indirectly.290 
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1.2 Non-surgical management of obesity and type 2 diabetes 
 
1.2.1 Obesity 
The management of obesity is approached in the same manner as any other chronic medical 
condition that predominantly presents an increased risk for secondary medical disorders.  The 
benefits of any intervention must be balanced against the risks, with interventions that carry 
the greatest risk primarily reserved for those who stand to receive the greatest benefit.291  
However, as in the management of diabetes (see below) it is tempting to view the treatment 
of obesity in a stepwise fashion starting with lifestyle changes, through to pharmaceutical 
therapy, through to bariatric surgery.  In practice, however, management strategies should be 
personalised, and more aggressive interventions should be considered early if clearly 
required.292 
The cornerstone of any approach to obesity is appropriate lifestyle modification alongside 
other selected interventions.  Simplified, any person wishing to lose weight needs to reduce 
caloric intake and increase physical activity to induce a negative energy balance.  The optimal 
diet for weight loss has been the subject of a significant volume of research in recent times. 
Both the diabetes prevention program (DPP) and Look-AHEAD studies (see 1.2.2) prescribed a 
low fat, caloric restricted diet and demonstrated weight loss of 5.5kg and 7.9kg placebo 
extracted weight loss respectively at an average of 2.8 and 1.0 years.324,327  Multiple randomised 
controlled trials of diets composed of varying proportions of macronutrients (protein, 
carbohydrate, fat) have shown similar outcomes with a recent review showing a mean weight 
loss of -4.4% in fifteen highly cited selected randomised controlled trials.293   Thus, the primary 
factor underlying successful weight loss is caloric restriction, with macronutrient content 
related perhaps more to diet tolerability and adherence.  This concept was supported by a 
study performed by Sacks et al, where 811 obese adults (mean BMI 33.0 kg/m2) were 
randomised to one of four diets containing varying percentages of protein, carbohydrate, and 
fat, but all resulting in a caloric deficit of approximately 750 kcal/day.294  Dietary plans were 
provided each fortnight, and group education sessions were held either weekly or fortnightly.  
The mean weight loss at 12 months for all participants was 6kg (-7% body weight change), 
although weight regain was seen in the second 12 months of the study.  The net weight change 
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at 24 months was similar irrespective of the dietary intervention at 4kg.  Disappointingly, only 
15% of participants had a body weight reduction of greater than 10% at study end. 
The tolerability of a diet is clearly an important factor in weight loss durability.  A study by 
Dansinger et al demonstrated weight loss through the use of a number of varying prescribed 
diets in all participants who were able to adhere to their diet.295  Furthermore, this study and 
others have suggested that adherence is often reasonable for three to six months, after which 
a return to less healthy eating habits heralds weight regain.  Therefore, future dietary strategies 
will need to aim to match each individual seeking weight loss with a particular diet most likely 
to be tolerable to that individual.  However, patient choice in dietary pattern may not be a 
predictive factor for successful weight loss.296   
An increase in physical activity, whilst less helpful for inducing weight loss, has been shown to 
be important in maintaining weight loss in a large number of studies.297,298  Moderate intensity 
physical activity of between 150 and 250 minutes per week is required to prevent weight 
regain, but will only induce weight loss if concurrent moderate caloric restriction is 
undertaken.299  More frequent physical activity (>250 minutes per week) is required before 
weight loss without dietary restriction is seen. Behavioural therapy, incorporating goal setting, 
self-monitoring, and stimulus control, is also an important aspect of successful weight loss and 
maintenance.300 
Medical options for the management of obesity are currently limited, following the withdrawal 
of a number of previously used drugs as a result of significant side effects.301  The development 
of new agents has been protracted and is not without difficulty, in part because regulators are 
rightly wary of the likely very high population exposure to licensed anti-obesity agents.  
Previous management strategies have suggested that there may be an indication for 
pharmaceutical agents to support weight loss, alongside dietary and physical activity 
interventions, in those with a BMI >30 kg/m2 or >27 kg/m2 if obesity related comorbidities are 
present. 302   These criteria apply to an increasingly large proportion of the New Zealand 
population, and thus any unforeseen complications resulting from these medications would 
likely have a hugely significant adverse population health effect. Furthermore, whilst an 
attractive model for weight loss might involve early pharmaceutical therapy to induce early 
weight loss followed by maintenance lifestyle changes, it is clear that weight regain would be 
likely under these circumstances.  Thus pharmaceutical therapy, once commenced, would need 
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to be continued in the long-term and the individual exposure to these agents would be 
significant.303   Criteria for obesity drug licensing have tended to favour, but not enforce, 
placebo subtracted weight loss of >10%, on the basis that this degree of weight loss is required 
to gain health benefits.304 Historically, single agent treatment achieves less significant effects 
than this; thus this well-intended criteria may have the unfortunate effect of restricting future 
market development, especially as the therapeutic strategies towards weight loss move more 
towards a multifaceted approach. 
Whilst pharmaceutical agents could potentially target either energy intake or expenditure, no 
agent has yet been produced which can successfully increase energy expenditure without 
unacceptable side effects. Agents acting on energy intake can be divided between those 
resulting in reduced digestion or absorption of foods, or those acting on appetite or satiety.  
Currently only 2 anti-obesity agents (orlistat and phentermine) are available in New Zealand, 
and three new anti-obesity agents are either in use or are close to market internationally (Table 
1-2). Additionally, existing medications such as the incretin mimetics have shown great promise 
as anti-obesity agents.   
  
1.2.1.1  Medications that effect fat absorption or metabolism 
Orlistat, a gastric and pancreatic lipase inhibitor, is the solitary anti-obesity drug currently 
available to New Zealand clinicians.  Digestive inhibition leads to a 30% decrease in absorbed 
fat, which is excreted along with the drug in the faeces.  Weight loss is modest, with most 
randomised studies showing placebo subtracted weight loss (PSWL) of -2.9kg (equating to 
approximately 2-5% of total body weight) alongside dietary and physical activity 
interventions.304, 305 , 306  Additional beneficial cardiovascular effects (reduction in total 
cholesterol and LDL cholesterol) have been reported in large randomised intervention studies, 
as well as a modest but statistically significant reduction in progression to type 2 diabetes in 
those patients who already had evidence of glycaemic dysfunction.307   Gastrointestinal side 
effects occur as a consequence of increased stool fat content; increased flatulence, oily stool, 
faecal urgency are seen in up to 40% of patients, although it should be noted that dropout 
rates, at least in the context of a clinical trial, do not exceed placebo.305,306,307  The frequency of 
gastrointestinal side effects reduces with time, although patients should be prescribed fat 
soluble vitamins (A, D, E, and K) alongside Orlistat therapy to prevent deficiencies.307 A novel 
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lipase inhibitor Cetilistat, may have an improved tolerability profile to Orlistat and is the subject 
of current phase 3 studies.308  
 
1.2.1.2 Medications that reduce food intake 
The majority of anti-obesity drugs that affect food intake do so primarily by affecting central 
neurotransmitter physiology.  The sympathomimetic Phentermine was the first medication 
approved by the FDA specifically for the treatment of obesity in 1959; numerous others have 
come to market since but have been withdrawn following the documentation of severe side 
effects (Flenfluramine and dexflenfluramine (valvulopathy), Aminorex (pulmonary 
hypertension), Phenylpropanolamine (stroke), Rimonabant (suicidal ideation) and Sibutramine 
(Myocardial infarction and stroke)) and will not be considered in this chapter.309 Other drugs 
(e.g. Topiramate), despite showing promise as weight loss agents, have been limited by poor 
tolerability at the required doses. Nonetheless, weight loss outcomes with these medications 
are often more significant than with other current pharmaceutical strategies; thus, recent 
approaches to obesity drug development have focused on either combined therapy (enabling 
exposure to lower doses of constitutive agents) or modifications of existing therapies (e.g. 
Lorcaserin, see below) so that negative effects are avoided.  
 
 Phentermine suppresses appetite primarily by increasing the hypothalamic release of 
noradrenaline.  A meta-analysis of 6 randomised studies showed PSWL of -3.6kg (95% CI, -0.6 
to -6.0) when phentermine was administered to obese persons for a mean of 13 weeks 
alongside lifestyle and dietary changes.310  Diethylproprion, which has a similar mechanism of 
action to Phentermine, is occasionally used, although the few published head to head studies 
suggest a similar weight loss effect as to that seen with Phentermine.310  Few studies exist 
exploring the longer term use of either drug as a single agent  and none longer than 12 months.  
However, a small study of 108 obese women followed for 36 weeks on Phentermine therapy 
showed PSWL of > -7.8kg.311  Thus, both drugs are approved only for up to 12 weeks treatment 
as an adjunct to other measures.  Despite concerns about the potential for addiction seen with 
other amphetamines, neither drug appears to cause psychological dependence or drug craving 
when used at the doses suggested for weight loss therapy.312  
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Topiramate, an anticonvulsant approved for the treatment of epilepsy and migraine, has long 
been known to be associated with weight loss in some recipients.  The mechanism remains 
incompletely understood, but PSWL of -5.6kg was noted in a meta-analysis of 11 studies.313  
However, a high frequency of side effects including paraesthesia, psychomotor disturbance, 
and abnormal taste lead to a high dropout rate in interventional studies.  A combination of 
Phentermine and Topiramate (Qsymia), at a dose often 10-50 times lower than required when 
Topiramate has been studied as a single agent, has recently been approved by the FDA as an 
anti-obesity agent.  This approval was on the basis of a phase 3 randomised 56 week trial of 2 
dose regimens versus placebo.314 Phentermine/Topiramate 92/15mg daily was associated with 
PSWL of -8.8kg; however, depression and/or anxiety related adverse occurred at almost double 
the frequency seen with the lower dose (Phentermine/Topiramate 46/7.4mg daily, PSWL -
6.7kg) where the frequency was similar to placebo.  Thus, the FDA have approved 
Phentermine/Topiramate 46/7.5mg daily for chronic weight management in obese patients 
(BMI>30mg/kg2 or 27mg/kg2 if obesity related co-morbidities are present) and suggest a review 
after 12 weeks of therapy.  If weight loss at that point is < 3%, patients may either stop the 
medication or increase to the higher dose, with regular observation for adverse effects. 
 
Lorcaserin, a serotonin 2C (5-HT2C) agonist, was also approved by the FDA in 2012 as an anti-
obesity agent on the basis of a 12 month randomised trial of 2 dose regimens versus placebo, 
in conjunction with a nutritional and physical activity program. 315  Hypothalamic serotonin 
receptor agonism results in appetite suppression, whilst the specificity of Lorcaserin for the 2C 
receptor subtype, as opposed to the 2B receptor located on cardiac valvular tissue, reduces the 
risk of valvulopathy, seen with the now withdrawn non-specific 5-HT agonists Fenfluramine and 
Dexflenfluramine.  Subjects randomised to Lorcaserin 10mg BD achieved a modest mean PSWL 
of -2.9kg, whilst Lorcaserin 10mg OD resulted in PSWL of -1.8kg.  Additionally, whilst a number 
of cardiovascular or lipid parameters were beneficially effected to a statistically significant 
degree in those on Lorcaserin, the clinical significance of these relatively small effects is 
debatable.316   Furthermore, the concern regarding valvular disease has not definitively been 
dismissed, and further study will be required to provide reassurance that the long term use of 
Lorcaserin is safe, especially in patients with pre-existing valvular dysfunction. 
 
Numerous other agents are at various stages of development.  A combination of Naltrexone, 
an opiate receptor antagonist used primarily for the treatment of opioid addiction and 
alcoholism, and  Buproprion, a dopamine and noradrenaline reuptake inhibitor used 
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individually for the treatment of depression and smoking cessation respectively, has shown 
promise as an anti-obesity agent.  A phase 3 randomised study of Naltrexone/Buproprion slow 
release 32/360mg versus placebo, in conjunction with lifestyle changes, demonstrated a PSWL 
of -2.9% in an intention to treat analysis.317  The FDA declined an application to approve this 
preparation in 2011 due to concerns about the longer-term cardiovascular safety profile of 
Naltrexone in particular.   
Developed primarily as anti-diabetic agents, the GLP-1 receptor agonists have shown promise 
as weight loss agents.  GLP-1 acts centrally to increase satiety, and also delays gastric emptying 
further reducing appetite.  A meta-analysis of nearly 3400 subjects enrolled in 21 studies, 
demonstrated a PSWL of -2.9kg (CI -3.6 to -2.2), although the majority of these studies focused 
on obese patients with type 2 diabetes. 318   When placebo controlled trials alone were 
considered (10 trials), the PSWL was a more modest -1.9kg (-2.9 to -0.9). However, lingering 
concerns as to an association between pharmaceutical GLP-1 exposure and pancreatitis, 
pancreatic tumour development, and medullary thyroid cancer means that further long term 
studies are required before these drugs can be recommended as anti-obesity agents.  
Rimonabant, an endocannabinoid receptor antagonist, resulted in a mean of 4.7 kg PSWL in 
four randomised controlled trials, but significant concerns as to the psychiatric side effects have 
resulted in the withdrawal of this drug.86,319 
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Table 1-2  Overview of drug options in the management of obesity 







120mg up to 
TDS 
Lipase inhibitor 2.8 Oily stool, flatulence, change in bowel habit Yes (NS) 2 
Phentermine 37.5mg OD 
Increased central 
noradrenaline activity 








Dry mouth, paraesthesia, constipation, respiratory 
infections 
No 
Lorcaserin 10mg OD/BD 
Hypothalamic Serotonin 
receptor agonism 












Nausea, constipation, headache No 




up to 1.8mg 
OD 
Increased central satiety/ 
Delayed gastric emptying 
1.9 Nausea, vomiting No 
 
PSWL = Placebo subtracted weight loss; TDS = Thrice daily; OD = Once daily; BD = Twice daily; S = Subsidised; NS = Not subsidised; 1= Expected weight loss expressed as placebo subtracted 
weight loss; 2 = Weight control in adults with initial BMI30kg/m2, in conjunction with low fat, calorie controlled diet; 3 = Available as a sustained release capsule (15-30mg daily) Short term 
adjunct to medical monitored comprehensive weight reduction regimen in obese patient (BMI30kg/m2); 4 = It should be noted that the duration of study for each of the listed medications 
differs significantly (see text and referenced studies for details.) 
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1.2.2 Type 2 diabetes 
Effective management of type 2 diabetes requires control of hyperglycaemia, as well as attention to 
microvascular and macrovascular risk factors through the management of blood pressure, 
dyslipidaemia, cardiovascular risk, and treatment of neuropathy.  In this section, only control of 
glycaemia is reviewed, but a more comprehensive review can be found elsewhere.320 
Lifestyle modification programs are effective in the prevention and management of type 2 diabetes 
and appear to have durable results.321  The Finish Diabetes Prevention Study (DPS) randomised 522 
overweight participants with impaired glucose tolerance to either individualised, supported intensive 
diet-exercise counselling (weight reduction goal of 5% of more, moderate physical activity for 30 
minutes daily) or a control group provided with verbal and written advice only.322  A 43% reduction in 
the relative risk of progression to type 2 diabetes was evident at a mean follow up of 7 years in the 
intensive therapy group.323  The US diabetes prevention study (DPS) randomised 3234 obese (mean 
BMI 34.0 kg/m2) individuals with impaired fasting and post prandial glucose tolerance to standard 
lifestyle recommendations plus Metformin 850mg twice daily, standard lifestyle recommendations 
plus placebo, or intensive lifestyle modifications.324  The intensive therapy targeted weight loss of 7% 
or more of baseline weight and 150 minutes or more of moderate intensity physical activity; 
individuals were supported by an individualised taught curriculum provided over 24 weeks, and 
subsequently attended consolidative group sessions.  At 2.8 years of follow up, the intensive 
treatment reduced the relative risk of type diabetes by 58% when compared to the standard/placebo 
group, whilst Metformin reduced the risk by 31%.  At a mean of 10 years of follow up the relative risks 
were 34% and 18% reduced respectively when compared to placebo, whilst additional work has 
confirmed the cost effectiveness of this approach.325,326 
 Once type 2 diabetes is established, the goal of management is to encourage “healthful eating 
patterns, emphasizing a variety of nutrient-dense foods in appropriate portion sizes…”.320  A number 
of large randomised controlled studies have explored the effectiveness of weight loss as treatment in 
type 2 diabetes.  Perhaps the most widely cited, the Look-AHEAD study recruited 5145 overweight 
individuals with type 2 diabetes and assigned participants to either an intensive lifestyle intervention 
(ILI, caloric restriction to achieve a minimum 7% reduction in body weight, portion controlled 
nutrition, and 175 minutes weekly of moderate physical activity) or diabetes support and education 
(DSE).327   ILI was supported through individual and group sessions at least every fortnight, whilst DSE 
participants attended 3 group sessions over the 12 month study period.  Participants in the ILI group 
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lost a mean of 8.6% of their baseline weight over 12 months, whilst mean HbA1c dropped by 10 
mmol/mol (56 to 46 mmol/mol), in comparison with weight loss of 0.7% and an HbA1c reduction of 
0.1 mmol/mol in the DSE group.  Additional studies have supported these findings, although it must 
be noted that an improvement in glycaemic control has not been reported in all weight loss studies in 
participants with type 2 diabetes, despite clear weight loss.328,329,330,331,332   Whilst caloric restriction is 
clearly required for weight loss, studies exploring the effect of varying macronutrient nutrition on type 
2 diabetes control have been inconclusive.250  However, the benefits of adjusting insulin therapy to 
ingested carbohydrate in type 1 diabetes are clearly documented., and the principles can be applied 
to those with type 2 diabetes using insulin.333,334 
Metformin reduces hepatic glucose production and to a lesser extent enhances peripheral glucose 
dispersal. 335  It is recommended as first line pharmacological therapy in combination with lifestyle 
modification for the treatment of type 2 diabetes by most guidelines (Figure 1-3).  Sulphonylurea 
medications increase glucose independent insulin secretion, by activating voltage dependent 
potassium channels on the beta cell membrane, thereby promoting depolarisation and insulin 
release.336  These two agents have been the cornerstone of the pharmacological management of type 
2 diabetes for over sixty years. Metformin and sulphonylureas reduce HbA1c values by approximately 
10 to 20 mmol/mol in treatment naïve individuals when compared with placebo, and are generally 
equivalent in head to head trials.337  However, sulphonylurea therapy is associated with weight gain 
and an increased risk of hypoglycaemia, whilst Metformin is weight neutral and does not 
independently promote hypoglycaemia. 338 , 339   Metformin is however associated with frequent 
gastrointestinal side effects and should be titrated from a low starting dose to reduce the risk of these 
limiting effects.340  Additionally, metformin promotes the accumulation of lactate through its hepatic 
actions, and can promote clinically significant lactic acidosis when lactate accumulation is favoured by 
other co-existent medical disorders (cardiac/renal failure).341,342 
The Thiazolidinediones (TZD) were the first class of medications developed specifically for the 
treatment of type 2 diabetes, but have fallen out of favour in recent years.343  They improve insulin 
sensitivity, thereby reducing hepatic glucose output and increasing peripheral glucose dispersal, by 
activating the peroxisome proliferator-activated receptor .344   Troglitazone (idiosyncratic hepatic 
injury) and Rosiglitazone (cardiac events) have since been withdrawn from the market because of 
associated severe side effects, although the FDA have recently reapproved the use of Rosiglitazone.   
Pioglitazone remains licensed in most countries.343  The effect on HbA1c reductions is generally 
equivalent to Metformin and sulphonylureas in placebo controlled and head to head studies.337  Like 
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Metformin, Pioglitazone does not increase the risk of hypoglycaemia, but may promote weight gain 
and fluid retention, which appears to increase the risk of heart failure in those with co-existent 
conditions promoting cardiac dysfunction.  Pioglitazone use is also associated with a reduction in bone 
mineral density and an increase in bone turnover markers, and an increase in the relative risk of hip 
and other fractures.345346,347 There is conflicting evidence as to whether pioglitazone use is associated 
with an increased risk of bladder cancer, although recent studies are reassuring. 348 , 349 ,350   Three 
additional agents that are not currently in widespread use are 
 
Figure 1-3   The current approach to the pharmacological management of hyperglycaemia in type 2 diabetes 













DPP-4-i, DPP-4 inhibitor; fxs, fractures; GI, gastrointestinal; GLP-1-RA, GLP-1 receptor agonist; GU, genitourinary; HF, heart failure; Hypo, 
hypoglycemia; SGLT2-i, SGLT2 inhibitor; SU, sulfonylurea. †Consider initial therapy at this stage when HbA1C is ≥9% (≥75 mmol/mol). 
‡Consider initial therapy at this stage when blood glucose is ≥300– 350 mg/dL (≥16.7–19.4 mmol/L) and/or HbA1c ≥10–12% (≥86–108 
mmol/mol), especially if patient is symptomatic or if catabolic features (weight loss, ketosis) are present, in which case basal insulin 1 
mealtime insulin is the preferred initial regimen. §Usually a basal insulin (e.g., NPH, glargine, detemir, degludec). 
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acarbose, colesevelam, and pramlintide.  Acarbose is a competitive inhibitor of alpha glucosidase, and 
enzyme present in the brush border of the small intestine that breaks down carbohydrates prior to 
absorption.352  Acarbose therefore reduces post prandial hyperglycaemia although the optimal effect 
is generally mild; most studies show an HbA1c reduction of 5 to 10 mmol/mol when compared against 
placebo.337  Furthermore, gastrointestinal side effects are common and include flatulence, abdominal 
discomfort, and altered bowel habit.  Colesevelam is a bile acid sequestrant and is a well established 
therapy for hyperlipidaemia.  The observation that treatment was associated with mild improvements 
in glycaemia lead to interest in its potential in type 2 diabetes.  Most studies suggest a reduction of 
approximately 5-10 mmol/mol following treatment, although gastrointestinal side effects are again 
limiting. 353   The mechanism of action remains unclear but a recent study suggested a more 
pronounced increase in circulating incretins and improved glucose disposal. 354   Pramlintide is a 
synthetic amylin analogue that represents an attractive method for treating hyperglycaemia but 
decreasing glucagon release (and therefore reducing hepatic glucose production), slowing gastric 
emptying, and decreasing food intake.355  However, the reduction in HbA1c and weight has been 
modest in randomised controlled trials (approximately 5 mmol/mol) in participants with type 2 
diabetes, and currently pramlintide is more frequently used in the management of type 1 
diabetes.356,357   
Sodium glucose cotransporter 2 inhibitors (SGLT2) are the most recent addition to the options for 
managing hyperglycaemia in type 2 diabetes.358  These agents increase urinary glucose excretion by 
inhibiting the SGLT2 in the proximal nephron; a reduction in HbA1c of approximately 5-10 mmol/mol 
has been reported in most studies, and appears similar to other standard available oral agents.359,360  
In addition, use of these agents is associated with small reductions in both weight (approximately 2kg) 
and systolic/diastolic blood pressure, and have a similarly low incidence of hypoglycaemia to 
metformin monotherapy.359  Volume depletion predictably may occur and can be clinically relevant in 
those patients using anti-hypertensive diuretic therapy.  An increase in urinary tract infections, 
including thrush, is apparent but not limiting in most studies.359  Whilst diabetes ketoacidosis has been 
reported as a possible complication in patients with type 2 diabetes treated with SGLT2 therapy, the 
incidence is not clearly different from that observed in observational studies involving patients with 
type 2 diabetes from the general population, and it is unclear whether these patients were insulin 
deficient.361,362 Conflicting data on the effect of SGLT2 therapy on bone turnover has been published, 
although most studies have shown no changes.363   Whilst short term studies have not shown a 
difference in fracture risk, longer term observation is required to allay this concern.364 
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Pharmaceutical manipulation of the incretin endocrine system has proved to be a highly valuable 
addition to the treatment armoury for the type 2 diabetes.  Two broad classes of agents exist; 
dipeptidyl peptidase 4 inhibitors (DPP4-I) and injectable GLP-1 receptor agonists.   DPP4 cleaves GLP-
1 to functionally inactive peptides, and therefore inhibition of this enzyme increase the duration of 
action of endogenous GLP-1.365  A number of oral DPP4-I are now available and in widespread use.   
The effect on HbA1c is modest with most studies demonstrating a reduction of approximately 5 
mmol/mol when used as monotherapy, and results in less of an additional reduction in HbA1c when 
used a second line treatment.365,366  However, as the glucose lowering effect is glucose dependent, 
DPP4-I have an incidence of hypoglycaemia similar to placebo, and are generally weight neutral.367 
DPP4-I appear not to impact on cardiovascular outcomes directly, with neither favourable or harmful 
effects evident in large randomised trials. 368 , 369    GLP-1 receptor agonists are administered 
subcutaneously and exert their favourable glycaemic effects by increasing insulin secretion in a 
glucose dependent manner, reducing glucagon secretion (thereby reducing hepatic glucose 
production), slowing gastric emptying, and increasing satiety. 370   A reduction in HbA1c of 5-20 
mmol/mol has been demonstrated in most randomised studies, as well as modest weight loss of 2-4 
kg.371  Like DPP4-I, GLP-1 receptor agonists are not associated with a significantly increased risk of 
hypoglycaemia but can cause nausea and vomiting.  Concern that GLP-1 receptor agonists may 
increase the risk of pancreatitis is not supported by recent meta-analyses, although longer observation 
is required.372 
Whilst progressive beta cell dysfunction is characteristic of type 2 diabetes, most patients retain some 
endogenous insulin production even many years after diagnosis.  Therefore, insulin therapy in type 2 
diabetes is predominantly aimed at controlling hyperglycaemia rather than the more complex 
treatment regimens required in type 1 diabetes where additional consequences of insulinopenia need 
consideration.  The majority of patients with type 2 diabetes requiring insulin therapy are commenced 
initially on basal treatment with either an intermediate or long acting insulin at a dose of 0.1 to 0.2 
units per kilogram of body weight per day.351  Basal insulin as the initial regimen has merit as it provides 
less complexity than prandial insulin, and predominantly effects fasting hyperglycaemia which is a 
frequent feature at this stage of diabetes management.  Prandial insulin can be added if significant 
post meal glucose excursions are evident despite optimal basal dosing.  Recent studies however have 
suggested that the addition of a GLP-1 receptor agonist as opposed to prandial insulin, in those with 
suboptimal glycaemia control on basal insulin, may be preferable, and is associated with improved 
glycaemic control, weight loss, and less frequent hypoglycaemia.373,374  Whilst a basal-bolus approach 
(basal insulin plus separate injections of rapid acting insulin with each mean) best mimics endogenous 
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physiology, mixed insulin preparations are available for situations where basal-bolus treatment is less 
ideal.375   
 
1.2.3 Summary 
Obesity and type 2 diabetes are increasingly prevalent conditions that frequently co-exist in 
individuals.  It is clear that the impact of each condition on health resources internationally and in New 
Zealand is significant, and will remain so unless effective strategies to both prevent the development 
and manage the consequences of obesity and type 2 diabetes are developed. 
Current therapeutic options for both conditions are limited, and generally control rather than cure.  
Studies exploring the role of lifestyle and pharmacological interventions for obesity and type 2 
diabetes illustrate this, with only very infrequent participants with established disease attaining a 
normal BMI or glycaemic status following the intervention. 
There is therefore a clear need to explore other therapeutic options that ideally address the unifying 
pathophysiological factors underlying the development of obesity and type 2 diabetes, likely in 
combination with current approaches.  Furthermore, interventional strategies would need to be 
durable and cost effective to justify intervention in large numbers of a population.  In the next section, 
I will explore the role of bariatric surgery under these circumstances. 
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1.3 Bariatric surgery for the management of obesity and type 2 
diabetes 
  
1.3.1 Evolution of bariatric surgery  
Population obesity, to the extent that medical interventions are a necessity, is very much a recent 
phenomenon, and the history of surgery intended to induce weight loss extends back only over the 
past one hundred years.  At the turn of the 20th century, jaw wiring was occasionally performed with 
this intent, but was frequently unsuccessful not least because recipients could still consume calorie 
rich liquid meals if they wished. 376   Consequent poor dental hygiene, emesis with an increased 
frequency of aspiration, and the clearly undesirable cosmetic effects rendered this procedure 
obsolete by 1950. 
The concept of gastric/intestinal surgery to induce weight loss was first proposed by Kremen in the 
early 1950’s, following the observation that resection of a measured segment of the dog intestine 
resulted in weight loss and fat malabsorption despite maintenance of caloric intake.377  The first such 
procedures in humans were performed in 1953 by Victor Henricksson (Sweden) and Richard Varco 
(USA), and further refined by Payne (USA) in 1963.384,378  Paynes’ initial procedure (jejunocolic bypass) 
involved transecting the jejunum and anastomosing the proximal segment directly to the transverse 
colon.  Thus, ingested food was diverted from the majority of the small intestine and the proximal 
segment of the colon. The jejeunuileal bypass (JIB) was developed as an alternative by the other 
proponents and subsequently adopted by Paynes.  Unsurprisingly the procedure resulted in significant 
complications as a result of fat malabsorption, malnutrition, electrolyte disturbances, and hepatic 
dysfunction and the procedure was abandoned. 379 , 380  However, the majority of recipients lost 
significant amounts of weight within the first few months after surgery, and the principle of a surgical 
treatment to correct obesity was born.   
Around this time, other surgeons noted that patients undergoing gastrectomy for indications other 
than obesity (ulceration, etc.) lost weight and maintained this weight loss.  In 1967, Mason described 
the earliest gastric bypass procedure whereby the stomach was divided into two segments using a 
staple line, and attaching the proximal gastric segment to the jejunum.381  Early weight loss was again   
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evident but was associated with severe dumping syndrome, marginal ulcers, malabsorption, and 
anatomical defects including staple failure.  The procedure underwent a number of modifications until 
a variation of a Roux-en-Y bypass was generally preferred (Figure 1-4). This procedure involves the 
formation of a small pouch (<30cc in volume) from the proximal gastric segment, and transection of 
the jejunum approximately 70cm from the pyloric sphincter.  The distal jejunum (Roux limb) is then 
anastomosed to the gastric pouch, whilst an entero-entero anastomosis is fashioned between the 
blind proximal loop and the distal small intestine.  A number of bariatric surgeons including Torres, 
Chapter 1: Literature review 
49 
 
Linner, and Alden have had significant input into the development of gastric bypass, but Mathias Fobi 
from California is perhaps the procedures most widely recognised proponent. 383 , 384  Indeed, he 
described the Fobi pouch whereby a silastic ring or band is placed slightly proximal to the gastrojejunal 
anastomosis and prevents stoma dilatation which had limited earlier surgical techniques. 385   Fobi 
further described transection of the stomach so that the blind loop is entirely isolated from the 
fashioned pouch.  This procedure, performed either in an open or laparoscopic manner, is now the 
most widely performed variation of the gastric bypass. 
The biliopancreatic diversion (BPD) procedure (Figure 1-4) developed as a modification of the JIB and 
was first performed by Scopinaro (Italy) in 1979.386  The procedure results in the fashioning of a small 
horizontal gastric pouch with removal of the remaining gastric tissue, and the formation of a 
gastroenterotomy.  The blind duodenal stump is closed, and the remaining proximal intestine is 
connected back to the distal ileum.  Whilst weight loss is often greater following this procedure than 
others, it is performed only in a small number of centres due to significant side effects, particularly 
frequent and voluminous stools.384 
The two remaining widely performed bariatric procedures were developed purely to induce 
restriction.  Gastric banding (GB), developed in the early 1980s, involves the placement of tight plastic 
band around the upper stomach, so that a pouch is fashioned.387  An adjustable band is inserted 
laparoscopically with modern surgery, and whilst band failure and weight regain were legitimate 
concerns early on, proponents point to the lower operative risks and hospital stays. 388 , 389  
Furthermore, the lack of a malabsorptive component and the easy reversibility are favourable.  Sleeve 
gastrectomy (SG) is the modern variation of the now seldom performed vertical banded gastroplasty 
(VBG).390 Whilst initially considered a restrictive procedure, there is considerable evidence to suggest 
that the mechanism of action extends beyond this.  Indeed, in terms of induced physiological changes, 
SG shares more in common with RYGB than LAGB (see 1.4). 391  The procedure involves significantly 
reducing the volume of the stomach by resecting the outer curvature leaving a tube like remnant from 
the gastroesophageal sphincter to the pyloric sphincter.  Whilst developed as a restrictive procedure, 
many studies have since demonstrated therapeutic effects unexplained simply by restriction. 
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1.3.2 Impact of bariatric surgery on weight outcomes 
Hundreds of studies of varying quality have reported on weight outcomes following bariatric surgery.  
In this section I will present only outcomes from randomised controlled trials including more than 20 
participants where a bariatric procedure was compared against a non-surgical obesity therapy, and 
reported weight changes as a primary or secondary outcome.  In addition, studies are separated by 
BMI inclusion thresholds at baseline. Firstly, I have presented only the studies that recruited 
participants with a body mass index of greater than or equal to 35 kg/m2, consistent with the majority 
of society statements recommending the indications for bariatric surgery in patients with type 2 
diabetes.392  Studies that included participants with a BMI of greater than or equal to 27 kg/m2 are 
reported separately.  It should be noted that weight outcomes are reported diversely within the 
bariatric literature.  Whilst many studies report weight loss as total body weight loss % (BWL%, see 
2.2.1), others instead report excess weight loss percentage (EWBL%).  Excess weight is calculated as 
the total body weight minus the ideal body weight, estimated from data compiled originally for 
medical insurance assessments.  The use of EWBL% almost always results in a greater value than 
BWL%, whilst use of differing ideal body weight estimates, medium frame versus maximum frame 
etc., results in significant variation in the use of EWBL%.393  Whilst EWBL% is considered by many to 
be more meaningful in a clinical sense, I have used BWL% where possible throughout this thesis to 
enable better comparison with the published literature.   
 
1.3.2.1 Studies reporting weight outcomes in those with a pre-surgery BMI of 35 kg/m2 
Only 4 randomised controlled trials reporting weight outcomes after bariatric surgery in those with a 
preoperative body mass index of greater than or equal to 35 kg/m2 were identified (Table 
1-3).394,395,396,397  Each had a duration of follow up of 12 to 24 months and showed a body weight loss 
of 27.8 to 33.6%.  In 2002 Mingrone et al reported weight outcomes in 79 participants randomised to 
BPD surgery or a lifestyle intervention, primarily consisting of a prescribed diet.394   BMI in those 
randomised to the surgical arm was 48.2 and 32.8 kg/m2 at baseline and 12 months respectively, 
equating to a body weight loss of 29.4%.  O’Brien and colleagues performed a randomised controlled 
trial of LAGB versus a lifestyle intervention in 50 adolescents (14 to 18 years of age); participants 
randomised to the surgical arm were also asked to maintain regular physical activity with 30 minutes 
moderate exercise daily.395  Mean BMI at baseline in the surgical group was 42.3 kg/m2 which had 
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fallen to 29.6 kg/m2 (28.3% body weight loss) after 24 months of follow up.  Interim weight outcomes 
were not reported.  Mingrone performed a second randomised controlled trial in 2012, recruiting 60 
participants between the ages of 30 and 60 with a history of type 2 diabetes of at least five years 
duration.396  Participants were randomised to either an intensive lifestyle/medical therapy, RYGB, or 
BPD.  The combined mean baseline BMI in the two surgical arms was 46.0 kg/m2 and 29.3 kg/m2 after 
two years of follow up, equating to a total body weight loss of 33.6%.  Again interim weight changes 
were not reported.  Finally, Dixon and colleagues reported weight loss of 27.8% at 24 months following 
AGB in 60 patients with recently diagnosed obstructive sleep apnoea.397 
 
 
1.3.2.2 Studies reporting weight outcomes in those with a pre-surgery BMI of ≥27 kg/m2 
A further six randomised controlled trials were identified when studies allowing recruitment of 
patients with a BMI of greater than or equal to 27kg/m2 were included (Table 1 4).397,398,399,400,401,402  
With the exception of the study by Schauer and colleagues, all studies defined a BMI of 30kg/m2 as 
the lower threshold for inclusion.  As with the above studies, each reported significant weight loss, 
although the final BMI and total body weight loss was lower in all studies than that seen in studies 
recruiting more obese patients (with the exception of the study by Mingrone et al395).  Two studies 
from the Melbourne obesity group both reported outcomes at 24 months in participants randomised 
to either LAGB or a lifestyle/medication program.397,398 Participants in the 2008 study all had 
established type 2 diabetes, although this was not a requirement for participation in the earlier 2006 
study.  Participants in both studies had lost a little over 20% of their body weight at final follow up.  
Ikramuddin and Liang both performed studies of RYGB in participants with established type 2 
diabetes.399,400  Follow up was conducted over a 12 month period, and whilst each study controlled 
against a lifestyle intervention, an additional arm in the Liang study employed the lifestyle intervention 
with the addition of the GLP-1 mimetic Exenatide.  Liang also recruited only those with established 
hypertension.  Participants in both surgical groups lost significantly greater body weight than any 
control group, with 21.8% body weight loss in the Ikramuddin study, and 24.5% body weight loss in 
the Liang study.  Schauer and Courcoulas both compared RYGB against SG (Schauer) or LAGB 
(Courcoulas) against a lifestyle intervention and both reported outcomes at 36 months.402,403  
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Table 1-3   Summary of studies reporting weight outcomes following bariatric surgery in those with a BMI of 35 kg/m2 at baseline 




Baseline Follow up 
Body weight loss 
(%) 
BMI (kg/m2) Weight (kg) BMI (kg/m2) Weight (kg) 
Mingrone394 BPD Lifestyle 12 48.2 133.9 32.8 94.5 29.4 
O’Brien395 LAGB Lifestyle 24 42.3 120.7 29.6 86.1 28.3 
Mingrone396 BPD/RYGB Lifestyle 24 46.0 133.9 29.3 86.9 33.6 
Dixon397 LAGB Lifestyle 24 46.3 134.9 36.6 107.0 27.8 
 
 
Table 1-4   Summary of additional studies reporting weight outcomes following bariatric surgery in those with a BMI of 27 kg/m2 at baseline 




Baseline Follow up 
Body weight loss 
(%) 
BMI (kg/m2) Weight (kg) BMI (kg/m2) Weight (kg) 
O’Brien398 LAGB Lifestyle 24 33.7 96.1 26.4 74.5 21.6 
Dixon399 LAGB Lifestyle 24 36.9 105.6 29.5 84.6 21.1 
Ikramuddin400 RYGB Lifestyle 12 34.9 98.8 25.8 73.0 21.8 
Liang401 RYGB Lifestyle 12 30.5 82.0 24.5 70.0 24.5 
Schauer402 RYGB/SG Lifestyle 36 36.6 103.8 28.9 80.0 22.8 
Courcoulas403 RYGB/LAGB Lifestyle 36 35.6 100.0 28.7 80.0 20.0 
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All participants in each study had type 2 diabetes and were a similar mean BMI and age at baseline.  
All participants in surgical arms in both studies lost significantly more weight than those in the lifestyle 
arms.  It is interesting to note however, that those who underwent RYGB lost significantly more weight 
than those who had undergone SG or LAGB.  Body weight loss after RYGB in the Schauer study was 
26.2% and 21.3% after SG (p=0.02), whilst body weight loss after RYGB and LAGB in the Courcoulas 
study was 25% and 15% respectively.  Furthermore, interim weight analysis in the Schauer study 
suggested gradual weight regain after initial weight loss in those who had undergone SG, which was 
not observed in the RYGB arm. 
 
1.3.2.3 Summary 
There is therefore good evidence from randomised controlled trials to support the efficacy of bariatric 
surgery as a short to medium term weight loss intervention when compared against optimal lifestyle 
modifications.  Longer follow up studies are required to confirm durability, with no high quality study 
yet published reporting outcomes beyond 36 months. 
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1.3.3 Impact of bariatric surgery on type 2 diabetes related glycaemia 
 
1.3.3.1 Glycaemic outcomes following bariatric surgery 
Whilst primarily developed as an intervention for weight loss, early pioneers of bariatric surgery 
recognised the early and sustained glycaemic benefits that those with pre-operative type 2 diabetes 
appeared to gain from surgery.404   The publication of an increasing number of studies reporting 
superior outcomes in those undergoing surgery in comparison to those optimising lifestyle and 
medical strategies only has confirmed the value of bariatric surgery in the treatment armoury for type 
2 diabetes.  Thus, in 2011, the International Diabetes Federation published a position statement on 
the position of bariatric surgery in the treatment armoury for type 2 diabetes, and concluded by 
acknowledging that bariatric surgery should be considered earlier in the management of obese 
persons with type 2 diabetes.405    In this chapter, a number of recent studies that have contributed to 
this opinion are presented. 
The published literature on diabetes outcomes following bariatric surgery is extensive, and the quality 
of study methodology is variable.  For the purposes of this chapter, a literature search was performed 
to capture all studies published up to 2015.  Studies of bariatric surgery versus a non-surgical group 
or alternative bariatric procedures, and reported glycaemic outcomes at least 12 months following 
surgery were selected for inclusion.  The design of each of these studies varies, and the list includes 
prospective randomised controlled studies, and prospective and retrospective case controlled studies.   
Additionally, a number of meta-analyses including data from smaller, uncontrolled studies are 
discussed.  A summary of the included studies is presented below (Table 1-5). 
 
1.3.3.2 Definition of diabetes outcome 
A number of terms intended to represent varying degrees of diabetes improvement are utilised within 
the bariatric surgery literature.   The conflict that may arise through the use of significantly different 
biochemical thresholds for diabetes remission or control, is illustrated using our research population 
later in this thesis (see 3.2).   
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However, use of terms such as ‘cure’, ‘resolved’ or ‘remission’ in this context is controversial for a 
number of reasons.  Firstly, the diagnosis of diabetes itself is not dichotomous; rather thresholds of 
glycaemia have been defined on the basis of the associated risk of micro and macro vascular 
complications.  It is not yet known whether these thresholds remain true in a post-bariatric surgery 
population, and consequently diagnostic criteria validated for a non-surgical population may be 
misleading when applied to those who have undergone bariatric surgery.  Secondly, the concept of 
“glycaemic memory” is well established, and relates to the latent effect that glycaemic control may 
have on improved outcomes later life, irrespective of changes in glycaemic control in the intervening 
period.406   The UKPDS trial illustrated this concept most vividly; participants randomised to the 
intensive treatment arm of the study predictably had significantly improved glycaemic control during 
the study period in comparison to those receiving standard treatment.407   Glycaemic control (as 
measured using HbA1c) deteriorated in the intensive arm following study completion, such that 
HbA1c concentrations became comparable between the two groups within 12 months.  At study end, 
and for the first years thereafter, cardiovascular mortality rates were not different between the two 
groups.  However, those who had been randomised to the intensive therapy arm had significantly 
lower cardiovascular mortality rates when reassessed 10 years later, suggesting that the period of 
improved glycaemic control during the study period had reduced the risk (albeit latently) of 
cardiovascular disease.  While improvements in cardiovascular disease after bariatric surgery has also 
been reported, it is not known what proportion of this improvement may be attributed to glycaemic 
improvement versus the combination with improvements in other cardiovascular risk factors such as 
hypertension and dyslipidemia.428  Conversely, whether the risk of microvascular and macro vascular 
disease among those who have achieved sustained normoglycaemia after bariatric surgery ever 
returns to the level seen among those without previous diabetes remains to be seen. Furthermore, 
progressive decline (albeit potentially reversible) in pancreatic beta cell function over time is 
characteristic of type 2 diabetes and it is unknown whether bariatric surgery alters this process.  Hence 
some of the heterogeneity in diabetes outcomes reported between studies may be due to the age 
and ethnicity of participants, the degree of obesity associated with diabetes, duration of diabetes, 
duration and extent of insulin therapy; each as potential markers of residual beta cell function.  
Thirdly, use of the term “cure” for a chronic disease mediated predominantly by lifestyle may not be 
helpful in encouraging longer term compliance to favourable dietary and exercise strategies.  
Regardless of these caveats, a better understanding of glycaemic outcomes following bariatric surgery 
is important for pre-operative patient counselling as to the likely glycaemic benefits from the 
procedure. 
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In the absence of definitive evidence addressing each of the issues above, the literature reporting 
diabetes outcomes following bariatric surgery is notable for the degree of variability with which 
diabetes remission is defined.  This is often confusing, and has possibly contributed to the delays seen 
for bariatric surgery to be accepted as an appropriate therapeutic option in the management of obese 
persons with type 2 diabetes.  An agreed set of definitions of diabetes outcomes would ideally be used 
when reporting on bariatric surgery outcomes, and thus the American Diabetes Association (ADA) 
released a consensus statement in 2009 providing recommendations on the definition of glycaemic 
outcomes post bariatric surgery. 408   This suggested the use of the terms “partial remission” 
(HbA1C<6.5% (47 mmol/L), fasting glucose 100-125 mg/dl (5.6 – 6.9 mmol/L)), and “complete 
remission” (HbA1c “in the normal range”, fasting glucose <100mg/dl (5.6 mmol/L)) provided that each 
of these assessments were persistent for at least 1 year duration, and in the absence of active 
pharmacologic therapy or ongoing procedures.  Additionally, the ADA defined prolonged remission as 
the thresholds required for satisfaction of complete remission, maintained for at least 5 years.  
Furthermore, comparison of bariatric surgery with non-surgical intensive medical management can 
only rely on achievement of similar glycaemic targets rather than diabetes remission as defined by 
achieving such glycaemic targets in the absence of glucose lowering therapy.  Indeed, the concept of 
a population glycaemic target is likely outdated.  The ACCORD study demonstrated an increased risk 
of mortality with intensive therapy compared against control, whilst other studies have demonstrated 
a U shaped curve when plotting HbA1c against mortality risk.409,410  This appears to be particularly 
relevant in those with established heart disease.  Thus, achieving an HbA1c specified by the above 
criteria may not be the target for an individual patient. 
 
1.3.3.3 Review of diabetes outcomes following bariatric procedures 
The literature reporting on diabetes outcomes following bariatric surgery is extensive and ranges from 
small case series through to high quality randomised controlled studies.  A number of meta-analyses 
have attempted to address this diversity of study quality, and some of these publications are discussed 
later in this chapter.  For the purposes of this chapter, only those studies that included a comparison 
or control group (either an alternative bariatric procedure or lifestyle/medical therapies) and reported 
on outcomes at 12 months or beyond are included.  A summary of the included studies is presented 
in Table 1-5 (page 73).  
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1.3.3.3.1 Studies reporting diabetes outcomes at 12 months 
Gastric bypass versus lifestyle/medical therapy 
3 studies were identified reporting diabetes outcomes at 12 months following gastric bypass. 
“Diabetes control” was achieved by 41-75% of those in the gastric bypass arm in these studies 
with the variability likely due to differences in the definitions utilised to define diabetes control 
and in the baseline characteristics of the participants in each study.411,412, 413     
 Hofso and colleagues performed a comparison study of gastric bypass versus a lifestyle based 
intervention in 146 morbidly obese adults (mean BMI 45.6 kg/m2) and reported outcomes at 
12 months.411 Ikramuddin and colleagues performed a 12 month randomised study of intensive 
medical management versus intensive medical management plus Roux-en-Y gastric bypass.412  
120 obese participants (BMI 30-39 kg/m2) with type 2 diabetes were recruited, and a primary 
composite outcome incorporating achievement of diabetes, blood pressure and lipid control 
targets was reported. Serrot and colleagues performed a retrospective case control study of 
obese (BMI 30-35 kg/m2) participants with type 2 diabetes who had undergone gastric bypass 
in their institution versus a control group (BMI matched persons with type 2 diabetes from a 
primary care database).413 
Considerable variability in study methodology and the tested intervention was evident. The 
study by Ikramuddin and colleagues defined only diabetes control and accepted a higher HbA1c 
threshold (<7.0% (53 mmol/mol)) than the other two studies; thus, this study reported the 
highest rates of diabetes control.  The studies by Hofso and Serrot both reported diabetes 
remission, requiring absence of glucose lowering medications) and control defined by a lower 
HbA1c threshold, but were confounded by a higher mean age of participant in the surgical arm 
(56 vs. 42 years), and a higher HbA1c at baseline (8.2 vs. 7.1% (66 vs. 54 mmol/mol). 
The control intervention employed in each study also differed considerably.  Hofso and 
colleagues offered an intensive lifestyle intervention; each participant in this arm was referred 
to a specialist inpatient weight loss centre and had four stays within the centre during the 12 
month study period.  Each admission was for between 1 and 4 weeks.  Participants received 
numerous interventions during each stay including input from a medical doctor, a nurse, a 
physiotherapist, and a specialist trained nurse.  Physical activity was increased, and all 
participants were provided with education on a healthy diet, which they were encouraged to 
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follow.  Group sessions focused on the psychosocial and emotional aspects of obesity and 
weight loss.   Weight loss drugs were not used.  Phone contact was maintained fortnightly while 
participants were away from the weight loss centre.  The lifestyle intervention offered by 
Ikramuddin and colleagues was less intensive and consisted of a reduced energy diet for all 
participants with the aim of weight loss in the order of 0.5 to 1 kilogram per week.  Increased 
physical activity was encouraged, and each participant had regular face to face contact with a 
study interventionist to discuss behavioural and social issues around weight loss.  Orlistat (and 
Sibutramine prior to withdrawal from the US market) were available for use by those in the 
lifestyle arm if agreed weight loss targets were not met.  The contemporary American Diabetes 
Association guidelines for the management of type 2 diabetes were followed for the medical 
management of each participant in the study.  
26% and 29% of participants in the Hofso study in the gastric bypass and lifestyle intervention 
arms respectively had type 2 diabetes at baseline.  Diabetes remission was defined as a fasting 
glucose <5.6 mmol/L, and a 2 hour glucose of <7.8 mmol/L post 75g oral glucose tolerance test, 
and an HbA1c of < 6.2% (44 mmol/mol) in the absence of glucose lowering therapy.  In addition, 
the study authors defined partial diabetes remission as glucose concentrations below the 
diagnostic thresholds at baseline (<7.0 and 11.1 mmol/L for fasting and 2 hour glucose 
respectively) and an HbA1c < 6.5% (47 mmol/mol) without the use of glucose lowering therapy.  
The overall diabetes remission rate by this criteria was significantly greater in the gastric bypass 
arm versus those in the lifestyle intervention arm (70 vs. 33%, OR 4.7 (1.2–18.4).  However, 
none of the participants in the lifestyle intervention arm achieved complete diabetes remission, 
whilst 11 out of the 14 participants (55% of those with type 2 diabetes at baseline) achieved 
complete diabetes remission at 12 months follow up.  75% of those randomised to gastric 
bypass in the Ikramuddin study achieved diabetes control (defined solely as an HbA1c of <7% 
(53 mmol/L)) at 12 months versus 32% of those randomised to intensive medical management 
only (OR, 6.0; 95% CI, 2.6-13.9).  Whilst the primary composite outcome was achieved in 49% 
(versus 19%) of those undergoing gastric bypass, there was no difference between the two arms 
when blood pressure and lipid outcomes were assessed as independent outcomes.  In the study 
by Serrot and colleagues, diabetes remission was defined as an HbA1c <5.7% (39 mmol/mol) in 
the absence of glucose lowering medications, whilst diabetes control was defined as an HbA1c 
<6.5% (47 mmol/mol) in the absence of glucose lowering medications.  At the 12 month follow 
up assessment 4/17 (24%) of surgical participants had achieved diabetes remission and a 
further 7 (41%) of participants had achieved diabetes control.  Classification outcomes in the 
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control group were not reported.  The mean HbA1c in those who had undergone surgery fell 
from a baseline level of 8.2% ((66 mmol/mol) ± 2.0%) to 6.1% ((43 mmol/mol) ± 2.7%), but did 
not change significantly in the control group ((7.0 (53 mmol/mol) ± 0.7% to 7.1 (54 mmol/mol) 
± 1.8%). 
 
Gastric bypass versus Sleeve gastrectomy 
Two randomised controlled studies and one prospective non-randomised study reported 
outcomes at 12 months following either gastric bypass or sleeve gastrectomy, with two of these 
studies including a lifestyle/medical arm.414,415,416  In addition, a further randomised controlled 
study primarily reporting on 24 month outcomes, presented 12 month outcomes.420 Lee and 
colleagues reported 12 month diabetes outcomes following randomisation to gastric bypass or 
sleeve gastrectomy in 60 overweight (BMI 25-35 kg/m2) Taiwanese participants with sub-
optimally controlled type 2 diabetes.414 Schauer and colleagues reported on diabetes outcomes 
of overweight and obese American participants (BMI 27-43 kg/m2) and type 2 diabetes at 12 
months of follow up.415 150 participants were recruited and randomised in equal numbers to 
one of three interventional arms (intensive medical therapy, gastric bypass plus intensive 
medical management, and sleeve gastrectomy plus intensive medical management). Vidal and 
colleagues performed a non-randomised prospective study comparing outcomes of severely 
obese (BMI >35kg/m2) participants with type 2 diabetes (n=91) who underwent either gastric 
bypass (n=52) or laparoscopic sleeve gastrectomy (n=39). 416  The groups were matched at 
baseline for duration, control, and treatment of diabetes. 
Again, the studies were significantly different from one another.  Lee defined diabetes 
remission as a fasting glucose of <126 mg/dl (7.0 mmol/L) and HbA1c of <6.5% (47 mmol/mol) 
and the absence of diabetes medications.  Participants were assessed by an extensive 
multidisciplinary team prior to surgery but the study does not report on medical interventions 
used in the post-operative period.   93% of those randomised to gastric bypass achieved 
diabetes remission at 12 months versus 47% of those who had undergone sleeve gastrectomy.  
Schauer defined diabetes control/remission as an HbA1c <42 mmol/mol with or without the 
use of diabetes medications, which was achieved by 12% of those randomised to medical 
therapy only, 42% of those randomised to the gastric bypass arm, and 37% of those randomised 
to the sleeve gastrectomy arm.  The definition of diabetes remission utilised for this study was 
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clearly limited by the acceptance of an HbA1c < 42 mmol/mol as evidence for remission even 
in the context of ongoing diabetes medication use.  It could be argued that those who required 
ongoing glucose lowering therapy should be defined as being, at best, partial responders.  
However, all of those in the gastric bypass arm who achieved diabetes remission did so without 
the ongoing use of diabetes medications, whilst 28% of those in the sleeve gastrectomy arm 
who were reported as achieving diabetes remission continued to require glucose lowering 
therapy; all of those in the medical management alone arm who achieved the primary endpoint 
remained on glucose lowering therapy. Lee defined diabetes remission as a fasting glucose <126 
mg/dl (7.0 mmol/L) and an HbA1c within the normal range (3.4-5.5% (14-37 mmol/mol)) in the 
absence of glucose lowering medications.  At 12 months following surgery diabetes remission 
had been achieved by 84.6% of those who had undergone gastric bypass and 84.6% of those 
who had undergone laparoscopic sleeve gastrectomy.  Interestingly, the study authors found 
no relationship between weight loss and diabetes remission, but did note a significant 
association between duration and severity, as defined by treatments required and HbA1c at 
baseline, of diabetes and diabetes remission. 
Whilst each study used stringent criteria for diabetes remission/control, it should be noted that 
participants in the study by Lee and colleagues demonstrating superior efficacy of GBP 
compared to SG, had a significantly lower BMI at baseline versus those in the studies by Schauer 
and Vidal which both showed similar efficacy of GBP compared to SG.  The apparent marked 
increase in surgical participants achieving diabetes remission in the study by Vidal 
(approximately 85%) when compared to those in the study by Schauer (approximately 40%) is 
of interest as, despite a similar age at surgery (mean approximately 48 years), participants in 
the Schauer study were not as super-obese, had a longer pre-operative duration of diabetes 
(approximately 8 years versus approximately 4 years) and a 4 fold higher pre-operative use of 
insulin (approximately 44% versus 10%), which may indicate less beta cell reserve. 
 
Biliopancreatic diversion versus lifestyle/medical therapy 
Scopinaro and colleagues performed a prospective, historical case controlled study of 
biliopancreatic diversion surgery versus medical management in overweight or obese persons 
(BMI 25-34.9 kg/m2) with type 2 diabetes. 417   Participants who underwent biliopancreatic 
diversion surgery had a mean age of 56 years and established diabetes, with a mean duration 
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of diabetes of 11 years, mean HbA1c at baseline of 78 mmol/mol, and 12/30 participants 
requiring insulin therapy at baseline).  The study authors defined three categories of diabetes 
outcomes; Diabetes remission was defined as a fasting glucose <126 mg/dl (7.0 mmol/L), and 
an HbA1c ≤6.0% (42 mmol/mol) without the use of glucose lowering medications; controlled 
diabetes was defined as an HbA1c ≤7.0% (53 mmol/mol) in the absence of glucose lowering 
medication; improved diabetes was defined as a >1% (10-11 mmol/mol) reduction in Hba1c 
concentrations when compared to baseline.  No participants in the historical control group 
achieved diabetes remission or diabetes control during one year of treatment (mean HbA1c at 
baseline = 8.8% (73 mmol/mol)).  Whilst two thirds of participants required an increase in their 
medication doses during this 12 month period, no participant was able to reduce medication 
doses.  In contrast, diabetes remission was achieved by 30% of those who had undergone 
biliopancreatic diversion, and diabetes control by a further 53% (83% total).  However, five 
participants (out of 12) who required insulin therapy at baseline remained on insulin therapy at 
12 months following biliopancreatic surgery. 
The relative low rate of diabetes remission following biliopancreatic diversion in this study, in 
contrast to very high rates more commonly reported following this procedure, may be 
explained by the baseline characteristics of the study cohort.  Specifically, this was an older 
cohort than other studies discussed above (mean age = 56.4 years), and participants had both 
a longer duration of diabetes (mean = 11.2 years) and a higher Hba1c (mean = 9.6% (81 
mmol/mol)) at baseline. 
 
1.3.3.3.2 Studies reporting on outcomes from 12 to 24 months 
Gastric bypass versus lifestyle/medical therapy 
Two studies of gastric bypass versus lifestyle medical therapy were identified that reported on 
outcomes at 24 months.418,422  A study by Adams and colleagues continued to follow up their 
cohort for a total of 72 months and is therefore discussed in the following section.  Leslie and 
colleagues performed a retrospective case control study of outcomes following gastric bypass 
versus medical managements for obese persons with type 2 diabetes.418  Rather than define 
diabetes outcomes using simply glycaemic markers, the study authors elected to use a 
composite end point of treatment goals as recommended by the American Diabetes Association 
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for the management of type 2 diabetes (HbA1c <7.0% (53 mmol/mol), low-density lipoprotein 
<100mg/dl, systolic blood pressure <130mmHg).  152 and 115 participants who had undergone 
gastric bypass or medical therapy alone respectively were included in the analysis.  The 
percentage of participants satisfying the ADA treatment goals who had undergone gastric 
bypass was 10.5% at baseline, increasing to 38.2% at 24 months follow up.  A smaller, non-
significant increase was noted in the medical therapy group from 13.9% at baseline versus 
17.4% at 24 months. 
 
Laparoscopic adjustable gastric band versus lifestyle/medical therapy 
One study was identified that reported on diabetes outcomes 24 months following laparoscopic 
adjustable gastric banding.  Dixon and colleagues reported diabetes outcomes at 24 months on 
60 obese participants (BMI 30-40 kg/m2, age range 20-60 years) with type 2 diabetes 
randomised to either laparoscopic adjustable gastric banding or an intensive lifestyle program 
without the use of bariatric surgery. 419   The lifestyle program was comprehensive and 
administered via a multidisciplinary team consisting of a physician, dietitian, and diabetes nurse 
via face to face meetings at 6 week intervals.  A low energy diet with reduced saturated fats 
was prescribed along with increased exercise activity; very low calorie diets and/or weight loss 
pharmaceutical agents were also available for use.  Diabetes remission was defined as a fasting 
glucose level of <126 mg/dl (7.0 mmol/L) and an Hba1c <6.2% (44 mmol/mol) in the absence of 
glucose lowering therapy.  This was achieved by 73% of those who in the laparoscopic 
adjustable gastric band arm versus 11-23% in the control arm.  This is based on the assumption 
that diabetes remission was (23%) or was not (11%) achieved by 4 participants randomised to 
the lifestyle arm who did not complete the study.  Furthermore, improvement in diabetes 
control was evident in those who underwent gastric banding with 26/30 participants not 
requiring glucose lowering therapy at study end versus 2 at baseline. 
The percentage of participants who achieved diabetes remission in the surgical arm of this study 
was high, and particularly notable given that the mean age at which participants underwent 
surgery (46.6 years), the mean HbA1c at baseline (7.8% (62 mmol/mol)), and a mean BMI at 
surgery (37.0 kg/m2) was comparable to baseline characteristics of cohorts in other studies 
discussed in this chapter following gastric bypass or biliopancreatic diversion surgery.  However, 
only one participant in the surgical group used insulin therapy at baseline, and although 
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duration of diabetes at surgery was not reported, the exclusion of participants with evidence of 
microvascular complications (retinopathy, nephropathy) is likely to result in the selection of 
those with a more recent diagnosis of diabetes, and therefore an increased likelihood of 
residual preserved beta cell function. 
 
Bariatric surgery versus lifestyle/medical therapy 
Three studies were identified that reported on outcomes in studies incorporating two or more 
bariatric surgery modalities.420,421,428  The Swedish Obesity Study (SOS) reported on outcomes 
at 24 months in addition to those at 120 months and is thus discussed in the section below.  
The studies by Kashyap and Mingrone both included a gastric bypass arm but reported markedly 
different diabetes outcomes at 24 months (33 versus 75% respectively). Kashyap and colleagues 
undertook a prospective randomised study of optimal medical therapy versus either gastric 
bypass or sleeve gastrectomy in 60 moderately obese (mean BMI =36.1 kg/m2) participants with 
type 2 diabetes at baseline.420 Mingrone and colleagues performed a single centre randomised 
controlled study of gastric bypass versus biliopancreatic diversion versus medical/lifestyle 
therapy only.421 
All patients in the study by Kashyap et al received intensive medical therapy as recommended 
by the American Diabetes Association, including dietary modifications, increased frequency of 
capillary glucose measurements, and the use of all available glucose lowering agents.  In 
addition, each participant received nutritional counselling by a study dietitian and underwent a 
psychological assessment, in part to assess suitability for bariatric surgeon.  Participants were 
then randomly allocated to either ongoing medical therapy alone, gastric bypass surgery, or 
sleeve gastrectomy. In the Mingrone study, 60 participants (age 30-60, BMI >35 kg/m2) were 
recruited, each of whom had had type 2 diabetes for at least 5 years and had a current HbA1c 
of >7.0% (53 mmol/mol).  Each participant had visits with a multidisciplinary team (including a 
diabetologist, dietitian, and study nurse) at baseline and then 1, 3, 6, 9, 12 and 24 months 
following commencement of the intervention.   Dietary and physical activity advice was 
provided to those in the medical arm.  The dietary prescription comprised <30% total fat, <10% 
saturated fat, and high fibre content, with ≥30 minutes of brisk walking every day.  Diabetes 
medications were adjusted based on regular HbA1c measurements.   
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The authors used significantly different definitions of diabetes outcomes that could potentially 
result in discordant outcomes.  Diabetes remission was defined by Kashyap as an HbA1c of less 
than 42 mmol/mol (6.0%).  44% and 26% of those who had undergone gastric bypass and sleeve 
gastrectomy respectively had an HbA1c of <6.0% (42 mmol/mol) at 12 months follow up, 
compared with 6% of those who had received medical therapy alone.  However, a reduction in 
the number of participants satisfying criteria for diabetes control at 24 months was evident (33, 
11, and 6% for gastric bypass, sleeve gastrectomy, and medical therapy respectively). In keeping 
with the definition suggested by the American Diabetes Association, Mingrone defined diabetes 
remission was defined as a fasting plasma glucose level < 100 mg/dl (5.6 mmol/L) and an HbA1c 
level < 6.5% (48 mmol/mol) for at least 1 year without active pharmacologic therapy.  Diabetes 
remission was achieved by 95% of those in the biliopancreatic diversion arm, 75% of those in 
the gastric bypass arm, and none of those in the medical arm.  Biliopancreatic diversion and 
gastric bypass were associated with a likelihood of diabetes remission of at least 9.5 (95% CI, 
2.54 to 35.51; P<0.001) and 7.5 (95% CI 1.97 to 28.61; P<0.001) respectively when compared 
with medical therapy alone.  Two participants randomised to the medical therapy arm of the 
study did not complete the 24 months of follow up, and for the purposes of calculating 
remission odds ratios the authors chose to conservatively assume that both of these 
participants had achieved diabetes remission. 
Thus, whilst Mingrone utilised seemingly more stringent criteria for resolution including a 
fasting glucose and HbA1c threshold, and the absence of glucose lowering medication, It should 
be noted though that this study accepted an HbA1c of <6.5% (48 mmol/mol) as evidence of 
diabetes remission. However, allowing for this difference does not explain the discordancy 
between these studies which is also not easily explained by differing baseline characteristics; 
whilst the two cohorts undergoing gastric bypass were of similar ages at operation (mean = 47.9 
years and 43.9 years for the Kashyap and Mingrone studies respectively), and had a similar 
duration and control of diabetes at baseline (7.4/6.0 years, 9.0%(75 mmol/mol)/8.5%(69 
mmol/mol) respectively), participants in the Mingrone study had a significantly higher BMI (44.6 
versus 36.1 kg/m2).  Additionally, differences in the medical/lifestyle program utilised in each 
study (prescribed for those in the surgical arms alongside surgery) do not appear likely to be a 
factor in this anomaly, as none of the medical/lifestyle arm of the Mingrone study achieved 
diabetes remission, in comparison to 6% of participants in the equivalent arm of the Kashyap 
study. 
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As noted earlier, the 95% diabetes remission rate in the biliopancreatic diversion arm of the 
above study by Mingrone and colleagues is significantly higher than the 30% at 12 months seen 
in the study by Scopinaro discussed in the section above.  Again, this is likely to be explained by 
the older age at surgery, and longer duration of diabetes of participants in the Scopinaro study. 
 
1.3.3.3.3 Studies reporting on outcomes beyond 2 years 
Bariatric surgery versus lifestyle/medical therapy 
Two studies reporting on outcomes beyond two years, comparing bariatric surgery against non-
surgical interventions were identified.422,423 Adams and colleagues performed a prospective 
study recruiting obese adults (BMI>35kg/m2) who underwent gastric bypass surgery over a 10 
year period (n=418). 422   Two control groups were included, the first of which included 
participants who had sought but not undergone gastric bypass surgery (n=417), and a second 
group comprised of obese adults selected from a regional registry (n=321). An explanation as 
to why each of the participants in the first control group had not undergone gastric bypass was 
not provided in the manuscript, which is an important omission as this likely adds significant 
selection bias.  Pontiroli and colleagues performed a prospective case controlled study of 
outcomes following laparoscopic adjustable gastric banding versus optimisation of lifestyle and 
medical therapies.423  The study investigators recruited 122 sequential patients (age range 18-
66) referred for the management of obesity, who met contemporary criteria for bariatric 
surgery (BMI > 40 kg/m2, or BMI > 35 kg/m2 in the presence of obesity related co-morbidities). 
The prevalence of diabetes within each group in the Adams study at baseline was not 
presented, although the mean HbA1c was 42 mmol/mol or less in each group.   Diabetes at 
baseline was defined as a fasting glucose of >126mg/dl (7.0 mmol/l), and/or an HbA1c of >6.5% 
(47 mmol/mol), and/or the use of glucose lowering medications, whilst remission of diabetes 
was defined as an Hba1c and fasting glucose within the normal reference range (absolute 
figures not provided) in the absence of ongoing glucose lowering therapy.  Using these 
definitions, diabetes remission was achieved by 75% (95% CI, 63%-87%) and 62% (95% CI, 49%-
75%) at 2 and 6 years post-surgery respectively in the gastric bypass group.  Diabetes remission 
rates at 6 years were significantly lower in those who had either sought gastric bypass but not 
undergone surgery (8%; 95%CI,0%-16%, OR, 16.5 versus gastric bypass) and population controls 
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(6%; 95% CI, 0%-13%, OR, 21.5).   The study authors also noted a significantly lower incidence 
of new diagnoses of diabetes during 6 year follow up in the gastric bypass group (2%; 95% CI, 
0%-4%) in comparison to those in the first control group (17%; 95% CI 10%-24%,  OR 0.11 
favouring gastric bypass; 95% CI 0.04- 0.34) and those in the population control group (15%; 
95% CI 9%- 21%, OR 0.21 favouring gastric bypass; 95% CI, 0.06-0.67). 
The absence or presence of type 2 diabetes was clarified in the Pontiroli study through an oral 
glucose tolerance test based on standard diagnostic criteria.  The participants were then 
followed within two intervention studies; the primary intervention study assessed the effect of 
laparoscopic adjustable gastric banding on the preventing progression from normal glucose 
tolerance or prediabetes to overt type 2 diabetes, whilst the secondary intervention study 
assessed the effect on only those with established type 2 diabetes.  Thus, 37 participants with 
established type 2 diabetes were enrolled in the secondary intervention section of the study.  
Each of these participants was offered laparoscopic adjustable gastric banding; 17 consented 
to surgery with the remainder wishing to utilise lifestyle/medical options.  The applied definition 
of diabetes remission was not specifically provided in the published manuscript, although it is 
implied that contemporary diagnostic criteria for the diagnosis of thresholds of dysglycaemia 
were utilised.  Thus, diabetes remission would be diagnosed on the basis of a fasting glucose 
level <6.1 mmol/L, and a 2 hour post glucose level of <7.8 mmol/L, presumably also in the 
absence of glucose lowering medications.  HbA1c measurements were recorded but are not 
specifically reported in the context of diabetes remission.  Using this definition, diabetes 
remission was achieved by 45% at four years by those who had undergone laparoscopic 
adjustable gastric banding, and 4% of those who had declined surgery.  Of note, none of those 
who had undergone laparoscopic adjustable gastric banding as a part of the primary prevention 
component of the study developed diabetes during the four years of follow up, whilst 17% of 
those who declined surgery did so. 
 
 
Studies comparing different forms of bariatric surgery 
Five studies meeting criteria have been published reporting outcomes of differing bariatric 
procedures beyond two years, some of which are extensions of previously reported 
cohorts.424,425,426,427,428  Iaconelli and colleagues performed a prospective case controlled study 
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of conventional lifestyle and medical therapy versus biliopancreatic diversion in obese 
participants with type 2 diabetes.424  Diabetes outcomes were reported at 10 years. The study 
team enrolled 110 obese participants with type 2 diabetes and initiated a three month run-in 
intervention comprising dietary optimisation.  At the end of the run-in period, participants who 
met the inclusion criteria for the study (age 25-60 years, BMI >35 kg/m2, and a residual diagnosis 
of type 2 diabetes on the basis of standard criteria, n=50) were offered either conventional 
lifestyle and medical therapy alone, or conventional therapy plus biliopancreatic diversion 
surgery (n=28 and 22 respectively).  The institutional ethics board declined an initial application 
to allow randomisation to each group, due to the long duration of planned follow up.  
Conventional therapy included dietary, exercise and medication optimisation as per current 
American Diabetes Association guidelines. The authors did not specify the definition used for 
diabetes remission in the study, although it is implied that diagnostic thresholds commonly used 
at the initiation of the study (fasting glucose >7.0 mmol/L (on 2 occasions) and/or a 2 hour 
glucose > 11.1 mmol/L following a 75g oral glucose tolerance test) were utilised to assess 
diabetes outcome. Allowing for these limitations, diabetes remission was achieved by 100% of 
participants at 12 months by those who had undergone biliopancreatic diversion surgery; the 
authors noted that none of these participants redeveloped diabetes during the remainder of 
follow up to 10 years.  The mean HbA1c at 10 years in the conventional treatment and 
biliopancreatic diversion surgery arms was 7.8% (62 mmol/mol) and 4.9% (30 mmol/mol) 
respectively.       
Pinheiro and colleagues performed a randomised study of two variations of Roux-en-Y gastric 
bypass in 105 participants with type 2 diabetes and severe obesity (BMI >50kg/m2).425  The 
diagnosis of diabetes and diabetes outcomes was defined on the basis of diagnostic thresholds.  
The primary intent of the study was to assess the varying effect of the resulting length of both 
the biliary and Roux limb of the gastric bypass.  In group 1, the biliary and Roux limbs were 50 
and 150 cm respectively, whilst in group 2 the biliary and Roux limbs were 100 and 250cm 
respectively, the so called long-long limb Roux-en-Y gastric bypass.  At 48 months follow up, 
diabetes control (glycaemic markers below diabetes diagnostic thresholds in the absence of 
glucose lowering medication) was achieved in 58% of those in group 1 and 93% of those in 
group 2.  A statistically higher proportion of participants in group 2 had improvement of 
dyslipidaemia, whilst there was no difference in the improvement in hypertension. 
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Pournaras et al performed a prospective comparison study of gastric bypass (n=22) versus 
gastric banding (n=12) in severely obese participants with type 2 diabetes.426  The study design 
allowed for an assessment of diabetes outcomes, along with exploration of the mechanism 
underlying the expected improvements in diabetes control.  The study investigators defined 
diabetes remission based on contemporary diagnostic thresholds; a fasting plasma glucose <7 
mmol/L in the absence of medical treatment for at least 3 days, and a 2-hour plasma glucose 
<11.1 mmol/L following an oral glucose tolerance test (OGTT).  In addition, an HbA1c <6.0% (42 
mmol/mol) after 3 months without the use of glucose lowering medication was required.  
Participants had established diabetes at baseline with a mean duration of diabetes of >5 years; 
55% of those who underwent gastric bypass and 30% of those who underwent gastric banding 
required insulin therapy prior to surgery.  68% of those in the gastric bypass arm had achieved 
diabetes remission at 12 months of follow up versus none in the gastric banding arm despite 
similar weight loss (20-25% body weight) at that assessment.  At 36 months follow up, the 
percentage of those in diabetes remission had increased to 72% and 17% for gastric bypass and 
gastric banding respectively. 
Following publication of diabetes outcome results after bariatric surgery at 12 months,8 Schauer 
and colleagues performed a further analysis of follow up outcomes at 36 months.427  137 (91%) 
of the original 150 randomised participants who had been randomised in equal numbers to 
intensive medical therapy, gastric bypass plus intensive medical therapy, and sleeve 
gastrectomy plus intensive medical therapy, were evaluated.  As in the original study, diabetes 
remission was defined as an HbA1c of <42 mmol/mol with or without the use of diabetes 
medications, and was achieved by 38% and 24% of those who had undergone gastric bypass 
and sleeve gastrectomy respectively, versus 5% of those randomised to intensive medical 
therapy alone.  Glycaemic relapse, defined as satisfying criteria for diabetes remission at 12 
months but not at 36 months, was seen in 80% of participants in the medical therapy group, 
24% of those who had undergone gastric bypass group, and 50% of those who had undergone 
sleeve gastrectomy.  Decrease in BMI following surgery (odds ratio, 1.33 for every 1 unit 
(mg/m2); 95% CI, 1.15 to 1.56; P<0.001) and the pre-surgical duration of type 2 diabetes 
(duration <8 versus >8 years; odds ratio, 3.3; 95% CI, 1.2 to 9.1; P = 0.02) were the only two 
predictors of diabetes outcome following either form of bariatric surgery.  
The Swedish Obese Subjects Study (SOS study) was a very large prospective non-randomised 
study performed in Sweden between 1987 and 2000. 428   Following a large scale national 
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recruitment drive, 4047 participants who met the study criteria (BMI >34 kg/m2 for men, BMI 
>38 kg/m2 for women, age 37-60 years) were recruited and offered either non-surgical or, if 
appropriate, surgical interventions.  Surgery was performed at 25 national centres and included 
gastric banding, sleeve gastrectomy, and gastric bypass.  Each participant who had chosen 
bariatric surgery was matched at the time of surgery to a participant who had elected medical 
therapy only, based on 18 variables including demographic, metabolic, psychosocial, and 
personality parameters.  Medical and lifestyle therapies were not standardised for this trial.  
The intervention for both the surgically treated participant, and their matched medical therapy 
only control, was considered to have commenced on the day of surgery.   
Outcomes following 10 years of follow up were reported in 2004 and included data on all 4047 
participants enrolled in the SOS study with at least 2 years of follow up data available, and 1703 
participants who had 10 years of follow up data available.  The study authors reported both 
diabetes incidence since baseline and diabetes outcomes.  The majority of enrolled participants 
did not have type 2 diabetes at baseline, although the study authors were still able to report on 
approximately 200 participants who did and had follow up data extending to 10 years.  The 
criteria used to define both disease and disease outcome were the same, and were reflective 
of contemporary diabetes diagnostic thresholds.  Thus, diabetes remission was defined as a 
fasting glucose of <7.0 mmol/L (126 mg/dl) in the absence of glucose lowering medications.   
590/4047 and 202/4047 participants had type 2 diabetes at baseline and 2 or 10 years of follow 
up data available respectively.  Of those with 2 years of follow up data, 246/342 (72%) of surgical 
participants and 52/248 (21%) of control participants had achieved diabetes remission (Odds 
ratio 8.42 95%CI 5.68-12.5).  Over the same period, 8% of control participants who did not have 
diabetes at baseline (n=1402) developed type 2 diabetes, compared to 1% of those who had 
undergone bariatric surgery (n=1489).  Of those with 10 years of follow up data, 42/118 (36%) 
of surgical participants and 11/84 (13%) of control subjects had achieved diabetes remission 
(Odds ratio 3.45 95%CI 1.64-7.28).  As expected the incidence of new diabetes in those who did 
not have type 2 diabetes at baseline, had increased further at 10 years such that 24% and 7% 
of control and surgical participants respectively had developed diabetes.           
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1.3.3.3.4 Meta-analyses of studies reporting on diabetes outcomes following bariatric surgery 
A large number of meta-analyses using a diverse range of selection criteria have been published.  The 
majority report on weight or short term outcomes only and are therefore beyond the scope of this 
chapter.  The reader is directed towards meta-analyses performed by Lai, Maggard-Gibbons, and Gloy 
and colleagues which all included either studies discussed in the paragraphs above, or studies 
reporting on diabetes outcomes <12 months following surgery. 429 , 430 , 431   In addition, Parikh and 
colleagues have recently published a meta-analysis of 39 studies reporting on diabetes outcomes in 
subjects with a BMI <35kg/m2.432 
The largest meta-analysis thus far published reporting outcomes of bariatric surgery (gastric banding, 
gastroplasty, RYGB and biliopancreatic diversion/duodenal switch (BD/DS)) included all studies 
published between 1990 and 2006, and updated a previous meta-analysis by the same group.433,434  
The meta-analysis included 621 studies, within which 103 arms specifically reported on diabetes 
outcomes (3188 subjects).  All study designs were included, with each study was assigned a level of 
evidence.  22.3% of the cohort (30,160/135,246 subjects) had pre-operative diabetes.  Weight loss 
across the whole cohort, expressed as excess body weight lost (EBWL%), was 48.98% for gastric 
banding, 56.48% for gastroplasty, 63.25% for RYGB, and 73.72% for BD/DS at ≥ 2 year follow up, 
although the majority of subjects remained obese (Mean pre-operative BMI 47.86, mean post-
operative BMI 33.89kg/m2).  Weight loss assessed at ≥ 2 years exceeded that reported at shorter post-
operative intervals for each modality.  Weight loss in patients with pre-operative diabetes was similar 
with 67.1 and 58.01% EBWL at <2 or ≥ 2 year follow up respectively when all surgical modalities were 
included (67.10 and 64.7% for RYGB specifically).  Sub group analysis of the subjects with diabetes 
included in the meta-analysis revealed that resolution of diabetes, defined as cessation of diabetes 
medications and either normal fasting glucose (<100 mg/dl (5.5 mmol/L)) or an HbA1c < 6% (42 
mmol/mol) across the whole cohort was 78.1% (80.27 and 74.59% at <2 and ≥ 2 year follow up 
respectively.  Resolution or improvement, defined as a reduction in number or dose of diabetes 
medications, or an improvement in fasting glucose to between 100-125 mg/dl (5.5 - 6.9 mmol/L), was 
seen in 86.61% (86.0 and 87.24% respectively).  Further assessment based on surgical procedure 
revealed that resolution of diabetes was seen in 56.73% (54.99 and 58.29% at <2 and ≥ 2 year follow 
up respectively) following gastric banding, 79.74% (81.44 and 77.46%) following gastroplasty, 80.28% 
(81.60 and 70.90%) following RYGB, and 95.05% (94.0 and 95.85%) following BD/DS.   
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In addition the authors performed a sub-analysis on 12 studies that included only subjects with 
diabetes (n=963) and reported overall resolution of diabetes in 79.29% (81.81 and 62.08%), and 
resolution or improvement in 98.91% (98.56 and 100%).  It should be noted however that data for ≥ 
2 year follow up in studies that recruited only those with diabetes included only 48 subjects (31 who 
underwent RYGB and 17 who underwent gastric banding).  Of those who underwent RYGB, 80.65% 
remained in remission from diabetes at ≥2 years whilst all patients had experienced at least 
improvement in glycaemic control.  Less impressively, only 41% (7/17 subjects) who had undergone 
gastric banding remained in remission from diabetes at 2 years.  Additionally, the definition of 
resolution or improvement of diabetes, or even the diagnosis of diabetes itself, varied significantly 
across the included studies.   Overt diabetes was generally defined as an HbA1c of > 53 mmol/mol 
(7%) whilst most international organisations that accept HbA1c as a diagnostic tool currently suggest 
cut off values of between 45 and 50 mmol/mol, with a lower range reflective of less severe 
abnormalities in glucose homeostasis. Secondly, resolution of diabetes was confirmed in some studies 
on the basis of a measured fasting glucose without the requirement of either further testing or 
perhaps more robust HbA1c assessments.  Improvements in diabetes control was also defined 
biochemically as a reduction of fasting glucose to between 5.5 -6.9 mmol/L irrespective of HbA1c.  As 
the rationale behind glucose lowering in patients with diabetes is to prevent longer term micro and 
macro vascular complications, and HbA1c correlates best with the risk of these complications 
irrespective of day to day fluctuations in plasma glucose measurements, this approach may incorrectly 
attribute improvement to an otherwise unaltered state.  The authors acknowledge that only 4.7% of 
the contributing studies were randomised controlled trials, and the level of evidence was generally 
poor.  Only 1.6% (10/621) studies were assessed as contributing class 1 evidence (systematic reviews) 
as per the Oxford Centre for evidence based medicine criteria. 
Yip and colleagues performed a large meta-analysis including all studies that reported on diabetes 
outcomes following either gastric bypass or sleeve gastrectomy.435  Inclusion criteria used to identify 
suitable studies were the recruitment of patients aged 18 years or over, the presence of type 2 
diabetes prior to bariatric surgery, participants undergoing either gastric bypass or sleeve 
gastrectomy, and the reporting of glycaemic outcomes with specified criteria.  On this basis, 2655 
studies were assessed, of which 33 were considered appropriate for inclusion.  The majority of these 
(30, 18 prospective and 12 retrospective) were not randomised, and 31/33 studies compared either 
gastric bypass or sleeve gastrectomy against a lifestyle/medical therapy “control” group.  Two of the 
randomised controlled studies compared gastric bypass against sleeve gastrectomy.  Reflective of the 
available literature reporting on diabetes outcomes following bariatric surgery, only 8/35 studies of 
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outcomes following gastric bypass and 1/16 studies of outcomes following sleeve gastrectomy had a 
duration of follow up of >12 months.  Reported definitions of glycaemic outcome required an HbA1c 
level below a specified threshold in the absence of glucose lowering therapy.   
Using this definition, diabetes remission was achieved by 67% and 56% in those who had undergone 
gastric bypass and sleeve gastrectomy respectively at 3 months, 76% and 68% at 12 months, and 81% 
and 80% at 36 months.  The authors noted that the differing definition of diabetes remission used had 
a significant effect on reported outcomes; in those participants who had undergone sleeve 
gastrectomy, collective studies that defined diabetes remission as an HbA1c <6.0% (42 mmol/mol), 
<6.5% (47 mmol/mol) or <7.0% (53 mmol/mol) reported diabetes remission in 44.0%, 67.8% and 
75.8% of participants respectively.  
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Table 1-5   Summary of studies reporting long term glycaemic outcomes following bariatric surgery 
Study Intervention 1 Intervention 2 
Duration of 
follow up 
Study design Definition of diabetes outcome 
Diabetes at baseline (%) 
Diabetes outcome at study 
end (%) based on study 
specific definition a 
Intervention 1  Intervention 2 Intervention 1 Intervention 2 




Complete = FG <5.6 mmol/L, and 
2HrG of <7.8 mmol/L, and HbA1c 
of < 6.2% (44 mmol/mol) in the 
absence of glucose lowering 
therapy.  Partial = FG <7.0 
mmol/L, and 2HrG<11.1 mmol/L, 
and HbA1c < 6.5% (47 mmol/mol). 
 











Medical therapy 12 months Randomised HbA1c <6.0% (42 mmol/mol) 100 100 44 / 23 6 
Lee et al Gastric bypass 
Sleeve 
gastrectomy 
12 months Randomised 
 
FG <126 mg/dl (7.0 mmol/L) and 
HbA1c of <6.5% (47 mmol/mol) in 
the absence of glucose lowering 
medications 
 






Lifestyle 12 months Randomised 
 
HbA1c <42 mmol/mol with or 
without the use of diabetes 
medications 
 
100 100 42 / 37 12 
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Study Intervention 1 Intervention 2 
Duration of 
follow up 
Study design Definition of diabetes outcome 
Diabetes at baseline (%) 
Diabetes outcome at study 
end (%) based on study 
specific definition a 









FG <126mg/dl (7.0 mmol/L) and 
HbA1c <6.0% (42 mmol/mol) in 
the absence of glucose lowering 
medications 
100 100 30 (83c) 0 
Serrot et al Gastric bypass Medical therapy 12 months 
Retrospective 
case control 
HbA1c <5.7% (39 mmol/mol) in 
the absence of glucose lowering 
medications for remission, HbA1c 
<6.5% (47 mmol/mol) in the 
absence of glucose lowering 
medications for control 
100 100 24 / 41 NR 






FG <126 mg/dl (7.0 mmol/L), and 
HbA1c 3.4-5.5% (14-36 
mmol/mol) in the absence of 
glucose lowering medications 
100 100 85 85 
Adams et al Gastric bypass 
 
Referred for but 








Hba1c and fasting glucose within 
the normal reference range 








Medical therapy 24 months Randomised HbA1c <6.0% (42 mmol/mol) 100 100 33 / 11 6 
Chapter 1: Literature review 
75 
 
Study Intervention 1 Intervention 2 
Duration of 
follow up 
Study design Definition of diabetes outcome 
Diabetes at baseline (%) 
Diabetes outcome at study 
end (%) based on study 
specific definition a 
Intervention1  Intervention2 Intervention1 Intervention 2 
Leslie et al Gastric bypass Medical therapy 24 months 
Retrospective 
case control 
Composite end point of ADA 
defined treatment goals 
(HbA1c<7.0% (53 mmol/mol), 
LDL<100mg/dl, SBP<130mmHg) 








24 months Randomised 
FG < 100 mg/dl (5.6 mmol/L) and 
HbA1c level < 6.5% (45 
mmol/mol) for at least 1 year 
without active pharmacologic 
therapy 









FG < 7.0 mmol/L or the use of 
glucose lowering medication 
 
100 100 72 21 
Pournaras et 
al 




FG <7.0 mmol/L and 2hrG <11.1 
mmol/L and HbA1c <42 mmol/mol 
in the absence of glucose lowering 
medication for > 3 months 
 






Lifestyle 36 months Randomised 
 
HbA1c <42 mmol/mol with or 
without the use of diabetes 
medications 
 
100 100 38 / 24 5 
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Study Intervention 1 Intervention 2 
Duration of 
follow up 
Study design Definition of diabetes outcome 
Diabetes at baseline (%) 
Diabetes outcome at study 
end (%) based on study 
specific definition a 
Intervention1  Intervention2 Intervention1 Intervention 2 
Pinheiro et 
al 
Gastric bypassg Gastric bypassh 48 months Randomised 
 
Normal range glucose 
concentrations in the absence of 
glucose lowering medication 
 















FG < 6.1 mmol/L, and 2hrG <7.8 
mmol/L in the absence of glucose 
lowering medications 
 
100 100 45 4 
Adams et al Gastric bypass 
Referred for, but 







Hba1c and fasting glucose within 
the normal reference range 









Not specified – implied that 
contemporary criteria for the 
diagnosis of diabetes used 
 





Medical/Lifestylee 120 months 
Prospective 
case control 
FG < 7.0 mmol/L or the use of 
glucose lowering medication 
100 100 36 13 
 
a = Figures in parentheses represent number achieving partial/incomplete control as per study specific definitions, unless otherwise indicated, b = Diabetes outcome inclusive of participants 
who achieved either complete or partial remission, c = Inclusive of participants who were deemed to have achieved diabetes control defined as an HbA1c <7.0% (53 mmol/mol) in the absence 
of glucose lowering medication, d = Inclusive of gastric banding, sleeve gastrectomy, and gastric bypass, e = Medical/lifestyle arm was not standardised, f = Further follow up of participants 
reported earlier by Schauer et al.  91% of participants available for this further analysis, g = Biliary limb of 50cm, Roux l imb of 150cm, h = Biliary limb of 100cm, Roux limb of 250cm, i = Remission 
rate at 12 months – 120 month figure not provided, although mean HbA1c at that stage was 62 mmol/mol
Chapter 1: Literature review 
77 
 
1.3.3.3.5 Summary of glycaemic outcomes 
Early improvements in glucose homeostasis were noted soon after the first bariatric procedures were 
performed, and a huge volume of evidence validating this phenomenon has since been published.  
Whilst the study quality and design has varied considerably, the overall assessment of this literature 
strongly supports bariatric surgery as valid treatment option, at least for glycaemic control, for obese 
persons with type 2 diabetes.  Indeed, in well designed randomised controlled trials, bariatric surgery 
is far superior to conventional lifestyle and medical therapy in terms of achieving improvements in 
glycaemic status alone.    Studies presented in this chapter that included a lifestyle/medical arm 
illustrate the difficulty in achieving improvements in diabetes control that could constitute remission 
even in a research setting; when stringent criteria for diabetes remission were applied, on average 10% 
or less of participants in these arms achieved diabetes remission.  These findings are clearly of high 
importance when considering the relative benefit of bariatric surgery in comparison to other treatment 
options for the management of type 2 diabetes in obese persons. 
The marked study heterogeneity with respect to criteria and severity of type 2 diabetes at recruitment, 
BMI at baseline, specific bariatric procedure performed even amongst studies purportedly studying the 
same bariatric modality, definitions of glycaemic outcomes utilised, and concurrent use of 
medical/lifestyle therapies, means that an absolute stratification of each bariatric procedure to the 
relative impact on glycaemic control is not possible.  Nonetheless, the suggestion of a trend of 
increasing benefit on glycaemic control with gastric banding (diabetes remission/control at greater than 
12 months follow up, seen in 17-73% of included studies), sleeve gastrectomy (11-85%), gastric bypass 
(24-93%), and biliopancreatic diversion (30-100%) is in keeping with the increasing weight loss seen 
respectively with each of these procedures in the published literature.  In many respects, the interest 
lies in the analysis of studies reporting on sleeve gastrectomy and gastric bypass as these two 
procedures are perhaps more comparable than other bariatric procedures.  With one exception where 
85% diabetes remission rates were seen in both arms,416 all other studies that included both gastric 
bypass and sleeve gastrectomy, showed improved rates of diabetes remission in those who had 
undergone gastric bypass.  Indeed, this relationship was preserved when one considers outcomes at 
each follow up interval with improved diabetes remission rates following gastric bypass at 12 months 
(42-93% versus 23-85% in those undergoing gastric bypass and sleeve gastrectomy respectively), 24 
months (33 versus 11%, one study reported420), and greater than 24 months (38 versus 24%, one study 
reported427).  Whether this apparent benefit on glycaemic outcome of gastric bypass against sleeve 
gastrectomy translates into clinically meaningful improvements, or is associated with favourable 
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diabetes related outcomes, such as improvements in micro and macro vascular complications (see 
section below), remains to be fully clarified, as significant reductions in body weight alone are seen 
following either procedure. 
Understandably, many physicians treating patients with type 2 diabetes have historically been reluctant 
to refer these patients for bariatric surgery, given a paucity of published data on longer term outcomes, 
and higher long term complication rates with earlier forms of bariatric surgery.  This is especially true 
of younger patients, where the expected long lifespan following surgery clearly increases the risk that 
any longer term consequences of surgery may negatively affect outcomes.  The studies presented 
above go some way to providing reassurance in this respect, and whilst well designed studies assessing 
the longer term effect of bariatric surgery on glycaemic complications are needed, longer term effects 
on glycaemic status alone are clearly impressive when compared with other currently available 
therapies.  At present there is no randomised data comparing outcomes beyond 36 months for bariatric 
surgery against lifestyle/dietary interventions or alternative bariatric procedures. Many authors feel 
that the more pertinent contemporary question is not if bariatric surgery should at the forefront of 
therapeutic strategies for obese persons with type 2 diabetes, but more “how early” it is performed.  
Inclusion criteria for many publically funded bariatric surgery programmes internationally select on the 
presence of more rather than fewer obesity or diabetes related complications; increasing evidence as 
to the long term efficacy and safety of bariatric procedures would surely therefore require that this 
approach is reassessed. 
In summary, whilst the degree of improvement varies across the published literature, the evidence thus 
far supports a significant and clinically important durable effect of bariatric surgery on glycaemic status.  
Control groups included in these studies highlight the difficulty in achieving these results without 
bariatric surgery, even in the context of intensive research based lifestyle and medical interventions.  
Further research is required to assess other diabetes related outcomes, but, as per recent statements 
from the International diabetes federation (IDF), bariatric surgery should now be considered early in 
the management of obese persons with type 2 diabetes. 
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1.3.4 Factors predicting glycaemic outcome following bariatric surgery 
A number of diabetes and non-diabetes factors have been associated with glycaemic outcome following 
bariatric surgery.436   Weight loss appears to be an important predictor of remission, with higher 
remission rates amongst those who lose more weight, and conversely, higher rates of persistent 
diabetes with inadequate weight loss.437,438,439,440,441 Whilst some studies have shown an association 
between pre-operative BMI and likelihood of remission, others have suggested that outcomes are 
similar in those with mild or severe obesity.440,442,443,444  Young patients appear to have higher rates of 
diabetes remission after bariatric surgery than older patients.442,443,445 ,446    Diabetes parameters at 
baseline are also of clear importance in predicting glycaemic outcomes after bariatric surgery.  A short 
duration of diabetes prior to surgery has been shown in many studies to predict diabetes 
remission,440,443,445,447,448,449 whilst the use of insulin or sulphonylurea therapy at baseline appears to 
reduce the likelihood of remission.438,443,450,451  Improved glycaemic control at baseline is favourable, 
445,446,448 as is a higher fasting c-peptide level.440,443,446,449,452  Considering each of these variables and 
others, a model has been created that appears to be of use in predicting glycaemic outcomes in 
participants with type 2 diabetes prior to RYGB (Figure 1-5).  The DiaRem model incorporates age, 
HbA1c at surgery, use of insulin, and type of oral antidiabetic medication used to calculate a likelihood 
of remission.436  
 
Figure 1-5   A pre-operative diabetes remission (DiaRem) score predicting the probability of diabetes remission 






Likelihood of diabetes remission after RYGB can be calculated by totalling score.   
0-2 (88-99%), 3-7 (64-88%), 8-12 (23-49%),13-17(11-33%),18-22 (2-16%) 
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1.3.5 Impact of bariatric surgery on microvascular complications of type 2 
diabetes 
The effect of bariatric surgery on microvascular outcomes is important to understand so as to allow the 
recommendation of appropriate post-surgery surveillance.  Unfortunately, the direct impact of bariatric 
surgery on diabetes microvascular complications is relatively under reported.  Even large randomised 
trials conducted in this field have usually failed to report microvascular outcomes, instead focusing on 
glycaemic effects, mortality, and surgery related morbidity.  Whilst prospective data reporting retinal 
outcomes exists, there is little published data thus far to address whether bariatric surgery has an 
impact on neuropathy and nephropathy.   
 
1.3.5.1 Retinopathy 
A rapid improvement in glucose concentrations in those with diabetic retinopathy has long been 
suggested to increase the risk of retinopathy deterioration.453 ,454 ,455  Indeed, analysis of early outcomes 
in the diabetes control and complications trial (DCCT) where participants with type 1 diabetes were 
randomised to intensive or conventional glucose control, demonstrated a two fold greater risk of 
retinopathy progression (13.1 versus 7.6%) in the interventional group within the first 12 months.456  
However, this study and subsequently many others have confirmed the favourable longer term effects 
of intensive glucose control on retinopathy outcomes, and that these benefits outweigh shorter term 
risks. 457   It is therefore reasonable to question whether the dramatic improvements in glucose 
concentrations commonly seen following bariatric surgery may be harmful.  Indeed, occasional case 
reports have been published of adverse early retinal effects following surgery.458 
Bariatric surgery was associated with a reduction in the cumulative incidence of microvascular 
complications in the Swedish Obese Study at a median follow up of 10 years.459  Retinopathy was not 
worsened or improved at two years follow up in the STAMPEDE study.460   A study of 28 patients 
undergoing various bariatric procedures with established diabetic retinopathy showed improvements 
in retinal disease on assessment 12 to 18 months after surgery.461  Bariatric surgery was associated with 
a lower risk of progressive retinopathy compared to routine non-surgical care in a retrospective cohort 
study using retinal photographs, although the study did not report how long after surgery subsequent 
retinal assessments were performed.462  A recent meta-analysis including studies reporting retinopathy 
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changes as a primary outcome after bariatric surgery (four studies, 148 patients) suggested that 
patients with pre surgery diabetic retinopathy (n=68) generally had no change or an improvement in 
retinal features (76.5%), whilst only 8% of those with no evidence of retinopathy prior to surgery 
progressed after surgery. 463   Nonetheless, 25% of those with pre surgery diabetic retinopathy 
experienced worsening of their retinal disease following surgery. 
 Thus, the data so far is not conclusive but outcomes from larger studies have generally supported a 
beneficial effect of improved glycaemic control via bariatric surgery on retinal outcomes.  Ongoing 
retinal surveillance is likely to be required given the reasonable prevalence of persistent or progressive 
disease. 
      
1.3.5.2 Nephropathy 
The Swedish obese study showed an adjusted hazard ratio of 0.37 for the development of albuminuria 
in participants with pre-operative type 2 diabetes and normal urinary albumin concentrations 
undergoing bariatric surgery versus non-surgical controls.  Furthermore, as noted above, a cumulative 
reduction in microvascular complications was evident at 10 years of follow up.459  However, participants 
undergoing surgery had lost a considerable greater amount of weight than those in the control groups, 
and weight loss has been shown to be an independent predictor of urinary albumin normalisation 
following bariatric surgery.464  Diabetic nephropathy resolved in 58% of participants with pre-operative 
microalbuminuria at 6.5 years of follow up in a study by Schauer’s group, although microalbuminuria 
developed in 25% of those with normal albumin excretion at baseline.465  Few other studies of bariatric 
surgery have reported renal outcomes; two recent reviews note that no randomised studies specifically 
reporting on diabetic nephropathy outcomes have been published.466 ,467   Presently, it is therefore 
prudent to continue surveillance for the development of progression of diabetic nephropathy after 
bariatric surgery has been performed. 
 
1.3.5.3 Neuropathy 
Fewer studies still have reported specifically on the effect of bariatric surgery on diabetic neuropathy.  
A pilot study reporting outcomes in twelve patients with type 2 diabetes and diabetic neuropathy 
undergoing RYGB showed resolution of neuropathy in 67% at 6 months.468  However, a second recent 
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study showed significant change in nerve conduction in patients with preoperative type 2 diabetes was 
noticed following RYGB.469   With the exception of the Swedish Obese Study reported above, there is 
little or no other published high quality data on neuropathy outcomes following bariatric surgery. 
 
1.3.6 Impact of bariatric surgery on macrovascular complications of type 2 
diabetes and obesity 
Bariatric surgery is associated with a reduction in all-cause mortality, predominantly because of an 
apparent reduction in cardiovascular outcomes.  A meta-analysis by Pontiroli et al including nearly 
200,000 participants from fourteen controlled trials specifically reporting cardiovascular outcomes 
demonstrated a reduced risk of global mortality (odds ratio 0.48, 95% confidence interval 0.34 to 0.64) 
and cardiovascular events (OR 0.54, CI 0.41 to 0.70), in agreement with a previous meta-analysis on 
this subject.470,471   In addition, the relative risk of myocardial infarction (OR 0.46, CI 0.30 to 0.69) and 
stroke (OR 0.49, CI 0.32 to 0.75) were reduced following bariatric surgery. 
The three major contributors to this meta-analysis were the Swedish Obese Study (SOS) and two 
American studies.472,473,474  Twenty eight cardiovascular deaths occurred during a median follow up of 
14.7 years out of the 2010 participants who had undergone bariatric surgery in the SOS (see 1.3.3.3.3), 
in comparison with 49/2037 participants in the non-surgical control group (adjusted hazard ratio 0.47, 
CI 0.29 to 0.76).472  Furthermore, a reduction in cardiovascular events in general was observed.   Adams 
et al reported long term cardiovascular outcomes in 7925 participants who had undergone bariatric 
surgery (mean follow up 7.1 years) against 7925 severely obese individuals matched for age, sex, and 
BMI.473  They reported a 40% relative mortality risk reduction in the surgical group, and a 56% relative 
risk reduction in cardiovascular outcomes (2.6 versus 5.9 per 10,000 years).  Miranda and colleagues 
reported a death adjusted hazard ratio of 0.76 (0.60 to 0.96) at follow up of between 5.9 and 8.5 years 
following bariatric surgery (most of which had undergone RYGB) when compared against non-surgical 
controls.474 
Therefore, in contrast to the paucity of data for microvascular outcomes after bariatric surgery, it 
appears clear that bariatric surgery reduces mortality, with a predominant reduction in all cause 
cardiovascular outcomes and mortality. 
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1.3.7 Effect of bariatric surgery on lipids 
Obesity and type 2 diabetes are strongly associated with dyslipidaemia, which contributes significantly 
to the increased cardiovascular risk associated with these conditions.  The dyslipidaemia of obesity and 
type 2 diabetes is characterised predominantly by fasting and postprandial hypertriglyceridaemia, 
which further promotes reduced high density lipoprotein (HDL) and increased low density lipoprotein 
(LDL) concentrations. 475 , 476   In obesity, increased adiposity leads to impaired lipoprotein lipase 
expression and reduced activity, resulting in the accumulation of free fatty acids (FFA).  These FFA in 
turn promote hepatic triglyceride production, which consequently increases very low density 
lipoprotein formation.  In health, insulin impairs the release of FFA from adipocytes; thus, 
hypertriglyceridaemia is further favoured by the insulin resistance characteristic of type 2 diabetes.477  
Bariatric surgery results in favourable improvements to the dyslipidaemia of obesity and type 2 
diabetes.  However, current evidence would suggest that a) outcomes may be different depending on 
the bariatric procedure, and b) the effect may be to some extent independent of weight loss.  Gastric 
bypass has been shown to have favourable effects on triglyceride and HDL concentrations in a number 
of studies, although the effect is variable and may be weight dependent. 478 , 479 , 480 , 481 , 482   Similar 
outcomes have been observed following SG, although LDL concentrations have not been shown to fall 
following either GB or SG.478, 483 , 484 , 485   Schauer and colleagues reported a 28% increase in HDL 
concentrations and a 40% reduction in triglyceride concentrations at 12 months following SG when 
compared to baseline values. 486   
In contrast, RYGB appears to be associated with favourable changes in HDL, LDL, and triglyceride 
concentrations.  Mingrone and colleagues reported a 30% increase in HDL concentrations, a 17% 
reduction in LDL concentrations, and a 21% reduction in triglyceride concentrations at 24 months 
following RGYB.487   Benaiges and colleagues performed a non-randomised prospective study of 51 
patients undergoing SG and 51 patients undergoing RYGB.483 As noted above, improvements were seen 
in HDL and triglyceride concentrations following procedures, although an additional significant 20% 
reduction in LDL concentrations was seen following RYGB.  This effect was not seen in those who had 
undergone GB despite a similar degree of excess body weight loss during the study period.  Consistent 
findings have been reported by Nguyen and colleagues and Woodard and colleagues, although the 
reduction in LDL following surgery was substantially greater in the former (74%). 488 , 489   There is 
insufficient literature at the present time to adequately compare bariatric procedures with respect to 
effect on HDL and triglycerides.  Remarkably similar improvements in both HDL and triglyceride 
concentrations were demonstrated at 1 year following SG or RYGB as discussed above,485  although the 
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increase in HDL concentrations was significantly greater at 1 year following SG when compared to RYGB 
in the study by Benaiges and colleagues.483  The mechanism underlying the apparently unique ability of 
RYGB to induce reductions in LDL is unclear, but LDL reductions have also been reported following 
BPD.487,490  This raises the possibility that intestinal bypass or malabsorption is beneficial with respect to 
LDL specific dyslipidaemia.  It is interesting to note that weight outcomes have been similar in 
comparative studies that have demonstrated an LDL lowering effect of RYGB, suggesting that this 
aspect may be weight independent.  Further research is required to clarify these questions. 
Thus in summary, all bariatric procedures appear to have a beneficial effect on HDL and triglyceride 
concentrations.  In addition, RYGB and BPD appear to lower LDL concentrations, whilst the effect of 
bariatric procedures, particularly those that are not purely restrictive, on dyslipidaemia may be 
independent to some extent on weight outcomes.  It should be noted however, that the use of lipid 
lowering medication is high in populations considered for bariatric surgery.  Thus, lipid lowering agent 
use at baseline may confound analysis of the size effect of bariatric surgery, after which these agents 
may be withdrawn. 
 
1.3.8 Summary 
Bariatric surgery results in significant weight loss irrespective of the chosen procedure, although weight 
regain may occur in some patients.  Furthermore, bariatric surgery results in improvement in glycaemic 
control in the majority of those with pre-operative type 2 diabetes, with this effect appearing durable 
over many years of follow up. Longer term follow up of randomised participants is required though to 
alleviate concerns as to weight regain and diabetes relapse following surgery.   
Bariatric surgery reduces all-cause mortality in patients with and without type 2 diabetes, and 
particularly reduces the likelihood of cardiovascular morbidity and mortality.  One factor possibly 
underlying this effect is a generally favourable effect on lipid profiles.  Further study is required to clarify 
the effects on diabetes related microvascular outcomes, although a favourable effect on retinal disease 
appears likely.  Both weight and glycaemic outcomes after bariatric surgery far exceed those achieved 
by lifestyle and/or pharmaceutical therapies.  There has therefore been considerable interest in 
improving understanding of the mechanisms underlying these improvements to both better 
understand the pathophysiology of each related disorder, and to explore whether these improvements 
can be induced in a non-surgical manner.  
Chapter 1: Literature review 
85 
 
1.4 Mechanisms underlying the effects of bariatric surgery 
In this chapter I will discuss the mechanisms underlying the effect of bariatric surgery both on weight 
loss and improvements in glucose homeostasis.  Whilst the principles through which surgery induces 
weight loss have become significantly clearer over recent years, the relative importance of each of 
these factors requires clarification.491,492  In contrast, there remains considerable debate as to the role 
of various postulated mechanisms in the improvements in glucose homeostasis frequently seen 
following surgery.  
 
1.4.1 Factors that reduce net caloric availability 
As discussed above (chapter 1.2.1), weight loss will occur when energy expenditure exceeds energy 
intake.  Whilst contributory, changes in energy expenditure induced through increased physical activity 
are proportionally small in comparison to the reduction in energy intake that can be induced through 
modified dietary behaviour.  Thus, the fundamental aspect underlying successful weight loss is caloric 
restriction, and a reduction in caloric intake after bariatric surgery is a consistent finding.493,494,495  In 
this section I will discuss the current literature exploring the mechanism by which bariatric surgery may 
decrease caloric intake. 
 
1.4.1.1 Reduced food intake 
Bariatric surgery was developed with the intent of causing malabsorption, as it was assumed that a 
reduction in net caloric intake would be an effective method of inducing weight loss.   Indeed, the 
earliest bariatric procedure, jejeno-ileal bypass (JIB), focused almost entirely upon this surgical goal.   
More recent ‘malabsorptive’ procedures such as Roux-en-Y gastric bypass additionally fashioned a 
reduced gastric volume, but retain the principle of gastrointestinal diversion with the intent of inducing 
malabsorption. 
Recent research in animal models however suggest that a reduction in food intake rather than 
malabsorption may be the primary driver of reduced caloric availability.  One study assessed weight 
loss in rats after RYGB, VSG, paired feeding (food intake matched to surgical groups) without surgery, 
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and ad lib fed rats undergoing sham bariatric surgery. 496    A significantly lower body weight loss was 
observed at day 28 and 105 in the surgical and paired fed rats in comparison to ad lib fed rats. There 
was no difference in the degree of weight change across the study period between rats in the RYGB, 
VSG, or paired feeding groups, although the mean weight in each group from day 60-80 on was 
comparable to baseline.  The same group have demonstrated a similar phenomenon in other 
studies.497,498   
Contradictory to these findings, a second group demonstrated 47% greater weight loss at 12 weeks in 
rats whose food intake was matched to that of rats who had undergone RYGB.499  As with the above 
study, rats in the paired feeding arm lost only 11% of their body weight by four weeks and had returned 
to baseline body weight at 3 months.  Additionally, rats in the RYGB arm lost only a relatively modest 
14% of their body weight.  Cumulative caloric intake was reported in the surgical group in comparison 
to an ad lib fed sham surgery group, and whilst the net caloric intake over 20 weeks was 16.8% lower 
in the RYGB rodents, the cumulative intake of calories across this period was similar to that in the above 
study (approximately 8500 calories).  A second group studied rats undergoing either JIB or a sham 
surgical procedure.500  The animals fed ad libitum, but a small group of 10 rats in the sham surgery arm 
were instead pair fed to match food intake in the JIB group.  The mechanism by which paired feeding 
was achieved was not reported.  Whilst the paired fed rats initially displayed weight loss comparable to 
that seen in the JIB arm, weight regain was seen by 8-12 weeks in the paired fed group and this group 
had returned to baseline weight by 24-28 weeks. 
Thus, it is not yet known whether a reduction in food intake alone is the primary driver of weight loss 
in bariatric surgery in humans, or whether a malabsorptive component provides an additional or more 
important element.  The mechanisms by which food intake may be reduced are discussed below. 
 
1.4.1.2 Reduced gastric volume 
To some extent, each of the more commonly performed bariatric procedures (LAGB/GB, SG, RYGB) 
involves a surgical reduction of the gastric volume and thus capacity.   Stretch receptors within afferent 
vagal nerve endings found within the gastric musculature relay information regarding gastric lumen 
distension to the brain.501  As would intuitively be expected, there is evidence of a strong positive 
relationship between increasing gastric distension and satiety.502  Early pioneers of bariatric surgery 
therefore reasonably proposed that an increase in gastric stretch, induced by restricting gastric volume, 
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would be an important factor in successful weight loss surgery.  However, there are a number of lines 
of argument that count against this assumption, and suggest that the beneficial effects of gastroplasty 
may lie outside of the resultant change in gastric volume alone. 
The purest comparison to support this argument is when outcomes following GB and SG are examined.  
GB involves simply volume restriction, whilst SG induces both restriction and alterations in gastric 
mucosal food contact.  Gastric volume is reduced to 15-25ml by modern laparoscopic banding 
techniques, and it is clear that band malfunction or slippage leading to an increase in gastric volume 
frequently leads to weight regain.503,504,505,506  In contrast, residual gastric volume is considerably greater 
following SG (80-200ml) and yet weight loss observed following SG is consistently greater than that 
seen following GB.507,426,428  Indeed, as discussed above (see chapter 1.3.2) early to medium term weight 
outcomes following SG in experienced centres are comparable to those following RYGB, yet the residual 
gastric volume following open or laparoscopic RYGB is usually less than 30ml.  Furthermore, and in 
contrast to GB, an increase in the gastric volume as a result of dilatation during follow up of SG is 
uncommon and is not always associated with less favourable weight outcomes.508  However, studies 
exploring the role of sleeve size specifically in weight outcome have produced discordant results.  
Weiner and colleagues randomised participants to sleeve gastrectomy with a) no calibration of sleeve 
size, b) use of a 44fr calibration tube, and c) use of a 32fr calibration tube.509  Post-operative sleeve 
volume was greater in participants who had no intra-operative sleeve size calibration.  Whilst early post-
operative weight loss was similar between groups, participants in group B and C had lost significantly 
more weight at 2 years of follow up than those in group A.  Net weight gain was evident in a minority 
of participants in group A at 5 years.  In contrast a meta-analysis of 10 studies reporting outcomes 
following SG found no relationship between sleeve volume and weight outcomes. 510   It has been 
hypothesized that the site of gastric resection as opposed to residual volume may be the more 
important factor.531  The gastric fundus is the major site of ghrelin secretion, and thus differences in the 
degree of fundal resection during SG may have an impact on post-operative ghrelin concentrations and 
thus appetite (see chapter 1.1.2.3.1 and 1.4.2.2).510,531 
It remains unclear whether residual gastric pouch size, below an upper threshold, following RYGB is a 
factor in weight outcomes.  RYGB is performed via both open and laparoscopic techniques depending 
on surgeon preference, although an open procedure is required by some surgeons to fashion a smaller 
pouch.  Studies that have reported on outcomes with both techniques have demonstrated discordant 
findings.  Many studies have shown similar outcomes following laparoscopic RYGB in comparison to 
open procedures, although it is acknowledged that the technique is significantly more difficult in super 
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obese patients.511,512,513,514  Topart and colleagues reported outcomes following laparoscopic RYGB in 
107 participants with three years of follow up.515   A 10-30ml gastric pouch was fashioned during 
surgery, and pouch dilatation was defined as >50ml at follow up.  Weight loss, reported as excess body 
weight loss, was similar in participants with pouch dilatation versus those who did not, even though 
some pouches had dilated above 100ml.  It should be noted however, that pouch dilation to some 
degree was evident in most patients during follow up without the use of a Fobi ring.  In contrast, other 
studies have reported an association between pouch size and weight outcomes.  Heneghan and 
colleagues reported an inverse relationship between pouch size and weight loss in 380 patients who 
underwent endoscopy following laparoscopic RYGB.516  Stoma size was also reported, and considered 
normal if <2cm in diameter.  Participants were divided into two groups based on weight outcome.  
Successful weight loss was defined as excess weight loss >50% or a decrease in BMI to ≤30 kg/m2.  Pouch 
and stoma size were considered normal in all participants with successful weight loss, but only 28% in 
those without.  Although pouch size, pouch length, pouch volume, and stoma diameter all showed an 
inverse correlation with excess weight loss, multivariate analysis suggested that only stoma diameter 
was independently associated with weight regain during follow up.   Furthermore, pouch resizing 
appears to be an effective method of correcting weight loss failure, at least in short term follow up, in 
patients with pouch dilation following earlier RYGB.517,518  
In summary, significant differences in residual gastric volume are expected following GB, SG, and RYGB.  
However, the between procedure differences do not correlate with predicted weight loss following 
each procedure, and therefore a reduction in gastric volume alone is unlikely to be a primary factor in 
weight outcomes.  The published literature is not conclusive on whether pouch size following SG and 
RYGB plays a role in long term weight outcomes for either procedure. 
 
1.4.1.3 Gastric transit 
Bariatric surgical procedures that incorporate gastroplasty or other gastric anatomical alterations can 
be expected to affect gastric kinetics.519    As noted above, gastric distension is known to correlate with 
satiety, and a reasonable expectation therefore is that a delay in gastric emptying would be a favourable 
outcome of bariatric surgery.  To support this hypothesis, early studies of gastric transit following 
successful gastric bypass suggested a delay in gastric emptying of solid food using radionuclide ingestion 
techniques.520 , 521 , 522    However, gastric transit of liquid substances was, in contrast, found to be 
increased in these studies.  This finding is supported by results of an uncontrolled study of seven 
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morbidly obese participants undergoing GB, where gastric transit was assessed using a D-xylose test 
before and one year following surgery.523   However, contradictory results have been produced by 
studies in animal models.  Suzuki and colleagues reported delayed gastric emptying following RYGB in 
a rat model when compared with sham operated pair fed rodents.524  This finding has been reproduced 
by this group in a second similar study using D-xylose absorption tests. 525  This group acknowledge that 
their results contrast with findings in human studies and suggest that their RYGB procedure leads to 
severance of the gastric-brain vagal connections that regulate autonomic gastrointestinal functions 
such as peristalsis, thereby effecting gut motility. 
In contrast to restrictive procedures such as LAGB and SG, RYGB removes the pyloric sphincter.  As an 
alternative rate limiting anatomical structure is not fashioned, increased gastric transit following RYGB 
would appear logical.  Until recently however, there was a surprising paucity of literature that has 
specifically examined this assumption.    Morinigo and colleagues performed a prospective study of 9 
obese individuals who underwent RYGB.526  Gastric emptying was assessed in six of these participants 
by means of a paracetemol ingestion test, with plasma paracetemol concentrations measured at 
regular intervals following ingestion.  RYGB was associated with a significant increase in the rate of 
gastric emptying.  A similar technique to measure gastric emptying was employed by Falken and 
colleagues in a study of 12 obese individuals undergoing RYGB.527   Gastric emptying, expressed as 
paracetemol absorption, was twice as fast following surgery when compared with pre-operative 
assessments, and the rate difference was durable over the 12 months of post-operative follow up.  A 
recent study of participants undergoing RYGB compared with nine healthy controls used an ingested 
radionuclide technique with scintigraphy to document transit of the tracer.528  Pouch emptying was 
more rapid to both food and liquid in the participants who had undergone RYGB.    In addition to the 
above studies assessing gastric transit only, Akkary and colleagues examined whether variations in 
pouch emptying following RYGB may predict weight outcomes.  Four hundred and five participants 
were recruited for the study and all underwent upper gastrointestinal endoscopy on post-operative day 
1 to exclude complications of surgery.  Three hundred and four participants were available for follow 
up at 12 months and all underwent gastric emptying studies again at this stage.  Participants were then 
divided in to group A (normal or enhanced pouch emptying) and group B (slow or no pouch emptying).  
Participants in group A had a statistically significant additional body weight loss of 3kg following surgery, 
although it should be noted that substantial weight loss occurred in both groups (50.6 versus 47.3kg).  
In summary, the few contemporary studies that have sought to address the question of gastric 
emptying following RYGB generally report more rapid gastric transit time following this procedure.  It 
should also be noted that the reduction in gastric emptying reported by earlier studies did not correlate 
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with weight loss and it is therefore possible that methodological or study design differences explain the 
discordancy between historical and contemporary studies. 
Despite retention of the pyloric sphincter, the majority of published studies assessing gastric kinetics 
following SG report an increase in gastric transit, although occasional studies report contradictory 
results.529  Melissas and colleagues reported on 23 morbidly obese individuals who underwent SG at a 
single institution.530  11 of the participants underwent studies of gastric transit before surgery and at 6 
months follow up using a scintigraphic technique.  Gastric emptying was significantly more rapid 
following surgery with an emptying half time of 47.6 versus 94.3 minutes before surgery.  The 
percentage of food emptied from the stomach at the end of the study period was also significantly 
greater (75.4 versus 49.2% at 90 minutes).  The same group reported outcomes at 24 months in nine 
of these participants and reported that this effect appears to be durable.  531    Markers of gastric 
emptying were not significantly different at 24 months when compared to studies at 6 months following 
surgery.  A second study reporting on gastric emptying in 20 obese individuals following SG showed 
similar results, although assessments were post-operative only and comparison was with a control 
group of healthy normal weight individuals.532  Gastric emptying of liquids (13.6 versus 34.9 minutes) 
and solids (38.3 versus 78 minutes) were both increased in comparison with rates in the control group.  
Shah and colleagues developed this study design further by studying gastric emptying in 23 individuals 
with type 2 diabetes who had previously undergone SG, 20 morbidly obese individuals with type 2 
diabetes who had not undergone bariatric surgery, and 24 normal weight non-diabetic controls.533  A 
scintigraphic technique was employed and demonstrated significantly increased gastric emptying in the 
SG group compared to both the non-surgical and control groups.  Additionally, intestinal transit time 
was found to be similarly increased by the same technique when compared with the control groups.  
Recently, Pilone and colleagues have reported consistent findings using a scintigraphic technique to 
assess gastric emptying in 45 individuals before and after SG.534   Pre-surgical measurements were 
compared against a retrospective control group of 20 individuals undergoing gastric emptying studies 
for other reasons. 
An interesting recent study has addressed the mechanisms underlying changes in gastric motility 
following SG.535  Dynamic MRI sequences were used to acquire images of gastric transit following the 
ingestion of water.  Participants underwent testing before surgery, and again at six days and six months 
following the procedure.  A more rapid gastric emptying time was again suggested by this technique.  
This was shown to relate entirely to an accelerated peristalsis in the residual antral component, with 
aperistalsis observed in the sleeve.  In summary, almost all studies assessing gastric transit following SG 
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have demonstrated a clear decrease in emptying time which appears to result from increased antral 
peristalsis. 
In contrast to RYGB and SG, LAGB/GB does not appear to effect gastric emptying.  Three recent 
prospective uncontrolled studied employing either scintigraphy or paracetemol absorption to assess 
gastric emptying, reported observations at 3-18 months following GB.536,537,538  Of these, one study 
compared gastric emptying measurements with weight outcomes.  No difference between pre-
operative and post-operative gastric emptying rates was noted in any study, irrespective of the weight 
loss achieved.  An additional prospective study assessing the use of GB in morbidly obese adolescents 
again demonstrated no change in gastric emptying following the procedure.539 
There appears therefore to be a paradox; bariatric procedures that appear to increase the rate of gastric 
transit, and therefore intuitively less likely to induce gastric stretch, are associated with the highest and 
more durable rates of surgical weight loss.  Indeed, this apparent contradiction is demonstrated in 
numerous other non-surgical scenarios where gastric transit is effected, and illustrates the complex 
relationship between gastric emptying and appetite/satiety.  Sibutramine, a centrally acting dopamine-
noradrenaline reuptake inhibitor, showed efficacy as a weight loss agent prior to its withdrawal due an 
apparent increased risk of cardiovascular disease. 540 , 541   Exogenously administered versions of 
endogenous gut hormones have also been shown to have weight loss effects when administered at 
pharmacological doses (discussed in chapter 1.2.1).  Each of these pharmaceutical interventions is 
associated with delayed gastric emptying, in direct contrast to the more rapid gastric transit seen after 
RYGB or SG. 542   Furthermore, the intentional enhancing of gastric emptying through the use of 
intravenous Erythromycin, a prokinetic macrolide antibiotic, results in a reduced caloric intake during 
ad libitum eating when compared with a placebo control group.543 
As discussed throughout this chapter, bariatric surgery induces weight loss through a number of 
mechanisms, but it is interesting to note such contrasting effects on gastric transit with different weight 
loss interventions.  Increased gastric transit results in an earlier deliverance of ingested nutrients 
following eating to the duodenum following SG, and to the jejunum following RYGB. It has been 
hypothesised that this results in favourable alterations to gut peptide secretion that may explain the 
apparent discordancy between gastric transit change and weight loss, and this is discussed later in this 
section (chapter 1.4.2)  
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It is therefore apparent that a) alterations in gastric transit may affect appetite and satiety and 
therefore caloric intake, but that this relationship is complex, and that b) the increased gastric transit 
seen after RYGB and SG is likely to be only a minor contributor to total weight loss. 
 
1.4.1.4 Malabsorption 
Whilst less of a factor in the weight loss effects of bariatric surgery than initially assumed, it is clear that 
malabsorption occurs after both RYGB and BPD but not LAGB or VSG.  However, the absorption of 
macronutrients appears to remain reasonably intact following RYGB; small studies have measured 
similar absorption of fat, protein, and carbohydrate before and up to 14 months after RYGB.544,545  Up 
regulation of intestinal glucose transports may ameliorate the carbohydrate malabsorption that may 
otherwise occur following this procedure.546 Clinically relevant protein malabsorption is seen only rarely 
and may necessitate revisional surgery.547,548  BPD likely induces a degree of fat malabsorption, and 
although it is unclear whether this is a factor is the more significant and durable weight loss seen after 
this procedure than other forms of bariatric surgery.396, 549 , 550   In contrast, malabsorption of 
micronutrients including iron, vitamin B12 and D, and calcium is frequently encountered following both 
before and after RYGB and BPD but does not contribute to weight outcomes.551 
 
1.4.1.5 Eating behaviour    
There is some evidence that food choice is effected by bariatric surgery, although the published 
literature is not conclusive.  Animal models present a more objective method of quantifying food choice 
than studies in humans, as they are less susceptible to the influence of other behavioural or social 
factors affecting decisions.  In general, animal models support a reduced preference for fat intake 
following RYGB.  Zheng and colleagues studied food behaviour in a rat model undergoing RYGB or sham 
surgery.552  Rats were observed for 15 weeks prior to surgery and four months after, and at all times 
had ad libitum access to a low fat (10%) or high fat (60%) liquid solution, and a low and high fat chow.  
Following surgery, the rats were studies at 2-3 weeks (acute phase of weight loss) and at 16-20 weeks 
(chronic phase).  Rats in the sham surgery group, and an additional no surgical control group, showed 
high preference for the high fat liquid at each time point (96% preference).  There was a slight reduction 
(86%) in high fat preference in the RYGB group within the acute phase, but a clear and statistically 
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significant difference (58%) by the chronic phase.  Rejection of high fat chow was absolute in those rats 
who had undergone RYGB at all times following surgery, whilst sham or control rats again demonstrated 
preference for high fat chow.  
A second study by le Roux and colleagues agrees with these findings. 553   Twenty six rats were 
randomised to RYGB or a sham procedure.  Prior to surgery the animals had ad lib access to three equal 
sized portion of two high fat chows (60% fat) and on normal chow (2% fat).   A food preference 
assessment was conducted at week eight of life (pre-surgery) and at 10 days following surgery.  Sham 
rats maintained similar preferences for each food option before and after surgery, with the low fat 
chow accounting for 3-5% of total food intake.  In contrast, rats that had undergone RYGB showed an 
increased preference for low fat chow at 10 days from 3.2% to 14% of total diet, whilst reducing their 
intake of both high fat chows by approximately 40%.  The overall intake of food remained the same 
before and after surgery in the sham group, but reduced by 37% in the RYGB group.  In addition, the 
RYGB animals showed less preference for a fat solution following surgery than the sham animals. 
Human studies have provided less clear results, partly because of significant methodological differences 
between studies.  Nonetheless, the majority of studies support that a reduction in preference for fat, 
substituted by a proportional increase in carbohydrate, is seen following RYGB.  Brolin and colleagues 
performed a prospective study of food intake before and after VBG and RYGB.554  The choice of surgery 
modality was based on the pre-operative eating habits of the participant.  Caloric intake fell dramatically 
following surgery (pre-operative caloric intake = 3120 for VBG and 2601 for RYGB) although increased 
again at each six month post-operative assessment for both groups.  However, daily caloric intake at 36 
months remained well below baseline at 1753 calories/day for VBG and 1386 for RYGB.  Fat intake was 
significantly reduced at most post-operative assessments for both procedures when compared with 
pre-operative intake.  Whilst not significant, the authors reported that the reduction in fat content was 
compensated by a small increase in both protein intake (for RYGB) and carbohydrate content (for both 
procedures).  Indeed, at 36 months following RYGB, fat and carbohydrate intake was statistically 
significantly lower and higher respectively than at the pre-operative assessment. 
Most patients who have undergone bariatric surgery can very readily identify a number of food 
substances that they have learnt to avoid, to avert undesirable outcomes.  It is therefore probable that 
changes in food choice behaviour following bariatric surgery develop partly as a result of symptoms 
experienced whilst eating, possibly alongside alterations in higher cerebral centres regulating food 
choice.  Indeed, Olbers and colleagues demonstrated the effect food intolerance has on food choice in 
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a prospective study of participants randomised to RYGB or VSG.555 Participants who had undergone 
RYGB consumed a significantly lower daily quantity of fat post-surgery, although the mechanism for this 
was not examined.  In contrast, participants who had undergone VSG restricted the intake of meat and 
vegetables and increased the intake of energy dense liquid products, an unfavourable phenomenon 
which has been demonstrated in other studies.554, 556   A prospective study of a food intolerance 
questionnaire in participants who underwent either RYGB or AGB showed that increased food 
intolerance was evident at three months following both procedures, when compared with baseline 
results in obese and non-obese controls.557  The questionnaire did not investigate intolerance of specific 
products.  Interestingly, food intolerance scores at 12 months following RYGB were not significantly 
different again to control scores, whilst participants who had undergone gastric banding had increasing 
food intolerance over the seven year study period.  A second prospective study used an alternative 
questionnaire that sought to associate specific food products with adverse symptoms.558  Participants 
undergoing LAGB, VSG, RYGB, or BPD were assessed at 3-6 months, 6-12 months, or greater than 12 
months.  Participants who had undergone LAGB had the highest rate of food intolerance at all time 
periods, and displayed the highest scores of food intolerance for all eight food product categories: red 
meat, white meat, salad, vegetables, bread rice, pasta, and fish.  As with the above study, participants 
in this study who had undergone VSG, RYGB, or BPD experienced a short term increase in food 
intolerance, with gradual improvement thereafter.  There was no significant difference with respect to 
tolerance of most food products between procedures, although red meat was better tolerated by 
participants who had undergone VSG. 
Dumping syndrome describes symptoms that result from the ingestion of high osmolar foods including 
those that are sugar rich, although the mechanism of this effect remains unclarified.559  It has been 
assumed that the more rapid deliverance of this food to the intestine as a result of altered anatomy, 
and the resultant significant fluid shift from the intestinal wall to the lumen, was responsible.  However, 
recent studies suggest that hypersecretion of gastrointestinal peptides in response to this food load 
stimulate the recognised symptoms of dumping syndrome.560  Symptoms vary from person to person 
but include light-headedness, flushing, tachycardia, nausea and vomiting, and diarrhoea which typically 
occur within 30 minutes of eating.  Whilst the syndrome is unpleasant, it is considered a beneficial 
effect of surgery by many authors due to the positive change in eating behaviour often taken by the 
patient to avoid episodes.  Dumping syndrome occurs in up to 76% of all patients who undergo RYGB, 
although the longer term frequency is unknown.561  The syndrome is also seen in patients who undergo 
BPD, but is not seen in those who undergo GB procedures.562  The majority of studies have not shown 
an increased risk of dumping syndrome following gastroplasty procedures.563,564 
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There is some evidence to suggest that bariatric surgery induces changes in the sensation of taste, 
which may be a further factor modulating eating behaviour following surgery.  82% of those who 
underwent RYGB reported subjective changes in taste sensation following surgery, as opposed to 46% 
of those who had undergone AGB.565  To support this finding, a small study that assessed the threshold 
at which participants could detect various taste before and after RYGB, showed an apparent increased 
acuity for bitter and sour, and saltiness at the expense of sweet tastes.566  Other studies since have 
supported this finding, and many surgeons will accordingly counsel pre-operative patients as to the 
likelihood of this change.  A recent study designed to assess taste acuity in rats following gastric bypass, 
came to same conclusion.  However, the group used two bottle choice and lick tests which may not 
accurately differentiate between taste thresholds and how much the animal prefers one product.  
Indeed, the degree to which taste thresholds have been reported to change in most studies, falls below 
conventionally accepted thresholds at which taste perception is altered in healthy humans.567 
Favourable changes in the “reward” achieved through the consumption of specific food products 
following bariatric surgery is also suggested by recent research.  A lick test can used to assess this in 
rats although care must be taken to differentiate whether the animal can actually taste the stimuli, a 
test of taste acuity, rather than like or dislike the food.  Several studies have demonstrated a decrease 
in lick rates for sucrose or sugar in rats following gastric bypass. 568 , 569 , 570   In humans, use of a 
questionnaire that assesses hedonistic appetite (i.e. the desire for food in the absence of a physiological 
need), suggests that gastric bypass may have a favourable reductive effect.571  Participants who had 
undergone gastric bypass were compared against a non-obese and an obese control group.  Overall, 
participants who had undergone gastric bypass recorded concentrations of hedonistic appetite of that 
were not significantly different from the non-obese control group, in contrast to the higher scores seen 
in the obese controls.  As would be expected with such sub conscious food behaviour alterations, 
changes in the function of the mesolimbic “reward” cerebral pathways have been demonstrated using 
functional MRI techniques.572  Ochner and colleagues demonstrated significantly reduced activation of 
this pathway by high density foodstuffs following gastric bypass, although no control group was 
employed. 
 
1.4.1.6 Changes in central nervous system energy homeostasis 
Given the central role of the hypothalamus in energy homeostasis (chapter 1.1.2.2), it is tempting to 
conclude that the significant and durable weight loss induced by bariatric surgery must entail 
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favourable effects on central nervous systems.  Indeed, clinical studies exploring the use of bariatric 
surgery for obesity related to hypothalamic dysfunction have occasionally supported the effects of this 
intervention under these circumstances.  Craniopharyngiomas are predominantly low grade tumours 
located within the hypothalamus or pituitary sella, and invasion of the tumour itself or surgical 
intervention frequently leads to hyperphagia and obesity.  A meta-analysis in 2013 identified 21 
patients with craniopharyngioma undergoing LAGB, VSG, RYGB, or BPD and demonstrated mean weight 
loss of 20.9kg at 6 months.573  However, weight loss in other hypothalamic disorders of obesity have 
been less impressive.  Prader-Willi syndrome is a complex genetic disorder resulting in hyperphagia and 
severe obesity; bariatric surgery results in modest weight loss only (less than 5%) and appear to have a 
high frequency of weight regain.574 
Studies in rodents have supported a possible direct effect of bariatric surgery on the hypothalamic 
circuitry.  RYGB/VSG rats have diminished hypothalamic activation during food restriction than non-
surgical or sham procedure controls.575  Furthermore, Aslan and colleagues reported the outcome of 
LAGB in an adolescent human with complete functional loss of the MC4R gene due to a heterozygote 
mutation, and consequent severe obesity.576  Whilst initial weight loss was observed, this individual 
experienced later weight regain, supporting the hypothesis that some of the longer term favourable 
effects of bariatric surgery may be mediated by central nervous system changes.   Neuroimaging studies 
using functional magnetic resonance imaging have also suggested relative increases in hypothalamic 
activity in response to food imagery in obese women in comparison to those who have undergone 
RYGB. 577   Whilst not matched by BMI, women who had undergone RYGB had similar functional 
hypothalamic responses to normal weight control women.  Whilst few studies have been performed 
exploring this possibility in more detail, VSG does not appear to directly affect hypothalamic functions 
in a rodent model.  Stefater and colleagues reported no differences in the expression of a number of 
appetite regulating hypothalamic neuropeptides after VSG, sham VSG, or diet controlled obese rats.578  
Thus, at present, and as a result of a limited literature, there is little strong evidence to suggest a direct 
effect of bariatric surgery on the hypothalamic centres regulating appetite, although this is question 
worthy of further study.579 
 
1.4.1.7 Changes in energy expenditure 
Energy expenditure (EE) is the sum of physical activity and non-resting energy expenditure (PA, 30% of 
total EE), the thermic effect of food (TEF, 10%) reflecting energy expended during digestion, and resting 
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energy expenditure (REE) or basal metabolic rate (60%) which is the energy required to maintain 
physiological activity.  In humans, REE increases with weight gain and decreases with weight loss, and 
has long been postulated as a major factor underlying the presence of an apparent defined body weight 
set point.580,581  The reduction in REE in response to caloric restriction induced weight loss is similar in 
men and women, and is most apparent early after commencement of weight loss.582  Furthermore, the 
reduction in REE appears to vary depending on the intervention used to induce caloric restriction.582  
Therefore, when investigating changes in EE and REE after bariatric surgery, changes should be 
compared against weight loss matched individuals; the significantly greater weight loss experienced 
after bariatric surgery makes recruitment of a suitable control group difficult. 
The literature on this topic is conflicting however, and reflects the great technical difficulties 
encountered when attempting to accurately measure energy expenditure.583,584  The gold standard 
method is to measure heat loss during containment in a sealed room, but this technique is limited by 
the availability of these facilities.585  Indirect calorimetry instead provides an estimate of EE through 
measurement of oxygen consumption and carbon dioxide production, but again is impractical outside 
of research settings.586  A number of equations have been proposed that estimate EE by considering 
factors including weight, height, age, gender, and then multiplying predicted REE by a PA 
coefficient.587 , 588 , 589    However, each calculation is validated in specific populations and may not 
therefore provide accurate estimations of REE in unselected groups. 
Studies exploring the effect of bariatric surgery on energy expenditure, perhaps limited by these 
methodological considerations, have reported contrasting results.  Earlier assessments of EE in humans 
after LAGB and BPD supported a decrease in total EE and REE that was proportional to body weight 
loss. 590 , 591 , 592   However, studies in rodents have often demonstrated the opposite effect, and 
furthermore, that this may be dependent on the bariatric procedure utilised.  RYGB increases total 
energy expenditure in rats when compared against sham operated animals, explained by contributory 
increase in both REE and TEF.593,594,595,596  More recently, a number of studies have reported favourable 
changes in REE in humans following RYGB/BPD but not VBG, suggesting that this may partially explain 
the differences in weight loss and subsequent weight regain seen after each procedure.  Using indirect 
calorimetry, an increase in TEF and energy expenditure during PA following BPD was reported in 20 
participants randomised to either BPD or diet induced weight loss.597  A second study including six 
obese females undergoing RYGB showed a decrease in total EE and REE following RYGB.  However, TEF 
increased as did the respiratory quotient when assessed 20 months after surgery.598  The same group 
have shown similar results at longer term follow up when comparing seven participants who had 
Chapter 1: Literature review 
98 
 
undergone RYGB against seven participants who had undergone VBG; despite matched body 
composition and weight before and after (nine years) following surgery, an increase in TEF by indirect 
calorimetry was noted in those who had undergone RYGB and explained the greater total EE when 
compared to those who had undergone VBG. 599  Dirksen and colleagues recently assessed factors 
underlying differences in weight outcomes in 33 patients deemed to have either good or bad weight 
outcomes after RYGB.  In contrast to results reported above, differences in energy expenditure in each 
group were explained by weight loss and did not predict outcomes.600 
In conclusion, the current evidence supports weight loss associated decreases in total EE after bariatric 
surgery, but suggests that an increase in TEF may be seen after RYGB and BPD.  Further studies are 
required to confirm this finding, and to clarify the role of this factor in weight loss and the subsequent 
variation in weight regain seen with different bariatric procedures. 
 
1.4.1.8 Summary of factors that reduce caloric intake (see also chapter 1.5) 
It is clear that there are a number of factors that reduce caloric intake following bariatric surgery, 
although eating behaviour in particular is hard to study.  Overall, the available evidence would suggest 
that bariatric surgery: 
 
 Leads to a reduction in food intake which, as opposed to any malabsorption induced by the 
procedure, may be the major factor resulting in a net reduction in caloric availability. 
 Leads to a reduction in gastric volume, although this alone may not be a major factor 
determining weight outcomes. 
 Increases the rate at which ingested food and liquid transits the stomach (RYGB and SG) and 
intestine. 
 Reduces the preference for high fat (RYGB) and high density calorie food stuffs, reduces the 
taste acuity for sweet foods, and reduces the cerebral reward available by consuming these 
products. 
 May reduce hypothalamic activity in response to food, but few studies exploring this area have 
yet been performed. 
 Rodent and human studies suggest that RYGB may increase the thermic effect to food, 
although the role of this effect is as yet unclear. 
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1.4.2 Gut peptide adaptations following bariatric surgery 
Predictably, the release of a number of gut and adipocyte peptides is altered by bariatric surgery (Table 
1-6).  In this section, I will present the available literature documenting these changes, and conclusions 
from the available evidence as to the role each plays in weight loss following bariatric surgery.  The 
physiology of each peptide is discussed above (1.1.2.1.1 and 1.1.2.3). 
 




After bariatric surgery 






Fasting concentrations are 
decreased.  Attenuation of 
the normal suppression of 
ghrelin by food intake. 
Increased in both 
fasted and fed state 
Increased after LAGB.  
Conflicting reports 






below those seen in 
obesity 
Increased post prandial 
concentrations 
GLP-1 
No effect on fasting 
concentrations.  Attenuation 
of normal post prandial 
increase. 
No clear change 
Increased post prandial 
concentrations after 
VSG, RYGB, BPD. No 
change after LAGB.  No 
change in fasting GLP-1 
concentrations 
GIP No effect 
Increased post prandial 
concentrations 
Stable or decreased 
fasting concentrations 
after RYGB.  Most 
studies report a 
reduced post prandial 
response after RYGB.  
Not affected by LAGB 
PYY 
Reduced fasting and post 
prandial concentrations 
Reduction in fasting 
and post prandial 
below those seen in 
obesity 
Increased post prandial 
concentrations after 
RYGB, VSG, BPD. No 
change after LAGB.  No 
change in fasting PYY 
concentrations 




In keeping with non-surgical weight loss, Leptin concentrations fall significantly following bariatric 
surgery.  This has been demonstrated after LAGB,602,603,604 VSG,605,606,607 RYGB,602,603,604,605,606,608,609,610 
and BPD.607,611  However, it is unclear whether the reduction in leptin following each procedure is simply 
a reflection of the associated weight loss, or whether there may procedure specific differences.  The 
decrease in leptin concentrations has been reported to be greater after RYGB than weight matched 
dietary weight loss,602,610  whilst other studies have reported a greater relative reduction in leptin 
concentrations after RYGB than after either LAGB or VSG. 602,603,605  Studies in rodents have shown 
greater reductions in leptin concentrations after VSG in comparison to pair fed animals of matched 
body weights.612  In contrast, other reports have shown no clear differences in the reduction in leptin 
concentrations after RYGB, VSG, or LAGB.604,606,613 
Thus, whilst a number of studies support an exaggerated effect of RYGB (and possibly VSG) on the 
reduction in leptin concentrations, this is not confirmed, and study of this question is difficult due to 
differing weight loss rates and final weight between procedures.   Furthermore, whilst a reduction in 
leptin with dietary loss is a factor underlying the propensity for weight regain due to increased appetite, 
weight regain after bariatric surgery is less significant.  As discussed above (chapter 1.4.1.1) appetite is 
reduced and satiety increased after RYGB and VSG in both humans and animal models.  It has therefore 
been proposed that an improvement in hypothalamic leptin sensitivity induced by bariatric surgery may 
be at play.614  However, whilst the sensitivity to infused exogenous leptin is increased in rats after VSG, 
the expression of hypothalamic leptin responsive genes is unchanged, and a similar improvement in 
leptin sensitivity is seen after matched caloric reduction weight loss.612  Therefore the available 
evidence currently would suggest that the reduction in leptin following bariatric surgery is a reflection 
of the associated fat weight loss, and that any improvement in leptin sensitivity is simply a consequence 
of this weight loss. 
1.4.2.2 Ghrelin 
The role of changes in Ghrelin concentrations after bariatric surgery as a factor in weight loss remains 
controversial.  As discussed above (chapter 1.1.2.3.1), ghrelin is produced predominantly in the gastric 
fundus; thus, procedures that either remove the fundus or exclude it from exposure to ingested 
nutrients may be predicted to reduce circulating ghrelin concentrations.  Indeed, multiple studies 
report a decrease in circulating ghrelin concentrations after SG.615 ,616 , 617 ,618    Furthermore, gastric 
banding results in either no change or an increase in circulating ghrelin, similar to changes after dietary 
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induced weight loss.615,619,620,621   In contrast, the published literature on the effect of RYGB on ghrelin 
reports variable outcomes; some publications support a reduction of circulating ghrelin concentrations 
after RYGB,619,621, 622  whilst others report no change.608,610,616  Whilst one study showed an early 
significant reduction in ghrelin after RYGB and VSG, ghrelin concentrations had risen again at three 
months follow up in those who had undergone RYGB, although remained significantly lower than 
controls.617  One possible explanation for this discordancy is differences in surgical practice with respect 
to the bypassed gastric tissue.  However, one study comparing ghrelin concentrations following either 
standard RYGB or RYGB with resection of the bypassed stomach, showed no significant differences in 
either circulating ghrelin concentrations or subsequent weight loss.623 
Furthermore, there are considerable technical difficulties to consider when evaluating studies reporting 
ghrelin outcomes after bariatric surgery.624  Whilst methodological concerns are present, of primary 
importance is the measurement of ghrelin as total ghrelin rather than acylated and des-acylated 
constituents.  As discussed above (chapter 1.1.2.3.1), GOAT mediated acylation of secreted ghrelin is 
required for ghrelin to bind to the GHSR and exert its actions.  Therefore, compensatory increases either 
in the expression of GOAT or the GHSR could nullify any reductions in secreted ghrelin.  To support this 
concept, some studies have shown no changes or even increased acylated ghrelin specifically after VSG 
and RYGB.625,626,627   Additionally, VSG results in comparable weight loss in ghrelin knockout and wild 
type mice.628 Thus, these data would suggest that ghrelin plays little role in weight loss after bariatric 
surgery.  In contrast, recent studies have reported reductions in acylated ghrelin following RYGB in 
humans, and furthermore have shown that higher post-surgical fasting total ghrelin predicts weight 
regain.629,630 
In conclusion, the available literature does not conclusively determine whether a reduction in ghrelin 
following either VSG or RYGB contributes significantly to the weight loss resulting from each of these 
procedures, and further research is required. 
1.4.2.3 Cholecystokinin (CCK) 
CCK concentrations following bariatric surgery have been reported in only a handful of studies.  
Gastrectomy, RYGB, and JIB appear to increase both the post prandial CCK peak and the post prandial 
AUC CCK.631,632,633,634 CCK secreting I cells appear to be present in higher numbers in the rat intestine 
following RYGB, due to hyperplasia of the intestine exposed to nutrients.635  It is therefore possible that 
the elevated post prandial CCK concentrations are simply a marker of increased I cell exposure, and 
may not factor in weight loss outcomes.  Indeed, one study comparing participants with good and poor 
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weight loss after RYGB, reported a more marked post-surgery increase in CCK concentrations in those 
who had lost less weight.600  
1.4.2.4 Glucagon-like peptide-1 (GLP-1) 
GLP-1 concentrations rise after bariatric surgery in the post prandial phase, but remain unchanged in 
the fasting state.  This has been demonstrated clearly after RYGB,608,617,636,637,649,655,657,665 VSG,617,618,633,638 
and BPD.639,640 LAGB appears to have little effect on GLP-1 concentrations.649,641,657,665 Matched weight 
loss through dietary means does not result in comparable increases in post prandial GLP-1 
concentrations, suggesting that the increase in post prandial GLP-1 relates directly to the surgical 
procedure.650  However, the mechanism of increased GLP-1 secretion after meals following these 
procedures is unclear.  Two suggested mechanisms have been proposed relating to foregut or hindgut 
factors.  The foregut hypothesis proposes that surgical bypass of a factor integral to the proximal 
intestine directly leads to an increase in GLP-1 secretion, although no such factor has as yet been 
identified.  The hindgut hypothesis instead proposes that increased distal intestine exposure to 
nutrients results in increased GLP-1 secretion.  The evidence from studies published recently would 
suggest that a mixture of these factors is more likely to be present.  Firstly, and in support of the hindgut 
hypothesis, an increase in GLP-1 secretion occurs after SG to an extent that may be comparable to RYGB 
and BPD, suggesting that proximal bypass is not important.638 Secondly, the rate of gastric pouch 
emptying and intestinal transit are both positively associated with the rise in post prandial GLP-1 
concentrations after bariatric surgery, supporting increased delivery to the distal gut as a factor in GLP-
1 secretion.642,643 Thirdly, studies in rats and humans have shown an increase in the density of distal gut 
GLP-1 secreting cells following RYGB.635,668 
Nonetheless, the lack of GLP-1 change following LAGB suggests that some degree of proximal 
gastrointestinal anatomical alteration may still be required to induce the observed changes in GLP-1 
secretion.  Furthermore, deliverance of nutrients after RYGB into the bypassed gastric remnant in 
humans does not result in the same increase in post prandial GLP-1 concentrations as when nutrients 
are delivered via the oral route.  Dirksen and colleagues describe a case of a patient with type 2 
diabetes, who developed symptoms consistent with a gastrojejenostomy leak on the second day after 
RYGB.644  Consequently a percutaneous gastric tube was inserted into the bypassed gastric remnant.  
Administration of a glucose challenge via the oral route resulted in a five fold greater rise in post 
prandial GLP-1 secretion when compared with administration via the gastric tube.   A second similar 
case, where post RYGB refractory hyperinsulinaemic hypoglycaemia required gastric remnant feeding 
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resulted in similar attenuation of the GLP-1 response. 645  It is therefore clear that the precise 
mechanisms underlying the increased post prandial GLP-1 response to a meal following bariatric 
surgery remain to be elucidated. 
Irrespective of the mechanism of release, it is currently unclear whether an increase in post-prandial 
GLP-1 concentrations is an important factor underlying weight loss seen following bariatric surgery.  As 
discussed above (1.2.2) the pharmacological administration of GLP-1 agonists results in modest weight 
loss in humans.  Le Roux and colleagues showed that patients who had lost less weight following RYGB 
had an attenuated post prandial GLP-1 response when compared with patients who had lost greater 
amounts of weight.659  Furthermore, the administration of a GLP-1 agonist to mice following gastric 
banding resulted in augmented weight loss; further studies are required to determine whether GLP-1 
agonism alone could overcome the differences in weight loss between banding and other bariatric 
procedures.646  However, little research has yet been performed exploring the direct effect of increased 
post prandial GLP-1 secretion on reduced food intake following bariatric surgery.   Furthermore, studies 
in GLP-1 receptor knockout mice have recently produced surprising results.  Knockout mice undergoing 
either VSG or RYGB lost a comparable amount of weight and maintained this weight loss over the follow 
up period.647,648   
In conclusion, GLP-1 concentrations predictably increase in the post prandial phase following bariatric 
surgery. However, the currently available literature does not definitively define either the mechanism 
of this increase, or the role increased GLP-1 concentrations play in weight loss following bariatric 
surgery.  
1.4.2.5 Gastrointestinal glucose dependent peptide (GIP) 
Changes in GIP do not appear to be important in weight outcomes following bariatric surgery on the 
basis that significantly variable GIP responses to surgery have been reported by multiple studies 
reporting similar effects on weight.  Indeed, concentrations appear not to be effected at all by LAGB, 
whilst fasting concentrations appear unchanged or reduced after RYGB and VSG. 649 , 650   Bariatric 
procedures which bypass the duodenum and jejunum, thereby preventing exposure of the GIP 
secreting K cells to ingested nutrients, might be expected to produce reduced post prandial GIP 
responses.  Most studies have indeed demonstrated this, whilst pre-operative type 2 diabetes appears 
to predict this reduction. 649,651,652,653,654  A small number of studies have reported an exaggerated post 
prandial GIP response following RYGB.655,656  
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1.4.2.6 Peptide YY (PYY) 
PYY secretion in response to a meal is increased after RYGB610,617,619, 657 , 658 , 659 , 660  and sleeve 
gastrectomy.616,633,661,662,663  In contrast, LAGB does not appear to significantly affect post prandial PYY 
concentrations,664,665 and certainly has less of an effect than RYGB.619,657,665  Fewer reports exploring PYY 
changes after BPD have been published, but generally support a similar favourable change to that seen 
with RYGB and VSG.663,666  One study reported a greater rise in post-prandial PYY concentrations after 
BPD when compared with RYGB.667  With a few exceptions, most studies have shown no differences in 
fasting PYY concentrations between surgical and non-surgical participants.   
The mechanism of increased PYY secretion remains unclear but as with CCK above, may relate to an 
increased density of PYY secreting cells in the intestine following bariatric surgery.668  Furthermore, an 
increase in post-prandial PYY could plausibly explain some of the weight loss effects of bariatric surgery.  
Morinigo and colleagues showed that an early increase in post-prandial PYY concentrations after RYGB 
positively predicted weight outcomes at 32 months.658 In a further study, participants who had lost the 
most weight had greater increases in post-prandial PYY concentrations than those who had responded 
poorly to bariatric surgery.659  Weight regain after initial losses has been associated with an attenuation 
of increased post prandial PYY concentrations over time.669  This favourable change is unlikely to relate 
to weight loss alone, as post prandial PYY concentrations are significantly greater than those seen in 
weight matched non-surgical participants achieving weight loss by dietary restriction.661  In addition, 
PYY knockout mice lose significantly less early weight after gastric bypass than diet matched wild type 
littermates.670 
In conclusion, it is likely that the increase in post-prandial PYY concentrations after RYGB, VSG, and BPD 
is a factor in the increased satiety observed after these procedure, and contributes to both weight loss 
and subsequent weight maintenance.  Further research will determine the relative contribution of PYY 
to weight loss and the mechanism of increased PYY secretion. 
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1.4.3 Gut microbiota 
The first attempt at metagenomic sequencing of the microbiome of the human distal gut was 
performed in 1996 with just one subject.671  Multiple similar studies have been performed since in 
participants from different populations and states of health, culminating in the recent Human 
Microbiome Consortium Study which provided for the first time metagenomic sequencing data of the 
distal gut microbiota from a large population sample (242 health Western subjects).672   Bacteroidetes 
(Bacteroides/Privatella) and Firmicutes (Clostridium/Lactobacillus) species predominate.  It therefore 
became possible for observations to be made regarding the pathogenic role that gut microbiota may 
play in obesity.  An increase in the ratio of Firmicutes to Bacteroides numbers is seen in the distal gut 
of obese humans compared to those of normal weight; conversely, a relative increase in the population 
of Bacteroides is seen in when these individuals lose weight.673,674,675,676    Furthermore, exposure of a 
normal weight mouse model to a high energy/high fat diet  resulted in a demonstrable increase in the 
Firmicutes to Bacteroides ratio in the distal gut, whilst germ free mice subsequently exposed to this 
microbiome via faecal transplantation gained significantly more adiposity than germ free mice exposed 
to the microbiome of mice administered a low fat/plant polysaccharide rich diet. 677   Thus, the 
constituents of the gut microbiota appear to be response to environmental changes, pathogenic in the 
development of obesity, and transfer the potential for diet induced adiposity. 
Few studies have thus far been performed reporting on the effect of bariatric surgery on the gut 
microbiome.  However, striking similarities in results are noted in both human and rodent studies.  SG 
in humans increased the Bacteroides to Firmicutes ratio in comparison to participants who obtained 
matched weight loss through a dietary intervention.678  Li and colleagues documented the expected 
reduction in the Firmicutes to Bacteroides ratio in non-obese mice undergoing RYGB or sham surgery.679  
However, the post-surgery microbiome was dominated by Proteobacteria, a finding also observed by 
Zhang and colleagues in human subjects after RYGB.680   This microbiome has not previously been 
observed in non-surgical healthy or obese populations.  Furthermore, colonization of germ free mice 
with gut microbiota obtained from mice who had previously undergone RYGB or VBG resulted in 
reduced fat deposition and a reduction in the utilisation of carbohydrate as an energy source.681  Finally, 
the peri and post-operative administration of Proteobacteria probiotics to humans undergoing RYGB 
resulted in greater weight loss at six and 12 weeks.682  
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1.4.4 Mechanisms underlying the improvements in glucose homeostasis 
following bariatric surgery 
Weight loss by any means results in improved glucose homeostasis.  It is therefore evident that many 
of the mechanisms underlying improvements in dysglycaemia following bariatric surgery are weight 
loss dependent.  However, dysglycaemia improves early after bariatric surgery, and before any 
measureable weight loss, whilst the bariatric surgery improves diabetes control significantly more 
effectively than any other current therapeutic option.  In the following section I will discuss those 
factors that are currently proposed to underlie the favourable effects of bariatric surgery on glucose 
homeostasis.  
 
1.4.4.1 Caloric restriction leads to early improvements in hepatic insulin sensitivity 
RYGB improves insulin sensitivity, as measured by HOMA-IR, within four weeks prior to significant 
weight loss. 619,650,683,684 Indeed, a number of studies have shown improvements within the first post-
operative week. 685 , 686   Furthermore, insulin sensitivity as measured by the hyperinsulinaemic 
euglycaemic clamp (HEC), insulin tolerance test, or HOMA-IR is clearly improved from baseline 
measurements six to 12 months after surgery, by which time substantial weight loss has 
occurred.687,688,689  In contrast, insulin sensitivity is not changed within four weeks when measured using 
the HEC.688,690,691  This apparent discordancy may be explained by the differing information provided 
about insulin resistance by HOMA-IR and the HEC;  whilst the HEC primarily reflects peripheral insulin 
resistance, HOMA-IR is a measure of hepatic insulin sensitivity only.692  HEC can be combined with tracer 
studies to assess hepatic glucose output, and studies utilising this technique have reported reductions 
in hepatic glucose production six months or more after RYGB.693,694  However, the current literature 
reporting specifically on hepatic glucose production in the first few weeks after RYGB is inconclusive.  
Two studies, reporting changes in hepatic glucose production using an HEC tracer technique at seven 
days and one month following RYGB, show a reduction in hepatic glucose production without changes 
in peripheral insulin sensitivity.695,696  However, two further studies reported no change in hepatic or 
peripheral insulin sensitivity using the same technique at 12 to 20 days after RYGB.694,697 It should be 
noted however that the number of participants in the study by Camastra et al was only 11, and a trend 
towards reduced endogenous glucose production (p=0.13) was noted, whilst endogenous glucose 
production (but not hepatic insulin sensitivity) was reduced at two weeks in the study by de Wijer et al.  
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Overall, the available evidence would support that hepatic glucose production is reduced and hepatic 
insulin sensitivity is increased within days/weeks of RYGB, whilst peripheral insulin resistance improves 
only with weight loss. 
It has long been known that non-surgical caloric restriction leads to rapid improvements in glucose 
homeostasis, often evident prior to weight loss.698,699 ,700  Henry and colleagues recruited 30 obese 
individuals with type 2 diabetes and restricted caloric intake to 330 kcal/day for 40 days.701  Despite 
steady and progressive weight loss over this period, there was an early improvement in glucose 
homeostasis reflected by significant decreases in fasting glucose and hepatic glucose production.  
Indeed, near maximal reductions in both of these parameters were evident after only 10 days of caloric 
restriction, at which point participants had lost a mean of only 4.6 of the 10.5kg they lost over the 40 
day period.  Furthermore, a subgroup of participants who were observed during refeeding 
demonstrated significant early increases in both fasting glucose and hepatic glucose production.  A 
second study compared caloric restriction of 400 or 1000 kcal/day in obese participants with type 2 
diabetes.702  Participants randomised to 400 kcal/day had more significant and early improvements in 
fasting glucose and insulin sensitivity despite comparable weight loss.  Interestingly, when these 
participants were subsequently provided with 1000 kcal/day, increases in both fasting glucose and 
insulin resistance above those observed in participants who had been on 1000 kcal/day for the duration 
of the study were observed.  More recently, the mechanism underlying this early response to caloric 
restriction has been shown to likely relate to a reduction in intrahepatic lipid content (IHL).  Peterson 
and colleagues measured IHL by magnetic resonance spectroscopy in obese participants with type 2 
diabetes before and after moderate weight loss (8kg) achieved through a hypocaloric low fat diet.703  
Prior to the intervention the participants had marked increases in both IHL and intramyocellular lipid 
(IML) content, associated with hepatic and muscle insulin resistance.  After eight weeks, IHL content 
had reduced by 81% and was associated with normalisation of fasting glucose, hepatic glucose 
production, and hepatic insulin sensitivity.  No significant change in peripheral insulin resistance or IML 
was observed. Other studies have since supported the relationship between IHL and hepatic insulin 
sensitivity.704   This phenomenon is utilised clinically in the preparation of patients for abdominal 
surgery, where a significant reduction in hepatic volume is observed through caloric restriction for two 
weeks prior to the day of operation.705  The conclusion from these studies and others is that significant 
caloric restriction results in an early reduction in IHL and consequently significant improvements in 
hepatic insulin sensitivity.  These improvements occur prior to significant weight loss and are rapidly 
reversible with an increase in caloric intake. 
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Patients undergoing bariatric surgery are subjected to a sudden decrease in daily caloric intake that 
exceeds that utilised in most dietary studies of caloric restriction.  It has been calculated that the 
average person presenting for bariatric surgery would require 3200 kcal per day to maintain their 
current weight.706 Whilst daily calorie intake in the first few weeks after RYGB  is surprisingly rarely 
reported, it is likely to total less than 500 kcal/day.707,708   Longer follow up studies suggest that daily 
caloric intake remains around 1500-1800 kcal/day.709   Could this reduction in caloric intake alone 
therefore explain the improvements in hepatic insulin sensitivity seen early after RYGB?  Lim and 
colleagues addressed this question in a recent study involving 11 obese participants with type 2 
diabetes. 710   Participants were intensively studied at 1, 4 and 8 weeks during supervised caloric 
restriction of 600 kcal/day.  Hepatic glucose production, hepatic insulin sensitivity, and peripheral 
insulin sensitivity were measured using validated tracer HEC techniques, whilst hepatic and pancreatic 
triacylglycerol content was measured using magnetic resonance imaging.  At one week, IHL had reduced 
by 30% and was associated with a significant improvement in hepatic insulin sensitivity, such that 
fasting glucose normalised and hepatic glucose production was comparable to that observed in obese 
controls.  Beta cell function, as measured by first phase and maximal insulin production, normalised 
over the eight week study period, matched by a gradual reduction in pancreatic lipid content over the 
same duration.  Further work by this group suggests that the reduction in pancreatic triacylglycerol 
content is not explained simply by whole body fat losses, but instead is specific to individuals with type 
2 diabetes.711 
A number of studies have attempted to assess the role of caloric restriction in the early improvements 
in hepatic insulin sensitivity observed after RYGB, and have shown similar,650,712,713,714 worsened,715 and 
improved707,716 parameters when compared with matched caloric intake.  Isbell and colleagues assessed 
glucose homeostasis at four days in 18 participants undergoing RYGB or a matched very low calorie diet 
(VLCD, 200-300 kcal/day plus water).712  50% of participants had type 2 diabetes.  Hepatic insulin 
sensitivity improved to a similar degree in both groups (25% reduction in HOMA-IR), despite the insulin 
response to a mixed meal remaining attenuated in both groups.  Jackness and colleagues performed a 
similar study in obese participants with type 2 diabetes randomised to RYGB or a matched very low 
calorie diet (500 kcal/day).713 Glucose homeostasis was assessed through the use of the frequently 
sampled intravenous glucose tolerance test.  Similar improvements in insulin resistance (HOMA-IR), 
insulin sensitivity, the acute insulin response, and the disposition index were observed at 21 days in 
each group.  Lips and colleagues recruited four groups of participants, two with normal glucose 
tolerance undergoing either GB or RYGB, and two with type 2 diabetes undergoing either RYGB or a 
matched VLCD.714   Improvements in glucose homeostasis were similar at three weeks in both groups 
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with pre-intervention type 2 diabetes, although were improved after RYGB in comparison to GB in those 
with pre-intervention normal glucose tolerance.  Similar outcomes have been demonstrated in an 
additional study where the dietary caloric intake was less restrictive.650  Lingvay and colleagues utilised 
an alternative study design whereby patients planned for RYGB underwent a pre-operative 10 day 
period of caloric restriction (identical to that consumed following subsequent RYGB).715  RYGB was then 
performed at least six weeks after the VLCD component.  All 10 participants had type 2 diabetes.  Daily 
glycaemia, measured by collating frequent capillary glucose readings, was improved during both 
periods, but to a greater degree during the VLCD component.  Improvements in fasting and maximal 
stimulated glucose during a meal test were similar in both groups.  Weight loss was greater during the 
VLCD period (7.3kg) than during the subsequent RYGB period (4.0kg).  It should also be noted that there 
was a trend towards lower fasting glucose, maximal stimulated glucose, and glucose AUC prior to the 
RYGB component than prior to the VLCD period, suggesting that improvements during the RYGB period 
may not have been entirely independent of changes engendered by the VLCD period. 
Two studies have shown an improvement in early glucose homeostasis beyond that seen with matched 
caloric restriction.   In contrast to the findings of Lingvay and colleagues, Foo and colleagues reported 
further improvements in glucose homeostasis after RYGB in participants who had previously undergone 
VLCD.707  Eight severely obese participants underwent a six day VLCD (456 kcal/day) prior to RYGB one 
to three weeks later.  A further 24 participants underwent RYGB without prior VLCD.  No participants 
in this study had type 2 diabetes.  Insulin resistance, measured by HOMA-IR, was significantly reduced 
at six days after each intervention, but was 50% lower after RYGB than VLCD.  It should be noted that 
HOMA-IR was also lower at the point of RYGB in those that had previously undergone VLCD when 
compared with those who had not (4.3 vs. 6.8).  Nonetheless, the final HOMA-IR was similar in each 
group.  Peripheral insulin resistance, assessed by an insulin tolerance test, worsened slightly at six days 
in those who had undergone RYGB in comparison to VLCD.  The authors concluded that RYGB resulted 
in an additional improvement in hepatic insulin sensitivity above that seen after matched caloric 
restriction alone.  Pournaras and colleagues noted similar findings in a study comparing early outcomes 
in participants with type 2 diabetes undergoing RYGB, GB, or VLCD.716  A fourth group of obese 
individuals with normal glucose tolerance undergoing VLCD was used as a control.  However, the VLCD 
in this study allowed considerably greater daily energy intake (1000 kcal/day) than that utilised in 
others.  As noted above, previous studies of non-surgical VLCD have shown a significant difference 
when participants are restricted to 400 kcal/daily as opposed to 1000 kcal/daily.  RYGB resulted in 
improvements in insulin resistance and production comparable to that evident in normal glucose 
tolerance controls, which was not observed after GB or VLCD. 
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In summary, non-surgical caloric restriction to the degree observed after RYGB results in significant 
improvements in glucose homeostasis within days.  A rapid reduction in intrahepatic lipid content, and 
consequent improved hepatic insulin sensitivity, is likely to be highly important in this phenomenon.  
Studies comparing RYGB against matched energy intake in humans with type 2 diabetes show similar 
early improvements in glucose homeostasis.  Thus, an improvement in hepatic insulin sensitivity as a 
result of caloric restriction is likely to explain a significant proportion of the early improves in glucose 
homeostasis after bariatric surgery.  Previous studies have shown that non-surgical VLCD has a greater 
effect on hepatic insulin sensitivity in those with type 2 diabetes when compared with normal glucose 
tolerance.  Studies that suggest RYGB rapidly improves hepatic insulin sensitivity above and beyond that 
seen with matched caloric intake either did not include participants with type 2 diabetes, or may be 
limited by the provision of significantly greater daily energy intake with a VLCD than after surgery. 
 
1.4.4.2 Improving beta cell function is observed early 
Insulin secretion in response to a stimulus appears to be improved immediately after RYGB.  Studies in 
participants with normal glucose tolerance or type 2 diabetes show a leftward shift of the insulin profile 
so that the peak insulin level is increased, whilst the time to peak is reduced.608,617,633,717,718,719,720,721  This 
is evident as early as day three after surgery and reported by many studies within the first post-
operative week.608,617,718,721  Presumably reflective of the simultaneous improvements in hepatic insulin 
sensitivity (see chapter 1.4.4.1), the total area under the curve for post prandial insulin is reduced in 
most studies.608,650   It should be noted that studies that employed an intravenously administered beta 
cell stimulant, such as the frequently sampled intravenous glucose tolerance test rather than an oral 
meal test, reported a more gradual improvement in beta cell function after bariatric surgery.  This is 
consistent with the concept that early improved beta cell function relates significantly to GLP-1 
stimulation, whilst intrinsic beta cell function improves days to weeks later (following a reduction 
intrapancreatic lipid content, see below and Figure 1-6, page 116) and, later still, with weight loss.720 
As discussed above (see chapter 1.1.3.4), first phase insulin secretion is typically diminished in type 2 
diabetes.  A number of studies have reported a gradual increase in first phase insulin secretion in the 
first year after bariatric surgery.667,722  As whole body insulin sensitivity improves by that point in relation 
to weight loss, the disposition index (insulin secretion x insulin sensitivity) is significantly increased in 
patients with preoperative type 2 diabetes.667, 718,720,722 
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The early improvement in insulin secretion after RYGB in response to an oral meal, strongly suggests 
that this is driven by an equally early increase in post prandial GLP-1 concentrations (see below, chapter 
1.4.4.3).  However, studies in non-surgical patients has revealed other potential mechanisms.  Beta cell 
function was assessed during the eight week VLCD study described above.710  First phase insulin 
secretion and maximal insulin response gradually increased over the study period to concentrations 
that matched controls with normal glucose tolerance.  At a similar rate, pancreatic triacylglycerol 
content fell from 8.0% to 6.2% (6.0% in controls).  Pancreatic triacylglycerol concentrations vary widely 
in humans with higher concentrations typically seen in those with type 2 diabetes.  Furthermore, an 
increase in pancreatic lipid content appears to precede the development of type 2 diabetes, at least in 
genetically susceptible rat models.  Beta cell exposure to high triacylglycerol/fatty acid concentrations 
impair beta cell performance. It is therefore possible that this apparent small increase in pancreatic 
lipid content may explain some of the beta cell dysfunction observed early in type 2 diabetes, and 
conversely, the reduction in pancreatic lipid content with caloric restriction may explain associated 
improvements in beta cell function. 
In summary, beta cell function improves rapidly after bariatric surgery, firstly with respect to insulin 
secretion and later with respect to first phase insulin release.  The present evidence would suggest that 
a marked early increase in GLP-1 concentrations underlies the early improvements in beta cell function, 
facilitated by simultaneous improvements in hepatic insulin sensitivity, whilst a decrease in pancreatic 
lipid content with caloric restriction and weight loss underlies the more intrinsic improvements 
observed in later months.  
 
1.4.4.3 Bariatric surgery induces favourable gut peptide alterations 
As discussed above (chapter 1.4.2), bariatric surgery results in significant changes in gut peptide 
concentrations.  Improvements in glucose homeostasis resulting from these changes are primarily the 
consequence of weight dependent mechanisms. In this section, I will therefore focus on the role of 
GLP-1 in post bariatric surgery improvements in glucose homeostasis. 
Type 2 diabetes is associated with an attenuated GLP-1 response to a meal, and this is largely resolved 
with bariatric surgery.723  Multiple studies have consistently demonstrated an increase in post prandial 
GLP-1 concentrations after RYGB, VSG, and BPD but not LAGB (see chapter 1.4.2.4).  Importantly, the 
increase in GLP-1 is evident within days of surgery. 617,659,685 More recently the focus has turned to 
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attempts to quantify the contribution that increased GLP-1 concentrations play in improved glucose 
homeostasis following bariatric surgery.  Jorgensen and colleagues studied nine participants with type 
2 diabetes before, one week after, and three months after RYGB.724  Two meal tests were performed 
at each time point, with an infusion of exendin-9 (GLP-1R antagonist) administered during one of the 
meals.  The GLP-1 response to a meal was blunted at baseline, whilst the infusion of exendin-4 did not 
affect glucose homeostasis prior to surgery.  At both one week and three months after surgery, the 
infusion of exendin-9 was associated with an increased GLP-1 and glucagon response to a meal, and 
increased post prandial glucose concentrations.  Beta cell glucose sensitivity, significantly improved 
after RYGB, returned to baseline concentrations during an infusion of exendin-9.  Very similar findings 
were reported in a study by Salehi and colleagues,725 and Shah and colleagues, where participants had 
undergone RYGB a mean of 5.0 years previously. 726   In addition, Dirksen and colleagues recently 
described a case where feeding via the bypassed gastric remnant was required early after RYGB (see 
chapter 1.4.2.4).644  GLP-1 level were five fold higher during a standardised meal test when feeding was 
provided via the per oral route in comparison to the bypassed stomach, and beta cell function was 
more than two fold improved. 
In contrast to these findings, Jimenez and colleagues reported a less clear role of endogenous GLP-1 
secretion.  Twenty three participants with preoperative type 2 diabetes who had undergone SG at least 
two years previously were recruited; six participants had relapsed type 2 diabetes, whilst 10 and seven 
participants had achieved remission or partial remission.  Participants were well matched at baseline.  
A standardised mixed meal was performed and demonstrated impaired beta cell function and increased 
glucagon release in relapsed or partial remission participants in comparison with those who had 
achieved remission.  Fasting, post prandial, and area under the curve values for GLP-1 were not 
different amongst the groups.  However, peak GLP-1 concentrations in each group were significantly 
higher than observed in a non-surgery control group and higher than reported after VSG in other 
studies.633  In a second study, the same group recruited 20 participants, eight of whom had undergone 
SG at least two years prior to the study, had preoperative type 2 diabetes, and had achieved diabetes 
remission, six of whom had undergone SG at least two years prior to surgery but had normal glucose 
tolerance at baseline, and eight of whom comprised a control group of normal weight individuals who 
had not undergone bariatric surgery.  Meal tests with and without exendin-9 infusions were 
administered.  Exendin-9 infusion increased fasting and post prandial glucose concentrations in all three 
groups, resulted in impaired insulin secretion in the surgical groups, but had minimal effect on overall 
glucose tolerance.  The authors therefore concluded that the increase in post prandial GLP-1 
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concentrations following SG could not alone explain the persistent improvements in glucose 
homeostasis seen during follow up. 
In conclusion, bariatric surgery results in a predictable post prandial increase in GLP-1 concentrations 
immediately after surgery and is likely therefore to be a major factor underlying the early improvements 
in beta cell function.727   The apparent contradictory nature of the studies reported above is likely 
explained by the differences in time following surgery at which the participants were studied; it is likely 
that the relative contribution of increased GLP-1 concentrations diminishes with time as improved 
hepatic sensitivity and peripheral resistance become evident. The exact mechanism underlying the 
rapid increase in post prandial GLP-1 release after RYGB requires further research.  Furthermore, the 
role of GLP-1 in the longer term maintenance of improved glucose homeostasis after bariatric surgery 
remission remains unclear. 
 
1.4.4.4 Bile acids concentrations are increased by bariatric surgery 
Bile acid concentrations are increased after RYGB in both the fasting and post prandial state, but are 
unchanged by LABG.728,729 ,730,731  It is unclear whether SG results in bile acid changes; whilst some 
studies in rodents have suggested increased bile acid concentrations after SG, most human studies 
report no change.732,733 In humans with type 2 diabetes, greater post-operative increases in bile acid 
secretion appear to predict diabetes remission.734  Furthermore, fasting bile acids concentrations after 
RYGB are positively associated with adiponectin and post prandial GLP-1 concentrations, and negatively 
associated with post prandial glucose concentrations.728 However, in a study of eight participants with 
pre-operative type 2 diabetes, plasma bile acid concentrations did not correlate with insulin sensitivity 
during an HEC, insulin response to a meal, or resting energy expenditure.  There is circumstantial 
evidence to support a role of bile acids in a number of favourable metabolic effects of bariatric surgery 
including lipid and cholesterol metabolism, gut microbiota, and energy metabolism.735 
A number of mechanisms have been proposed to explain the possible favourable effects of increased 
bile acid concentrations on glucose homeostasis.  An increase in post prandial GLP-1 concentrations is 
a consistent finding after RYGB, as is a positive correlation with increased bile acid concentrations.  Bile 
acids are a substrate for the TGR5 receptor, expressed by GLP-1 secreting intestinal L cells.736   The 
direct delivery of bile to the distal small intestine in rodents increases local expression of TGR5 and 
proglucagon genes, and an increase in GLP-1 release.737,738  Study of a mouse model of biliary diversion 
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from the common bile duct to the mid-distal jejunum showed great weight loss, improved glucose 
tolerance, greater post prandial GLP-1 increases, and reduced hepatic steatosis when compared with 
sham surgery littermates.739   
An alternative mechanisms relates to a recently identified enterohepatic pathway involving bile acids 
and fibroblast growth factor 19 (FGF19).  FGF19 is produced in the ileum in response to bile acid 
activation of the farnesoid X receptor (FXR).740,741  FGF19 acts through two hepatic receptors to regulate 
the expression of CYP7A1 which converts cholesterol to bile acids.  FGF19 stimulates glycogen synthesis 
and inhibits gluconeogenesis.742  In addition FGF19 appears to augment cerebral insulin independent 
glucose uptake.743   Transgenic mice expressing human FGF19 had improved glucose homeostasis, 
whilst the administration of FGF15 (mouse equivalent of human FGF19) in mice results in improved 
glucose tolerance.744,745 Thus, whilst the literature is incomplete, the available evidence would support 
a favourable effect of increasing FGF19 concentrations on glucose homeostasis.  FGF19 concentrations 
are reduced in obese persons with type 2 diabetes but are increased after RYGB.734,746   
Irrespective of the mechanism, it remains unclear whether the increase in bile acid and FGF19 
concentrations after bariatric surgery contribute to improved glucose homeostasis.  Jorgensen and 
colleagues performed a liquid meal test on 25 participants (13 with type 2 diabetes) before and after 
RYGB.747As with other studies, hepatic insulin sensitivity was improved at one week, and improvements 
in post prandial GLP-1 release were evident.  However, both fasting and post prandial bile acid and 
FGF19 concentrations were unchanged immediately after surgery.  Fasting and post prandial bile acid 
and post prandial FGF19 concentrations were increased at three months post-surgery and increased 
gradually thereafter until 12 months of follow up. 
In summary, the majority of studies report and increase in fasting and post prandial bile acid and FGF19 
concentrations after RYGB, although there is disagreement as to when these changes become evident.  
At present there is insufficient evidence to conclude what, if any, role bile acid changes play in glucose 
homeostasis improvements following bariatric surgery.  
 
1.4.4.5 Intestinal gluconeogenesis 
The small intestine is the predominant site of dietary glucose absorption.  There is debate as to whether 
the intestine is also a site of gluconeogenesis, but recent work using mice models would support 
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this.748,749  Mice with a combined deletion of glucose-6 phosphatase catalytic subunit (G6PC) in the liver 
and intestine fail to maintain normal glucose concentrations during a fast, whilst mice with a liver 
specific G6PC deletion are able to do so.  In addition, the expression of gluconeogenic enzymes is 
increased in the intestine in response to fasting in mice with liver specific G6PC deletions.  It has been 
suggested that the intestine may be subject to obesity related insulin resistance as seen in other 
tissues.750  
There is therefore interest as to whether alterations in intestinal gluconeogenesis may play a role in the 
improvements in glucose homeostasis seen after bariatric surgery.  Early work provided the rather 
paradoxical possibility that bariatric surgery may improve glucose homeostasis by enhancing intestinal 
gluconeogenesis.  Troy and colleagues performed either GB or a modified bypass procedure in mice fed 
a high fat diet, and demonstrated increased intestinal gluconeogenesis, assessed via tracer methods 
and portal sampling, after bypass but not GB.751  This was associated with improvements in hepatic 
insulin sensitivity and a reduction in appetite.   The authors postulated that these favourable effects 
were the consequence of increased portal glucose concentrations resulting from increased intestinal 
gluconeogenesis, and noted previous studies supporting hypophagia and enhanced whole body glucose 
disposal after intraportal glucose infusion.752,753  Portal ‘sensing’ of glucose concentrations appears to 
be mediated by GLUT-2 transporters.752  Furthermore, these favourable effects were not seen in GLUT-
2 knockout mice or after portal vein denervation.  In addition, intestinal glucose uptake, measured using 
PET imaging, is increased six months after RYGB and SG and correlates with whole body insulin 
sensitivity.750  However, if changes in intestinal gluconeogenesis contribute to improved glucose 
homeostasis following bariatric surgery, the current evidence would suggest that this is not an early 
effect.754   There was no difference in central or portal glucose concentrations before or six days after 
RYGB in eight obese human participants with pre-operative type 2 diabetes. 
Thus, further research is required to quantify the contribution of intestinal gluconeogenesis to glucose 
control.  The current evidence would suggest that improved intestinal gluconeogenesis may contribute 
to the longer term favourable effects of bariatric surgery on weight loss and glycaemia, but is unlikely 
to be a major factor underlying early improvements.  
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1.5 An integrated model explaining weight loss and improved glucose 
homeostasis after bariatric surgery 
It is clear that a number of factors of variable importance underlie the significant improvements in 
glucose homeostasis observed after bariatric surgery (see Figure 1-6).  It is also clear that each of these 
factors is evident at differing times after surgery, and therefore the contribution of a single factor to 
overall glucose homeostasis at any one point during follow up may change. 
 
 
Figure 1-6   A schematic of the suggested mechanisms explaining the early and significant improvements in 
glucose homeostasis following RYGB and VSG 
 
 
With respect to RYGB, the earliest documented change after surgery is an almost immediate 
improvement in insulin secretion, likely related to a marked increase in the GLP-1 response to a meal.    
Within days, a significant improvement in hepatic insulin sensitivity is observed which appears to be of 
a similar magnitude to that observed after matched calorie restriction and is likely to relate to a 
reduction in intrahepatic lipid.  Thus, whilst insulin secretion is enhanced, there is an early reduction in 
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total insulin secretion after a meal due to improved hepatic insulin sensitivity.   First phase insulin 
release is improved within weeks, and along with other improvements in beta cell function, may relate 
to a reduction in intrapancreatic lipid.  Significant weight loss over the subsequent months results in 
improvements in peripheral insulin resistance, further enhancing beta cell function.  The role of bile 
acids, FGF19, gut microbiota, and intestinal gluconeogenesis remains unclear but current evidence 
would suggest that these factors are less likely to contribute to early post-operative changes. 
Can we therefore definitively state which early hypothesis (foregut or hindgut) to explain the dramatic 
effects of bariatric surgery was correct? The clear role of GLP-1 in enhancing beta cell function suggests 
that structures in the hindgut certainly underlie some of the early improvements in glucose 
homeostasis.  The exact mechanism explaining why post prandial GLP-1 concentrations are increased 
though remains to be clarified.  An increase in L cell density after RYGB may explain the longer term 
increase in GLP-1 concentrations but could not explain how this response is evident within hours to 
days of surgery.   Whilst VSG is associated with an increase in GLP-1, LAGB is not, and reports of an 
absence of the increased GLP-1 concentrations after bypassed stomach feeding in patients after RYGB 
suggest that some anatomical diversion in the proximal gut may be required to engender these effects.  
Thus, the present evidence does not refute the principle underlying the foregut hypothesis; that a 
process integral to the proximal gut (secretion of a hormone, digestive processes, etc.) may be the 
driver behind the rapid increases in post prandial GLP-1 concentrations.  Further study is clearly 
required in this area. 
In contrast, the mechanism explaining early improvements in hepatic insulin sensitivity appears clearer.  
Whilst further study is required, numerous studies have now demonstrated similar early improvements 
in hepatic insulin sensitivity by caloric restriction alone, and furthermore have related this to reductions 
in hepatic lipid content.     
 




Obesity and type 2 diabetes are interlinked conditions that are increasingly prevalent in New Zealand 
and internationally.  Current therapeutic strategies for obesity are minimally effective and often poorly 
tolerated.  Bariatric surgery has emerged as the most effective treatment option for both conditions, 
either in isolation or combination, but little evidence is available as yet detailing longer term outcomes.  
As noted above (chapter 1.3.2) there are no randomised data reporting outcomes beyond three years.  
There is therefore a need for additional data reporting on weight, glycaemic, metabolic, quality of life, 
and nutritional outcomes to complement the available literature.  In chapter 3, I present outcome data 
from a prospective follow up study of 118 participants with and without dysglycaemia who underwent 
RYGB at least five years prior to recruitment.  A second study in this chapter will address the issue of 
variable reporting of diabetes outcomes in the bariatric literature. 
Significant improvements in our understanding of the mechanisms underlying bariatric surgery induced 
weight loss and improved glucose homeostasis have occurred recently.  However, large gaps in the 
literature remain, and it is vital for a number of reasons to better understand this process.  Firstly, 
outcomes after bariatric surgery clearly differ from patient to patient.  It would be preferable to have 
better methods for predicting the response to bariatric surgery prior to operation.  Secondly, an 
improved understanding of the exact mechanisms underlying bariatric surgery may allow the 
development of augmented strategies to facilitate weight loss/diabetes remission in those patients who 
have initially responded poorly to bariatric surgery.  Similarly, weight regain and/or worsening glucose 
homeostasis is a reasonably common occurrence after an initial good response.  An ability to identify 
the mechanism underlying these changes may allow a stepwise approach with the addition of further 
pharmaceutical therapy to complement and ensure the durable effect of bariatric surgery.   Finally, and 
perhaps most importantly, an improved understanding of the mechanisms underlying bariatric surgery 
may enhance our ability to both prevent obesity and type 2 diabetes developing, or to allow the design 
of pharmaceutical therapies that induce the same significant improvements in weight and glucose 
homeostasis currently seen only after surgery.  In chapter 4, I will present two studies, one exploring 
the effect of surgery itself on the assessment of glucose homeostasis in the first few post-operative 
days, and the second providing an initial exploration of the role of gut peptides in the longer term 
outcomes after bariatric surgery.
 
 










2 Chapter two:   Methodology 
 
2.1   RYGB surgery 
2.2   Measurement of physical characteristics 
2.3   Methodology of biochemical characteristics 
2.4   Assessment of co-morbid conditions 
2.5   Assessment of quality of life measures  




2.1 Roux-en-Y gastric bypass surgery 
RYGB surgery was performed at Wakefield Hospital by a single surgeon (Professor Richard Stubbs).  
Extracts from previous publications describing the silastic ring RYGB755 and Fobi pouch RYGB756 are 
included below.  
 








2.1.1.1 Silastic ring RYGB 
Surgery was performed under general anaesthesia with epidural analgesia.  An upper midline incision 
was used.  A window into the lesser sac was created adjacent to the lesser curve of the stomach some 
9cm from the angle of His, and a passage was created from this point, behind the stomach, to the 
angle of His.  A TA90B stapler (US surgical) was paced between these two points and its position 
adjusted prior to firing to produce a blind lesser curve stomach pouch approximately 9cm in length 
and 1.5cm in diameter.  A 5.5cm length of 8F silastic rubber tubing was passed circumferentially 
around the lesser curve pouch some 6cm from the angle of His.  This was fixed in place with an internal 
2/0 prolene structure.  A 40cm Roux loop of jejunum was fashioned with the entero-entero 
anastomosis being performed with two layers of 2/0 chromic catgut at a convenient point some 20-
40cm from the ligament of Treitz.  The Roux loop was passed in a retro-colic fashion and anastomosed 




side-to-side to the blind end of the gastric pouch just distal to the silastic ring.  This anastomosis was 
made with two layers of 2.0 chromic catgut over a length of 1.5-2.0cm.  Mesenteric defects were 
closed, and cholecystectomy performed if gallstones were present.  The abdominal cavity was lavaged 
with normal saline containing the antibiotic Cefamandole® (Eli Lily), and the abdomen was closed with 
a mass No.1 nylon suture.  The subcutaneous fat layer was vigorously lavaged with the same antibiotic 
containing saline so as to dislodge all loose fat, and the skin was closed with subcuticular vicryl suture 
(Johnson & Johnson) and steri-strips.  All patients received a single intra-operative dose of a 
prophylactic antibiotic, and were commenced on preoperative Fragmin® (Fisons) 2500 units 
subcutaneously for DVT/PE prophylaxis.  The latter was continued postoperatively for 4-5 days.  
Epidural analgesia was continued postoperatively for 3-4 days.  Urinary catheters were not employed, 
and patients were initially mobilized off the side of the bed 4 hours postoperatively. 
 
2.1.1.2 Fobi pouch/transected RYGB 
Fobi pouch was performed under general anaesthesia with epidural analgesia.  Through an upper 
midline incision, a window was produced adjacent to the lesser curvature of the stomach 9cm from 
the angle of His, and a passage was created to this point behind the stomach, to the angle of His.  A 
TCT-10® linear stapler-cutter (Johnson & Johnson) was positioned between these two points, and its 
position was adjusted before firing, so as to produce a blind lesser curvature gastric pouch 7-8cm in 
length and 1.5-2cm in diameter.  Firing of the stapler achieves gastric transection, with 2 rows of 
staples on either side.  The staple-line on the bypassed stomach was oversewn with a continuous 2/0 
Ethibond suture.  A 70cm Roux-loop of jejunum was fashioned, with the entero-entero anastomosis 
performed with two layers of 2/0 chromic catgut at a convenient place 40-60cm from the ligament of 
Treitz.  The Roux-loop was passed in a retrocolic, retrogastric fashion to lie alongside the newly created 
lesser curvature pouch, separating this from the oversewn distal stomach.  The Roux-loop is sutured 
to the lesser curvature pouch, in two layers with 2/0 polypropylene (Prolene®) in such a way as to 
create a serosal patch over a buried staple line.  A 6.0cm (for age <50 years) or 6.5cm (for age >50 
years) length of 8F silastic rubber tubing was passed circumferentially around the lesser curve pouch 
5cm from the angle of His, and defined the size of the pouch above the ring (approximately 10-15ml).  
This was fixed in pace with an internal 2/0 Prolene suture.  The Prolene sutures creating the serosal 
patch above the ring were continued to a point 1-2cm beyond the silastic ring, at which point a 2-layer 
end-to-side gastro-jejunal anastomosis 1-1.5cm long was created, after removal of a portion of the 




staple-line.  The inner layer was fashioned with all coats 2/0 chromic catgut, and the outer 
seromuscular layer completed with 2/0 Prolene.   
Mesenteric defects were closed, and cholecystectomy was performed if gallstones were present.  The 
upper abdominal cavity was lavaged with warm saline and the abdomen was closed with a mass No.1 
nylon suture.  The subcutaneous fat layer was vigorously lavaged with saline so as to dislodge all loose 
fat, and skin was closed with subcuticular Vicryl® suture (Johnson & Johnson) and steristrips.  All 
patients received a single intra-operative dose of a prophylactic antibiotic (Usually Cefotetan® 2g), and 
were commenced on preoperative Clexane® (Aventis) 20mg subcutaneously for DVT/PE prophylaxis.  
The latter was continued daily after surgery, until discharge.  Epidural analgesia was continued 
postoperatively for 4 days. Urinary catheters were not employed and patients were initially mobilized 
off the side of the bed 4 hours postoperatively.  




2.2 Measurement of physical characteristics 
 
2.2.1 Measurement of body weight parameters 
Body weight was measured using calibrated weighing scales in each study.  In study 3.1, weight was 
measured on a TBF 300 Tanita scale throughout the study.  The accuracy of the scale was assessed each 
week by a study nurse using a 10kg weight.  Scales were recalibrated if a deviation of +/- 0.1 kg was 
detected.  Participants were instructed to wear minimal clothing, no shoes or socks, and to have an 
empty bladder.  Clothing weight was entered as 300g and weight was recorded to the nearest 10g.  In 
study 4.1 and study 4.2, weight was measured on anolog scales located in Wakefield obesity clinic and 
the surgical ward at Wakefield hospital.  Weight was expressed in kilograms (Kg). 
Height was measured using a full length stadiometer and expressed in meters.  The body mass index 
was then calculated as: 
 
 Body mass index (BMI, kg/m2)        =        Weight (kilograms) 
      ________________ 
          Height (meters) 2 
 
Body weight loss percentage (BWL) was calculated by comparing the BMI before and after the study 
intervention: 
  
              Body weight loss %    =    (BMI (kg/m2) at baseline – BMI (kg/m2) at follow up) 
                   __________________________________________   * 100 
        BMI at baseline 
 
  




2.2.2 Measurement of blood pressure and heart rate   
Blood pressure was obtained indirectly by sphygmomanometry of either the left or the right brachial 
artery.757  Participants were asked to sit during the procedure, which was performed after five minutes 
of rest.   The cuff was first inflated to a pressure at which the ipsilateral radial pulse was no longer 
palpable.  The cuff was then released, and reinflated to 20 mmHg above that pressure.  The brachial 
artery was then auscultated with a stethoscope, and the cuff was slowly deflated.  The systolic blood 
pressure (SBP, mmHg) was taken as the pressure at which arterial pulsation first became auscultatable 
(first Korotkoff phase).  The diastolic blood pressure (DBP, mmHg) was taken as the pressure at which 
the Korotkoff sounds completely disappear (fifth Korotkoff sound).  Blood pressure measurements 
were obtained on three occasions during the physical examination, and mean values were calculated 
and used in each study. 
In addition, the mean arterial pressure (MAP, mmHg) was calculated as: 
 
              
 MAP (mmHg)  =  DBP (mmHg)    +     ⅓ (SBP (mmHg)  +  DBP (mmHg)) 
         
 
Hypertension at each study time point was defined as either a systolic blood pressure > 120 mmHg 
and/or diastolic blood pressure > 80mmHg, or the current use of anti-hypertensive medication.  In 
addition, hypertension at baseline was defined if the participants reported a previous diagnosis of 
hypertension.    
The heart rate was measured via pulse oximetry over twenty second intervals so as to ensure a stable 
heart rate was recorded.  As with blood pressure, the heart rate was measured on three separate 
occasions and a mean heart rate was calculated. 
 
 




2.3 Measurement of biochemical characteristics 
 
2.3.1 Measurement of markers of glucose homeostasis 
4ml of venous blood was collected in an EDTA vacutainer for the measurement of HbA1c (mmol/mol) 
concentrations (Bio-Rad laboratories Pty Ltd, Albany, Auckland, CV 3.7% at 35 mmol/mol and 2.6% at 
81 mmol/mol).  A separate 6ml of venous blood was obtained using an EDTA vacutainer for the 
measurement of insulin concentrations.  The sample was refrigerated immediately before being 
centrifuged (2000 rpm for 10 minutes at 4 degrees Celsius).  Plasma was then pipetted into two 
separate 1ml standard tubes, which were both then stored at -80 degrees Celsius.  Samples were 
couriered to the Diabetes and Lipid laboratory, Department of human nutrition, University of Otago, 
Dunedin under appropriate conditions to maintain integrity.  An in house assay was used to report 
insulin concentrations, with a CV% of <2 for concentrations < 50 pmol/L, and 4% for concentrations ≥50 
pmol/L. 
Venous glucose was measured following collection with a standard SST vacutainer and analysed at 
Wellington Regional Hospital laboratory (Roche diagnostics assay,  Sandhofer Strasse 116, Mannheim, 
Germany, CV% <5). 
 
2.3.2 Assessments of insulin sensitivity and insulin secretion 
The reference method for calculating whole body insulin resistance is the euglycaemic 
hyperinsulinaemic clamp (EHC).758  This technique involves the simultaneous infusion of insulin and 
glucose.759  The insulin infusion is commenced at a rate adjusted by body mass.  The rate of glucose 
infusion is thereafter adjusted to maintain plasma glucose concentrations at a predetermined level.  
Frequent sampling of insulin concentrations during the later steady state phase, provides an index of 
insulin sensitivity.   The EHC is however, time consuming, difficult to perform, and suitable only for 
supervised research conditions.  Therefore, a number of other methods that provide a more obtainable 
surrogate assessment of glucose homeostasis have been derived.  Aside from simply measuring 
glucose/insulin ratios in the fasting or post prandial state, the Homeostasis Model Assessment (HOMA) 




is perhaps the most widely applied such tool.  The model requires the sampling of glucose and insulin 
concentrations in the fasted state, and therefore provides an assessment primarily of hepatic insulin 
sensitivity.  The model was developed on the concept of a hepatic-beta cell feedback loop; in this model, 
increasing fasting glucose levels (resulting from hepatic gluconeogenesis) provoke a compensatory 
increase in insulin secretion.760  Therefore, fasting hyperglycaemia implies diminished insulin sensitivity.  
This model was adapted by Matthews et al, who reported a set of linear equations describing this 
relationship, and was then further updated by Levy et al to better account for variations in hepatic and 
peripheral glucose resistance (HOMA2).761,762  This model uses non-linear approximations of insulin 
sensitivity and presents these as HOMA-%B (beta cell function), HOMA-%S (insulin sensitivity), and 
HOMA-IR (insulin resistance, or the reciprocal of HOMA-%S).  HOMA-%B, and HOMA-%S are 
comparative percentages against a normal reference population.   Thus, HOMA-%B is a surrogate 
marker of the appropriateness of insulin secretion for a given concentration of glucose, whilst HOMA-
%S is a surrogate calculation of the sensitivity of target tissue to insulin. 
In this thesis, HOMA-%B, HOMA-%S, and HOMA-IR were calculated using fasting measurements of 
glucose and insulin as described above, and using the HOMA2 calculator available online.763 
 
2.3.3 Diabetes definitions at baseline and follow up 
Diabetes status at baseline in each study is reported using the American Diabetes Association (ADA) 
diagnostic criteria (2015).764   
- Type 2 diabetes is defined as an HbA1c greater than or equal to 48 mmol/mol, and/or 
a fasting glucose greater than or equal to 7.0 mmol/L, and/or a 2 hour glucose 
concentration during a 75g oral glucose tolerance test greater than or equal to 11.1 
mmol/L, and/or the ongoing use of glucose lowering medications. 
  
- Prediabetes) is defined as an HbA1c of 39 to 47 mmol/mol inclusively, and/or a fasting 
glucose of 5.7 to 6.9 mmol/L inclusively, and/or a 2 hour glucose concentration during 
a 75g oral glucose tolerance test of 7.8 to 11.0 mmol/L inclusively, (providing none of 
these values exceed the threshold for the definition of type 2 diabetes), and the 
absence of glucose lowering medication. 




- Normal glucose homeostasis is defined as an HbA1c less than or equal to  38 
mmol/mol, and fasting plasma glucose less than or equal to 5.6 mmol/L, and a 2 hour 
glucose concentration during a 75g oral glucose tolerance test of less than or equal to 
7.7 mmol/L, and the absence of glucose lowering medications. 
 
 
The ADA criteria for the diagnosis of diabetes differ significantly from those suggested by the New 
Zealand Society for the Study of Diabetes (NZSSD).  The NZZSD criteria consider diabetes to be present 
in symptomatic individuals if the HbA1c is greater than or equal to 50 mmol/mol, and/or the fasting 
glucose is greater than or equal to 7.0 mmol/L, and/or a random glucose concentration is greater than 
or equal to 11.1 mmol/L.765   A repeat confirmatory test is required in asymptomatic individuals.  
Individuals are considered to have normal glucose tolerance if the HbA1c concentration is less than or 
equal to 40 mmol/mol, and the fasting glucose concentration is less than or equal to 6.0 mmol/L.  
Individuals with at least one measurement between the thresholds set for normal glucose tolerance 
and diabetes, are considered to have prediabetes, also termed dysglycaemia or borderline diabetes.  
To allow comparison with the international literature, the criteria proposed by the ADA for the diagnosis 
of diabetes are used in this thesis.    
Diabetes status at follow up is reported using the criteria suggested by the ADA specifically for the 
assessment of diabetes following bariatric surgery.766 
- Complete remission  
HbA1c “in the normal range” and fasting glucose <100mg/dl (5.6 mmol/L)) provided 
that each of these assessments are persistent for at least one year duration, and in 
the absence of active pharmacologic therapy or ongoing procedures.   
 
- Partial remission 
HbA1C<6.5% (48 mmol/L) and fasting glucose 100-125 mg/dl (5.6 – 6.9 mmol/L)), 
provided that each of these assessments were persistent for at least 1 year duration, 
and in the absence of active pharmacologic therapy or on-going procedures. 
 





- Persistent diabetes 
HbA1c ≥ 6.5% (48 mmol/mol) and/or fasting glucose ≥ 125 mg/dl (6.9 mmol/L), 
and/or the ongoing use of active pharmacologic therapy or ongoing procedures. 
 
2.3.4 Measurement of hormone concentrations 
1ml of venous blood was collected in an EDTA tube for the assessment of Aldosterone.  The sample was 
centrifuged immediately at 4 degrees Celsius on receipt by the laboratory at Wellington Regional 
Hospital, and transported in a deep frozen state to Endolab, Christchurch.  Aldosterone was measured 
on an immunodiagnostic system (IDS) iSYS automated immunoassay analyser, Tyne and Wear, UK using 
a two site chemiluminescence assay.  The assay has a limit of detection of 102.5 pmol/L and a CV of 
8.4% at low concentrations (mean 297.2 pmol/l), 6.2% at medium concentrations (mean 660.5 pmol/l), 
and 3.5% at high concentrations (mean 1686.1 pmol/L).   
1ml of venous blood was collected in an EDTA tube for prolactin concentration measurement (mU/L).  
The assay used was manufactured by Roche Diagnostics NZ, Mount Wellington, Auckland (CV 2% at 206 
mU/L, 2% at 464 mU/L, and 2% at 1229 mU/L). 
Measurements of fasting ghrelin, leptin, amylin, and PYY were obtained on samples collected at 
surgery, on day six following surgery, and again at the follow up assessment at >5 years.  Venous blood 
was immediately centrifuged and plasma was stored at -80 degrees Celsius.  200 microlitre aliquots 
were created from each sample and sent to the Diabetes and Lipid laboratory, Department of human 
nutrition, University of Otago, Dunedin for analysis.  Samples were couriered under appropriate 
conditions to maintain integrity.  A multiplex assay (Category number HGT-68K, Merck Millipore, 
Billerica, Massachusetts, 01821 USA) was used to measure levels of each peptide in duplicate in a 
blinded fashion.  Two quality control samples were used in house to assess the precision of each peptide 
measurement.  Fasting ghrelin (coefficient of variance % = 7.4 and 9.6%), fasting leptin (CV% = 1.6 and 
6.7), fasting amylin (CV% = 5.0 and 15.9), and fasting PYY (CV% = 8.0 and 16.2) were measured and 
expressed as pg/mL. 
 




2.3.5 Measurement of other markers 
A standard SST vacutainer was used to obtain 1ml of venous blood for the measurement of C reactive 
protein (CRP) concentrations.  The samples were immediately transferred to the laboratory at 
Wellington Regional Hospital where they were analysed (Roche diagnostics assay,   Sandhofer Strasse 
116, Mannheim, Germany, CV% <5).  
6ml of venous blood was drawn for the measurement of zinc and copper concentrations.  A BD navy 
top vacutainer was used containing K2 EDTA and a clot activator. Samples were placed immediately into 
a fridge and centrifuged (2000 rpm for 10 minutes) within 5 minutes of collection.   1ml of plasma was 
then obtained by pipette and transferred into a 1ml standard tube, which was then frozen at -80 
degrees until analysis.  An in house assay (Diabetes and Lipid laboratory, Department of human 
nutrition, University of Otago, Dunedin) was used to measure zinc (CV% = 4.7) and copper (CV% = 2.8) 
concentrations. 
Venous blood for vitamin B12 concentration measurement was obtained using a standard SST 
vacutainer.  The samples were delivered immediately to the laboratory at Wellington regional hospital.  
An electrochemiluminescence immunoassay (Cobas, Roche diagnostics, Sandhofer Strasse 116, 
Mannheim, Germany) was used to measure vitamin B12 concentration (CV% = 3.0 to 8.7) 
 
2.3.6 Measurement of urinary markers 
Urine was collected and divided into two urine containers for each 24 hour collection.  This was 
necessary as urinary catecholamine and metanephrine concentrations decrease as a result of 
degradation if they are not stored in an acidified solution.  Urinary cortisol concentrations are not 
affected by degradation to the same extent, and therefore urine can be collected within an empty 
container.  Thus, the actual volume of urine assessed for each hormone was equivalent in volume to a 
12 hour urine collection, but was reflective of 24 hour excretion.  This issue was overcome by reporting 
hormonal concentrations as a ratio per mmol of urinary creatinine (i.e. urinary noradrenaline, reported 
as an absolute level in nmol, was reported as nmol/mmol UCr).  Urinary catecholamines (noradrenaline, 
adrenaline, and dopamine) and metanephrines (normetadrenaline, metadrenaline) were measured 
using an in house assay (cation exchange/alumina extraction and reverse phase high performance liquid 




chromatography with electrochemical detection).  The laboratory report inter-assay coefficient of 
variance of <8% for catecholamines and <10% for metanephrines.   Urinary free cortisol concentrations 
were measured using a Roche assay (Cobas e-601 electrochemiluminescence) with a reported inter-
assay coefficient of variation of <5%. 
2.4 Assessment of co-morbid conditions 
Due to the retrospective nature of this study, data on co-morbid conditions at baseline was limited and 
predominantly based on patient self reports.  A diagnosis of ischaemic heart disease at either baseline 
or follow up was accepted in the context of angina, evidence of coronary artery disease on angiography 
(with or without subsequent intervention), or previous myocardial infarction.  The prevalence of 
myocardial infarction was reported separately.  A diagnosis of previous stroke was made on the basis 
of a self reported diagnosis, and corroborated with available medical records.  The diagnosis of sleep 
apnoea, arthritis, gout, depression, and fractures was self reported and corroborated with medical 
records where available. 
 
2.5 Assessment of quality of life using IWQOL-lite 
The impact of weight on quality of life (IWQOL-Lite) questionnaire was used to assess a number of 
parameters related to quality of life.  The questionnaire itself and the scoring system manual are 
included in Appendix i-8 and Appendix i-9 (pages 360/362) respectively.  The questionnaire includes 31 
questions covering physical function, self-esteem, sexual life, public distress, and work, and provides a 
total score.  The original IWQOL was a 74 item questionnaire, although this was shortened to the 
IWQOL-lite format by removing items that did not contribute to the psychometric performance of the 
test.767,768 Psychometric validation was performed using a cohort of nearly 1000 participants who had 
completed the IWQOL-lite questionnaire in a variety of settings included an outpatient medical weight 
loss centre,  an inpatient intensive treatment centre, during the assessment for and after bariatric 
surgery, and control groups including community volunteers.  Effect sizes were estimated between 
increasing BMI categories, and effect sizes were calculated longitudinally based on the degree of weight 
loss. 




The questionnaire is undertaken by the participant without oversight by the clinician/researcher.  The 
participant is asked to read each of the 31 questions and assign a response (1= never true, through to 
5= always true) to each.  Once completed, the clinician/researcher may check to see if a response has 
been provided to each question, although the scoring system allows absent responses.  Participants 
may decline to answer particular questions because they are deemed either sensitive or not applicable. 
A detailed description of the IWQOL-Lite scoring system is included in Appendix i-9, page 362.  At least 
50% of questions must be answered in each section for that sections score to be included in the total 
score.  The average score in each section is then calculated, and multiplied by the total number of items 
in that section, which is then rounded to the nearest integer.  This ‘raw’ score can then be converted 
to a more intuitive scaled score of 0 (worst) to 100 (best).  The raw score is subtracted from the 
maximum score for each section, which is then divided by the range of possible scores for each section, 
and finally multiplied by 100.  This method then provides a score out of 100 for each domain.  The total 
score is calculated in exactly the same way, averaging the answers to each item in the questionnaire 





























3 CHAPTER THREE:   CLINICAL STUDIES 
RYGB surgery for the treatment of obesity and type 2 diabetes 
 
 
3.1.   Long term metabolic follow up of obese persons with and without dysglycaemia after RYGB 








3.1 Long term metabolic follow up of obese persons with and without 
dysglycaemia undergoing RYGB  
 
3.1.1 Introduction 
The prevalence of both type 2 diabetes and obesity is rising at a rapid rate internationally (chapter 
1.1.1).2   Obesity is a strong risk factor for the development of type 2 diabetes, and therefore the 
prevalence of type 2 diabetes is closely related to that population’s obesity prevalence.  In New 
Zealand, 28.4% of New Zealand adults are obese, whilst 63.8% are overweight (BMI >25 kg/m2).3  The 
same report showed that 198,000 adults (5.5%) in New Zealand had diabetes, with men more likely 
to have diabetes than women (6.3% in males, 4.8% in females).3  Pacific (9%), Maori (7%), and Asian 
(6%) adults were all more likely to have diabetes than the national average.  Given the asymptomatic 
nature of early dysglycaemia, it is likely the true prevalence is higher still.   8.3% of the world 
population had type 2 diabetes in 2011, and this is predicted to increase to approximately 10% by 
2040.9  Furthermore, the financial burden placed on New Zealand’s health resulting from obesity and 
type 2 diabetes is significant with an annual health care cost attributable to obesity alone of NZ$686 
million, or 4.5% of the health budget.12   Type 2 diabetes presents additional significant healthcare 
costs, which is expected to increase to NZ$1.8 billion per annum by 2022.14 
Current non-surgical therapeutic options for the management of both obesity and type 2 diabetes are 
limited with only a small number of obese patients with type 2 diabetes attaining a normal BMI or 
glycaemic status following non-surgical interventions (chapter 1.2).  Lifestyle changes remains the 
cornerstone of treatment for both conditions.  Dietary changes alone however rarely result in 
significant weight loss which is sustained over long term follow up.294  The development of 
pharmaceutical therapies to induce weight loss has been frustrated by significant drug side effects, 
whilst the effect of those still available is modest (see Table 1-2).    Despite a significant recent increase 
in medical therapies for the glycaemic and metabolic management of type 2 diabetes, only 50% of 
patients attain a target HbA1c in population observation studies, and fewer still achieve target levels 
of glycaemia, bloods pressure, and lipids.11   




Bariatric surgery was developed initially as a weight loss only therapy (chapter 1.3.1).  Four large 
randomised studies reporting weight outcomes at 12-24 months after bariatric have now been 
published alongside countless other non-randomised reports in patients with a BMI of ≥35 kg/m2 prior 
to surgery (Table 1-3 and Table 1-4, chapter 1.3.2).394,395,396,397  A further six large randomised studies 
have reported outcomes in those with a BMI of ≥27 kg/m2.398,399,400,401,402,403  Each study reports body 
weight loss of between 20 and 34%, with greater weight loss tending to be observed in those with a 
higher BMI at baseline.  However, early in the development of bariatric surgery, it became apparent 
that significant and early improvements in glucose homeostasis were also observed.404  A significant 
number of publications have since reported diabetes outcomes after bariatric surgery, although the 
quality of study varies (chapter 1.3.3 (page 54)).  Twenty publications have reported the prevalence 
of diabetes resolution after bariatric surgery when compared with an alternative intervention (Table 
1-5).  Unfortunately, disparity with respect to the definition of diabetes resolution employed in each 
study makes it difficult to confirm exact expected diabetes outcomes after bariatric surgery, although 
it is apparent that the effect far exceeds that observed with lifestyle/medical therapy alone.  In 
addition, there is a paucity of higher quality longer term outcome data for both weight and diabetes 
outcomes.  Indeed, no randomised study reported weight outcomes beyond 36 months, whilst 
Schauer and colleagues have recently reported diabetes outcomes at 36 months, which represents 
the longest duration of observed follow up in a randomised study against lifestyle therapy alone.402,403  
With international guidelines now in agreement that bariatric surgery should be considered at an 
earlier stage of diabetes, and therefore at a younger age, evidence to justify this approach and to 
reassure that longer term complications do not develop is of high interest.405  Particularly, it is 
important that the complete metabolic consequences of bariatric surgery, including effects on blood 
pressure and lipid concentrations, are properly understood as the published evidence thus far is not 
definitive (chapter 1.3.5 and chapter 1.3.7).  We therefore determined to report outcomes after 
bariatric surgery in a cohort of obese individuals with and without type 2 diabetes who had undergone 
RYGB at least five years previously. 
  





To assess long term outcomes (greater than five years) in a cohort of individuals following bariatric 
surgery. 
 
3.1.3 Participants and methods 
 
3.1.3.1 Study overview and design 
This was a retrospective non-experimental cohort study of metabolic outcomes in 120 participants 
who had previously undergone bariatric surgery at least five years prior to recruitment for this study. 
All patients who had undergone bariatric surgery at Wakefield obesity clinic at least 5 years prior to 
commencement of the study were identified from a database and invited to attend for an interview.  
Invitation was by letter, with further attempts to contact potential participants by telephone.  Baseline 
data were collected before surgery and stored in a database.  These data were extracted for the 
participants included in this study.  Weight, height, and anthropometric data were measured or 
collected during the interview and compared with baseline values.  Markers of glucose homeostasis 
were measured on blood samples taken immediately prior to surgery and at a follow-up at least five 
years after surgery.  Diabetes outcomes are reported using a number of commonly utilised definitions 
within the published literature.  Micronutrient status of Vitamin B12, zinc and copper were 
determined to assess post-operative adequacy.  A validated quality of life score was used to assess 
participant’s wellbeing at follow up.  
A universal trial number (UTN) was allocated (U1111-1130-1613).  The study was registered in advance 
with the Australian New Zealand Clinical Trials Registry (ANZCTR) and allocated the registration 
number ACTRN12612000505808. 
The study was approved by the New Zealand multiregional Health and Disability Ethics Commission 
(HDEC) in June 2012 (Appendix i-1, page 335).  The study approval number was MEC/11/04/040.  
Approval was sought from the hospital Maori research group, and received after recommendations 
were accepted (Appendix i-2 and Appendix i-3, page 336). 




3.1.3.2 Study Participants 
Study participants were 120 patients who had undergone bariatric surgery at least five years before 




 Bariatric surgery performed at Wakefield Obesity Clinic by a single surgeon at least 
five years before assessment (chapter 2.1, page 120) 




 Further bariatric surgery, either revision or repair, performed since original procedure 
and within five years of study commencement 
 Initial surgery performed for other medical conditions.  e.g. cancer 
 
3.1.3.3 Methods 
This study used data previously collected pre-operatively as the baseline.  Prospective data were 
collected at a follow up appointment conducted at least five years after surgery. The participant 
characteristics were recorded as part of the admission for gastric bypass surgery and obtained by 
review of the clinical records for that admission. Additional data were extracted from a database 
maintained by Wakefield Obesity Clinic. These data were: weight, height and BMI, blood markers of 
glucose homeostasis (fasting glucose, fasting insulin, and HbA1c) and lipid measurements (total 
cholesterol, HDL, LDL, triglycerides), and blood pressure (chapter 2.1 and 2.3).  Most participants had 
a standard 75g oral glucose tolerance test performed prior operation as this was the accepted 
contemporary practice for the diagnosis of diabetes. 




Potential participants were invited by letter (Appendix i-4, page 339) to attend for an interview and 
examination at our research unit, with those who did not respond to the initial letter receiving an 
additional phone call to invite participation.  An appointment was arranged for those who did wish to 
participate, at which the study was discussed in detail and informed consent obtained (Appendix i-6, 
page 341).  The study design initially included the recruitment of a control group of participants who 
had considered bariatric surgery, but had not eventually undergone the procedure for various reasons.  
A letter of invite (Appendix i-5, page 340) was also sent to these potential participants, but 
unfortunately no participant responded favourably to the letter.  The decision was therefore taken to 
abandon this aspect of the study and report outcomes as a retrospective non experimental cohort 
study instead.   
The interview proceeded through the use of a standardised questionnaire (Appendix i-7, page 349) 
and was conducted by either the author or a research nurse.  In addition, participants were asked to 
complete a quality of life questionnaire directed specifically at issues around obesity (Appendix i-8 
(360) and Appendix i-9 (362)).  A brief physical examination was then performed to measure weight, 
height, neck, waist, and hip circumference measurements, heart rate and blood pressure (see chapter 
2.2.1, page 123, and chapter 2.2.2, page 124).  Fasting blood samples and a mid stream spot urine 
collection were obtained (chapter 2.3, page 125).  The American Diabetes Association criteria for the 
diagnosis of diabetes were applied to define glycaemic status at baseline and during follow up (chapter 
2.3, page 125).   
Information on co-morbidities at baseline was collected by the surgical team at admission for gastric 
bypass surgery, and was not checked against other medical records.  The prevalence of each co-
morbid condition is based on a confirmed diagnosis of a clinical event (e.g. myocardial infarction 








3.1.4 Outcomes following RYGB surgery 
 
3.1.4.1 General baseline characteristics 
The study included 120 participants who had undergone bariatric surgery at least five years ago, 
although two who had undergone revision surgery were excluded.  The mean (SD) age of those 
included in this analysis was 47.5 (10.7) and 57.5 (11.3) years at baseline and follow up respectively, 
and displayed normal distribution.  Ninety (76%) of the participants were female, and the mean (SD) 
duration of follow up after bariatric surgery was 10.2 (6.1) years.    
 
Table 3-1   Baseline characteristics of the study participants 
 
 
N=118 Mean (SD) IQR Minimum Maximum 
Age at operation (years) 47.5 (10.7) 14.7 23.4 68.5 
Age at follow up (years) 57.5 (11.3) 15.9 30.1 78.1 
Duration of follow up (years) 10.2 (6.1) 5.8 5.1 30.6 
Pre-operative weight (kg) 128.8 (26.8) 36.0 83.0 202.0 
Pre-operative BMI (kg/m2) 46.6 (8.6) 11.8 33.0 74.9 
 N/118 (%) 





Cook Island Maori 
Chinese 












3.1.4.2 Type of bariatric surgery performed (Table 3-2) 
Ninety-nine (84%) of participants underwent a transected RYGB (tRYGB) which became the bariatric 
procedure of choice at Wakefield Obesity Clinic in the year 2000.  The mean (SD) age at surgery for 
this procedure was 48.1 (10.9) and the mean (SD) duration of follow up was 7.8 (2.5) years (Table ii-1, 
(363)).  Thus, the mean (SD) age of participants at the follow up assessment was 55.9 (11.2) years.   
 
Table 3-2   Frequency of each bariatric procedure 
Surgical procedure N/118 (%) 
Transected Roux-en-Y Gastric Bypass 99 (84) 
Silastic ring RYGB 13 (11) 
Vertical banded gastroplasty 1 (1) 
Gastric bypass 5 (4) 
 
Thirteen (11%) of the participants underwent a silastic ring RYGB (sRYGB), performed between 1988 
and 2000, with a mean (SD) age at surgery of 47.0 (9.0) years.  Given that this procedure predated the 
tRYGB the mean (SD) duration of follow up was 18.4 (2.9) years and the mean (SD) age of participants 
at the follow up assessment was 65.4 (9.9) years.   There was no clear difference in age at operation 
between participants who underwent tRYGB and sRYGB; estimated difference in age (years) 1.14 years 
(95% CI -5.1 to 7.4, p=0.71).   However, participants who had undergone a sRYGB were predictably 
both older (estimated difference 9.6 years (95% CI 3.0 to 16.0, p=0.004) and had a longer duration of 
follow up (estimated difference 10.6 years (95% CI 9.2 to 12.1, p<0.001) to those who had undergone 
tRYGB.  A further one (0.8%) and 5 (4%) participants underwent vertical banded gastroplasty or gastric 
bypass surgery respectively.  Baseline data for these groups are presented in Table ii-1 (363).   
 




3.1.4.3 Smoking status, alcohol use and employment status at follow up 
Data on current smoking status at baseline were not available for this study.  Fourty five (38%) of 
participants were either current smokers at the follow up appointment (seven (6%)) or were ex-
smokers (38 (32%)) (see Table 3-3).   The mean (SD) number of pack years of smoking was 21.4 (25.1) 
in those who had previously stopped smoking, and 20.6 (11.9) who were current smokers.  Sixty-six 
(56%) of participants in this study had never smoked. 
 
 
Table 3-3   Smoking status, alcohol use, and employment history of cohort (n=118) at follow up 
 
 Status N (%) Mean (SD) IQR Minimum Maximum 
Smoking 
Never 66 (56) Pack years 
Ex 38 (32) 21.4 (25.1) 25.5 1.0 120.0 
Current 7 (6) 20.6 (11.9) 20.0 5.0 40.0 
Alcohol 
Never 40 (34) Units per week 
Ex 39 (33) 10.2 (13.2) 12.0 1.0 60.0 




94 (80) Hours per week 
Employed at 
follow up 





Forty (34%) of participants did not drink alcohol, whilst 39 (33%) had consumed alcohol previously but 
no longer did (Table 3-3).  Baseline data on alcohol use prior to surgery was not available, and 
therefore no formal analysis can be performed on the timing of alcohol intake cessation.  However, 
most participants who reported previous alcohol use stopped drinking alcohol at the time of surgery.  
The mean (SD) number of self-reported units per week in those who reported previous but not current 
alcohol use was 10.2 (13.2). 
Thirty-two (27%) of participants reported regular alcohol intake at the follow up interview, with a 
mean (SD) intake of 7.7 (8.6) units per week.  Thus, the weekly alcohol intake of participants who 




continued to consume alcohol following bariatric surgery was less than the previous intake of those 
who stopped alcohol intake following surgery (Current users mean (SD) 7.7 (8.6) units per week, ex 
users mean (SD) 10.2 (13.2) units per week; estimated difference (95% CI) 2.47 (-2.95 to 7.88) units 
per week, P=0.37). 
Ninety-four (80%) of participants were in active employment at baseline although data on 
employment type and hours per week of work were not available (table 4-4).  Seventy one (60%) 
participants were in active employment at the time of the follow up visit.  The mean (SD) hours of 
work per week was 37.0 (17.2) with a range of 2.5 to 80.0 hours. 
Smoking status, alcohol history, and employment history of participants based on type of bariatric 








3.1.4.4 Weight at baseline and follow up 
All participants had data on weight available at both baseline and follow up.  The mean (SD) weight at 
baseline in all participants was 128.8 (26.8) kg with a mean BMI (kg/m2) of 46.6 (8.6), whilst the mean 
(SD) weight at follow up in all participants was 90.3 (21.5) kg with a mean (SD) BMI of 32.7 (7.0) kg/m2 
(Table 3-4).  Frequency histograms of weight and BMI at baseline and follow up in all participants 
demonstrated right skewed distribution, and Shapiro-Wilk testing failed to reject the null hypotheses 
(Figure ii-1 and Figure ii-2, and Table ii-3 and Table ii-4 (365-366)).   The distribution of weight and BMI 
at baseline and follow up was normalised through logarithmic transformation.   Box plots to show 
weight and BMI at baseline and follow up in all participants and those who underwent tRYGB and 
sRYGB are presented in Figure 3-1 (145). 
 Each participant in this study had lost weight over the period of follow up (Figure 3-2 (146)).  The 
mean (SD) body weight loss % in all participants, those who had undergone tRYGB, and those who had 
undergone sRYGB was 29.6 (10.7), 30.3 (10.5), and 25.7 (10.3) % respectively.  The mean (SD) 
reduction in weight in all participants, those who had undergone tRYGB, and those who had 
undergone sRYGB was 38.5 (17.4), 39.4 (16.6), and 34.3 (21.2) kg respectively.  The mean (SD) 
reduction in BMI in all participants, those who had undergone tRYGB, and those who had undergone 
sRYGB was 14.0 (6.3), 14.2 (6.1), and 12.7 (7.6) kg/m2 respectively. 
Statistically significant reductions in weight and BMI were evident at follow up for all participants and 
those who had undergone tRYGB; estimated differences between baseline and follow up weight and 
BMI are presented in Table 3-4.  Change in weight (and thus body weight loss %) and BMI, displayed 
normal distribution for all participants and those who had undergone tRYGB (Figure ii-3 (367)).     
 
 
    
 
 




Table 3-4   Weight (kg) and BMI (Kg/m2) at baseline and follow up for all participants and those undergoing tRYGB 
n=118 
Baseline Follow up Paired T test * Equivalence 




All participants (n=118) 
Weight (kg) 128.8 (26.8) 36.0 83.0/202.0 90.3 (21.5) 31.7 47.9/171.0 0.36 0.33 to 0.39 <0.001 1.43 1.39 to 1.48 
BMI (kg/m2) 46.6 (8.6) 11.8 33.0/74.9 32.7 (7.0) 9.0 19.4/51.5 0.36 0.33 to 0.39 <0.001 1.43 1.39 to 1.48 
Transected RYGB (N=98) 
Weight (kg) 129.4 (26.8) 40.4 83.0/202.0 90.0 (22.6) 34.7 47.9/171.0 0.37 0.34 to 0.40 <0.001 1.45 1.40 to 1.49 
BMI (kg/m2) 46.4 (8.6) 12.4 33.0/73.6 32.2 (7.2) 9.1 19.4/51.5 0.37 0.34 to 0.40 <0.001 1.45 1.40 to 1.49 
 
*Paired t test performed following logarithmic transformation 




Figure 3-1   Box plots showing weight (kg, left column) and BMI (kg/m2, right column) at baseline and after at 





















Figure 3-2   Bar chart to show body weight loss (%) in all 118 participants 
 




3.1.4.4.1 Prediction of weight loss using baseline variables 
To assess whether the degree of obesity at baseline affected weight loss outcomes, participants were 
stratified according to the World Health Organisation classification of obesity (Table 3-5). An 
additional category of class 4 obesity (super-obese) was added for this analysis and includes 
participants with a BMI of greater than or equal to 50.0 kg/m2. 
 
Table 3-5  World Health Organisation classification of obesity, with the numbers of participants in each 
category at baseline and follow up 
 
BMI (kg/m2) Classification Baseline (%) Follow up (%) 
<18.5 Underweight 0 (0) 0 (0) 
18.5 – 24.9 Normal weight 0 (0) 14 (12) 
25.0 – 29.9 Overweight 0 (0) 33 (28) 
30.0 – 34.9 Class 1 obesity 8 (7) 37 (31) 
35.0 – 39.9 Class 2 obesity 18 (15) 15 (13) 
40.0 – 49.9 Class 3 obesity 56 (47) 18 (15) 
≥ 50.0 Class 4 obesity 36 (30) 2 (2) 
 
 
Using this classification 8/118 (7%) participants had class 1 obesity at baseline, 18/118 (15%) had class 
2 obesity, 56/118 (47%) had class 3 obesity, and 36/118 (30%) had class 4 obesity.  The baseline and 
follow up characteristics of participants, stratified by obesity classification at baseline, are presented 
in Table ii-5 (368). 
 




At the follow up assessment 14/118 (12%) of participants had achieved a normal weight (18.5 – 24.9 
kg/m2) according to the WHO of obesity (Figure 3-3).  A further 33 (28%) were overweight, 36 (31%) 
had class 1 obesity, 15 (13%) had class 2 obesity, 18 (15%) had class 3 obesity, and 2 (2%) had class 4 
obesity.  Both participants with class 4 obesity had class 4 obesity at baseline and both participants 
had lost weight (body weight loss of 2.4% and 31.4%).  
  
 
Figure 3-3  Pie charts to show percentage of participants within each WHO class of obesity at a) baseline, and 
b) follow up 




Of the 8 (7%) of participants with class 1 obesity at baseline, 3 (38%) and 4 (50%) had improved to 
normal weight and overweight respectively, whilst 1 (13%) remained with class 1 obesity (Table 3-6).  
18 (15%) of participants had class 2 obesity at baseline, with 4 (22%), 10 (56%), and 3 (17%) of 
participants improving to normal weight and overweight respectively, whilst 3 (17%) and 1 (6%) 
remained with class 1 and class 2 obesity.  The majority of participants (57 (48%)) had class 3 obesity 
at baseline.  Seven (12%) of these improved to normal weight and 15 (26%) to overweight following 
surgery, whilst 25 (46%), 7 (12%), and 2 (4%) remained with class 1, class 2, and class 3 obesity 




respectively.  Thirty six (30%) of participants were super-obese at baseline (class 4 obesity).  Two (6%) 
of these participants were the only participants in the study cohort who remained with class 4 obesity 
at follow up.  A further 16 (44%) had class 3 obesity, whilst 7 (19%) of participants improved to both 
class 1 and class 2 obesity.  Only 4 (11%) of those with class 4 obesity at baseline improved to 
overweight at follow up, and none of these participants had a normal body weight.  Cross tabulation 
of obesity classification at baseline and follow up is shown is presented in Table 3-6  
 
Table 3-6   Cross tabulation of obesity classification at baseline against obesity classification at follow up 
 
N=118 
Obesity classification at follow up 




1 3 4 1 0 0 0 8 
2 4 10 3 1 0 0 18 
3 7 15 25 7 2 0 56 
4 0 4 7 7 16 2 36 
Total 14 33 36 15 18 2 118 
 
 
When stratified by obesity classification at baseline, and thus by BMI, and indirectly weight, an 
incremental increase in the baseline BMI or weight was associated with an incremental increase in the 
weight classification at follow up (Figure 3-4).   Furthermore, there was an incremental increase in the 








Figure 3-4   Boxplots showing a) weight at baseline, b) BMI at baseline, and c) body weight loss (%) for each 































Therefore, an analysis of the relationships between weight and BMI at baseline and follow up was 
performed.  To assess whether change in BMI following bariatric surgery can be predicted at baseline, 
univariate and multivariate regression analysis was performed.  Variables included in this analysis 
were age at operation, gender, BMI at baseline, weight at baseline, diabetes status and markers of 
glucose homeostasis, lipid status and lipid profile, and blood pressure status.  Coefficients calculated 
from regression modelling are presented in Table ii-6 (370). 
Linear regression established that BMI (kg/m2) at baseline predicts change in BMI over the study 
period (r=0.58, f=62.5, p<0.001), and accounted for 33% of the change in BMI (Figure 3-5).  The 
regression equation was: 
 
 Change in BMI (kg/m2) = -6.23 + (0.43 * BMI at baseline (kg)) 
 
Acknowledging that weight is a requisite component of BMI, weight (kg) at baseline was also an 
independent predictor of the change in BMI during follow up (r=0.49, f=37.5, p<0.001), accounting for 
24% of the change in BMI (Figure 3-5).  The regression equation was: 
 
 Change in BMI (kg/m2) = -1.03 + (0.12 * weight at baseline (kg)) 




Figure 3-5   Regression variable plot for a) BMI (kg/m2) at baseline, and b) weight at baseline against change in 
BMI (kg/m2) 








Furthermore, baseline weight and BMI also predicted final BMI (kg/m2).  BMI (kg/m2) (R=0.69, F=107.1, 
p<0.001) and, weight (R=0.59, F=60.6, p<0.001), at baseline (Figure 3-6).  BMI at baseline accounted 
for 48% of the variation in final BMI (kg/m2) whilst weight at baseline accounted for 34%.  The 
regression equations were: 
 Final BMI (kg/m2) = 6.23 + (0.57 * BMI (kg/m2) at baseline) 
 Final BMI (kg/m2) = 12.8 + (0.15 * weight (kg) at baseline)   
 
Figure 3-6  Regression variable plots to show a) BMI (kg/m2) at baseline, and b) weight (kg) at baseline, against 
final BMI (kg/m2) 









With respect to other continuous independent baseline variables, HOMA-IR and total cholesterol 
(mmol/L) also predicted change in BMI using linear regression.  HOMA-IR showed mild correlation 
with change in BMI (f=4.2, p<0.04) and accounted for only 4% of the change in BMI.  The regression 
equation was: 
 
 Change in BMI (kg/m2) = 11.0 + (0.97 *HOMA-IR) 
 
 
Total cholesterol also demonstrated mild correlation with change in BMI (f=4.0, p=0.04) and 
accounted for only 3% of change in BMI.  The regression equation was: 
 
 Change in BMI (kg/m2) = 21.3 – (1.3 * total cholesterol (mmol/L)) 
 
 
Both categorical variables used in this analysis predicted change in BMI over the study period.  
Diabetes status at baseline showed mild correlation (f=5.5, p=0.02), but accounted for only 4% of 
change in BMI.  The regression equation was: 
 
 Change in BMI (kg/m2) = 12.2 + (1.7 * ADA status) 
 
where ADA status is expressed as 0=normal glucose tolerance, 1= prediabetes, 2 = type 2 diabetes.  
Hypertension at baseline (0=normal blood pressure, 1 = hypertension) showed mild correlation (f=5.8, 
p=0.02), but accounted for only 4% of the change in BMI over the study period.  The regression 
equation was: 
  
Change in BMI (kg/m2) = 10.7 + (4.1 * Hypertension status) 
 
 
Regression variable boxplots for models including the above two categorical variables are shown in 
Figure 3-7.   




Figure 3-7   Regression variable boxplots to show outcomes of categorical independent inputs. a) Glycaemic 
status at baseline against BMI change over the study period (coefficient =1.86, p=0.02), and b) blood pressure 
status at baseline (coefficient = 4.0, p=0.02) 








Multivariate regression analysis was then performed to explore whether use of a combination of 
baseline measured variables could better predict the change in BMI (kg/m2) following surgery than 
any one variable alone.  Given the sample size of 118 participants, a maximum of six variables could 
be used in a multivariate model. 
 
An optimal model was obtained when BMI at baseline, age at baseline, diabetes status at baseline, 
and hypertension status at baseline were included (Table 3-7).  The change in BMI (kg/m2) following 
surgery was predicted by this model, F(4,103)=18.1, p<0.001, R2=0.41, although explained only 39% 
of the total variation in BMI change.  Furthermore, of all the independent variables, only BMI at 
baseline added statistically significantly to the prediction, p<0.05.  The addition of gender to the list 










Table 3-7   Multivariate regression analysis incorporating BMI at baseline and the listed independent variables 
to predict change in BMI (kg/m2).  Table a presents the model summary and table b presents the coefficients.  
a) 
Model summary ANOVA 
R R2 Adjusted R2 F P value 















Constant -11.0 3.7  -3.0 0.004 -18.4 to -3.7 
Age at 
operation 
0.05 0.05 0.09 1.0 0.31 -0.05 to 0.16 
Hypertension 
at operation 




0.58 0.69 0.07 0.84 0.40 -0.78 to 1.9 
BMI (kg/m2) 
at baseline 
0.42 0.056 0.59 7.6 <0.001 0.31 to 0.53 




3.1.4.4.2 Prediction of weight loss using additional follow up variables 
To assess whether additional variables not available at baseline may affect weight loss following RYGB, 
additional regression analyses were performed.   Linear regression established that age at follow up 
(years), duration of follow up (years) and diabetes status at follow up could not predict change in BMI 
over the study period (Table 3-8).   To support the conclusion that duration of follow up does not 
predict change in BMI following RYGB, a scatterplot showed no clear relationship (Figure 3-8) 
 
Table 3-8   Univariate regression analyses outcomes for follow up variables (independent) against change in 
BMI over study period (dependent variable) 
Independent variable 
ANOVA Coefficients 
F p value Constant 
Independent 
variable 
Age at follow up (years) 0.29 0.9 14.5 -0.01 
Duration of follow up (years) 3.0 0.08 15.6 -0.2 
Diabetes status at follow up 0.31 0.6 14.25 -0.5 
 
Figure 3-8   Scatter plot to show duration of follow up (years) against change in BMI (kg/m2) 
  




3.1.4.4.3 Comparison of outcomes stratified by duration of outcomes 
To further explore the relationship between duration of follow up and weight outcomes, outcomes in 
those with 5.0 to <10.0 years of follow up were compared against those with greater or equal than 
10.0 years of follow up.  The mean (SD) duration of follow up in all 118 participants was 10.1 (6.0) 
years.  Eighty one (69%) of participants had a follow up duration of between 5.0 and 10.0 years (mean 
(SD) 6.9 (1.4) years), whilst 37 (31%) of participants had a follow up duration of greater than 10 years 
(mean (SD) 17.3 (6.1) years, maximum 30.6 years) (Table ii-7 (371)).  Furthermore, BMI data at 1 and 
2 years following surgery was available in 76 (92%) and 17 (46%) of those with the shorter or longer 
duration of follow up respectively.  All 81 (100%) participants with 5.0 to less than 10.0 years of follow 
up had undergone tRYGB.  Seventeen (46%) of those with greater than or equal to 10 years of follow 
up had undergone tRYGB, with a further 14 (38%) undergoing sRYGB, one undergoing vertical banded 
gastroplasty, and the remaining five (14%) having undergone gastric bypass.   
The mean (SD) age at operation and follow up in those with 5.0 to less than 10.0 years of follow up 
was 48.1 (11.2)  and 54.9 (11.3) years, whilst the mean (SD) age at operation and follow up in those 
with great than or equal to 10.0 years of follow up was 46.3 (8.9) and 63.6 (8.2) years respectively.  
The two groups were not clearly different with respect to age at operation (estimated difference 1.72 
years (95% CI -2.4 to 5.9, p=0.4)), although those with a longer duration of follow up were predictably 
significantly older at the follow up assessment (estimated difference 8.7 years (95% CI 4.6 to 12.8, 
p<0.001).  
The mean (SD) BMI at baseline in those with less than or ≥10.0 years of follow up was 47.3 (8.8) and 
45.2 (8.1) kg/m2, and at follow up was 32.6 (7.4) and 32.9 (6.4) kg/m2 (Figure 3-9).  There was no clear 
difference in baseline or follow up BMI between the groups.  The estimated difference in baseline BMI 
was 2.02 kg/m2 (0.04 (95% CI 0.01 to 0.17, p=0.25, equivalent to a mean ratio of 1.04 (95% CI 1.01 to 
1.19). The estimated difference in follow up BMI was 0.3 kg/m2 (0.01 (95% CI -0.07 to 0.1), p=0.74, 
equivalent to a mean ratio of 1. 01 (95% CI -1.08 to 1.11).  The mean (SD) absolute reduction in BMI 
(kg/m2) during the study period was 14.7 (6.3) kg/m2 for those with 5.0 to 10.0 years of follow up, and 
12.3 (6.0) kg/m2 for those with greater than 10 years of follow up; estimated difference 2.3 kg/m2 
(95% CI -0.1 to 4.8, p= 0.06).   
 



















3.1.4.5 Glycaemic status at baseline and follow up 
The distribution of data for fasting glucose, HbA1c, fasting insulin, and HOMA-IR at baseline and follow 
up was right skewed as demonstrated by inspection of histograms (Figure ii-4 (372)) and assessment 
using the Shapiro-Wilk test (Table ii-8 (373)). Box plots to each variable at baseline and follow up are 
presented in Figure 3-10, and illustrate outlying results.  Logarithmic transformation of all the data 
resulted in a better approximation of normal distribution allowing parametric analysis (Figure 
ii-5(374)).   Furthermore, logarithmic transformation of the change in each variable from baseline to 
follow up also resulted in a better approximation of normal distribution (Figure ii-6 (375)). 
 
Figure 3-10   Box plots to show a) fasting glucose, b) HbA1c, c) fasting insulin, and d) HOMA-IR at baseline and 
follow up  
















Participants were classified as having normal glucose tolerance, prediabetes, or overt type 2 diabetes 
at baseline and follow up as per criteria described above.  Table 3-9 presents the frequency of each 
diagnosis using the ADA criteria for assessing diabetes outcomes following bariatric surgery.  Thus, the 
percentage of participants with normal glucose tolerance at baseline was 25% when those where a 
diagnosis was not available from baseline data were excluded.  Using the same method, 37.5% 
participants had prediabetes at baseline, whilst 37.5% of participants had type 2 diabetes at baseline. 
At follow up, 58 participants had normal glucose tolerance (53.7% of those whose glycaemic status 
could be assessed), whilst 38 (35.2%) and 12 (11.1%) had prediabetes and type 2 diabetes respectively 
(Table 3-9) when the 10 (8.5% of whole cohort) in whom a diagnosis at follow up was not available 
were excluded. 
 
Table 3-9   Frequency of participants with each category of glucose tolerance using diagnostic criteria 
suggested by the ADA.  Absolute (calculated from the whole cohort) and valid (calculated just using 




 Baseline Follow up 
 n/118 % Valid % n/118 % Valid % 
Normal glucose tolerance 28 23.7 25.0 58 49.2 53.7 
Prediabetes 42 35.6 37.5 38 32.2 35.2 
Type 2 diabetes 42 35.6 37.5 12 10.2 11.1 
Unknown 6 5.1 N/A 10 8.5 N/A 
 
 
Participants that had data available at both baseline and follow up were included in an analysis to 
compare the means, following appropriate logarithmic transformation where required.  Results are 
presented in Table 3-10.  Comparison of the means using a paired T test is also presented.   
 




Table 3-10   Baseline and follow up characteristics and markers of glycaemic status for all participants at baseline.  A paired T test is shown. 
 
 
Baseline Follow up Paired T test * 
n (%) Mean (SD) IQR Min/Max n (%) Mean (SD) IQR Min/Max n (%) 
Est. 
diff 
95% CI P value 
All participants (n=118) 
Fasting glucose (mmol/L) 105 (89) 6.16 (2.1) 1.75 3.90/13.90 111 (94) 5.00 (1.20) 0.70 3.40/13.50 98 (83) 1.18 0.83 to 1.54 <0.001 
HbA1c (mmol/mol) 92 (78) 47.1 (14.7) 16.0 28/99 109 (92) 39.6 (8.2) 7.0 28/83 83 (70) 7.5 5.2 to 9.8 <0.001 
Insulin (pmol/L) 94 (80) 159.3 (89.6) 110.3 5.3/482.0 100 (85) 47.5 (22.8) 22.4 6.1/164.9 77 (65) 117.7 97.1 to 138.3 <0.001 
HOMA-IR 83 (70) 2.84 (1.34) 2.1 0.73/6.54 91 (77) 0.92 (0.40) 0.43 0.40/2.83 61 (52) 2.0 1.7 to 2.4 <0.001 
HOMA-%B 83 (70) 147.6 (63.1) 85.9 26.6/345.7 91 (77) 93.4 (38.5) 38.1 12.0/300.3 61 (52) 56.0 43.2 to 72.7 <0.001 
HOMA-%S 83 (70) 45.2 (25.3) 30.0 15.3/137.0 91 (77) 126.6 (46.4) 62.2 35.3/247.9 61 (52) 83.6 71.5 to 95.7 <0.001 
 
*p values for BMI, fasting glucose, HbA1c, fasting insulin, and HOMA following logarithmic transformation




Twenty-four (20%) participants were using oral glucose lowering therapy at baseline, whilst six (5%) 
of these were also using insulin therapy.  The mean (SD) duration of treatment with oral glucose 
lowering therapy was 8.9 (5.2) years, and the mean (SD) duration of treatment with insulin therapy 
was 4.8 (3.3) years.  All participants on either oral glucose lowering therapy or insulin had type 2 
diabetes at baseline by definition. 
 
When the whole cohort were considered, the mean (SD) fasting glucose at baseline and follow up 
were 6.16 (2.1) and 5.00 (1.20) mmol/L respectively; estimated difference 1.18 mmol/L (95% CI 0.83 
to 1.54, p<0.001) (Table 3-10).  The corresponding mean (SD) HbA1c measurements were 47.1 (14.7) 
and 39.6 (8.2) mmol/mol respectively (estimated difference 7.5 mmol/mol, p<0.001), whilst those for 
fasting insulin were 159.3 (89.6) and 47.5 (22.8) pmol/L respectively (estimated difference 117.7 
pmol/L, p<0.001).  The mean (SD) HOMA-IR at baseline was 2.84 (1.34) and 0.92 (0.40) at follow up; 
estimated difference 2.0, p<0.001.  Thus, the mean concentrations of insulin and HOMA-IR normalised 
over the follow up period, whilst the mean diabetes status using ADA criteria improved from type 2 
diabetes to prediabetes. 
The mean (SD) age at operation for those with normal glucose tolerance was 40.9 (11.0) with a mean 
(SD) duration of follow up of 10.2 (4.7) years and thus a mean (SD) age at follow up of 51.0 (12.4) 
years.  The respective values for those with prediabetes were 48.0 (9.6), 8.7 (4.3) and 56.6 (10.6).  The 
estimated difference (95% CI) between age at baseline in those with normal glucose tolerance and 
prediabetes was 7.1 (2.2 to 12.1) years, P=0.005). The estimated difference (95% CI) between duration 
of follow up in those with normal glucose tolerance and prediabetes was 1.5 (-0.7 to 3.7) years, P=0.2), 
whilst the estimated difference (95% CI) between age at follow up was 5.7 (-0.1 to 11.1) years, P=0.05). 
The mean (SD) age at operation for those with type 2 diabetes was 52.8 (8.2) with a mean (SD) 
duration of follow up of 9.1 (4.9) years and thus a mean (SD) age at follow up of 62.0 (8.7) years. The 
estimated difference (95% CI) between age at baseline in those with normal glucose tolerance and 
type 2 diabetes was 12.0 (7.4 to 16.6) years, p<0.01), whilst the estimated difference (95% CI) between 
those with prediabetes and type 2 diabetes was 4.9 (1.0 to 8.7) years, P=0.01). The estimated 
difference (95% CI) between duration of follow up in those with normal glucose tolerance and type 2 
diabetes was 1.1 (-1.3 to 3.4) years, p=0.4), whilst the estimated difference (95% CI) between those 
with prediabetes and type 2 diabetes was 0.4 (-2.4 to 1.6) years, P=0.7). The estimated difference (95% 
CI) between age at follow up in those with normal glucose tolerance and type 2 diabetes was 10.9  




Figure 3-11   Boxplots to show change in each variable over the follow up period.  Box plots are categorised by 
ADA diagnosis at baseline (0= normal glucose tolerance, 1= prediabetes, 2= type 2 diabetes). 
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years (5.9 to 15.9) years, p<0.01), whilst the estimated difference (95% CI) between those with 
prediabetes and type 2 diabetes was 5.3 (1.1 to 9.5) years, P=0.01). 
Thus, participants with normal glucose tolerance at baseline were younger and had a longer duration 
of follow up than participants with either prediabetes or type 2 diabetes.  Additionally, those with 
normal glucose tolerance were significantly younger at follow up than those with type 2 diabetes, but 
were not clearly different from those with prediabetes.  Participants with prediabetes at baseline were 
younger at both baseline and follow up than those with type 2 diabetes.  However, the duration of 
follow up was similar in these two groups.   
Eight of the 95 (79%) of participants with a fasting insulin concentration available at baseline had 
concentrations within the normal reference range (<60 pmol/L).  Six of these participants were 
categorised as having prediabetes by the ADA criteria and the remaining two were deemed to have 
normal glucose tolerance.  The mean (SD) fasting insulin concentration in those with normal glucose 
tolerance was 110.1 (52.1) pmol/L whilst the mean (SD) fasting insulin concentration in those with 
prediabetes was 142.3 (87.2); estimated difference 32.2 pmol/L (95% CI -15.3 to 79.0, P=0.18).  The 
mean (SD) fasting insulin concentration in those with type 2 diabetes at baseline was 200.8 (89.2) 
pmol/L; estimated difference (95%) against normal glucose tolerance 90.7 pmol/L (41.3 to 140.4) 
pmol/L, P=0.01; estimated different (95%) against those with prediabetes 58.5 pmol/L (19.0 to 98.1), 
p=0.04. The mean (SD) HOMA-IR scores at baseline for participants with normal glucose tolerance, 
prediabetes, and type 2 diabetes were 1.98 (0.91), 2.61 (1.22), and 3.63 (1.33) respectively. The 
estimated difference (95% CI) between HOMA-IR at baseline in those with normal glucose tolerance 
and prediabetes was 0.63 (-0.05 to 1.3, p=0.68), 1.65 (0.9 to 2.4, p<0.01) between those with normal 
glucose tolerance and type 2 diabetes, and 1.01 (0.4 to 1.6, p=0.002 between those with prediabetes 
and type 2 diabetes. 
 
Thus, participants were increasingly hyperinsulinaemic with each deteriorating category of glycaemic 
status, and those with type 2 diabetes had statistically significant higher fasting insulin concentrations 
at baseline than those with normal glucose tolerance.  In addition, participants with type 2 diabetes 
at baseline were significantly more insulin resistant at baseline than those with normal glucose 
tolerance and prediabetes. 
 




One hundred and two (85%) of participants had a complete set of glycaemic data at both baseline and 
follow up time points, and could therefore be included in an analysis on diabetes outcomes (Table 
3-11).  Note that the ADA criteria for the assessment of diabetes following bariatric surgery are 
intended to apply only to those people with a diagnosis of dysglycaemia prior to surgery; however, 
the diabetes status at follow up was not altered by use of the ADA diagnostic criteria instead.   
Of the 26 participants with normal glucose tolerance at baseline, twenty-one remained with normal 
glucose tolerance and five had progressed to prediabetes (Table 3-11).  None of these 26 participants 
developed type 2 diabetes during the period of follow up. Fourty participants had prediabetes at 
baseline, with twenty-five (63%) having normal glucose tolerance at follow up after surgery.  A further 
14 (35%) participants remained with prediabetes, whilst one participant had progressed to type 2 
diabetes at follow up.  Thirty six participants had type 2 diabetes prior to surgery.  Of these, nine (25%) 
of participants had normal glucose tolerance at follow up, 17 (47%) had prediabetes, and 10 (28%) 
remained with type 2 diabetes. 
 
 
Table 3-11   Cross tabulation of ADA diagnosis at baseline against ADA diagnosis at follow up of the 102 
available participants  
 
 
ADA diagnosis at follow up 
 
NGT Prediabetes T2DM Total 
ADA Diagnosis 
at baseline 
NGT 21 5 0 26 
Prediabetes 25 14 1 40 
T2DM 9 17 10 36 
Total  55 36 11 102 
 
 




3.1.4.5.1 Glycaemic outcomes in those with normal glucose tolerance at baseline 
28 participants had normal glucose tolerance at baseline and 26 of these participants had sufficient 
data at follow up to comment on diabetes status outcome (Table 3-11 (page 165)).  23 (82%) of these 
participants underwent a transected RYGB whilst five (18%) underwent a silastic ring RYGB (Table 
3-12). 21 (81%) of these participants remained with normal glucose tolerance at follow up whilst 5 
(19%) had progressed to prediabetes.   Baseline data for all participants with normal glucose tolerance 
at operation is presented in Table 3-13. 
 
 
Table 3-12  Type of bariatric surgery performed in those with normal glucose tolerance at baseline 
N=28 n (%) 
Transected Roux-en-Y Gastric Bypass 23 (82) 
Silastic ring RYGB 5 (18) 
 
Fasting glucose concentrations did not differ significantly at either baseline or follow up between 
those with normal glucose tolerance at follow up and those with prediabetes (estimated difference 
0.3 mmol/L for baseline glucose (95% CI -0.13 to 0.75, P=0.16) and 0.3 mmol/L for follow up glucose 
(95% CI -0.07 to 0.7, p=0.15) despite fasting glucose concentrations being a factor that defines 
glycaemic status.  The maximum fasting glucose concentration in those with prediabetes was 5.4 
mmol/L, whilst the ADA criteria accept a glucose of less than 5.6 mmol/L for the criteria of normal 
glucose tolerance. In contrast, whilst HbA1c values at baseline were similar between those with 
normal glucose tolerance and prediabetes at baseline (estimated difference 0.6 mmol/mol (95% CI -
4.9 to 3.8, p=0.8), HbA1c concentrations at follow up in those with prediabetes were clearly higher 
than those with normal glucose tolerance (estimated difference 5.7 mmol/mol (95% CI 3.1 to 8.3, 
p<0.001).  The minimum HbA1c value at follow up in those with prediabetes was 37 mmol/mol and 
thus entirely explained the differences in glycaemic status.   Thus change in HbA1c (following 
logarithmic transformation) over the study period is used as the dependent variable in regression 
analysis below.




Table 3-13   Baseline and follow up characteristics and markers of glycaemic status for participants with normal glucose tolerance at baseline.  A paired T test is shown. 
 
 
Baseline Follow up Paired T test * 
n (%) Mean (SD) n (%) Mean (SD) n (%) Est. diff 95% CI P value 
Normal glucose tolerance (n=28) 
Age (years) 28 (100) 40.8 (11.0) 28 (100) 51.0 (12.4) 28 (100) 10.2 8.3 to 12.0 <0.001 
BMI (kg/m2) 28 (100) 45.1 (6.7) 28 (100) 33.4 (8.2) 28 (100) 11.7 10.0 to 13.4 <0.001 
Fasting glucose (mmol/L) 26 (93) 4.83 (0.44) 26 (93) 4.67 (0.35) 26 (93) 0.09 -0.02 to 0.36 0.08 
HbA1c (mmol/mol) 19 (68) 35.0 (2.7) 19 (68) 34.1 (3.35) 19 (68) 0.9 -1.2 to 3.0 0.4 
Insulin (pmol/L) 18 (65) 106.7 (51.5) 18 (65) 36.6 (14.9) 43 (83) 70.1 48.4 to 91.8 <0.001 


















93.9 63.4 to 124.4 <0.001 
* p values for BMI, fasting glucose, HbA1c, fasting insulin, and HOMA following logarithmic transformation




Fasting insulin concentrations were not clearly different at either baseline or follow up in those with 
normal glucose tolerance or those with prediabetes (estimated difference 28.1 pmol/L for baseline 
insulin (95% CI -106.7 to 50.4, P=0.5) and 2.7 pmol/L for follow up insulin (95% CI -17.2 to 11.9, p=0.7).    
Given the absence of differences in the other dependent factor (fasting glucose), calculations of 
HOMA-IR, HOMA-%B, and HOMA-%S were also not clearly different at either baseline or follow up in 
either group.  
The mean (SD) age at operation of those who remained with normal glucose tolerance during the 
study period was 41.8 (11.7) years and 37.6 (9.9) years in those who progressed to prediabetes during 
follow up.  The mean (SD) duration of follow up was also similar in the two groups with 9.8 (4.4) and 
12.8 (6.5) years of follow up for those with normal glucose tolerance and prediabetes respectively.  
Consequently, the age at follow up was not clearly different between the two groups (mean (SD) of 
51.5 (12.3) years in those with normal glucose tolerance at follow up and 50.4 (16.0) years in those 
with prediabetes (estimated difference 3.1 years (95% CI -12.2 to 14.54), p=0.87).  
BMI at baseline and follow up were similar irrespective of whether normal glucose tolerance or 
prediabetes were evident at follow up (mean (SD) 44.3 (7.0) kg/m2 in those who remained with normal 
glucose tolerance and 46.4 (5.7) kg/m2 in those who progressed to prediabetes; estimated difference 
2.1 kg/m2 (95% CI -4.9 to 9.1, p=0.5).  Likewise, participants had obtained a very similar BMI at follow 
up irrespective of glycaemic outcome with a mean (SD) BMI of 32.1 (7.6) kg/m2 in those who remained 
with normal glucose tolerance and 34.2 (7.8) kg/m2 in those with prediabetes. Mean (SD) Body weight 
loss (%) was similar in both groups at follow up at 27.9 (8.8) % in those with normal glucose tolerance 
at follow up, and 26.8 (10.0) % in those with prediabetes (estimated difference 1.1% (95% CI -8.2 to 
10.3, p=0.8). 
Univariate regression analysis was performed to assess whether any variable could predict diabetes 
status outcome in those participants with normal glucose tolerance at baseline.  As n=28, multivariate 
analysis was not appropriate.  With the exception of HbA1c at follow up (not relevant as the groups 
were defined by this marker alone as above) only HbA1c at baseline (r=0.65, f=12.3, p=0.003) and 
follow up (r=0.8, f=29.2, p<0.001) predicted the change in HbA1c over the study period at follow up 
and accounted for 39% and 61% of the observed variation respectively.  The regression equations 
were:  
 




Change in LnHbA1c (mmol/mol)   =   -3.8 + (1.1 * Ln(x) HbA1c (mmol/mol) at baseline) 




Table 3-14   Univariate regression analyses outcomes for baseline variables (independent) against the change 
in logarithmic transformed HbA1c over the study period (dependent variables) in participants with normal 
glucose tolerance at baseline 




Age at operation (years) -0.02 0.001 0.7 
Age at follow up (years) -0.005 0.001 0.8 
Duration of follow up (years) 0.09 -0.007 0.5 
BMI at baseline (kg/m2) -0.5 0.15 0.4 
BMI at follow up (kg/m2) -0.16 0.06 0.7 
Change in BMI (kg/m2) -0.06 0.03 0.7 
Fasting glucose at baseline (mmol/L) -0.05 0.04 0.9 
Fasting glucose at follow up (mmol/L) -0.02 0.03 0.95 
HbA1c at baseline (mmol/mol) -3.8 1.1 0.003 
HbA1c at follow up (mmol/mol) 3.7 -1.0 <0.001 
Fasting insulin at baseline (pmol/L) -0.19 0.05 0.5 
Fasting insulin at follow up (pmol/L) -0.3 0.09 0.3 
HOMA-IR at baseline -0.01 0.05 0.5 
HOMA-IR at follow up 0.05 0.09 0.5 
* following logarithmic transformation for fasting glucose, 
 HbA1c, insulin, and HOMA-IR 
 
  




3.1.4.5.2 Diabetes outcomes in those with prediabetes at baseline 
42 participants had prediabetes, and 40 of these had sufficient data to categorise diabetes status at 
baseline and follow up.  37 (88%) participants had undergone transected RYGB whilst the remaining 5 
(12%) participants had undergone silastic ring RYGB.  Descriptive data for this group are presented in 
Table 3-16.   
 
Table 3-15  Type of bariatric surgery performed in those with prediabetes at baseline 
N=42 n (%) 
Transected Roux-en-Y Gastric Bypass 37 (88) 
Silastic ring RYGB 5 (12) 
 
The mean (SD) duration of follow up in this group was 8.7 (4.3) years (minimum 5.1, maximum 22.2 
years).  Twenty-five (63%) of these participants had an improvement in glucose tolerance to normal 
concentrations at follow up.   14 (35%) remained with prediabetes, whilst one (2%) had progressed to 
type 2 diabetes.  In keeping with the ADA definitions for diabetes status following bariatric surgery, 
no participant within this group used diabetes medications at follow up. 
As with those with normal glucose tolerance at baseline, fasting glucose concentrations in those with 
prediabetes at baseline did not differ significantly at either baseline or follow up between those who 
had improved to normal glucose tolerance at follow up and those who remained with prediabetes 
(estimated difference 0.1 mmol/L for baseline glucose (95% CI -0.3 to 0.52, P=0.6) and -0.09 mmol/L 
for follow up glucose (95% CI -0.2 to 0.35, p=0.5).  The maximum fasting glucose concentration at 
follow up in those with prediabetes was 5.5 mmol/L which falls below the threshold of 5.6 mmol/L set 
by the ADA as a definition of prediabetes. 




Table 3-16   Baseline and follow up characteristics and markers of glycaemic status for participants with prediabetes at baseline.  A paired T test is shown. 
 
 
Baseline Follow up Paired T test * 
n (%) Mean (SD) n (%) Mean (SD) n (%) Est. diff 95% CI P value 
Prediabetes (n=42) 
Age (years) 42 (100) 48.0 (9.6) 42 (100) 56.6 (10.6) 42 (100) 8.7 7.3 to 10.0 <0.001 
BMI (kg/m2) 42 (100) 46.3 (9.1) 42 (100) 31.6 (7.5) 42 (100) 14.7 12.7 to 16.7 <0.001 
Fasting glucose (mmol/L) 40(95) 5.47 (0.64) 40(95) 4.77 (0.40) 40(95) 0.71 0.48 to 0.94 <0.001 
HbA1c (mmol/mol) 33 (79) 40.3 (3.3) 33 (79) 37.5 (3.7) 33 (79) 2.8 1.6 to 4.1 <0.001 
Insulin (pmol/L) 30 (71)  154.8 (91.7) 25  45.9 (20.5) 25  108.9 73.1 to 144.8 <0.001 
HOMA-IR 25 (60) 2.91 (1.25) 25 (60) 0.90 (0.36) 25 (60) 2.0 1.5 to 2.5 <0.001 
HOMA-%B 25 (60) 171.7 (65.5) 25 (60) 98.3 (28.9) 25 (60) 73.4 46.7 to 100.0 <0.001 
HOMA-%S 25 (60) 42.0 (21.5) 25 (60) 128.1 (45.2) 25 (60) 86.1 66.5 to 105.7 <0.001 
 
 
*p values for BMI, fasting glucose, HbA1c, fasting insulin, and HOMA following logarithmic transformation




Hba1c values at follow up were clearly different between the groups as expected and, as with those 
with normal glucose tolerance at baseline, was the sole determinant of glycaemic status. In contrast, 
HbA1c values at baseline in those participants with prediabetes before surgery were higher in those 
who had remained with prediabetes at the follow up appointment, than those who had improved to 
normal glucose tolerance.  The mean (SD) HbA1c at baseline was 39.2 (3.4) and 42.1 (2.3) mmol/mol 
in those with normal glucose tolerance and prediabetes at follow up respectively (estimated 
difference 2.92 mmol/mol (95% CI 0.7 to 5.1 to 5.41, p=0.01).  
Fasting insulin concentrations were not clearly different at either baseline or follow up in those with 
normal glucose tolerance or those with prediabetes (estimated difference 24.4 pmol/L for baseline 
insulin (95% CI -42.7 to 91.4, P=0.5) and 9.5 pmol/L for follow up insulin (95% CI -4.9 to 24.0, p=0.2).    
Given the absence of differences in the other dependent factor (fasting glucose), calculations of 
HOMA-IR, HOMA-%B, and HOMA-%S were also not clearly different at either baseline or follow up in 
either group. The mean (SD) HOMA-%S at baseline and follow up in those who had normal glucose 
tolerance was 45.4% (24.7) and 141.5% (50.7) respectively, whilst the mean (SD) at the same time 
points who those who remained with prediabetes at follow up was 43.8 (23.1) and 106.9 (42.4).  The 
estimated difference in HOMA-%S at follow up between the two groups was 34.6 (95% CI 2.3 to 71.6) 
although this did not reach statistical significance (p=0.07). Beta cell steady state function, as assessed 
by HOMA-%B, was increased in all those with prediabetes at baseline, and normalised in both groups 
at follow up (mean (SD) 88.0 % (20.4) in those who obtained normal glucose tolerance and 112.3 (37.4) 
in those who remained with prediabetes; estimated difference 15.2% (95% CI -2.67 to 33.1, p=0.09).  
Thus, the major determinant of the differences in glucose homeostasis, as assessed using the HOMA 
model, in those with preoperative prediabetes was an improvement in insulin sensitivity to 
concentrations greater than the population normal control average. As illustrated by both the fall in 
fasting insulin concentrations and HOMA-%B in this cohort, this allowed normalisation of preoperative 
hyperinsulinaemia.   
There was no difference in the age at operation of participants who obtained normal glucose tolerance 
versus those who remained with prediabetes (estimated difference 3.1 years (95% CI -3.2 to 9.5, 
p=0.3).   However, participants who obtained normal glucose tolerance had a significantly longer 
duration of follow up (mean (SD) 9.5 (4.4) versus 6.7 (1.4) years, estimated difference 2.8 years (95% 
CI 0.3 to 5.3, p=0,03)) than those who remained with prediabetes; consequently, participants with 
normal glucose tolerance at follow up were older at that point (mean (SD) 58.2 (10.5) versus 52.3 




(10.3), estimated difference 5.9 years (95% CI -1.1 to 13.0) although this was not statistically significant 
(p=0.1)   
BMI at baseline and follow up were similar irrespective of whether normal glucose tolerance or 
prediabetes were evident at follow up.  The mean (SD) BMI at baseline for those who obtained normal 
glucose tolerance was 46.7 (9.9) kg/m2 and 453.3 (7.8) kg/m2 in those who remained with prediabetes 
(estimated difference 1.3 kg/m2 (95% CI -4.9 to 7.6, p=0.7).  The mean (SD) BMI at follow up was 31.6 
(7.1) kg/m2 in those who remained with normal glucose tolerance and 31.6 (8.2) kg/m2 in those with 
prediabetes; estimated difference 0.03 kg for baseline weight (95% CI -5.1 to 5.0, P=1.0).  Mean (SD) 
Body weight loss (%) at follow up was slightly greater in both groups than that seen in those with 
preoperative normal glucose tolerance, at 30.2 (10.9) % in those with normal glucose tolerance at 
follow up, and 30.9 (10.9) % in those with prediabetes.  However, there was no clear difference 
between those with prediabetes at baseline and normal or prediabetes at follow up (estimated 
difference 0.71% (95% CI -5.74 to 7.15, p=0.83). 
Univariate regression analysis was performed to assess whether any variable could predict the change 
in HbA1c over the follow up period in those participants with prediabetes at baseline (Table 3-17). 
HbA1c at follow up was the sole differentiator of the groups (as above) and therefore follow up values 
were not considered. HbA1c at baseline did however predict the change in HbA1c and therefore 
diabetes status at follow up (r=0.4, f=4.5, p0.04), although accounted for only 10% of the variance in 
HbA1c change. Fasting glucose at baseline also predicted the change in HbA1c over the study period 
(r=0.43, f=6.8, p=0.01) and accounted for 16% of the total variation.  Regression plots are shown in 
Figure 3-12, and the regression equations were:  
 
Change in HbA1c (mmol/mol)   =   -1.4 + (0.4 * Ln(x) HbA1c (mmol/mol) at baseline) 












Table 3-17   Univariate regression analyses outcomes for baseline variables (independent) against diabetes 
status at the follow up assessment (dependent variables) in participants with prediabetes at baseline 
 




Age at operation (years) 0.07 <0.001 0.9 
Age at follow up (years) 0.07 <0.001 0.9 
Duration of follow up (years) 0.07 <0.001 1.0 
BMI at baseline (kg/m2) -0.68 0.2 0.05 
BMI at follow up (kg/m2) -0.08 0.05 0.6 
Change in BMI (kg/m2) -0.06 0.05 0.08 
Fasting glucose at baseline (mmol/L) -0.52 0.35 0.01 
Fasting glucose at follow up (mmol/L) 0.5 -0.27 0.2 
HbA1c at baseline (mmol/mol) -1.4 0.4 0.04 
HbA1c at follow up (mmol/mol) 2.2 -0.58 <0.001 
Fasting insulin at baseline (pmol/L) -0.03 0.02 0.25 
Fasting insulin at follow up (pmol/L) 0.19 -0.03 0.4 
HOMA-IR at baseline -0.01 0.09 0.03 
HOMA-IR at follow up 0.06 -0.1 0.06 
* following logarithmic transformation for fasting glucose, 





HOMA-IR at baseline predicted the change in HbA1c over the study period (r=0.41, f=5.6, p=0.03) and 
accounted for 14% of the observed variation.  The regression equation was: 
 
 Change in HbA1c (mmol/mol)  =   -0.014 + (0.09 * HOMA-IR at baseline) 
 




Figure 3-12  Regression variable plots for a) Ln(x) HbA1c at baseline, b) Ln(x) fasting glucose at baseline against 
change in HbA1c over the follow up period. 
 










































Multivariate regression analysis was then performed with models restricted to include only two 
independent variables as n=40.  An optimal model included baseline concentrations of HbA1c and 
fasting glucose as shown in Table 3-18. The change in HbA1c over the follow up period was predicted 




by this model (F(2,30)=5.0, P=0.01 r=0.50, r2=0.25) but explained only 20% of the total variation in the 
observed change in HbA1c. 
 
 
Table 3-18  Multivariate regression analysis incorporating baseline values of HbA1c and fasting glucose 
(following logarithmic transformation) to predict the change in HbA1c over the follow up period in participants 




Model summary ANOVA 
R R2 Adjusted R2 F P value 
















Constant -1.55 0.65  -2.38 0.02 -2.9 to -0.2 
Baseline HbA1c 
(mmol/mol) 
0.30 0.18 0.27 1.67 0.1 -0.06 to 0.67 
Baseline fasting glucose 
(mmol/L) 




A receiver operator curve was constructed to further assess the use of baseline HbA1c in those with 
prediabetes as a predictor of glycaemic outcome at follow up (Figure 3-13).  The attached table 
presents coordinates of this curve and shows that an HbA1c of >39.5 mmol/mol at baseline (and ≤47 
mmol/mol given the limitations of criteria for prediabetes) was 92% sensitive for persistent 
prediabetes at follow up, but only 50% specific. An HbA1c of >40.5 mmol/mol at baseline was 85% 
sensitive and 65% specific for persistent prediabetes at the follow up assessment. 
 
 




Figure 3-13   Receiver operator curve (ROC) and coordinates for HbA1c at baseline to predict persistent 























32.0 1.000 1.000 
33.5 1.000 .900 
35.0 1.000 .850 
37.0 1.000 .750 
38.5 1.000 .650 
39.5 .923 .500 
40.5 .846 .350 
41.5 .308 .250 
42.5 .308 .150 
43.5 .308 .100 
44.5 .231 .050 
45.5 .154 .000 
47.0 .000 .000 




3.1.4.5.3 Diabetes outcomes in those with type 2 diabetes at baseline 
42 participants had type 2 diabetes at baseline, 36 (86%) of participants had sufficient data available 
to categorise diabetes status at baseline and follow up.    38 (92%) of the participants had undergone 
transected RYGB whilst three (5%) and one (2%) participant had undergone silastic ring RYGB and 
gastric bypass respectively (Table 3-19). Descriptive data for this group are presented in Table 3-20.  
 
 
Table 3-19  Type of bariatric surgery performed in those with Type 2 diabetes at baseline 
 
N=41 n (%) 
Transected Roux-en-Y Gastric Bypass 38 (92) 
Silastic ring RYGB 3 (6) 
Gastric bypass 1 (2) 
 
The mean (SD) age at operation and follow up was 52.8 (8.24) and 61.6 (8.4) respectively, resulting in 
a mean (SD) of 8.8 (4.6) years).  26 (72%) of these participants had an improvement in glucose 
tolerance to either normal glucose tolerance (9 participants (25%)) or prediabetes (17 participants 
(47%)) at follow up.  10 participants (28%) remained with type 2 diabetes at follow up.   
It is important to note that 24/42 participants in this analysis were using diabetes medications at 
baseline with six of those participants using insulin therapy. Two (34%) participants with type 2 
diabetes at baseline but normal glucose tolerance at follow up were using oral diabetes medications 
at the time of surgery, with the remainder using dietary methods only.  11/17 (65%) of those with 
prediabetes at follow up were using oral diabetes medications at baseline, and one of these 
participants was also using insulin therapy.  10/11 (91%) of those with persistent type 2 diabetes at 
follow up were using oral diabetes medications at baseline, and four of these participants were also 
using insulin therapy.  Furthermore, 5/11 (42%) of those with persistent type 2 diabetes at follow up 
remained on diabetes medications (four using metformin, one additionally using a 




Table 3-20   Baseline and follow up characteristics and markers of glycaemic status for participants with type 2 diabetes at baseline.  A paired T test is shown. 
 
 
Baseline Follow up Paired T test * 
n (%) Mean (SD) n (%) Mean (SD) n (%) Est. diff 95% CI P value 
Type 2 diabetes (n=42) 
Age (years) 42 (100) 52.8 (8.2) 42 (100) 61.9 (8.7) 42 (100) 9.1 7.6 to 10.6 <0.001 
BMI (kg/m2) 42 (100) 48.2 (9.5) 42 (100) 32.9 (5.8) 42 (100) 15.3 13.2 to 17.4 <0.001 
Fasting glucose (mmol/L) 32 (77) 8.08 (2.71) 32 (77) 5.49 (1.86) 32 (77) 2.59 1.73 to 3.46 <0.001 
HbA1c (mmol/mol) 31 (75) 61.7 (15.9) 31 (75) 45.1 (11.2) 31 (75) 16.6 12.3 to 20.9 <0.001 
Insulin (pmol/L) 29 (71) 200.8 (89.2) 29 (71) 53.4 (21.3) 29 (71) 156.4 121.5 to 191.4 <0.001 














72.2 45.8 to 89.6 <0.001 
 
*p values for BMI, fasting glucose, HbA1c, fasting insulin, and HOMA following logarithmic transformation




sulphonylurea, and one on insulin therapy).   By definition, none of the participants with normal 
glucose tolerance or prediabetes at follow up were using diabetes medications.  In those with 
persistent type 2 diabetes at follow up only, the mean (SD) number of medications at follow up was 
0.6 (0.73).  
 
Table 3-21   Independent T test analysis to compare age at diagnosis and duration of diabetes prior to surgery 





A diagnosis of type 2 diabetes was made during the assessments for surgery in 4/42 participants, 
whilst 10/42 participants had not received a diagnosis of type 2 diabetes prior to surgery from their 
usual health practitioner, despite confirmatory biochemistry.  Thus, 28 participants were questioned 
about duration of diabetes prior to surgery.  The mean (SD) duration of diabetes in all those with type 
2 diabetes at baseline was 9.1 (7.0) years (minimum = 0 (i.e. informed of diagnosis during assessment 
for surgery, maximum = 23 years).   The mean (SD) age of diabetes diagnosis was 43.2 (9.7) years 
(minimum 20.0, maximum 61.0).  There was no apparent difference in either the age of onset, or 
duration prior to surgery, of diabetes in those who improved to prediabetes at follow up or remained 
with type 2 diabetes (Table 3-21).   
 
 
ADA diagnosis at follow up 
Independent T test 
Prediabetes (n=17) Type 2 diabetes (n=12) 
n (%) Mean (SD)  n (%) Mean (SD)  
Est. 
Diff 
95% CI  P value 









9.5 (7.9) 9 (82) 12.7 (4.3) 3.2 -1.96 to 8.4 0.3 




Univariate regression analysis was performed to assess whether any variable could predict the change 
in HbA1c over the follow up period in those participants with type 2 diabetes at baseline (Table 3-22). 
HbA1c at follow up was the key differentiator of the groups (as above) and therefore is irrelevant in 
this analysis. Fasting glucose, HbA1c, fasting insulin, and HOMA-IR (all following logarithmic 
transformation) at baseline did however predict the change in HbA1c and therefore diabetes status 
at follow up.  Fasting glucose predicted the change in HbA1c (r=0.58, f=12.2, p=0.002) and accounted 
for 31% of the observed variation in this outcome.  HbA1c predicted the change in HbA1c (r=0.56, 
f=13.3, p=0.001) and accounted for the 29% of the variation.  Fasting insulin and HOMA-IR (r=0.43, 
f=6.4, p=0.02; and r=0.47, f=5.9, p=0.03) accounted for 16 and 18% of the variation respectively. 
Regression plots are shown in Figure 3-14, and the regression equations were: 
 
Change in HbA1c (mmol/mol)    =   -0.49 + (0.38 * Ln(x) fasting glucose (mmol/L) at baseline 
Change in HbA1c (mmol/mol)   =   -1.6 + (0.47 * Ln(x) HbA1c (mmol/mol) at baseline) 
Change in HbA1c (mmol/mol)     =   -0.77 + (0.21 * Ln(x) fasting insulin (pmol/L) at baseline) 
Change in HbA1c (mmol/mol) =   -0.03 + (0.26 * Ln(x) HOMA-IR at baseline) 
 
 
Furthermore, the change in BMI following RYGB also predicted the change in HbA1c (r=0.43, f=6.4, 
p=0.02) and accounted for 15% of the observed variation.  The regression equation was: 
 
Change in HbA1c (mmol/mol) =   -0.13 + (0.17 * change in Ln(x) BMI (kg/m2)) 
Thus, univariate regression modelling predicts that, in participants with pre-operative type 2 diabetes, 
the change in HbA1c over the follow up period will be greater with a greater baseline fasting glucose, 
HbA1c, fasting insulin, and HOMA-IR, and in those who lose a greater amount of weight following 
surgery.  Duration of diabetes prior to surgery or the age at which diabetes was diagnosed did not 
predict glycaemic outcomes. 




Table 3-22   Univariate regression analyses outcomes for baseline variables (independent) against change in 
HbA1c over the follow up period (dependent variables) in participants with type 2 diabetes at baseline  
 




Age at operation (years) 0.55 -0.005 0.3 
Age at follow up (years) 0.52 -0.003 0.4 
Duration of follow up (years) 0.3 0.008 0.6 
BMI at baseline (kg/m2) -1.0 0.4 0.07 
BMI at follow up (kg/m2) -0.19 0.14 0.5 
Change in BMI (kg/m2) -0.13 0.17 0.02 
Fasting glucose at baseline (mmol/L) -0.49 0.38 0.002 
Fasting glucose at follow up (mmol/L) 0.45 -0.08 0.6 
HbA1c at baseline (mmol/mol) -1.59 0.5 0.001 
HbA1c at follow up (mmol/mol) 1.4 -0.29 0.09 
Fasting insulin at baseline (pmol/L) -0.77 0.21 0.02 
Fasting insulin at follow up (pmol/L) 0.61 -0.078 0.3 
HOMA-IR at baseline -0.03 0.26 0.03 
HOMA-IR at follow up 0.3 -0.13 0.3 
Age at diagnosis of diabetes 0.45 -0.003 0.5 
Duration of diabetes pre surgery 0.331 -0.001 0.9 
* following logarithmic transformation for fasting glucose, 










Figure 3-14 Regression variable plots for a) Ln(x) fasting glucose at baseline, b) Ln(x) HbA1c at baseline, c) Ln(x) 






































Multivariate regression analysis was then performed with models restricted to include only two 
independent variables as n=36.  The optimal model included the change in BMI (kg/m2) over the follow 
up period, and either the baseline fasting glucose (mmol/L, model A, Table 3-23) or the baseline HbA1c 
(mmol/mol, model B, Table 3-24).  The change in HbA1c over the follow up period was predicted by 
model A (F(2,23)=14.1, P<0.001, r=0.74, r2=0.55) and explained 51% of the total variation in the 
observed change in HbA1c.   The change in HbA1c over the follow up period was predicted by model 
B (F(2,28)=12.2, P<0.001, r=0.68, r2=0.47) and explained 43% of the total variation in the observed 
change in HbA1c.   




Table 3-23 Multivariate regression analysis incorporating baseline values of fasting glucose (following 
logarithmic transformation) and the change in BMI following surgery, to predict the change in HbA1c over the 
follow up period in participants with type 2 diabetes at baseline.  Table a presents the model summary and 
table b presents the coefficients 
 
a) 
Model summary ANOVA 
R R2 Adjusted R2 F P value 















Constant -0.96 0.24  -4.01 <0.001 -1.45 to -0.47 
Baseline fasting glucose 
(mmol/L) 
0.37 0.09 0.56 4.04 0.001 0.18 to 0.56 
Change in BMI (kg/m2) 
over follow up 
0.2 0.06 0.46 3.31 0.003 0.07 to 0.32 
 
 
Table 3-24   Multivariate regression analysis incorporating baseline values of HbA1c (following logarithmic 
transformation) and the change in BMI following surgery, to predict the change in HbA1c over the follow up 
period in participants with type 2 diabetes at baseline.  Table a presents the model summary and table b 
presents the coefficients 
 
a) 
Model summary ANOVA 
R R2 Adjusted R2 F P value 















Constant -1.9 0.48  -3.9 <0.001 -2.9 to – 0.9 
Baseline HbA1c 
(mmol/mol) 
0.44 0.12 0.53 3.9 0.001 0.21 to 0.68 
Change in BMI (kg/m2) 
over follow up 
0.15 0.06 0.39 2.8 0.009 0.04 to 0.27 
 




Receiver operator curves were constructed to further assess the use of baseline fasting glucose and 
HbA1c values in those with type 2 diabetes as a predictor of glycaemic outcome at follow up (Figure 
3-15).  A fasting glucose of greater than or equal to 8.15 mmol/L at baseline was 75% sensitive and 
73% specific for persistent type 2 diabetes at follow-up.   Alternatively, a fasting glucose of ≥9.70 
mmol/L was only 62.5% sensitive for persistent type 2 diabetes at follow up, but 90% specific.  An 
HbA1c of greater than or equal to 62 mmol/mol at baseline was 87.5% sensitive for persistent type 2 
diabetes at follow up, and 78.3% specific.  Alternatively, and HbA1c of ≥66.5 mmol/mol was 75% 
sensitive but 91.3% specific for persistent type 2 diabetes.  Conversely, 80% specificity for normal 
glucose tolerance in those with type 2 diabetes at baseline was not reached until a fasting glucose and 
Hba1c threshold of 10.25 mmol/L and 89.5 mmol respectively, rendering the clinical use of this tool 
for predicting diabetes resolution limited. 
 
 
Figure 3-15  Receiver operator curves (ROC) and coordinates for a and c) Fasting glucose (mmol/L) and b and d) 
HbA1c (mmol/mol) at baseline in participants with type 2 diabetes, as a predictor of persistent type 2 diabetes 
status at follow up  
 


















   
  
Fasting glucose 
(mmol/L) greater than 
Sensitivity 1 - Specificity 
3.3000 1.000 1.000 
4.7000 1.000 .955 
5.2500 1.000 .909 
5.4500 1.000 .818 
5.6500 1.000 .773 
5.9000 .750 .727 
6.1500 .750 .682 
6.3500 .750 .636 
6.6500 .750 .591 
7.1000 .750 .500 
7.4000 .750 .455 
7.5500 .750 .409 
7.7500 .750 .364 
8.0000 .750 .318 
8.1500 .750 .273 
8.2500 .625 .227 
8.6000 .625 .182 
9.1500 .625 .136 
9.7000 .625 .091 
10.2500 .500 .091 
11.1500 .500 .045 
12.6000 .375 .045 
13.5000 .250 .045 
13.7500 .125 .045 




Sensitivity 1 - Specificity 
37.0000 1.000 1.000 
38.5000 1.000 .957 
40.0000 1.000 .913 
41.5000 1.000 .870 
45.5000 1.000 .826 
49.5000 1.000 .783 
50.5000 .875 .739 
52.5000 .875 .652 
54.5000 .875 .565 
55.5000 .875 .522 
56.5000 .875 .478 
58.5000 .875 .304 
62.0000 .875 .217 
64.5000 .750 .174 
65.5000 .750 .130 
66.5000 .750 .087 
73.0000 .750 .043 
80.0000 .625 .043 
82.0000 .500 .043 
85.0000 .375 .043 
89.5000 .250 .000 
95.5000 .125 .000 
100.0000 .000 .000 




3.1.4.6 Blood pressure at baseline and follow up 
Data for systolic, diastolic and mean arterial blood pressure at baseline and follow up were normally 
distributed as demonstrated by inspection of histograms (Figure ii-7 (377)) and assessment using the 
Shapiro-Wilk test (Table ii-9 (377)).  Furthermore, the change from baseline to follow up of each of 
these variables also displayed normal distribution (Figure ii-8 (378)).  Thus, parametric models were 
used for comparison of the data at baseline and follow up.  Box plots of systolic, diastolic, and mean 
arterial blood pressure are at baseline and follow up in all participants and those with hypertension at 
baseline are presented in Figure 3-16. 
 
Figure 3-16   Box plots to show a) systolic blood pressure, b) diastolic blood pressure, and c) mean arterial 



























The mean (SD) systolic and diastolic blood pressure at baseline was 141.9 (20.7) mmHg and 81.9 (12.1) 
mmHg respectively, whilst the mean (SD) SBP and DBP at follow up was 129.8 (21.4) and 78.7 (10.2) 
mmHg respectively. The mean arterial pressure (MAP) at baseline was 101.9 (13.9) mmHg, and 95.7 
(12.7) mmHg at follow up.     
Systolic blood pressure (SBP) was significantly lower at follow up when compared to baseline 
measurements (Figure 3-16 and Table 3-25).  The mean (SD) SBP at baseline was 141.9 (20.7) and 
129.8 (21.4) mmHg at follow up; estimated difference 11.3 mmHg (95% CI 7.3 to 15.4, p<0.001).  
Predictably the mean (SD) systolic blood pressure at baseline was higher (146.6 (18.6) mmHg) when 
only those with hypertension (n=96) were considered, but a similar reduction in blood pressure at 
follow up was noted (mean (SD) SBP at follow up 133.9 (21.3) mmHg; estimated difference 12.7 mmHg 
(95% CI 8.1 to 17.3, p<0.001). 
Diastolic blood pressure (DBP) was also significantly reduced at follow up in those with and without 
hypertension at baseline (Figure 3-16 and Table 3-25).  The mean (SD) DBP at baseline in all 
participants was 81.9 (12.1) mmHg, and at follow up was 78.7 (10.2) mmHg; estimated difference 3.1 
mmHg (95% CI 0.5 to 5.7, p=0.02).  The mean (SD) DBP in those with hypertension at baseline (n=96) 
was 84.0 (11.5) mmHg, and at follow up was 80.0 (10.1) mmHg; estimated difference 4.0 mmHg (95% 
CI 1.2 to 6.7, p=0.006).  Predictably, similar results were therefore noted when comparisons were 
made of mean arterial blood pressure (MAP) at baseline and follow up.  The estimated reduction in 
MAP in all participants was 7.9 mmHg (95% CI 4.0 to 11.8, p<0.001), whilst the estimated reduction in 
those with hypertension at baseline was 7.0 mmHg (95% CI 4.0 to 9.9, p<0.001). 




Table 3-25   Descriptive blood pressure data for all participants and those with hypertension at baseline and follow up. Results of a paired T test are shown.  
 
n=118 
Baseline Follow up (>5 years) Paired T test for  
Estimated difference 
Mean (SD) IQR Min/Max Mean (SD) IQR Min/Max Mean 95% CI P value 
All participants (n=118) 
Systolic blood pressure 
(mmHg) 
141.9 (20.7) 30.0 100.0/200.0 129.8 (21.4) 25.1 86.0/195.0 11.3 7.3 to 15.4 <0.001 
Diastolic blood pressure 
(mmHg) 
81.9 (12.1) 13.5 50.0/120.0 78.7 (10.2) 12.7 47.0/110.0 3.1 0.5 to 5.7 0.02 
Mean arterial pressure 
(mmHg) 
101.9 (13.9) 15.3 66.7/133.3 95.7 (12.7) 15.6 67.1/130.0 5.9 3.2 to 8.6 <0.001 
Number of blood pressure 
medications 
0.70 (0.88) 1.0 0/3 0.36 (0.56) 1.0 0/2 0.35 0.19 to 0.50 <0.001 
Hypertension at baseline (n=96) 
Systolic blood pressure 
(mmHg) 
146.7 (18.5) 24.8 104.0/200.0 133.9 (20.9) 23.0 94.0/195.0 12.7 8.2 to 17.3 <0.001 
Diastolic blood pressure 
(mmHg) 
84.0 (11.5) 17.0 63.0/120.0 80.0 (10.3) 13.6 47.0/110.0 4.0 1.2 to 6.8 0.006 
Mean arterial pressure 
(mmHg) 
104.9 (12.5) 17.0 77.3/133.3 98.0 (12.4) 16.9 67.1/130.0 7.0 4.0 to 9.9 <0.001 
Number of blood pressure 
medications 
0.86 (0.90) 1.0 0/3 0.40 (0.60) 1.0 0/2 0.47 0.29 to 0.65 <0.001 




Participants used fewer anti-hypertensive medications at follow up than at baseline.  When all 
participants were considered, the mean (SD) number of anti-hypertensive medications used was 0.7 
(0.9) and 0.36 (0.56) at baseline and follow up respectively; estimated difference 0.35 (95% CI 0.19 to 
0.50, p<0.001).  The reduction was greater still in those with hypertension at baseline with an 
estimated difference of 0.47 (95% CI 0.29 to 0.65, p<0.001). 
In contrast to participants with hypertension at baseline, there were no clear changes following 
surgery in those with normotension at baseline (n=15).  The estimated difference in SBP was a 
reduction of 3.7 mmHg (95% CI -4.1 to 11.5, p=0.32) from baseline to follow up, whilst DBP was slightly 
higher at follow up than at baseline; estimated difference 1.69 mmHg (95% CI -5.5 to 8.8, p=0.62).  
MAP measurements were very similar at both time points; estimated difference 0.1 mmHg (95% CI -
6.6 to 6.8, p=0.97).  Four (27%) of these participants developed hypertension by the study criteria 
during the period of follow up; two on the basis of blood pressure thresholds, and two who were using 
anti-hypertensive medication (both beta blockers). 
Regression analysis was performed to explore relationships between the change in blood pressure 
following surgery and measured baseline variables.  An initial analysis to assess whether baseline 
variables predict blood pressure outcomes included age at operation and follow up, gender, diabetes 
status and markers of glucose homeostasis, and did not reveal any relationship with the change in 
systolic, diastolic, or mean arterial pressure during follow up.   Linear regression established that 
systolic, diastolic, and mean arterial blood pressure at baseline all predict the change in systolic, 
diastolic, and mean arterial blood pressure at follow up (Table ii-10 (379)).  The duration of follow up 
since surgery predicted the change in diastolic blood pressure over the follow up period (r= 0.3, f=9.2, 
p=0.003) although accounted for only 8% of the variation in this outcome.  The blood pressure status 
(normotensive versus hypertensive), number of blood pressure medications, duration of 
hypertension, and duration of treated hypertension at baseline did not relate to change in systolic, 
diastolic, or mean arterial blood pressure.  Results pertaining to mean arterial blood pressure are thus 
discussed in more detail. 
The systolic, diastolic, and mean arterial blood pressure at baseline each predicted mean arterial blood 
pressure at follow up ((r=0.46, f=24.7, p<0.001), (r=0.58, f=47.1, P<0.001), (r=0.56, f=43.1, p<0.001), 
and accounted for 20, 33, and 31% of the variance in mean arterial blood pressure at follow up 
respectively (Figure 3-17).  The regression equations were: 










Figure 3-17   Regression variable plots for a) systolic blood pressure (mmHg), b) diastolic blood pressure 
(mmHg), and c) mean arterial blood pressure at baseline (mmHg), against the change in mean arterial blood 
pressure (mmHg) at follow up 
 
































Mean arterial blood pressure 
(mmHg) at follow up 
 
= 35.4 + (-0.3 * Systolic blood pressure at baseline) 
 
= 46.1 + (-0.5 * Diastolic blood pressure at baseline) 
 
   = 48.5 + (-0.6 * Mean arterial blood pressure) 




Thus, the degree of change in mean arterial blood pressure increased with increasing systolic, 
diastolic, and mean arterial blood pressure at baseline.  
Multivariate regression analysis was then performed to assess whether a model including multiple 
independent variables could better predict the mean arterial blood pressure at follow up than any one 
independent variable alone.  As with previous analysis, a multivariate model was restricted to a 
maximum of six independent variables (n=118).  An optimal model was obtained by including mean 
arterial blood pressure (mmHg), the number of blood pressure medications used at baseline, and the 
duration of hypertension prior to surgery (Table 3-26).  The change in mean arterial blood pressure at 
follow up was predicted by this model (F(3,36)=9.6, P<0.001, r=0.67, r2=0.45) and explained 40% of 
the total variation in mean arterial blood pressure.  However, only the mean arterial blood pressure 
at baseline added significantly to the prediction, p<0.05, and therefore it is unlikely that the other 
independent variables (duration of hypertension prior to surgery and number of blood pressure 
medications at baseline) contribute. Furthermore, inclusion of any of these additional independent 
variables available only at follow up did not add to the multivariate model. 
 
Table 3-26 Multivariate regression analysis incorporating systolic blood pressure at baseline and the listed 
independent variables to predict mean arterial blood pressure at follow up.  Table a presents the model 
summary and table b presents the coefficients 
a) 
Model summary ANOVA 
R R2 Adjusted R2 F P value 
















Constant 61.4 14.4  4.3 <0.001 32.2 to 90.6 
Systolic blood pressure 
at baseline (mmHg) 
-0.65 0.13 -0.65 -5.2 <0.001 -0.9 to -0.4 
Hypertension duration 
prior to surgery (years) 
0.06 0.2 0.04 024 0.8 -0.4 to 0.51 
Number of blood 
pressure medications 
used at baseline 
2.85 3.7 0.1 0.78 0.4 -4.6 to 10.3 




3.1.4.6.1 Stratification by blood pressure status at follow up 
Whilst statistically significant reductions in systolic, diastolic, and mean arterial blood pressure were 
evident in all participants and those with hypertension at baseline, this did not translate into change 
in the blood pressure status of most participants.  Of the 15 participants with normotension at 
baseline, 11 (73%) remained with normotension at follow up, whilst 4 (27%) had developed 
hypertension (Table 3-27).  Ninety-three participants with hypertension at baseline had adequate 
information to categorise at both baseline and follow up.  Of these, 19 (20%) had improved to 
normotension, whilst 74 (80%) remained with hypertension. 
 
 
Table 3-27   Cross tabulation of blood pressure status at baseline against Blood pressure status at follow up 
N=108 






Normotension 11 4 15 
Hypertension 19 74 93 
Total 30 78 108 
 
 
However, the 74 participants with persistent hypertension at follow up had better controlled 
hypertension than at baseline.  The mean (SD) number of anti-hypertensive medications used by this 
group at baseline was 0.96 (0.87) and had fallen to 0.51 (0.62) at follow up; estimated difference 0.45 
(95% CI 0.25 to 0.64, p<0.001).  Furthermore, a reduction in SDP was evident with a mean (SD) of 149.7 
(19.0) and 139.9 (19.5) mmHg at baseline and follow up respectively; estimated difference 9.8 mmHg 
(95% CI 4.4 to 15.3, p=0.001).  Despite similar DBP measurements at baseline and follow up (estimated 
difference 2.0 mmHg (95% CI -1.2 to 5.2, p=0.22), this translated into a significant reduction in MAP 
with a mean (SD) measurement of 106.7 (13.1) and 102.0 (10.5) mmHg at baseline and follow up 
respectively; estimated difference 4.7 mmHg (1.2 to 8.1, p=0.01). 
 




Duration of hypertension prior to surgery and duration of treatment with anti-hypertensive agents 
prior to surgery did not appear to predict blood pressure status outcomes.  Forty eight participants 
with hypertension at baseline (50%) also had information on duration of hypertension prior to surgery.  
Twenty eight (58%) had received a diagnosis of hypertension within 10 years of surgery (mean (SD) 
3.1 (2.9) years), whilst 20 (42%) had had hypertension for 10 years or longer prior to surgery (mean 
(SD) 19.2 (7.0) years) (Table 3-28).  Three (12%) participants with less than 10 years of hypertension 
pre surgery were normotensive at the follow up appointment, in comparison to 1 (5%) of those with 
greater than 10 years of hypertension.  Conversely, 25 (88%) of those with less than 10 years of 
hypertension were normotensive at the follow up appointment in comparison to 19 (95%) of those 
with the longer duration of hypertension.  The absence of any relationship between duration of 
hypertension prior to surgery and blood pressure status at follow up was supported by regression 
analysis (R=0.15, F=1.1, p=0.3). 
 
  
Table 3-28   Cross tabulation of the duration of hypertension prior to surgery against blood pressure status at 
follow up 
N=48 








3 25 28 
≥10 
years 
1 19 20 




Forty (42%) of participants with hypertension at baseline had information on the duration of 
hypertension treatment prior to surgery; this duration was slightly less than the mean duration of 
hypertension (estimated difference 1.1 more years since hypertension diagnosis than commencement 
of treatment (95% CI 0.02 to 2.2, p=0.05). Twenty one (53%) had commenced treatment for 




hypertension within 10 years of surgery (mean (SD) 3.0 (3.1) years), whilst 19 (47%) had had 
hypertension treatment for 10 years or longer prior to surgery (17.4 (6.3) years) (table 4-x).   One (5%) 
participant in each group had normotension at the follow up assessment, whilst 20 and 19 (both 95%) 
of those with less than or more than 10 years of treatment respectively had persistent hypertension 
at follow up.  Again, the absence of any relationship between duration of hypertension prior to surgery 
and blood pressure status at follow up was supported by regression analysis (R=0.02, F=0.1, p=0.9). 
 
Table 3-29   Cross tabulation of the duration of hypertension treatment prior to surgery against blood pressure 
status at follow up 
  
N=40 









1 20 21 
≥10 
years 
1 18 19 




Furthermore, there were no clear differences when the mean systolic, diastolic and arterial pressure 
at follow up were compared in those with differing durations of hypertension, or differing durations 
of hypertension treatment prior to surgery.  With respect to duration of hypertension, the estimated 
difference in mean systolic blood pressure between those with less than 10 years of hypertension 
prior to surgery, or greater than or equal to 10 years was 9.5 mmHg (95% CI -22.3 to 3.3, p=0.14).  The 
estimated difference in mean diastolic blood pressure was 0.1 mmHg (95% CI -5.1 to 5.3, p=0.96), 
whilst the estimated difference in mean arterial pressure was 3.1 mmHg (95% CI -10.0 to 3.8, p=0.4).  
With respect to the duration of hypertension treatment prior to surgery, the estimated difference in 
mean systolic blood pressure between those with less than 10 years of hypertension treatment prior 
to surgery, or greater than or equal to 10 years was 10.7 mmHg (95% CI -24.7 to 3.3, p=0.13).  The 




estimated difference in mean diastolic blood pressure was 0.3 mmHg (95% CI -6.1 to 5.5, p=0.93), 
whilst the estimated difference in mean arterial pressure was 3.7 mmHg (95% CI -11.3 to 3.8, p=0.3). 
 
The number of medications used to control hypertension at baseline, did appear to relate to blood 
pressure status at follow up.  Ninety-three participants had a record of both the medication use at 
baseline and adequate data to categorise blood pressure status at follow up (Table 3-30).  Of these 19 
(20%) had improved to normotension at follow up, and of these participants, 14 (74%) were not using 
anti-hypertensive medication at baseline.   
  
Table 3-30   Cross tabulation of the duration of the number of anti-hypertensive medications used at baseline 
against blood pressure status at follow up 
  
N=93 







0 14 26 40 
1 3 28 31 
2 0 17 17 
3 2 3 5 




As only 5 participants used 3 medications at baseline, further meaningful analysis including this group 
was not possible.  However, in support of the hypothesis that the number of medications required at 
baseline may predict blood pressure outcomes after surgery, the median systolic and mean arterial 
pressure increased with each incremental increase in the number of medications used (figures 4-x).   
  




3.1.4.7 Lipids at baseline and follow up 
Ninety-two (78%) of participants had data on baseline total cholesterol, HDL (and therefore 
cholesterol to HDL ratios), LDL, and Triglyceride concentrations available.  Data for total cholesterol 
and LDL concentrations at baseline and follow up, and the change from baseline to follow up, were 
normally distributed as demonstrated by inspection of histograms (Figure ii-9 (380) and Figure ii-11 
(382)) and assessment using the Sharpiro-Wilk test (Table ii-11 (381)).  Thus, parametric models were 
used for analysis of the change from baseline to follow up.  Data for HDL and triglyceride 
concentrations showed right skew as shown in Figure ii-9 (380).  Logarithmic transformation resulted 
in normal distribution of this data (Figure ii-10 (381) and Table ii-12 (382)), allowing parametric 
analysis. 
Seventy two (61%) denied a previous diagnosis of dyslipidaemia at baseline, whilst 38 (34%) had 
previously received a diagnosis of dyslipidaemia or were using lipid lowering therapy at baseline.  Of 
those with a known diagnosis of dyslipidaemia at baseline, 29 (76%) of participants had information 
on the duration of dyslipidaemia, with a mean (SD) duration of 5.0 (4.8) years.  Nineteen (50%) of 
those with a previous diagnosis of dyslipidaemia reported the use of a lipid lowering medication at 
baseline. Only 19/118 (16%) of participants reported the use of lipid lowering therapy at baseline.  A 
similar number (18/118 (15%) were using lipid lowering therapy at follow up, and no participants was 
using more than one agent.  The estimated difference in number of lipid lowering therapies used at 
baseline and follow up was 0.008 (95% CI -0.06 to 0.07, p=0.8) (Table 3-31). 
The mean (SD) fasting total cholesterol, HDL, LDL, and triglycerides concentration at baseline were 
5.40 (0.99), 1.33 (0.34), 3.20 (0.97), and 1.82 (1.02) mmol/L respectively (Table 3-31 and Figure 3-18). 
The mean (SD) total cholesterol to HDL ratio was 4.25 (1.13) mmHg. 84 (71%) of participants had data 
at both baseline and follow up.  LDL concentrations were significantly lower at follow up than at 
baseline.  The mean (SD) LDL concentration at baseline was 3.24 (0.93) and 2.80 (0.81) mmol/L at 
follow up; estimated difference 0.43 mmol/L (0.21 to 0.65, p<0.001). Additionally, HDL concentrations 
were significantly increased at follow up in comparison to baseline, resulting in significant 
improvements in the cholesterol to HDL ratio.  The mean (SD) HDL at baseline and follow up was 1.33 
(0.34) and 1.91 (0.54) mmol/L respectively; estimated difference 0.58 mmol/L (p<0.001 after 
logarithmic transformation).  




Table 3-31   Descriptive lipid data for all participants at baseline and follow up.  Results of a paired T test are shown.  
 
 
Baseline Follow up (>5 years) Paired T test for 
Estimated difference * 
n Mean (SD) IQR Min/Max n Mean (SD) IQR Min/Max Mean 95% CI P value 
Total cholesterol (mmol/L) 92 5.40 (0.99) 1.42 3.30/7.60 110 5.24 (0.98) 1.30 2.9/7.3 0.18 -0.05 to 0.42 0.13 
HDL (mmol/L) 92 1.33 (0.34) 1.71 0.69/2.40 110 1.91 (0.54) 0.7 0.8/3.9 0.35 0.30 to 0.40 <0.001 
LDL (mmol/L) 92 3.24 (0.93) 1.41 0.99/5.31 110 2.80 (0.81) 1.16 1.02/4.43 0.43 0.21 to 0.65 <0.001 
Triglycerides (mmol/L) 92 1.82 (1.02) 0.95 0.70/7.30 110 1.13 (0.43) 0.6 0.5/3.1 0.42 0.32 to 0.51 <0.001 
Cholesterol:HDL ratio 92 4.25 (1.13) 1.48 2.10/8.20 110 2.92 (0.83) 1.0 1.6/6.3 1.30 1.04 to 1.56 <0.001 
Number of lipid lowering 
medications 
118 0.16 (0.37) 0.0 0/1 118 0.15 (0.36) 0.0 0/1 0.008 -0.06 to 0.07 0.8 
 
* Paired T tests for HDL and Triglycerides report logarithmic transformed data to better approximate normal distribution 
 




Figure 3-18   Box plots to show a) total cholesterol, b) HDL, c) LDL, and d) Triglycerides at baseline and 
follow up 
 















The estimated difference in mean total cholesterol to HDL ratio was 1.3 mmol/L (95% CI 1.04 to 
1.56, P<0.001). Thus, whilst the mean total cholesterol concentration was lower at follow up 
when compared to baseline measurements, the estimated difference was not statistically 
significant (Table 3-31 and Figure 3-18).  
A significant reduction in fasting triglyceride concentrations was noted.  The mean (SD) 
triglyceride concentration at baseline and follow up was 1.82 (1.02) and 1.13 (0.42) mmol/L 
respectively; estimated difference 0.69 (p<0.001 after logarithmic transformation).  
Each of these relationships persisted when only those participants not on cholesterol lowering 
therapy at either baseline or follow up were included in the analysis (n=67) as presented in Table 
ii-13 (383). 




Univariate and multivariate analysis was performed to explore relationships between the change 
in lipid concentrations following surgery and other measured variables.  An initial analysis did not 
reveal any association between the change in LDL, HDL, or Triglyceride concentrations and age at 
operation, gender, BMI at baseline, diabetes status and markers of glucose homeostasis (fasting 
glucose, HbA1c, fasting insulin, and HOMA-IR), and blood pressure status and concentrations 
(Table ii-14 (384)).  Additionally, there was no evident association between lipid markers and 
change in markers of glucose homeostasis from baseline to follow up. 
LDL level at baseline predicted the change in LDL over the follow up period (r=0.66, f=63.6, 
p<0.001), and accounted for 43% of this variation (Table ii-14 (384)).  This finding persisted when 
only those participants not using cholesterol lowering therapy at baseline or follow up were 
considered.  Furthermore, in this group the change in LDL was also predicted by BMI at follow up 
(r=0.31, f=7.0, p=0.01), the percentage change in body weight over the study period (r=0.38, 
f=11.1, p=0.001), although each variable accounted for only 8 and 13% of the variability in LDL 
change respectively.  HDL level at baseline did not however predict the change in HDL over the 
study period, but was predicted by BMI at follow up (r=0.31, f=9.1, p=0.003).  Triglyceride level at 
baseline predicted the change in triglyceride concentrations over the follow up period (r=0.92, 
f=429.8, p<0.001), and accounted for 84% of this variation.  HDL level at baseline also predicted 
change in triglycerides over the follow up study (r=0.37, f=13.1, p=0.001), and accounted for 13% 
of the total variation in triglyceride change.  Change in triglycerides was independent of BMI at 
baseline or follow up, or the change in body weight during the follow up period. 
Duration of follow up predicted change in LDL (mmol/L) and HDL (mmol/L) from baseline to follow 
up ((r=0.27, f=6.5, p=0.01) and (r=0.27, f=6.63, p=0.01) respectively), suggesting that an increase 
in the duration of follow up since surgery was associated with a reduction in LDL concentrations 
and an increase in HDL concentrations (Table ii-14 (384) and Figure 3-19). The regression 
equations were: 
 Change in LDL (mmol/L) = -0.43 + (0.11 * duration of follow up (years) 
Change in HDL (mmol/L) = 0.2 + (0.05 * duration of follow up (years) 
 




Figure 3-19 Regression variable plot for duration of follow up (years) against a) change in LDL (mmol/L) 
and b) change in HDL (mmol/L) over the follow up period 









Of the 38 participants who had previously received a diagnosis of dyslipidaemia or were using 
lipid lowering therapy at baseline, 29 (76%) were able to confirm the duration of this diagnosis.  
The mean (SD) duration of dyslipidaemia in this group was 5.0 (4.8) years (range 0.0 to 17.0 years), 
and thirteen (34%) of these participants were able to confirm the duration of lipid lowering 
therapy prior to surgery (mean (SD) 6.5 (3.7) years (range 1.0 to 14.0 years)). 
 
The duration of dyslipidaemia prior to surgery (years) predicted both the change in LDL (r=0.42, 
f=4.6, p=0.04) and change in HDL (r=0.58, f=11.6, p=0.002), and accounted for 14% and 31% 
respectively of the variation in each (Table ii-14 (384) and Figure 3-20).  Change in triglyceride 
concentrations was not predicted by duration of dyslipidaemia.  Thus, the change in LDL from 
baseline to follow up reduced with an increasing duration of preoperative dyslipidaemia, whilst 
the change in HDL increased with time.  The regression equations were: 
 
 
Change in LDL (mmol/L)     = 0.94 + (-0.14 * Duration of dyslipidaemia (years)) 
 
Change in HDL (mmol/L)   = 0.32 + (0.05 * Duration of dyslipidaemia (years)). 
 
 




Figure 3-20 Regression variable plot for duration of dyslipidaemia (years) against a) change in LDL 
(mmol/L) and b) change in HDL (mmol/L) over the follow up period 










To explore whether the duration of dyslipidaemia prior to surgery predicts lipid outcomes 
following surgery, variables of interest in these two groups were compared using an independent 
T test (Table ii-15 (385)).  The two groups were of a similar mean age at baseline and follow up 
(estimated difference 1.7 years at baseline (95% CI -5.3 to 8.7, p=0.6), and 1.6 years at follow up 
(95% CI -5.7 to 8.9, p=0.7).  Thus the mean duration of follow up was also similar with an estimated 
difference of 0.1 years (95% CI -1.9 to 2.1, p=0.9).  Whilst participants with the longer duration of 
dyslipidaemia were lighter at baseline and follow up, this did not translate in to a clear statistical 
difference.  The estimated difference, after logarithmic transformation, between mean BMI at 
baseline was 0.05 (95% CI -0.1 to 0.2, p=0.5; equivalent to a mean ratio of 1.05 (95% CI 0.9 to 
1.22)). The estimated difference between mean BMI at follow up was 0.08 (95% CI -0.05 to 0.1, 
p=0.3; equivalent to a mean ratio of 1.08 (95% CI 0.95 to 1.10)).   Mean (SD) body weight loss (%) 
over the 7.6 years of follow up was similar in each group at 28.0 (9.1) % in those with less than 
five years of diagnosed dyslipidaemia prior to surgery, and 29.8 (12.6) % in those with five or more 
years; estimated difference 1.8% (95% CI -10.2 to 6.5, p=0.7). Participants with five or more years 
of dyslipidaemia did however use more lipid lowering therapy (estimated difference 0.4 (95% CI 
0.1 to 0.8, p=0.02) than participants with less than five years of follow up; ten out of fourteen 
(71%) of those with the longer duration of dyslipidaemia were on lipid lowering therapy at 
baseline, in comparison to 4/15 (27%) of the second group.  Thus, with the exception of 
medication use, the two groups were similar in character and further study to explore the 
relationship between preoperative duration of dyslipidaemia and change in LDL and HDL 
concentrations following surgery is justified. 




3.1.4.8 Other co-morbidities at baseline and follow up 
Table 3-32 below presents data on other co-morbidities reported by participants at baseline and 
follow up. Outcomes represent events that occurred either prior to surgery (baseline) or between 
surgery and the follow up assessment (follow up).   Outcomes of McNemar’s test to assess 
differences in the proportion of participants with each diagnosis at each time point are shown. 
 
 
Table 3-32   Frequency of co-morbid conditions at baseline and follow up.  Results of McNemar’s test to 
compare categorical variables are reported. 
Co-morbidity Baseline (%) Follow up (%) McNemar’s test 
Ischaemic heart 
disease 
9 (8) 6 (5) 0.55 
Myocardial 
infarction 
3 (3) 0 (0) 0.25 
Coronary artery 
bypass graft 
4 (4) 0 (0) 0.13 
Stroke 3 (3) 1 (1) 0.63 
Depression 32 (27) 23 (20) 0.08 
Arthritis 39 (34) 51 (44) 0.052 
Sleep apnoea 39 (34) 5 (5) <0.001 
Gout 12 (10) 4 (4) 0.003 
Cholecystectomy 58 (49) 5 (5) <0.001 
Osteoporotic 
fracture 








3.1.4.8.1 Ischaemic heart disease 
Eight (7%) participants had an established diagnosis of ischaemic heart disease at baseline, three 
(3%) of whom had previously suffered a myocardial infarction, and four (4%) of whom had 
previously undergone coronary artery bypass graft surgery.   Six (5%) further participants 
developed ischaemic heart disease during the period of follow up, although no further myocardial 
infarctions were reported, and no participant underwent coronary artery bypass graft surgery 
during this period. McNemar’s test determined there was no clear difference in the frequency of 
ischaemic heart disease or related co-morbid conditions at baseline and follow up (p=0.55). 
 
3.1.4.8.2 Stroke 
Three (3%) of participants had suffered a stroke prior to acceptance for surgery.  A further 
participant suffered a stroke between surgery and the follow up assessment.  McNemar’s test 




Thirty two (27%) participants had a diagnosis of depression at baseline.  Depression had resolved 
by the follow up assessment in 18 (15%) of these participants, but was persistent in 14 (12%).  A 
further nine (8%) participants developed depression between surgery and the follow up 
assessment.  Seventy-seven (65%) of participants had never received a diagnosis of depression. 
Twenty three (20%) of participants reported a current diagnosis of depression at the follow up 
assessment. McNemar’s test determined that there was a trend towards a reduction in the 
frequency of depression after gastric bypass surgery although this did not reach statistical 
significance (p=0.08). 
 
Univariate regression analysis did not suggest any relationship between BMI and the likelihood of 
depression at baseline (r=0.08, f=0.7, p=0.4), or any relationship between either the degree of 
weight loss over the study period and depression (r=0.04, f=0.2, p=0.7) or the BMI at follow up 
and depression (r=0.09, f=0.8, p=0.4).  The presence of diabetes did not appear to increase the 
risk of depression at either time points by regression analysis (r=0.05, p=0.6 at baseline, r=0.14, 




p=0.2 at follow up).  Indeed, none of the participants with type 2 diabetes at the follow up 
appointment reported a diagnosis of depression, whilst four (31%) participants experienced 
resolution of depression, a percentage which exceed that seen in those with normal glucose 
tolerance (14%) and prediabetes (14%) at follow up     
 
3.1.4.8.4 Arthritis 
Thirty nine (34%) participants reported a diagnosis of arthritis at baseline, which resolved 
following surgery in ten (10%) participants.  Arthritis was still evident at the follow up assessment 
in the remaining 29 (24%) of participants, and a further 22 (19%) participants had developed 
arthritis during the period of follow up. McNemar’s test determined that there was an increase 
in the frequency of arthritis after gastric bypass surgery (p=0.052).   
 
3.1.4.8.5 Sleep Apnoea 
Sleep apnoea was common at baseline, with 39 (34%) of participants reporting either the use of 
nocturnal positive pressure ventilation therapy at baseline, or a previous diagnosis of sleep 
apnoea.  Sleep apnoea resolved following surgery in 34 (87%) of these participants and was 
persistent in 5 (13%).  One (1%) participant developed sleep apnoea between surgery and the 
follow up assessment.  McNemar’s test determined that there was a significant reduction in the 
frequency of sleep apnoea after gastric bypass surgery (p<0.001). 
 
3.1.4.8.6 Gout 
Twelve (10%) participants reported a previous diagnosis of gout at the time of surgery.  This 
resolved following surgery in 11 (92%), whilst three (3%) participants developed gout between 
surgery and the follow up assessment. McNemar’s test determined that there was a clear 
difference reduction in the frequency of gout in this cohort from baseline to follow up (p=0.003). 
 
 





Fifty-seven (48%) participants had undergone a cholecystectomy at baseline.  In twenty of these 
participants, cholecystectomy was performed at the same time as gastric bypass, due to the 
perceived risk of post-operative cholelithiasis resulting from expected significant weight loss.  
Thirty-seven participants had undergone cholecystectomy prior to gastric bypass.  Five (8% of 
those who had not undergone cholecystectomy by the time of gastric bypass surgery) participants 
subsequently underwent cholecystectomy between baseline and the follow up assessment. 
McNemar’s test determined that there was a clear difference in the proportion of participants at 
each time point eligible for cholecystectomy who had undergone this procedure (p<0.001).  When 
only participants who had already undergone cholecystectomy at baseline (i.e. the procedure was 
not prophylactic) were compared to those who subsequently underwent cholecystectomy 
following gastric bypass were considered, McNemar’s test determined that there was still a clear 
difference reduction in the frequency of cholecystectomy in this cohort from baseline to follow 
up (p<0.001). 
 
When only those participants who had not undergone cholecystectomy prior to or at baseline 
were considered, five (8%) participants required cholecystectomy by the time of the follow up 
assessment, whilst 56 (92%) did not.  The small numbers limit the likelihood of statistically 
significant differences being confirmed, but interesting trends are noted.  Participants who 
required subsequent cholecystectomy tended to be older at follow up than those who did not 
(Figure 3-21).  The mean (SD) age at follow up in those who underwent cholecystectomy was 61.4 
(11.3) years and 55.5 (11.8) years in those who did not; estimated difference 5.9 years (95% CI -
5.1 to 17.0, p=0.3).  As the age at baseline was similar in both groups, there was an increase in 
the duration of follow up in those who subsequently underwent cholecystectomy (16.8 (12.4) 
years versus 9.4 (5.8) years respectively; estimated difference 7.4 years (95% CI 1.3 to 13.4, 
p=0.02) (Figure 3-21).   However, the confidence intervals for this calculation are considerable, 
and the range of duration of follow up was similar in each group (5.1 to 29.5 years in those who 
did subsequently undergo cholecystectomy, and 5.2 to 30.6 years in those who did).  There were 
no clear differences in this cohort with respect to weight/BMI at baseline and follow up, or total 
body weight loss when those who underwent cholecystectomy subsequent to gastric bypass and 
those who did not were considered.  However, despite similar weight and BMI at baseline, 
participants who required cholecystectomy following gastric bypass showed a trend towards less 




weight loss during the follow up period and consequently a higher weight and BMI at follow up.  
The mean (SD) weight at follow up was 97.7 (25.3) kg in those who subsequently underwent 
cholecystectomy and 93.0 (22.4) kg in those who did not; estimated difference when logarithmic 
transformed data used 0.05 (95% CI -0.2 to 0.3, p=0.6), equivalent to a mean ratio of 1.05 (95% 
CI 0.81 to 1.35). The mean (SD) BMI at follow up was 36.8 (9.4) kg/m2 in those who subsequently 
underwent cholecystectomy and 32.9 (6.9) kg/m2 in those who did not; estimated difference 
when logarithmic transformed data used 0.1 (95% CI -0.1 to 0.3, p=0.3), equivalent to a mean 
ratio of 1.11 (95% CI 0.9 to 1.35). The mean (SD) body weight loss (%) at follow up was 24.6 (13.4) 
kg/m2 in those who subsequently underwent cholecystectomy and 28.9 (11.1) kg/m2 in those who 
did not; estimated difference 4.3% (95% CI -6.2 to 14.8, p=0.4). 
Figure 3-21   Boxplots to show a) age at follow up, b) duration of follow up, c) in those participants who 
underwent cholecystectomy after gastric bypass but before the follow up assessment (n=5), and those 
participants who had not undergone cholecystectomy at the time of gastric bypass surgery and did not 
undergo this procedure by the time of follow up (n=56) 
















3.1.4.8.8 Osteoporotic fractures 
There was no clear difference in the frequency of osteoporotic related fracture before or after 
gastric bypass surgery in this cohort.  Eleven (9%) participants had suffered a fracture related to 
osteoporosis prior to surgery, and 11 (9%) participants suffered an osteoporotic fracture between 
baseline and the follow up assessment. 
 
3.1.4.8.9 Nephropathy 
13/103 (13%) of participants had nephropathy at the follow up visit.  The mean (SD) 
microalbuminuria to creatinine ratio was 24.2 (42.8) in those with elevated ratios (range 3.0 to 
152.7).  Similar data was not obtained at baseline and therefore a comparative analysis is not 
possible.  The microalbumin to creatinine ratio at follow up was not predicted by body weight 








3.1.4.9 Micronutrient status, intake, and multivitamin use at follow up 
One hundred and nine (92%) of participants reported current use of multivitamin tablets at the 
follow up appointment, whilst nine (8%) of participants acknowledged that they never took 
multivitamin supplementation.   Those participants who did not take multivitamin tablets had a 
significantly longer duration of follow up than those who did; mean (SD) 17.0 (8.5) years versus 
9.5 (5.5) years, estimated difference 7.5 years (95% CI 3.6 to 11.4, p<0.001).  There were no other 
clear differences in age or post-surgery outcomes between these two groups. 
 
Of the 109 participants who took regular multivitamin tablets, 94 (86%) took multivitamin tablets 
on a daily basis, and 10 (9%) took tablets at least four times per week (Figure 3-22).  Two (2%) 
participants took tablets weekly but less than at least four times per week, and three (3%) 
participants took tablets irregularly.   
 
 
Figure 3-22   Use of multivitamin supplements in participants who reported regular use (n=109) 
 




Fifty three (45%) participants were prescribed regular vitamin B12 injections at the time of follow 
up.  There were no clear differences in age or weight outcomes between those who took B12 
injections and those who didn’t.  Participants who received regular B12 injections had a longer 
duration of follow up (mean (SD) 11.4 (6.8) years) than those who didn’t (9.1 (5.2) years); 
estimated difference 2.3 years (95% CI 0.2 to 4.5, p=0.04).  However, the range of duration of 
follow up was large and similar in each group (5.1 to 29.9 years, and 5.1 to 30.6 years) raising 
doubt as to significance of this finding. 
 
 
Table 3-33    Descriptive data for vitamin B12, zinc, and copper concentrations in all participants at the 
follow up assessment 
 
 Normal reference 
range 
n (%) Mean (SD) IQR Min/Max 
All participants (n=118) 
Vitamin B12 (pmol/L) 170 to 800 100 (85) 491.2 (411.5) 527.3 90.0/1476.0 
Zinc (µg/dL) 68.0 to 149.0 109 (92) 68.3 (10.5) 11.6 47.5/116.0 




The mean (SD) vitamin B12 concentration at follow up in all participants was 491.2 (411.5) pmol/L 
(Table 3-33). The distribution of vitamin B12 concentrations was not normal (Figure ii-12 (386)), 
and was not normalised by logarithmic transformation.  Therefore, the Mann-Whitney test was 
applied to estimate the differences in mean vitamin B12 concentration between participants 
receiving vitamin B12 injections and those who were not. The mean (SD) vitamin B12 
concentration was significantly greater in those participants receiving regular vitamin B12 
injections (n=53) at 701.6 (457.0) pmol/L, in comparison to 338.9 (296.0) pmol/L in those 
participants who were not (n=47), (U=584.0, p<0.001).   
 




Thirteen participants (13% of participants with available data) had a vitamin B12 concentration 
below the reference range at follow up (range 90 to 167.0 pmol/L).  Two of these participants 
were receiving vitamin B12 injections at the time of measurement, whilst 11 were not.  Thus, 
36/47 (77%) of these participants had concentrations of vitamin B12 within the normal reference 
range despite an absence of supplementation, at a mean (SD) duration of follow up of 9.1 (5.2) 
years.  Conversely, 21 participants had vitamin B12 concentrations above the normal reference 
range.  Fourteen of these participants were receiving vitamin B12 supplementation, but seven 
had obtained these concentrations in the absence of supplementation.  Analysis of boxplots of 
vitamin B12 concentrations stratified by frequency of use of oral multivitamin supplementation 
does not discount the possibility that vitamin B12 concentrations may have been increased by 
regular supplementation (Figure 3-23), although the analysis is limited by small numbers in each 
category. However, regression analysis after logarithmic transformation did not support a 
relationship between dietary B12 intake at follow up and vitamin B12 concentrations in those not 




Figure 3-23    Boxplots to show vitamin B12 concentrations in those participants receiving multivitamin 



















The mean (SD) zinc concentration at follow up in all participants was 68.3 (10.5) µg/dL (Table 
3-33). The distribution of zinc concentrations was left skewed, but was normalised through 
logarithmic transformation (Figure ii-13 (386)).  An assessment of normality using the 
Kolmogorov-Smirnov test returned a statistic of 0.72, where p>0.2.   
 
 The mean (SD) zinc concentration was similar in those participants receiving multivitamin 
supplementation (n=100, 68.5 (10.8) µg/dL), to those participants who were not (n=9, 65.8 (6.6) 
µg/dL); estimated difference after logarithmic transformation 0.03 µg/dL (95% CI -0.07 to 0.14, 
p=0.5), equivalent to a mean ratio of 1.03 (0.93 to 1.15).  53 (49%) of the 109 participants with an 
available measurement, had a zinc concentration below the published reference range (108.5 
µg/dl ±2 standard deviations).  Univariate regression analysis suggested that the dietary intake of 
zinc at the follow up assessment did not relate to zinc concentrations (after logarithmic 
transformation, r=0.1, f=2.1, p=0.15).  Furthermore, there was no evident change in zinc 
concentration at follow up when participants were stratified by the frequency of multivitamin 
tablet use (Figure 3-24), suggesting that multivitamin administration is unable to correct the zinc 
deficiency.    Zinc concentration at follow up did not relate to age, BMI, or body weight loss % at 
follow up. 
 
Figure 3-24    Boxplots to show zinc concentrations in those participants receiving multivitamin 

















The mean (SD) copper concentration at follow up in all participants was 104.8 (22.4) µmol/L in 
the 109 participants with a measurement available at follow up (Table 3-33). One outlying 
participant had a total copper concentration of 243.8 µg/dl, 100.0 µg/dl (170%) greater than any 
other measured concentration.  This value was therefore not included in the following analysis. 
The distribution of zinc concentrations was normally distributed (Kolmogorov-Smirnov test 
statistic = 0.52, p>0.2, Figure ii-14 (387)).   
 
The mean (SD) copper concentration was similar in those participants receiving multivitamin 
supplementation (n=99, 104.0 (18.0) µg/dl), to those participants who were not (n=9, 98.7 (18.7) 
µg/dl); estimated difference 5.3 µg/dl (95% CI -7.2 to 17.7, p=0.4), and there was no evident 
change in copper concentration at follow up when participants were stratified by the frequency 
of multivitamin tablet use (Figure 3-25).  Furthermore, dietary copper intake did not clearly relate 
to copper concentrations (r=0.17, f=3.0, p=0.09).  Only one participant had a copper 
concentration at follow up that fell below the reported reference ranges.   Copper concentration 
at follow up did not relate to age, BMI, or body weight loss % at follow up. 
 
Figure 3-25    Boxplots to show copper concentrations in those participants receiving multivitamin 

















3.1.4.10 Symptoms related to gastric bypass surgery 
Participants were questioned as to the presence of a number of symptoms known to be 
associated with RYGB.  57/116 (49%) of participants reported having experienced dumping 
syndrome which occurred at a mean (SD) of 16.8 (22.8) minutes after eating (maximum = 60 
minutes).  32/48 (67%) participants reported frequent vomiting after meals, whilst 13/48 (27%) 
reported post prandial indigestion.  20/48 (42%) of participants reported a change in bowel habit 
since RYGB.  The presence of dumping syndrome, frequent vomiting, indigestion, or altered bowel 
habit did not predict body weight loss during the study by linear regression analysis, and did not 
appear to negatively impact on high participant satisfaction following RYGB (see chapter 
3.1.4.11.2) 
Participants were less likely to derive enjoyment from eating following RYGB (see Table 3-34).  At 
baseline, 46/48 (96%) of participants stated that they always enjoyed food, with the remaining 
two (4%) stating that they never enjoyed food.  At follow up, 28/46 (61%) of those who enjoyed 
food at baseline felt they still derived enjoyment from eating, although 17 (37%) stated that they 
occasionally didn’t enjoy food, and one (2%) stated they now never enjoyed food.  Of the two 
participants who never enjoyed food at baseline, only one participant improved to occasional 
enjoyment at follow up.  It is should be noted that these data were obtained at follow up only 
and not prior to surgery. 
 
Table 3-34   Crosstabulation to show the enjoyment of food at baseline and follow up. 1=Always enjoyed 




1 2 3 
Baseline 
1 28 17 1 46 
3 0 1 1 2 
Total 28 18 2 48 
 




3.1.4.11 Patient satisfaction and quality of life 
Participants were provided with two questions during the interview to assess their satisfaction 
with the outcomes of gastric bypass surgery.  The first questioned their satisfaction with the 
obtained weight following surgery. The second question asked whether the participant felt any 
beneficial effects from surgery they may have experienced outweighed any negative effects that 
were likely attributable to surgery. 
 
 
3.1.4.11.1 Weight satisfaction following surgery 
Participants were asked to select from one to five to represent their satisfaction with obtained 
weight following gastric bypass surgery, one representing “very unsatisfied” through to five 
representing “very satisfied”.  The frequency of each option in this cohort is presented in Figure 
3-26. 
 








One participant declined to answer the question.  Forty-four (37%) of participants were 
unsatisfied with their achieved weight at follow up; 14 (12%) of these were very unsatisfied, whilst 
30 (25%) were unsatisfied.  Thirteen (11%) participants expressed indifference as to their 
obtained weight loss, whilst 60 (51%) of participants were either satisfied (43 (36%) participants) 
or very satisfied (17 (14%) with the obtained weight loss. 
Boxplots were constructed to explore whether participants’ weight satisfaction at follow up could 
be associated with one or more clear predictive variables at either baseline or follow up (Figure 
3-27).   There were no clear differences in age at operation or follow up, or weight/BMI at 
operation in those who selected differing weight satisfaction scores at follow up.  However, as 
would be predicted, weight and BMI at follow up were both clearly associated with the weight 
satisfaction score chosen by the participant.   To quantify these differences, participants who had 
selected either “unsatisfied” or “satisfied” were compared using an independent T test.  The 
mean (SD) weight at follow up in participants who were “unsatisfied” with their weight was 99.7 
(24.8) kg, whilst the mean (SD) weight in those who were “satisfied” was 85.6 (15.3) kg; estimated 
difference when logarithmic transformed data was used 0.13 (95% CI 0.03 to 0.24, p=0.005), 
equivalent to a mean ratio of 1.14 (95% CI 1.03 to 1.27).  The difference was greater still when 
those who were “very unsatisfied” and “very satisfied” were compared; mean (SD) weight at 
follow up 100.1 (26.7) versus 75.4 (17.1) kg; estimated difference following logarithmic 
transformation 0.3 (95% 0.07 to 0.5, p=0.008), equivalent to a mean ratio of 1.35 (95% 1.07 to 
1.65). 
Similarly, the mean (SD) BMI at follow up in participants who were “unsatisfied” with their weight 
was 36.1 (6.5) kg/m2, whilst the mean (SD) BMI in those who were “satisfied” was 30.6 (4.9) 
kg/m2; estimated difference when logarithmic transformed data was used 0.16 (95% CI 0.08 to 
0.24, p<0.001), equivalent to a mean ratio of 1.17 (95% CI 1.08 to 1.27).  Again, the difference 
was greater still when those who were “very unsatisfied” and “very satisfied” were compared; 
mean (SD) BMI at follow up 38.1 (10.0) versus 26.5 (3.9) kg/m2; estimated difference following 
logarithmic transformation 0.34 (95% 0.17 to 0.5, p<0.001), equivalent to a mean ratio of 1.4 (95% 
1.18 to 1.65). 
 
 




Figure 3-27   Boxplots to show a) weight at baseline, b) BMI at baseline, c) weight at follow up, d) BMI at 
follow up, e) and body weight loss (%), and f) duration of follow up (years) stratified by participants 
selection of weight satisfaction at the follow up assessment 







c)           d) 





e)          f) 
  




Thus, body weight loss (%) during the period of follow up was also closely associated with the 
weight satisfaction score chosen by participants.  The mean (SD) body weight loss (%) in those 
who selected “unsatisfied” was 22.5 (9.1) %, and 32.4 (8.8) % in those who were “satisfied” with 
their achieved weight.  The estimated difference was 9.9% (95% CI 5.7 to 14.1, P<0.001). 
A trend towards increasing weight satisfaction score and decreasing duration of follow up was 
suggested by examination of box plots (Figure 3-27).  This approached statistical significance 
when participants were grouped into those who were “unsatisfied” (both “very unsatisfied” and 
“unsatisfied”) and those were “satisfied” (similarly grouped).  The mean (SD) duration of follow 
up in those who were “unsatisfied” was 11.1 (6.4) years and 8.9 (4.8) years in those who were 
“satisfied”; estimated difference 2.13 years (95% CI -0.05 to 4.3, P=0.06). 
Participant’s choice of weight satisfaction score did not appear to associate with the likelihood of 
depression.  Table 3-35 shows cross tabulation of the frequency of depression for each weight 




Table 3-35   Cross tabulation of frequency of depression at follow up against weight satisfaction score 
 
 
Weight satisfaction score (%) 
Total 
1 2 3 4 5 
Depression 
at follow up 
No 7 (50) 26 (87) 12 (92) 34 (79) 15 (94) 94 
Yes 7 (50) 4 (13) 1 (8) 9 (21) 1 (6) 22 
Total 14 30 13 43 16 116 
 
 




3.1.4.11.2 Do the benefits of surgery outweigh the negatives? 
Forty seven participants (40%) were additionally asked whether they felt the benefits they may 
have received from undergoing gastric bypass surgery outweighed any negative effects they may 
have suffered as a consequence of this intervention.  Forty five (96%) participants responded 
positively, whilst only two (4%) participants felt that the net effect of gastric bypass on their 
health and circumstances was negative. 
 
One of these participants did not lose substantial weight following gastric bypass (BMI at baseline 
52.8 kg/m2 and 51.5 kg/m2 at follow up) and indeed, remained with class 4 obesity.  The other 
participants had lost a substantial amount of weight (BMI 45.0 kg/m2 at baseline and 24.7 kg/m2 
at follow up) resulting in an improvement from class 3 obesity to normal weight at follow up.  
However, this participant remained troubled by frequent vomiting, indigestion, and an adverse 
change in bowel habit, as well as symptoms related to pre and post meal hypoglycaemia and 
dumping syndrome.  In addition, this participant suffered from depression at baseline which had 
not resolved during the period of follow up.  Both participants had normal glucose tolerance at 
baseline and follow up. 




3.1.4.11.3 Quality of life assessments after RYGB surgery 
The impact of weight on quality of life (IWQOL-Lite) questionnaire (see chapter 2.4 and Appendix 
i-8/Appendix i-9, page360) was used to assess a number of parameters related to quality of life.  
In the following section, each section of this questionnaire is analysed individually, prior to 
reporting of participant’s scores, associations with weight and weight loss, and relationships to 
outcomes in validated cohorts.  Participants were asked to choose one of five options that best 
applied to them in the past week (1 – never true, 2 rarely true, 3 – sometimes true, 4 – usually 
true, 5 – always true).  Neither participant who had undergone revision surgery was included in 
this analysis.  The frequency of each option along with the mean score is presented in Table ii-16 




Physical function (11 questions) 
115 (98%) answered all 11 questions in this section, with the exception of one participant 
who elected not to answer question 9.   The mean (SD) score in the physical function domain 
was 18.9 (7.8).  
 
 
Self-esteem (7 questions) 
115 (98%) participants answered all seven questions in this section.  The mean (SD) score in 
the physical function domain was 13.8 (7.7). 
 
 
Sexual life (4 questions) 
14 (14%) participants elected not to provide answers to questions in this section.  The other 
104 (86%) participants provided answers to each question. The mean (SD) score in the 
physical function domain was 8.5 (8.5). 
          




         Public distress (5 questions) 
110 (92%) participants provided answers to all questions in this section, with the exception 
of two participants who elected not to provide answers to question 4 and 5. The mean (SD) 
score in the physical function domain was 7.6 (4.2). 
 
Work 
110 (92%) of participants provided answers to question one and two of this section, with the 
exception of three participants who declined to answer question 3 and two participants who 




Table 3-36   IWQOL-lite % scores for each domain 
 





All participants (n=118) 
Physical function 114 (97) 82.4 (17.4) 79.1 to 85.6 13.6 100.0 
Self esteem 113 (96) 77.1 (25.8) 72.3 to 81.9 0.0 100.0 
Sexual life 101 (86) 85.6 (21.5) 81.4 to 89.9 0.0 100.0 
Public distress 108 (92) 87.6 (20.1) 83.8 to 91.4 10.0 100.0 
Work 105 (89) 92.7 (13.2) 90.1 to 95.2 43.8 100.0 
Total 97 (82) 84.6 (16.5) 81.3 to 88.0 26.6 100.0 
 
  




3.1.4.11.4 Association of IWQOL-lite score with BMI at follow up 
Figure 3-28 shows IWQOL-lite scores for each domain stratified by BMI at follow up.  Validated 
reference data for the IWQOL-lite in non-surgical cohorts (n=11,640) of differing BMI are 
available.769  Table ii-17 (390) presents this data and similar data for this cohort when stratified 
by the same BMI categories 
 
An incremental reduction in % score in each domain was noted with increasing obesity 
classification (and therefore BMI) at follow up, with the exception of sexual life score.   
Participants who had obtained normal weight or were overweight by classification generally 
reported scores of greater than 90% in each domain. 
 
Participants who had achieved a normal weight (BMI 18.0 to 24.9 kg/m2) by the follow up 
assessment, had similar IWQOL-lite scores in each domain to reference controls who were of a 
similar weight but had not undergone bariatric surgery (Table ii-17 (390)).  In contrast, overweight 
or obese participants who had undergone bariatric surgery had higher scores in each domain than 
those of similar BMI who had not undergone surgery. The estimated differences were statistically 
significant with respect to physical function and total scores in each of the obesity strata from 
overweight to class 3 obesity.  Self-esteem scores were higher in those who had previously 
undergone bariatric surgery and had achieved overweight or class 1 obesity by follow up, when 
compared to non-surgical reference controls of a similar BMI.  However, there were no clear 
differences in self-esteem scores in those who remained with class 2 or greater obesity at follow 
up and non-surgical controls. 
 
Statistically significant higher sexual life scores were noted in those who were overweight or had 
class 2 obesity at follow up in comparison with the reference population.  However, this finding 
should be interpreted with caution as the confidence intervals on these estimations are broad, 
and differences were not noted in the other weight categories.  Surgical participants who had 
been overweight at follow up had statistically higher public distress scores than non-surgical 
controls, although both groups scored in excess of 95%.  There were no other clear differences in 
public distress between the groups.  Work scores were clearly better in those who had undergone 
surgery in each BMI category, with the exception of class 2 obesity.   




Figure 3-28   Boxplots to show IWQOL-lite % scores for a) physical function, b) self-esteem, c) sexual life, 
d) public distress, e) work, and f) total score, stratified by obesity classification at follow up (NW = normal 
weight, 18.0 to 24.9 kg/m2, OW = overweight, 25.0 to 29.9, class 1 = 30.0 to 34.9, class 2 = 35.0 to 39.9, 
class 3 > 40.0). 












e)      f) 
  




Moderate, but highly statistical significant relationships were noted between participants score in 
each IWQOL-lite domain and the BMI (kg/m2) at follow up (Table 3-37).  An inverse relationship was 
noted such that reducing BMI was associated with higher IWQOL-lite scores in each domain.  However, 
inspection of regression variable plots suggested that the apparent relationship between sexual life 
and work scores, and BMI may be weaker than suggested by calculations of Pearson’s coefficient 
(Figure ii-15 (392)).  Weaker, but statistically significant, relationships were noted between body 
weight loss by the follow up assessment and scores for physical function, self-esteem, public distress, 
work, and total score, such that greater body weight loss was associated with higher scores in each of 
these domain.  There was no evident relationship between body weight loss and sex life score. 
 
 
   
 
Table 3-37   Bivariate correlation using Pearson’s coefficient to show relationships between BMI and body 
weight loss, and scores in each IWQOL-lite domain 
 
 
Against BMI at follow up 
(kg/m2) 
Against body weight loss (%) 
 N R P N R P 
Physical function 114 -0.52 <0.001 114 0.27 0.004 
Self esteem 113 -0.58 <0.001 113 0.32 0.001 
Sexual life 101 -0.36 <0.001 101 0.08 0.4 
Public distress 108 -0.58 <0.001 108 0.27 0.006 
Work 105 -0.50 <0.001 105 0.19 0.06 
Total 97 -0.63 <0.001 97 0.25 0.01 
 
 




3.1.4.11.5 Relationship between IWQOL-lite scores and other variables 
There was no clear relationship between IWQOL-lite score at the follow up assessment and age at 
follow up, duration of follow up, or a diagnosis of depression at follow up or baseline. 
 
Diabetes status at follow up appeared to relate to physical function score on the IWQOL-lite 
questionnaire, but did not relate to any other domain.  The mean (SD) physical function score at follow 
up for the 35 participants with normal glucose tolerance at follow up was 87.3 (13.6) %, whilst the 
mean (SD) score for those with prediabetes (n=55) and type 2 diabetes (n=15) was 83.1 (17.1) and 
69.1 (17.7)% respectively; estimated difference compared to those with normal glucose tolerance was 
14.0% (4.0 to 24.0, p=0.007) for those with prediabetes, and 18.2% (8.9 to 27.4, p<0.001) for those 
with type 2 diabetes.  Furthermore, Pearson’s correlation coefficient for physical function score % 
against HbA1c at follow up was r=-0.36, p<0.001, n=106, suggesting a weak but statistically significant 
relationship, whilst the incremental reduction in score with each strata of glycaemic status also 
supports a true relationship. 
 
 
3.1.4.12 Comparison of study cohort with non-recruited surgical controls 
Approximately 850 people who had undergone bariatric surgery at the Wakefield obesity clinic were 
appropriate for recruitment to this study.  120 (14.1%) were recruited at study close.  The study is 
therefore potentially limited by selection bias.  To assess this, three analyses were performed.  Firstly, 
the baseline characteristics of the 118 recruits were compared against the baseline characteristics of 
the non-recruited 1114 persons who underwent bariatric surgery through Wakefield obesity clinic.  
Secondly, outcomes in both populations in those with available data at 1 and 2 years (n=684) were 
compared.  Thirdly, a similar analysis comparing the recruited cohort against potential recruits who 
specifically declined participation in the study was performed.  Table ii-18 (393) shows relevant 
baseline characteristics of the 118 recruited persons and the 1114 potential recruits who did not 
participate in the study.  Figure 3-29 shows box plots comparing baseline characteristics of both 
populations.  




Figure 3-29   Box plots to show a) age (years), b) weight (kg), c) BMI (kg/m2), d) fasting glucose (mmol/L), e) 
HbA1c (mmol/mol), f) mean arterial blood pressure (mmHg), at baseline of the recruited (n=118) and non-
recruited populations (n=1114) 
 





















Outcomes from randomised studies have confirmed bariatric surgery to be a superior therapeutic 
option to lifestyle and/or medical therapy over follow up to 3 years, for weight loss and glycaemic 
control in the management of obesity and type 2 diabetes.  This study was proposed to provide data 
on longer term weight, glycaemic, and metabolic follow up outcomes after RYGB, and adds to the 
increasing body of literature reporting on longer term outcomes.   Furthermore, the study provides 
reassurances that the weight and diabetes related effects of RYGB are durable over many years follow 
up and does not raise new concerns about significant longer term complications.  Each outcome of the 
study is discussed in more detail below. 
 
3.1.5.1 Weight outcomes 
Every participant in this cohort lost weight after RYGB, and maintained a lower weight than 
documented at baseline throughout the follow up period.  The mean body weight loss in this cohort 
was 29.6% at a mean of 10 years of follow up, which is comparable to that observed after RYGB in the 
randomised studies reporting 1-3 year follow up outcomes noted in chapter 1.3.2.  However, it should 
be noted that the majority (61% of cohort) of patients remained obese at follow up with a mean BMI 
of 32.7 kg/m2.  Only 12% attained a normal weight (BMI 18.5 to 24.9 kg/m2) whilst 28% were overweight 
at follow up (25.0 to 29.9 kg/m2).  As seen with other measurements, this reduction in BMI is clinically 
relevant and not just of cosmetic value.   A metanalysis including studies reporting hazard ratios for all 
cause mortality based on BMI showed that subjects who were obese had a higher hazard ratio than 
those who were not (1.18, CI 1.12 – 1.25).770  However, closer inspection of the obese group revealed 
interesting differences.  Whilst those with grade 2 or 3 obesity had a significantly higher risk of mortality 
(HR 1.29, CI 1.18 to 1.41, p<0.05) than those of normal weight, subjects with grade 1 obesity (BMI 30-
34.9 kg/m2) had a risk that was not clearly different (0.95, CI 0.88-1.01).  Furthermore, those subjects 
who were overweight had a significantly lower hazard risk for all-cause mortality than those who were 
either of normal weight or were obese (0.94, CI 0.91-0.96).  We can not of course confirm that these 
results are conferrable to subjects after a reduction in BMI induced by bariatric surgery, although these 
data illustrate that attaining normal weight may not be the optimal therapeutic goal.  Further research 
is required to determine whether attainment of a particular BMI category after bariatric surgery 
conveys additional benefit. 




Amount of weight lost after RYGB was predicted by BMI at baseline, and increased with increasing 
baseline BMI.  However, differences in body weight loss between groups stratified by BMI at baseline 
was not great, such that final BMI also increased with increasing baseline BMI.   BMI at baseline alone 
explained 33% of the variation in subsequent change in BMI over the study period, and multivariate 
modelling added little value.  Other studies have reported conflicting outcomes with respect to the 
prediction of weight loss from baseline BMI.  Consistent with our data, some studies have reported 
greater weight loss with increasing baseline BMI.771,772  Inge and colleagues reported little difference in 
body weight loss in adolescents undergoing RYGB based on baseline BMI but, as in our study, reported 
increasing BMI at follow up with increasing BMI at baseline.773  However, a large number of studies 
have reported an apparent negative relationship between increasing BMI at baseline and subsequent 
weight loss.774,775,776  It is likely however, that this relates to the differing definitions of weight loss used 
in the bariatric literature, as each of these studies reported excess weight loss.  The absolute weight 
loss was greater with increasing BMI in a number of these studies.774  It is perhaps unsurprising that 
heavier patients lost less excess weight after surgery, as, given that excess weight increases in 
proportion to increasing BMI, the same absolute reduction in weight would be interpreted as less 
excess weight loss.  Our data are therefore consistent with the likelihood that weight loss after RYGB is 
similar between populations of differing baseline BMI. 
These data suggest that weight loss following RYGB is durable, at least over the average of 10 years of 
follow up provided by this study.  Regression analysis and bivariate analysis did not suggest increasing 
weight regain over time.   The participants with a shorter duration of follow up, 5 to <10 as opposed to 
>10 years, were slightly heavier at baseline although this did not reach statistical significance.  This likely 
relates to an increasing acceptance of super-obese surgical candidates as the surgical programme 
developed.  Consistent with the above findings, these participants lost slightly more weight than those 
with the longer duration of follow up.  This suggested difference though is likely to relate to differences 
in early weight loss, rather than reflect differences in weight regain or total loss.  When only those 
participants with BMI data at 2 years were considered, weight regain between the 2 year and the 
greater than 5 year assessment was not clearly different; the mean (SD) 3.0 (3.9) kg/m2 in those with 
<10.0 years of follow up and 3.4 (5.8) kg/m2 in those with >10 years of follow up; estimated difference 
0.4 kg/m2 (95% CI -1.8 to 2.7, p=0.7).  Thus, participants with the shorter duration of follow up had lost 
more weight (BMI) by the follow up assessment, but were heavier at baseline and had a similar BMI to 
those with a longer duration of follow up at the follow up assessment.  Weight regain after the early 
period of extreme weight loss was similar in both groups. 




In addition to the arguments presented above to support the durable effect of RYGB on weight loss, 
body weight loss was similar in each of two studies reporting outcomes at more than five years after 
RYGB presented in chapter 1.3.3.3.3 (Table 1-5), and selected from the large number of published 
outcome studies for their superior quality.  Whilst these two studies are presented above to illustrate 
glycaemic outcomes, weight outcomes were also reported with body weight loss at 6 years of 27.7% in 
the study by Adams and colleagues, and body weight loss at 10 years of 25% in the study by Sjostrom 
and colleagues.   However, it should be acknowledged that some weight regain was observed in both 
of these studies from nadir weight loss at 12 to 24 months.  Longitudinal data from randomised 
controlled studies are needed to comment firstly on whether this a genuine trend, and secondly, 
whether the rate of weight gain over that period exceeds that seen in the control group, as weight gain 
with advancing age is to some degree expected.777 
 
3.1.5.2 Diabetes outcomes 
RYGB had favourable effects on glucose homeostasis and diabetes in this study.  Fasting concentrations 
of glucose and insulin, and assessments of HbA1c and HOMA-IR fell significantly after surgery in the 
majority of participants.  Indeed, the mean concentrations of insulin and HOMA-IR normalised over the 
follow up period, whilst the mean diabetes status using ADA criteria improved from type 2 diabetes to 
prediabetes.  
81% of participants undergoing bariatric surgery with normal glucose tolerance at baseline remained 
with normal glucose tolerance at follow up, whilst 19% of participants had developed prediabetes 
during that time period.  With the exception of HbA1c at baseline, no plausible measured variable at 
baseline predicted glycaemic outcome in this group, and furthermore classical risk factors for 
prediabetes including BMI at follow up or the degree of body weight loss did not differentiate the 
groups.    
In those with prediabetes at baseline, twenty-five (63%) participants had an improvement in glucose 
tolerance to normal concentrations at follow up, 14 (35%) remained with prediabetes, whilst one (2%) 
had progressed to type 2 diabetes at a mean duration of follow up of 8.7 years.  HbA1c and fasting 
glucose at baseline appear to predict diabetes outcome in this group, such that a higher HbA1c and/or 
fasting glucose at baseline is associated with a greater reduction in HbA1c over the follow up period. 




Increasing baseline HOMA-IR also predicted a lower reduction in HbA1c over the study period.  Whilst 
not reaching statistical significance, these data suggest that body weight loss may be a factor underlying 
glycaemic improvements after surgery.  There was no clear additional associations between glycaemic 
outcome and classical risk factors for prediabetes.  The improvement in glucose homeostasis in both 
groups was primarily the result of an improvement in insulin sensitivity as assessed by HOMA modelling.   
Nine (25%) and 17 (47%) of participants with preoperative type 2 diabetes had improved to normal 
glucose tolerance and prediabetes respectively, whilst 10 (28%) remained with type 2 diabetes at a 
mean (SD) duration of follow up of 8.8 (4.6) years.  Fasting glucose, HbA1c, fasting insulin, and HOMA-
IR at baseline all appear to predict likelihood of persistent type 2 diabetes, whilst age at diagnosis and 
duration of type 2 diabetes did not.  Increasing body weight loss after surgery appears to predict a 
higher likelihood of resolution of type 2 diabetes at follow-up.  As well as improvements in fasting 
glucose and HbA1c, those participants who remained with type 2 diabetes also required less 
medications following surgery, suggesting that overall glycaemic control was improved despite 
persistent type 2 diabetes.  A multivariate regression model employing body weight loss after surgery 
and either baseline fasting glucose or HbA1c, accounted for approximately 50% of the observed 
variation in the change in HbA1c following surgery.  Both fasting glucose and HbA1c at baseline appear 
to be useful tools with which to predict persistent type 2 diabetes at follow up with optimal 
sensitivity/specificity of 75/73% and 87.5/78.3% respectively.  However, these markers are less helpful 
when predicting diabetes resolution.  Given the known progressive natural history of diabetes it is 
notable that duration of follow up did not appear to predict diabetes status at follow up irrespective of 
the diabetes status at baseline.  This might suggest that RYGB fundamentally changes the underlying 
pathogenic mechanism of type 2 diabetes. 
These outcomes are similar to those reported in other studies of bariatric surgery, despite a significantly 
longer duration of follow up (chapter 1.3.3.3).  As discussed in chapter 3.2 however, the comparison of 
published studies is significantly limited by the use of highly variable definitions of diabetes, both at 
baseline and follow up.  As in multiple other studies, body weight loss appears to be an important factor 
underlying the likelihood of glycaemic improvements after RYGB.438,440,441  This relationship was less 
apparent in those with either normal glucose tolerance or prediabetes at baseline, although a similar 
trend was suggested in those with prediabetes.  Furthermore, these data are consistent with the 
published literature in supporting that improved glycaemic outcomes following bariatric surgery in 
patients with type 2 diabetes at baseline are predicted by better glycaemic control prior to 




surgery.440,443,446  Interestingly however, and in contrast to other studies,443,445,446,447 there was no 
apparent relationship between glycaemic outcomes and either the age at which the participant 
underwent RYGB, or the duration of diabetes prior to surgery.  This is of clinical interest and would be 
a point of difference between this study and similar studies.  Duration of diabetes is generally taken as 
a surrogate of likelihood of beta cell failure, and should therefore intuitively predict glycaemic 
outcomes.  It is possible this finding relates to the duration of follow up at which diabetes outcomes 
are reported.  Each of the studies above reported outcomes within 24 months as opposed to 10 years 
as in our study.  Perhaps these factors better predict early improvements in glycaemic control, whereas 
weight loss predominates in longer term observations?  Longitudinal studies reporting these 
measurements in the same participants would be required to address this apparent discrepancy.  The 
diabetes outcomes were similar in each study, and therefore this alone is unlikely to confound this 
assessment. 
 
3.1.5.3 Blood pressure and lipid outcomes 
Systolic, diastolic, mean arterial blood pressure were all reduced significantly at follow up when all 
participants or those with baseline hypertension were considered.  There was no clear change in blood 
pressure in those participants with normal blood pressure at baseline.  However, the majority of 
participants with baseline hypertension remained hypertensive at follow up, although required fewer 
medications.   Most,396,412,778 but not all studies,402 have reported similar outcomes after RYGB.  Indeed 
recent meta-analyses concluded that bariatric surgery resulted in a 0.52 (0.42 to 0.64) risk reduction 
for a diagnosis of hypertension at 12 to 24 months in those with hypertension at baseline, which 
remained stable up until five years.779,780  However, it must be acknowledged that this cohort did not 
have optimised blood pressure control at baseline.  Twenty six participants with measured 
hypertension at baseline were not using anti-hypertensive medications, whilst a further 28 and 17 
participants were using only one or two anti-hypertensive medications respectively.  Therefore, the 
effect size of bariatric surgery on hypertension in this study may be over estimated.   
Blood pressure improvements over the study were associated with baseline blood pressure 
measurement, such that greater reductions in mean arterial pressure were observed with increasing 
mean arterial pressure at baseline.  However, within the entire cohort, blood pressure outcomes were 
not associated with weight or diabetes outcomes, or with the duration of hypertension prior to surgery 




or medication use at baseline.  Furthermore, the duration of follow up did not predict any blood 
pressure outcomes. Whilst surprisingly few studies have reported factors predicting blood pressure 
outcomes after bariatric surgery, it is clear that in non-surgical studies weight loss is favourable.  A 
systematic review of randomised trials reporting weight outcomes after dietary interventions 
suggested that each kilogram of body weight loss predicts a 1 mmHg reduction in diastolic blood 
pressure.781  A more recent systematic review supported the favourable effect of weight loss alone on 
both systolic and diastolic blood pressure, although reported a lower effect size.782  Therefore, the lack 
of any association between body weight loss and blood pressure outcomes in this study is unexpected.  
It is possible however, that this may be explained by the confounding effects of anti-hypertensive 
medication use.  When only those participants not using anti-hypertensive medication at baseline or 
follow up, with or without hypertension at either time point (n=47) were considered, increasing body 
weight loss was associated with an increasing reduction in mean arterial pressure (R=0.33, F=5.6, 
p=0.02) at follow up.  Furthermore, and perhaps consistent with the conclusions of Neter and 
colleagues,781 this association was predominantly attributable to the relationship between increasing 
body weight loss and increasing reductions in diastolic blood pressure (r=0.3, f=5.4, p=0.02).  It has also 
been suggested that the improvement in blood pressure markers after bariatric surgery may relate to 
an improvement in renal function, although our study was not designed to assess this.783 
Concentrations of LDL, HDL, and triglycerides were reduced significantly at follow up in this cohort, and 
support the findings in multiple other studies.396,402,403,784,785  However, the number of lipid lowering 
agents per participant was not altered.   As with blood pressure, this finding most likely reflects the sub-
optimal medical management of participants prior to referral for surgery; 85% of participants were not 
using lipid lowering medication at baseline.  In contrast to the findings of others (see chapter 1.3.7), the 
change in LDL over the study period was predicted by body weight loss (r=0.38, f=11.1, p=0.001) and 
the change in BMI (r=0.3, f=6.3, p=0.02) when only those participants not using lipid lowering therapy 
at either time point were considered (n=66).  This suggests that the beneficial effects of RYGB on LDL 
concentrations are to some extent weight related, but this study is of course not able to comment on 
the possibility that the effect of RYGB may be greater than other bariatric surgery procedures. 
Changes in each lipid concentration was associated body weight loss over the course of the study.  
Surprisingly however, both the change in LDL and HDL concentrations over the study period appeared 
to be associated with the duration of follow up.  However, these relationships were both weak (r2=0.07 
for LDL and HDL) and account for only 6% of the variation seen in change in both.  Furthermore, 




stratification of the study population into those with less or more than 10 years of follow up did not 
support this finding.  The mean (SD) LDL at baseline in those with <10 years and 10 years of follow up 
was 3.14 (0.92) and 3.65 (0.91) mmol/L respectively (estimated difference 0.5 mmol/L (95% CI 0.02 to 
1.0, p=0.04), whilst the mean (SD) LDL at follow up was 2.80 (0.79) and 2.79 (0.85) mmol/L (estimated 
difference 0.01 mmol/L (95% CI -0.3 to 0.3, p=0.91).  Thus, the difference in the change in LDL in these 
two groups (estimated difference 0.36 mmol/L (95% CI -0.17 to 0.9, p=0.18) is likely to be explained by 
the higher baseline LDL in those with a longer duration of follow up.  The mean (SD) HDL at baseline in 
those with < 10 years and  10 years of follow up was 1.32 (0.33) and 1.37 (0.39) mmol/L respectively, 
whilst the mean (SD) HDL at follow up was 1.85 (0.48) and 2.02 (0.64) mmol/L.   Following logarithmic 
transformation, there was no clear difference at either baseline (estimated difference 0.05 mmol/L, 
p=0.7 following logarithmic transformation) or follow up (estimated difference 0.17 mmol/L, p=0.2 
after logarithmic transformation).   Finally, when only participants not using lipid lowering therapy at 
any point during the study were considered (n=66), there was no clear relationship between duration 
of follow up and change in LDL (r=0.15, p=0.2).  An apparent relationship with the change in HDL 
remained however, with a slight increase in the increase in HDL with increasing duration of follow up 
(r=0.33, f=7.8, p=0.007).  This was not explained by coincidental differences in HDL at baseline for 
differing durations of follow up. 
 
3.1.5.4 Co-morbidity outcomes  
There was no clear difference in the frequency of cardiac events or stroke before or after surgery in 
this study.  However, event numbers for both were small with only nine (8%) of participants having 
established ischaemic heart disease at baseline, and only three (3%) having had a stroke.  However, no 
patient in this study suffered a myocardial infarction or underwent invasive coronary interventions 
following bariatric surgery.  This study is therefore unable to contribute significantly to the literature 
indicating the effects of bariatric surgery on these outcomes.  However, the small number of events is 
not particular to this study and is reported in most bariatric follow up studies, likely because surgical 
candidates are, by selection, at a relatively low risk for cardiovascular events at baseline.421,427,434  A 
similar phenomenon has been observed in studies exploring medical therapy for type 2 diabetes.  
Earlier published studies were unable to confirm the cardiovascular benefits of medical interventions 
in patients with type 2 diabetes because event rates were low.786  More recent studies, specifically 




recruiting only participants considered to be at high risk of cardiovascular events, have still failed to 
clearly show the benefits of medical intervention,787 which may only become evident after extended 
follow up.788  As presented in chapter 1.3.6, large systematic reviews and meta-analyses have been 
required to clearly demonstrate the cardiovascular benefits of bariatric surgery. 
Both obesity and type 2 diabetes are established risk factors for the development of depression.789,790  
It is likely that these relationships are bidirectional, with evidence that depression is both a 
consequence and a cause of obesity and type 2 diabetes.791,792  However, the relationship between BMI 
and depression may not linear.  Whilst some studies have reported an increasing likelihood of 
depression with increasing obesity,793,794,795 other studies have reported a U shaped curve, with higher 
rates of depression in the underweight and obese when compared with normal weight individuals.796,797  
As the prevalence of obesity and type 2 diabetes is naturally very high in those seeking bariatric surgery, 
numerous studies have confirmed a high prevalence of depression in this context.798,799  Thus, it is 
expected that the prevalence of depression at baseline in this cohort may exceed that seen in healthy 
sample populations.  The study was not designed to test this hypothesis, but a high prevalence within 
the cohort was observed.  In contrast to studies noted above, our data did not show a relationship 
between BMI at baseline or glycaemic status and the likelihood of depression, which may be explained 
by both the small cohort numbers and the fact that the presence of depression was assessed purely on 
the basis of simple questioning during the interview.  Use of a more robust depression assessment may 
have yielded different results. 
Nonetheless, the frequency of depression was significantly reduced in this cohort following gastric 
bypass surgery.  This is consistent with findings of numerous similar studies following bariatric 
surgery.800,801,802  However, the likelihood of depression at follow up did not appear to relate to weight, 
BMI, body weight loss, or the presence of diabetes.  Furthermore, the presence of depression at 
baseline did not predict outcomes after bariatric surgery.  These findings are surprising, and may relate 
again to the dichotomous definition of depression (yes or no) utilised in this study rather than a tool 
that quantified depressive symptoms.  Certainly, the severity of depression at baseline has been shown 
to predict subsequent weight loss in other studies,803 whilst body weight loss has been shown to predict 
improvement in depressive symptoms.804  An alternative explanation for this apparent discordancy, is 
that the relationship between these measures changes with the duration of follow-up.  Perhaps factors 
other than body weight loss develop greater importance as predictors of depressive symptoms once a 
number of years since surgery have elapsed?  Unfortunately, the data obtained from this study cannot 




answer this question, and a longitudinal study utilising a detailed depression assessment tool would be 
required. 
The frequency of gout was significantly reduced in this cohort following gastric bypass.  Of the 12 
participants who reported a diagnosis of previous gout at baseline, only one of these reported further 
attacks after bariatric surgery.  Gout is strongly associated with hyperuricaemia, which is itself 
associated with obesity.805,806,807  A number of studies have now demonstrated clinically significant 
reductions in uric acid levels following bariatric surgery.428,808  Furthermore, because of the uricosuric 
effect of hyperglycaemia, subjects without type 2 diabetes tend to have higher concentrations of uric 
acid than those with.809  Despite this, reductions in uric acid have been demonstrated in both diabetic 
and non diabetic populations following bariatric surgery.  A recent study in Auckland demonstrated 
significant reductions in uric acid following laparoscopic sleeve gastrectomy in participants with type 2 
diabetes, with and without a diagnosis of gout at baseline.810  In non-surgical populations, there is a 
relationship between the frequency of gout attacks and the level of serum uric acid, in that increasing 
levels predict more frequent episodes.811  Furthermore, lowering of serum uric acid by pharmaceutical 
means reduces the frequency of episodes.812  There is as yet, little published evidence to demonstrate 
the clinical effect of the reduced serum uric acid concentrations induced by bariatric surgery, although 
based on these non-surgical findings, it may be reasonable to consider these changes favourable.  In 
addition, hyperuricaemia has been associated with a number of other adverse medical conditions 
including cardiovascular mortality.813  Nonetheless, bariatric surgery appears to increase the risk of gout 
attacks in the early post-operative period, presumably as a consequence of renal dysfunction, fasting, 
or rapid weight loss.814,815  Consistent with this, three further participants in this study without a history 
of gout at baseline, reported at least one episode of gout after surgery.  Further work is therefore 
required to describe the clinical effect of bariatric surgery induced lowering of uric acid levels.       
The frequency of arthritis was significantly greater after gastric bypass surgery than before.  However, 
univariate regression analysis determined that age at either baseline or follow up strongly predicted 
the likelihood of arthritis at that time point (r=0.36, f=17.3, p<0.001 at baseline, and r=0.33, f=14.6, 
p<0.001) but was not predicted by the duration of follow up (r=0.02, f=0.06, p=0.8), suggesting that the 
apparent increase in frequency of arthritis is the result of an increase in age.  Furthermore, neither BMI 
at baseline (r=0.07, p=0.5) or at follow up (r=0.09, p=0.3) predicted the likelihood of arthritis, nor did 
the change in body weight over the study period (r<0.01, p=0.9), supporting the hypothesis that the 
apparent increase in the prevalence of arthritis is independent of surgery.  Consistent with this, 




musculoskeletal complaints have been reported to decrease following bariatric surgery when assessed 
with specialist tools.816,817 
Obstructive sleep apnoea and sleep dysfunction is common in bariatric surgery candidates, and 
frequently unrecognised.818  Both surgical and non-surgical weight loss has been shown to be effective 
in reducing the severity of sleep apnoea.819   In this study, sleep apnoea was common at baseline, and 
was significantly reduced following gastric bypass, although it is acknowledged that sleep apnoea was 
not diagnosed through the use of appropriate sleep studies in this study.  Participants who remained 
with sleep apnoea at follow up were significantly heavier at follow up than those who did not, and had 
experienced less body weight loss.   The five participants with sleep apnoea at the follow up assessment 
were significantly heavier at both baseline and follow up than those who had never received a diagnosis 
of sleep apnoea, or had resolution of sleep apnoea with gastric bypass surgery.  The mean (SD) BMI at 
baseline was 46.2 and 55.4 kg/m2 for those without sleep apnoea and with sleep apnoea at follow up 
respectively; estimated difference 9.2 kg/m2 (p=0.03 after logarithmic transformation).  The mean (SD) 
BMI at follow up was 32.3 and 41.2 kg/m2 for those without sleep apnoea and with sleep apnoea at 
follow up respectively; estimated difference 8.9 kg/m2 (p=0.02 following logarithmic transformation).  
Thus, participants with sleep apnoea at follow up also had a lower mean body weight loss after gastric 
bypass than those who did not have sleep apnoea although this difference was not statistically 
significant; mean (SD) body weight loss (%) 25.0 versus 29.7% respectively; estimated difference 4.72% 
(95% CI -5.0 to 14.5, p=0.4).   Furthermore, univariate regression analysis established that the final BMI 
(kg/m2) predicted the likelihood of sleep apnoea at that time point (r=0.3, f=8.1, p=0.005) but 
accounted for only 6% of the variation seen.  
Cholecystectomy was performed in twenty (17%) participants during gastric bypass as a prophylactic 
procedure.  Allowing for this, the frequency of cholecystectomy was significantly reduced following 
gastric bypass.  Cholecystectomy was required in 8% of participants following gastric bypass.  There 
were no clear baseline factors that predicted the requirement for cholecystectomy following gastric 
bypass. 
 




3.1.5.5 Micronutrient status 
Bariatric surgery can be predicted to cause alterations in the absorption and availability of minerals and 
micronutrients.  Vitamin B12 absorption requires the release of the vitamin from food, regulated by R 
protein and pancreatic proteases, the production of gastric intrinsic factor which binds to vitamin B12, 
and an intact intestinal mucosa to allow absorption.820  Dysfunction in any of these areas may result in 
vitamin B12 deficiency. Whilst vitamin B12 concentrations were predictably lower in those participants 
not receiving vitamin B12 supplementation, only 13% of all participants had vitamin B12 concentrations 
below the reported reference range.  Eleven (85%) of these participants were not receiving regular 
vitamin B12 injections, although the remaining 36 participants not receiving supplementation had 
normal concentrations of vitamin B12.  Thus, 23% of participants not using vitamin B12 
supplementation were deficient.  A compensatory effect on vitamin B12 concentrations through oral 
supplementation appears unlikely given the lack of relationship with dietary intake.  These data are in 
keeping with findings in other studies where vitamin B12 deficiency prevalence rates of between zero 
and 37% have been observed at 12 to 48 months of follow up.821  Furthermore, vitamin B12 deficiency 
is common in the general population at approximately 5%,822 and is more common in the context of 
type 2 diabetes, particularly when Metformin is used.823,824  Indeed, Hauesler and colleagues recently 
reported a 19% prevalence of vitamin B12 deficiency in New Zealanders with type 2 diabetes using 
metformin, although the cut-off used to define deficiency was slightly higher in that study that this.  
Therefore, deficiency rates after RYGB may not differ significantly from the background expected 
prevalence rates in populations that are likely to be considered for surgery.  Nonetheless, it would be 
reasonable to continue to recommend the measurement and, where necessary, supplementation of 
vitamin B12, as deficiency is associated with severe clinical consequences. 
Zinc deficiency is common in the obese general population,825,826 and has been associated with alopecia, 
hypogonadism, impaired neuropsychological performance, and skin disorders.827   In addition to an 
increased likelihood of zinc deficiency at baseline, oral zinc intake is likely to decline following surgery 
as zinc rich foods including meat and fish, may be less desirable.827  Zinc is primarily absorbed in the 
small intestine, and therefore intestinal bypass through bariatric surgery may further reduce 
availability.827  Therefore, a high prevalence of zinc deficiency is expected after bariatric surgery.  
Indeed, 49% of participants in this study had zinc deficiency at follow up.  Only a handful of studies have 
reported the frequency of zinc deficiency after bariatric surgery, but are consistent with our data, 
showing prevalence rates of between 12 and 68%.827,828,829,830  BPD appears to be more likely to cause 




zinc deficiency than RYGB.   In our study, oral multivitamin supplementation neither prevented zinc 
deficiency, nor had an effect on zinc concentrations, consistent with findings by others.830    
As the small intestine appears to be the major site of dietary copper absorption, concerns as to the 
potential for copper deficiency following bariatric surgery have reasonably been raised.  Indeed, a 
number of case reports of severe copper deficiency resulting in neurological and haematological 
dysfunction have been published.831  The prevalence of copper deficiency following RYGB has been 
reported in only a few cohorts, with prevalence rates of between four and 15%.832,833,834  In contrast, 
the prevalence following BPD appears to be higher.832  The prevalence of copper deficiency at long term 
follow up after RYGB in our study was only 1%, using the same thresholds to define deficiency as used 
in the above studies.  The majority of participants in this cohort had normal concentrations of copper 
at follow up, whilst oral multivitamin supplementation does not appear to effect copper 
concentrations.  It is therefore possible, that the exact length of bypassed small intestine has a bearing 
on the likelihood of copper deficiency during long term follow up.  Furthermore, whilst the prevalence 
of copper deficiency in the general population is not known, a prevalence of 1% after RYGB surgery may 
not be significantly different.  
 
3.1.5.6 Quality of life and patient satisfaction 
Whilst it is tempting to consider only weight, diabetes, and metabolic measures as important outcomes 
after bariatric surgery, it would be wrong to neglect the impact on quality of life, which may be tied to 
one or more of the weight/metabolic outcomes.  Obesity is known to severely impact upon quality of 
life as a consequence of physical disability, an increased risk of co-morbid conditions, and, not least, 
because of discrimination.835,836  Obesity predicts poor health related quality of life with a similar effect 
size to that observed with poverty.837  Furthermore, obese patients are less likely to perceive their 
health as being excellent, and appear to report poor health on more days than non obese persons.838,839 
Thus, the effect of bariatric surgery should be judged by improvements in obesity related quality life as 
well as more standard measures.840 
In this study, quality of life was assessed through the use of the IWQOL-lite questionnaire (Appendix 
i-8, page 360), validated in many populations including subjects who had previously undergone bariatric 
surgery.  Quality of life, assessed through five domains, was judged to be higher by overweight or obese 




participants in our study who had undergone RYGB, than by referenced control non-surgical 
populations matched to BMI category.  These differences were significant for physical function and 
total scores.  BMI, and to a lesser extent body weight loss, correlated with participant’s physical 
function, self-esteem, public distress, work, and total percentage scores on the IWQOL-lite test.  Sexual 
life did not correlate with either outcome.  Physical function score appeared to correlate with glycaemic 
status at follow up. 
These conclusions are consistent with the findings of other studies.  A recent systematic review 
including over 9,000 participants from 72 studies calculated that the average effect of bariatric surgery 
on quality of life was significantly positive (average effect size 0.88 (95% 0.80 to 0.96)).841 The analysis 
included studies of all bariatric procedures, and whilst the authors identified a greater favourable effect 
on quality of life by combined restrictive/malabsorptive procedures when compared with restriction 
alone, this was not statistically significant.  As with our data, the time after surgery at which quality of 
life was assessed did not appear to predict quality of life either, supporting the durable effect of 
bariatric on quality of life.  The effect on physical markers of quality of life appears to be greater than 
that on mental markers, consistent with our data where the difference in reported physical function 
between post-surgical participants and controls was statistically significant. 
In summary, RYGB appears to have a favourable effect on quality of life, particularly physical quality of 
life, which is closely related to the obtained weight loss and final achieved BMI. 
 
3.1.5.7 Study limitations 
This study has a number of limitations.  The conclusions that can be derived from a retrospective non-
experimental cohort study are limited, and the quality of evidence is poorer than would have been 
obtained from a randomised study.  Unfortunately the retrospective nature of this study precluded 
randomisation.  Furthermore, the initial study design incorporated a control group of participants who 
were referred or self referred for bariatric surgery but did not undergo the procedure.  This study design 
would have been inherently biased as patients may not have undergone surgery because of factors that 
would have directly determined longer outcomes.  For example, patients with existing heart disease or 
those with very poorly controlled glycaemic control, and therefore presenting a more significant 
anaesthetic and operative risk, may not have been referred for surgery in the first place.  Furthermore, 




they may have very reasonably been declined for surgery by the operating surgeon.  After commencing 
recruitment for this study, it quickly became apparent that no control group participant invited to 
partake in the study was willing to do so.  Thus, on the basis that the initial proposed study design was 
inherently limited, and recruitment of a suitable control group was not proceeding as planned, we 
decided to abandon this study design and report outcomes only in those who had undergone bariatric 
surgery. 
RYGB was provided in a private capacity, which may have introduced further selection bias and make 
the outcomes of this study less relevant to the general population.  At the time that the participants in 
this study underwent surgery, bariatric surgery was provided in the private sector only which would 
likely result in less standardisation of patient selection.  It is possible that this factor resulted in an 
ethnicity bias within the cohort, as Maori in particular were under represented in comparison to the 
local population. 
As the study was conducted retrospectively, data collection at baseline was limited to that which 
seemed most relevant at the time it was collected and did not always include the parameters collected 
at follow up.  For example, no record of smoking history was recorded at baseline.  Likewise, quality of 
life data was not obtained prior to surgery for a comparative analysis with similar data at follow up.  
Furthermore, documentation of the prevalence of co-morbid conditions at both baseline and follow up 
was obtained primarily by questioning participants as to their clinical history and was not confirmed via 
medical records.  However, the major outcomes of the study were quantitative, with complete data 
available at baseline and follow up.  Furthermore, blood samples obtained at baseline in this study were 
analysed in a number of regional laboratories over a period of 30 years.  It is therefore not possible to 
comment specifically as to whether any significant differences in assay methodology used by these 
laboratories would impact on the comparability of biochemical markers at baseline and follow up.  
However, all samples were analysed within a suitably accredited laboratory and it is unlikely that 
significant variation would occur that might effect the interpretation of this dataset.  
Recruitment numbers for this study were fewer than expected.  Approximately 900 participants were 
suitable for inclusion in this study, with 120 recruited at study completion.  Numerous reasons were 
provided by potential participants as to their decision not to participate, including relocation out of 
region, dissatisfaction with outcomes, and being unable to provide the time.  However, the majority of 
potential participants not recruited for this study simply declined to respond to the study invite or to 
subsequent phone calls.  Indeed, only 31 people specifically declined to participate, 24 of which had 




data within the original surgical database.  There was no difference in age at operation, weight and BMI 
at operation, blood pressure parameters at operation, or markers of fasting glucose, HbA1c, and total 
cholesterol between these 24 people and the recruited participants at baseline, one, or two years.  
Whilst the low recruitment numbers are not ideal, it should be noted that the cohort was larger than 
all the randomised studies reporting weight outcomes presented in chapter 1.3.2 and comparable in 
size to most of those that reported diabetes outcomes (chapter 1.3.3). 
Nonetheless, the possibility that the recruited cohort may not be representative of the entire possible 
cohort should be entertained.  To address this question, the recruited population was compared against 
non-recruited controls (chapter 3.1.4.12).  The recruited study population were older at operation than 
the non-recruited population of patients who had undergone bariatric surgery at Wakefield obesity 
clinic; estimated difference 3.7 years (95% CI 1.7 to 5.8, p<0.001).  There is no clear explanation as to 
why this difference occurred.  The inclusion criteria for the study stipulated participants should be 18 
years or older, but only three people in the non-recruited cohort were younger than this cut off.  Age 
at operation was not shown to predict any study outcome in a positive or negative fashion, and it is 
unclear whether this apparent selection bias will have affected the legitimacy of the study.  The 
recruited population and non-recruited population were otherwise not clearly different at baseline.  
Furthermore, there was no clear difference between outcomes at one and two years after surgery in 
the recruited group and those in the non-recruited group (n=684), when weight, BMI, blood pressure 
parameters, and concentrations of fasting glucose, HbA1c, and total cholesterol were compared (Table 
ii-19 (394)).  Thus, there is no clear evidence to suggest significant selection bias with respect to the 












In this study, longer term outcomes after RYGB are reported in 118 obese participants with or without 
type 2 diabetes.  These data support the published literature on shorter term outcomes, and suggest 
that these effects are durable over extended follow up.  Each participant lost weight after surgery, and 
the majority achieved improvements in markers of glucose homeostasis, blood pressure, and lipids.  
Outcomes with respect to diabetes status were similar or better than those in the published literature 
despite a significantly longer duration of follow up.  Despite a high prevalence of persistent symptoms 
directly related to RYGB, patient satisfaction is extremely high and quality of life is improved.  
Micronutrient deficiencies do not appear to be a significant factor after RYGB in this context, although 
more active measures should be taken during follow up to prevent zinc deficiency. 
In summary, this study supports the conclusion that bariatric surgery is an effective and durable 
treatment for obesity, type 2 diabetes, and the multitude of complications that frequently result from 
both disorders. 
  




3.2 The application of differing definitions of diabetes outcomes 
following bariatric surgery 
 
3.2.1 Introduction 
Obesity and Type 2 diabetes are major health issues worldwide with high prevalence in Westernised 
countries, and an alarming increase in incidence in developing countries (chapter 1.1.1).2,3,4,842 ,843  
Whilst diet and lifestyle modification remain the cornerstone of weight management, no single strategy 
for achieving sustained clinically important weight loss in obese individuals has been identified, with 
weight regain following periods of weight loss frequently observed.844 ,845,846,847  Many studies have 
demonstrated weight loss of the order 10% of body weight, often with improvements in metabolic and 
cardiovascular parameters. However, even with this degree of weight loss, morbidly obese individuals 
with established type 2 diabetes remain obese and still require antidiabetic medication.  
 
Bariatric surgery has emerged as the most effective treatment for obesity and type 2 diabetes and 
results in significant improvements in glycaemic dysfunction in most patients.  Diabetes outcomes 
following bariatric surgery are of significant clinical interest, and accurate representation of the 
likelihood of diabetes remission is important when discussing surgery with potential patients.  Reported 
diabetes outcomes are, however, likely to be highly variable depending on the definitions used to 
classify resolution and partial resolution. 
 
Buchwald and colleagues published a large meta-analysis of studies assessing glycaemic outcome 
following RYGB and concluded that diabetes remission was seen in 78.1% of patients.433  Diabetes 
resolution in this analysis was defined as an HbA1C of <6.0% (42 mmol/mol) or a fasting blood glucose 
of <100mg/dl (5.6 mmol/L) off diabetes medications.  More recently, two randomised controlled trials 
have been published, each using a further disparate definition of diabetes outcome. Schauer and 
colleagues performed a randomized, non-blinded, single-centre trial, comparing intensive medical 
therapy alone versus medical therapy plus RYGB surgery or sleeve gastrectomy in 150 obese patients 
with uncontrolled type 2 diabetes.415  The primary endpoint was the proportion of patients with and 
HbA1c of <6.0% (42 mmol/mol) at 12 months post-surgery with or without the use of diabetes 




medications.  50 subjects underwent RYGB surgery and the primary endpoint was reached in 42% of 
patients (as opposed to 12% in the non-surgical arm (p=0.002), with no patient requiring on going 
diabetes medications.  Mingrone and colleagues  performed a single-centre, non-blinded, randomized, 
controlled trial comparing conventional medical therapy alone versus medical therapy plus RYGB 
surgery or biliopancreatic diversion in 60 patients with type 2 diabetes of at least 5 years duration and 
an elevated BMI (>35 kg/m2).421  Remission of diabetes was defined as a fasting plasma glucose level of 
less than 100 mg per decilitre (5.6 mmol per litre) and an HbA1c level of less than 6.5% (47 mmol/mol) 
for at least 1 year without active pharmacologic therapy.  At 2 years follow up, 75% of patients who had 
undergone RYGB surgery had achieved diabetes remission as opposed to none in the non-surgical arm 
(p<0.001).  Further studies by Adams et al and Ikramuddin et al have used further disparate definitions 
of diabetes outcome.422,412   
 
In light of this inconsistency The American Diabetes Association (ADA) has released a consensus 
statement providing recommendations on the definition of glycaemic outcomes post bariatric 
surgery.848  This suggested the use of the terms “partial remission” (HbA1C≤6.5% (47 mmol/L), fasting 
glucose 100-125 mg/dl (5.6 – 6.9 mmol/L)), and complete remission (HbA1c “in the normal range”, 
fasting glucose <100mg/dl (5.6 mmol/L)) provided that each of these assessments were persistent for 
at least 1 year duration, and in the absence of active pharmacologic therapy or ongoing procedures.  
Additionally, the ADA defined prolonged remission as the thresholds required for satisfaction of 
complete remission, maintained for at least 5 years. 
 
To assess the effect of the use of disparate definitions of diabetes outcomes following bariatric surgery, 
we assessed diabetes outcomes in participants with pre-operative dysglycaemia who had undergone 
RYGB at least 5 years ago.  This cohort was a subgroup from a larger surgical follow up study (chapter 










To assess of the application of various published definitions of diabetes outcomes following bariatric 
surgery, to a cohort of participants with dysglycaemia at baseline who had undergone gastric bypass 
surgery at least five years ago. 
 
 
3.2.3 Participants and methods 
 
3.2.3.1 Study overview and design 
This was a retrospective non-experimental cohort study of glycaemic outcomes in 84 participants who 
had previously undergone RYGB, were participating in a long term follow up study (chapter 3.1), and 
had dysglycaemia (prediabetes or type 2 diabetes, see chapter 2.3.3, page 126) before surgery.  
Markers of glucose homeostasis were measured on blood samples taken immediately prior to surgery 
and at a follow-up at least five years after surgery.  Diabetes outcomes are reported using a number of 
commonly utilised definitions within the published literature.   
 
Inclusion criteria 
 Gastric bypass surgery performed at least five years before assessment  
 BMI ≥30kg/m2 at baseline 
 Dysglycaemia at baseline based on American Diabetes Association classifications 2015: 
o Prediabetes (one or more of the following) 
 Fasting plasma glucose 5.7 to 6.9 mmol/L 
 2 hour glucose during a 75g oral glucose tolerance test of 7.8 to 11.0 
mmol/L 
 HbA1c 39 to 47 mmol/mol (5.7 to 6.4%) 
o Type 2 diabetes 




 Fasting plasma glucose ≥ 7.0 mmol/L 
 2 hour glucose during a 75g oral glucose tolerance test ≥ 11.1 mmol/L 
 HbA1c ≥ 48 mmol/mol (6.5%) 
 Dysglycaemia on the basis of current use of oral glucose lowering therapy or insulin 
treatment. 





 Further bariatric surgery (either revision or repair) performed since original procedure 
 
3.2.3.2 Methods 
The study design and protocol for the bariatric follow up study is described in chapter 2 and chapter 3.  
Diabetes outcome definitions were extracted from the manuscript of the included studies and are 
reported in detail below (see 3.2.4.2 and Table 3-48).  Limitations encountered when applying each 
definition are noted in the discussion. 
  





The study included 84 participants who had undergone gastric bypass surgery at least five years ago, 
and had participated in the bariatric follow up study described elsewhere (chapter 3.1).  The mean (SD) 
age of those included in this analysis was 50.4 (9.2) and 59.3 (10.0) years at baseline and follow up 
respectively.  Sixty-one (737%) of the participants were female, and the mean (SD) duration of follow 
up after gastric bypass was 8.9 (4.6) years.  
 
Table 3-38   Baseline characteristics of the study participants 
n=93 Mean (SD) IQR Min/Max 
Age at operation (years) 50.4 (9.2) 13.6 27.9/68.5 
Age at follow up (years) 59.3 (10.0) 14.7 34.0/78.1 
Duration of follow up (years) 8.9 (4.6) 4.3 5.1/29.9 
Pre-operative BMI (kg/m2) 47.2 (9.3) 12.6 33.0/74.9 
BMI (kg/m2) at follow up 32.2 (6.7) 7.7 19.4/50.5 
 N/84 (%) 
Female 61 (73) 




Cook Island Maori 
Samoan 
Chinese 






1 (1)  
4(5) 
 
 Current smoker 6 (7) 
Ex-smoker 30 (36) 
Current alcohol user 30 (36) 
In current employment 54 (64) 
 Mean (SD) IQR Min/Max 
Cigarette pack years 21.5 (12.8) 23.8 5.0/40.0 
Alcohol units (per week) 8.8 (9.2) 7.8 1.0/33.6 
Hours of work (per week) 37.2 (17.7) 20.0 1.0/80.0 




3.2.4.1 Diabetes assessments at baseline and follow up 
At baseline, fourty-two (50%) of the participants had prediabetes before surgery, and forty-two (50%) 
had type 2 diabetes.  Frequency histograms to demonstrate the distribution of each variable along with 
results of Shapiro-Wilk testing are shown in Figure iii-1 (396) and Table iii-1 (397).  The distribution of 
each variable showed right skew at baseline and follow up, due to outlying results, identified by 
boxplots (Figure 3-30).  Logarithmic transformation improved the distribution (Figure iii-2 (397)) 
allowing parametric analysis. Boxplots to show change in each variable over the study period are shown 
in Figure 3-30.  A summary of diabetes assessment data is presented in Table 3-39. 
 
Figure 3-30   Box plots showing a) fasting glucose (mmol/L), b) HbA1c (mmol/mol), c) fasting insulin (units/L), d) 

















23 participants with type 2 diabetes used oral glucose lowering therapy (27% of whole dysglycaemic 
cohort and 59% of those with type 2 diabetes), whilst six used insulin therapy (7% of whole cohort, and 
14% of those with type 2 diabetes). 
Baseline and follow up fasting glucose was 6.62 (2.2) and 5.13 (1.33) mmol/l respectively, resulting in a 
mean fasting glucose at follow up within the normal population reference range (<6.1 mmol/L).  The 
estimated difference was 1.55 mmol/L (95% CI 1.09 to 2.00, p<0.001 after logarithmic transformation). 
Mean HbA1c declined by a clinically significant degree following surgery.  Baseline and follow up fasting 
HbA1c was 49.0 (14.7) and 40.3 (8.5) mmol/mol respectively.  Thus, the mean HbA1c level of the cohort 
reduced from a level diagnostic of type 2 diabetes, to a level consistent with prediabetes.  The 
estimated difference in HbA1c was 9.5 mmol/mol (95% CI 6.7 to 12.2, p<0.001 after logarithmic 
transformation.   
Baseline and follow up fasting insulin was 175.4 (98.2) and 48.6 (20.8) pmol/L respectively; estimated 
difference 132.7 pmol/L (95% CI 107.2 to 157.3, p<0.001 after logarithmic transformation). HOMA-IR 
improved following surgery; the result of favourable changes in both beta cell function and insulin 
sensitivity.  The estimated difference was 2.3 (95% CI 1.9 to 2.7, p<0.001).  By definition, no participant 
with prediabetes used glucose lowering medication.  
  
3.2.4.2 Diabetes outcomes utilising different definitions 
Diabetes outcomes are reported below for all participants, for those with prediabetes/prediabetes 
before surgery only, and for those with type 2 diabetes before surgery. The definition of diabetes 
outcomes are those used in recently published studies of bariatric surgery for persons with type 2 
diabetes.  Where provided, definitions are used to categorise participants at follow up into those with 
resolution of diabetes, those with partial resolution, and those with type 2 diabetes.  It should be noted 
that only two participants with prediabetes/prediabetes at baseline had progressed to type 2 diabetes 
at follow up, and that this was only when two of the included eight definitions were applied.   Results 
using each definition are compared against those achieved when using the criteria suggested by the 
American diabetes association for the assessment of diabetes status following bariatric surgery. 




Table 3-39    Baseline diabetes and follow up characteristics of the study participants stratified by diabetes status. Results of a paired T test are shown. 
 
 N (%) 
Baseline Follow up Paired T test * 
Mean (SD) IQR Min/Max Mean (SD) IQR Min/Max 
Estimated 
difference 
95% CI P value 
All participants (n=84) 
Age (years) 84 (100) 50..4 (9.2) 13.6 27.9/68.5 59.3 (10.0) 14.7 34.0/78.1 8.9 7.9 to 9.9 <0.001 
Follow up duration (years) 84 (100) N/A N/A N/A 8.9 (4.6) 4.3 5.1/29.9 N/A N/A N/A 
BMI (kg/m2) 84 (100) 47.2 (9.3) 12.6 33.0/74.9 32.2 (6.7) 7.7 19.4/50.5 15.0 13.6 to 16.4 <0.001 
Fasting glucose (mmol/L) 78 (93) 6.62 (2.2) 2.25 3.90/13.90 5.11 (1.33) 0.8 3.80/13.50 1.55 1.09 to 2.00 <0.001 
HbA1c (mmol/mol) 72 (86) 50.5 (16.0) 16.0 33/99 41.1 (8.7) 6.8 28/83 9.5 6.7 to 12.2 <0.001 
Insulin (pmol/L) 71 (85) 174.5 (93.9) 109.0 5.26/482.0 50.3 (24.8) 24.8 6.1/164.9 132.7 107.2 to 157.3 <0.001 
HOMA-IR 61 (73) 3.1 (1.3) 1.9 0.9/6.5 0.98 (0.4) 0.47 0.4/2.8 2.3 1.9 to 2.7 <0.001 
Prediabetes (n=42) 
Age (years) 42 (100) 48.0 (9.6) 12.2 27.9/68.5 56.6 (10.6) 14.2 34.0/78.0 8.7 7.3 to 10.0 <0.001 
Duration of follow up (years) 42 (100) N/A N/A N/A 8.7 (4.3) 4.0 5.1/22.2 N/A N/A <0.001 




 N (%) 
Baseline Follow up Paired T test * 
Mean (SD) IQR Min/Max Mean (SD) IQR Min/Max 
Estimated 
difference 
95% CI P value 
BMI (kg/m2) 42 (100) 46.3 (9.1) 12.6 33.9/74.9 31.6 (7.5) 10.5 19.4/50.5 14.7 12.7 to 16.7 <0.001 
Fasting glucose (mmol/L) 42 (100) 5.45 (0.7) 1.0 3.90/6.90 4.77 (0.4) 0.57 3.80/5.60 0.71 0.48 to 0.94 <0.001 
HbA1c (mmol/mol) 35 (83) 40.5 (3.3) 4.0 33.0/46.0 37.8 (4.0) 4.8 28.0/50.0 2.8 1.6 to 4.1 <0.001 
Insulin (pmol/L) 36 (86) 148.9 (92.4) 108.8 5.3/473.0 44.1 (19.6) 24.4 15.2/100.2 108.9 73.1 to 144.8 <0.001 
HOMA-IR 33 (79) 2.73 (1.2) 1.71 0.91/5.92 0.86 (0.34) 0.43 0.41/1.79 2.02 1.49 to 2.55 <0.001 
Type 2 diabetes (n=42) 
Age (years) 42 (100) 52.8 (8.2) 12.7 33.2/65.2 61.9 (8.7) 10.5 38.7/78.1 9.1 7.6 to 10.6 <0.001 
Duration of follow up (years) 42 (100) N/A N/A N/A 9.1 (4.9) 5.6 5.2/29.9 N/A N/A N/A 
BMI (kg/m2) 42 (100) 48.2 (9.5) 13.5 33.0/73.6 32.9 (5.8) 6.6 24.3/48.9 15.3 13.2 to 17.4 <0.001 
Fasting glucose (mmol/L) 36 (86) 8.00 (2.6) 2.92 4.30/13.90 5.49 (1.80) 1.23 3.80/13.50 2.59 1.73 to 3.46 <0.001 
HbA1c (mmol/mol) 37 (88) 60.0 (15.4) 15.0 38/99 44.7 (10.8) 11.75 32/83 16.6 12.3 to 20.9 <0.001 
Insulin (pmol/L) 35 (83) 200.8 (89.2) 114.0 66.0/482.0 56.6 (28.1) 30.5 6.1/164.9 156.4 121.5 to 191.4 <0.001 
HOMA-IR 28 (67) 3.63 (1.33) 2.2 1.18/6.54 1.10 (0.5) 0.63 0.53/2.83 2.67 2.03 to 3.30 <0.001 
* Paired T test after logarithmic transformation (fasting glucose, HbA1c, fasting insulin, HOMA-IR) 




3.2.4.2.1 ADA suggested definitions for diabetes outcomes after bariatric surgery 
As noted above, the American Diabetes Association (ADA) has released a consensus statement 
providing recommendations on the definition of glycaemic outcomes post bariatric surgery.848  These 
criteria define “partial remission” as an HbA1C ≤6.5% (47 mmol/L), and/or a fasting glucose of 100-125 
mg/dl (5.6 – 6.9 mmol/L)), and complete remission  as an HbA1c “in the normal range”, and a fasting 
glucose concentration of <100mg/dl (5.6 mmol/L)) provided that each of these assessments were 
persistent for at least 1 year duration, and in the absence of active pharmacologic therapy or ongoing 
procedures.  Prolonged remission is satisfaction of complete remission criteria maintained for at least 
5 years.  The ‘normal range” HbA1c is not clearly defined in this statement but is assumed to represent 
the upper limit of normal in the ADA criteria for the diagnosis of diabetes (<39 mmol/mol).   For unclear 
reasons, the ADA stipulate that a fasting glucose level of less than or equal to 5.6 mmol/L is required as 
a component of the criteria for “normal” glucose homeostasis, but that the fasting glucose level must 
be less than 5.6 mmol/L as a component of the criteria for diabetes resolution following bariatric 
surgery.  This simple difference resulted in one participant being categorised as having achieved 
diabetes resolution when the ADA diagnosis criteria were applied, but with partial resolution when the 
ADA criteria post bariatric surgery were used. 
 
 
Table 3-40    Diabetes outcomes using definitions as defined by the ADA criteria for diabetes outcomes following 
bariatric surgery. Complete remission = HbA1c ≤ 38 mmol/mol, and fasting glucose < 5.6 mmol/L, and the 
absence of glucose lowering medications.  Partial remission = HbA1c 39-47 mmol/mol and/or fasting glucose 5.7 








Residual type 2 
diabetes (%) 
All participants 76 34 (45) 31 (41) 11 (14) 
Prediabetes before surgery 40 25 (63)  14 (35) 1 (2) 
Type 2 diabetes before 
surgery 
36 9 (25) 17 (47) 10 (28) 
 




When the ADA criteria for the assessment of diabetes outcomes after bariatric surgery are applied 34 
(45%) and 31 (41%) of all participants with dysglycaemia at baseline were in complete remission or 
partial remission respectively at follow up, with type 2 diabetes evident in only 11 (14%) (Table 3-40).  
In those with type 2 diabetes at baseline, 26 (72%) had improved to either normal glucose tolerance or 
prediabetes at follow up, whilst 10 (28%) remained with type 2 diabetes. 
 
3.2.4.2.2 New Zealand Society for the Study of Diabetes (NZZSD) criteria for diabetes diagnosis 
Type 2 diabetes is defined as an HbA1c greater than or equal to 50 mmol/mol, and/or a fasting glucose 
of great than or equal to 7.0 mmol/L, and/or the ongoing use of glucose lowering medications. 
Prediabetes (prediabetes) is defined as an HbA1c less than or equal to 49 mmol/mol, and fasting glucose 
less than or equal to 6.9 mmol/L (with one or both of these being above the threshold defining normal 
glucose homeostasis), and the absence of glucose lowering medication, and is used here as a definition 
of partial resolution. Normal glucose homeostasis is defined as an HbA1c less than or equal to 40 
mmol/mol, and fasting plasma glucose less than or equal to 6.0 mmol/L, and the absence of glucose 
lowering medications, and is used here as the definition of diabetes resolution. 
 
Using these criteria, 57 (67%) of the total cohort were in diabetes remission at the greater than five 
year follow up assessment, whilst 19 (22%) and 9 (11%) had partial resolution or persistent type 2 
diabetes respectively (Table 3-41).  Diabetes resolution was achieved in all but six participants who had 
prediabetes before surgery (44/50 (88%), whilst no participant with pre surgery prediabetes progressed 
to type 2 diabetes.  In those with preoperative type 2 diabetes, 27 (77%) had improved to either normal 
glucose tolerance (13 (37%)) or prediabetes (14 (40%)) at follow up, whilst 8 (23%) participants 












Table 3-41   Diabetes outcomes using definitions as defined by the NZSSD.  Normal (resolution) = HbA1c ≤ 40 
mmol/mol, and fasting glucose ≤ 6.0 mmol/L, and the absence of glucose lowering medications.  Prediabetes 
(Partial resolution) = HbA1c ≤ 49 mmol/L and/or fasting glucose ≤ 6.9 mmol/L (but one or both being above the 
threshold for resolution), and the absence of glucose lowering medications.   Type 2 diabetes = HbA1c ≥ 50 






Residual type 2 
diabetes (%) 
All participants 78 49 (63) 20 (26) 9 (12) 
Prediabetes before surgery 40 34 (85) 5 (13) 1 (2) 
Type 2 diabetes before 
surgery 
38 15 (40) 15 (40) 8 (20) 
 
Diabetes status differed significantly when outcomes with the ADA criteria and NZSSD diagnostic 
criteria were applied.  For the entire cohort, 13 (17%) fewer participants were deemed to have achieved 
complete remission by the ADA criteria, 9 (22%) more participants were deemed to have prediabetes 
at follow up, and 2 (5%) more patients had type 2 diabetes.  One participant deemed to have progressed 
to type 2 diabetes from prediabetes by the ADA criteria, was considered to remain with prediabetes by 
the NZSSD criteria given an HbA1c of 48 mmol/mol.  Nine additional participants with prediabetes at 
baseline were considered to remain with prediabetes at follow up by the ADA criteria, but have 
achieved resolution when the NZSSD diagnostic criteria were applied, each as a consequence of the 
difference HbA1c values used in each definition and entirely independent of fasting glucose 
concentrations. 
An additional two participants with type 2 diabetes at baseline, were considered to have residual type 
2 diabetes at follow up by the ADA criteria when compared to the NZSSD criteria (10 (28%) and 8 (20%) 
respectively).  A further two participants with type 2 diabetes at baseline were considered to have 
partial remission at follow up by the ADA criteria, but normal values by the NZSSD diagnostic criteria.  
Again, this difference was entirely attributable the lower HbA1c thresholds stipulated by the ADA 
criteria; participants deemed to have persistent type 2 diabetes each had an HbA1c at follow up of 
between 48 and 49 mmol/L, whilst those deemed to have prediabetes rather than normalisation had 
values of 40 mmol/mol.    




3.2.4.2.3  American Diabetes Association (ADA) criteria for diabetes diagnosis 
The ADA suggest slightly different criteria for the diagnosis of type 2 diabetes to those suggested for 
assessing diabetes status following bariatric surgery.  A diagnosis of type 2 diabetes is defined as an 
HbA1c greater than or equal to 48 mmol/mol, and/or a fasting glucose of great than or equal to 7.0 
mmol/L, and/or the ongoing use of glucose lowering medications. Prediabetes) is defined as an HbA1c 
less than or equal to 47 mmol/mol, and fasting glucose less than or equal to 6.9 mmol/L (with one or 
both of these being above the threshold defining normal glucose homeostasis), and the absence of 
glucose lowering medication, and is used here as a definition of partial resolution. Normal glucose 
homeostasis is defined as an HbA1c less than or equal to 38 mmol/mol, and fasting plasma glucose less 
than or equal to 5.6 mmol/L, and the absence of glucose lowering medications, and is used here as the 
definition of diabetes resolution. 
Using these criteria, 35 (46%) of the total cohort were in diabetes remission at the greater than five 
year follow up assessment, whilst 30 (40%) and 11 (15%) had partial resolution or persistent type 2 
diabetes respectively (Table 3-42).  Only one participant was reclassified when the ADA diagnosis as 
opposed to assessment post bariatric surgery criteria were applied.  As noted above, the ADA diagnosis 
criteria accept a fasting glucose of 5.6 mmol/L or less as consistent with normal glucose tolerance, 
whilst the post bariatric surgery criteria require that the fasting glucose be less than 5.6 mmol/L.  One 
participant had a fasting glucose of 5.6 mmol/L, and HbA1c of 36 mmol/mol, and was not using diabetes 
medication at follow up, thereby being classified as in diabetes remission by the diagnosis criteria but 
with only partial remission by the post bariatric surgery criteria. 
 
3.2.4.2.4    Buchwald et al criteria for diabetes outcomes 
Diabetes resolution in this meta-analysis was defined as an HbA1C of < 42 mmol/mol or a fasting blood 
glucose of < 5.6 mmol/L, in the absence of glucose lowering medications.  Partial resolution was defined 
as a reduction in the number or dose of glucose lowering medications, or a fasting glucose level of 5.6 
to 6.9 mmol/L.  Interestingly, the authors chose not to include an HbA1c threshold in the definition of 
partial remission. Those participants who did not meet either of these criteria were classified into 
‘unchanged’ and ‘worsened’ categories.  Full information on glucose lowering medication dose at 
baseline was not available for this study and is therefore not considered in this analysis. 




Table 3-42    Diabetes outcomes using definitions as defined by the ADA. Normal (resolution) = HbA1c ≤ 38 
mmol/mol, and fasting glucose ≤ 5.6 mmol/L, and the absence of glucose lowering medications.  Prediabetes 
(Partial resolution) = HbA1c ≤ 47 mmol/L and/or fasting glucose ≤ 6.9 mmol/L (but one or both being above the 
threshold for resolution), and the absence of glucose lowering medications.   Type 2 diabetes = HbA1c ≥ 48 







Residual type 2 
diabetes (%) 
All participants 76 35 (46) 30 (40) 11 (15) 
Prediabetes before surgery 40 25 (63) 14 (35) 1 (2) 
Type 2 diabetes before 
surgery 





Table 3-43  Diabetes outcomes using definitions as defined meta-analysis by Buchwald et al. Resolution = HbA1c 
< 42 mmol/mol, or fasting glucose < 5.6 mmol/L, and the absence of glucose lowering medications.  Partial 
resolution = fasting glucose 5.6 to 6.9 mmol/L, or a reduction in dose or number of glucose lowering 







Residual type 2 
diabetes (%) 
All participants 78 65 (83) 9 (12) 4 (5) 
Prediabetes before surgery 40 39 (98) 1 (2) 0 (0) 
Type 2 diabetes before 
surgery 









The acceptance of either an HbA1c or fasting glucose level below a threshold resulted in quite marked 
differences in outcomes when the criteria employed by Buchwald and colleagues were used and when 
all other included definitions were used (Table 3-43 and Table 3-48), and resulted in the inclusion of 
two additional participants who had fasting glucose concentrations only obtained.  When all 78 
participants with dysglycaemia at baseline were considered, use of the ADA criteria rather than the 
Buchwald criteria resulted in 31 (40%) fewer participants deemed to have achieved complete remission, 
22 (28%) more participants having prediabetes at follow up, and 7 (8%) more participants having type 
2 diabetes. All 14 (35%) participants with prediabetes at baseline and considered to have achieved 
partial resolution only by the ADA criteria, were considered to have achieved diabetes resolution using 
the Buchwald criteria because of a fasting glucose <5.6 mmol/L despite an HbA1c > 42 mmol/mol.   The 
one participant considered to have progressed from prediabetes to type 2 diabetes by the ADA criteria 
was considered to have remained with prediabetes by the Buchwald criteria, as a result of the higher 
fasting glucose thresholds employed by the Buchwald criteria. 
 
The differences were just as striking in those with type 2 diabetes at baseline, although each of the nine 
(25%) of participants considered to have achieved complete remission by the ADA criteria had also done 
so when the Buchwald criteria were applied.  The two additional participants who could be included in 
this analysis using the Buchwald criteria both had type 2 diabetes at baseline and had both achieved 
complete remission at follow up.  2 participants with partial remission at follow up by the ADA criteria 
were also considered to have achieved partial remission by the Buchwald criteria, whilst the remaining 
15 (43%) were considered to have achieved complete remission.  In each case, the discrepancy was 
entirely attributable to the Buchwald criteria not considering HbA1c for the diagnosis of partial 
remission.  Of the 10 participants with type 2 diabetes at baseline and considered to remain with type 
2 diabetes at follow up by the ADA criteria, 2 (6%) were considered to have achieved complete 
remission by the Buchwald criteria, 5 (14%) had achieved partial resolution, and only 3 (8%) were also 
considered to remain with type 2 diabetes.     
 
In addition to the clear differences in obtained results with the more flexible criteria applied by 
Buchwald, the authors also included a reduction in dose or number of glucose lowering medications as 
a criteria that independently confirmed partial resolution; the above analysis is not able to include this 
criteria, but it is likely that reported diabetes outcomes would be improved further if this criteria were 
included. 
 




3.2.4.2.5 Schauer et al criteria for diabetes outcomes 
The primary outcome in this study was defined as an HbA1c less than or equal to 42 mmol/mol, with or 
without the ongoing use of glucose lowering medications. Fasting glucose concentrations were not 
considered in analysis of the primary outcome.  The authors used the term glycaemic control in place 
of diabetes resolution.  Thresholds for partial responses were not defined.   Thus, for the purpose of 
this analysis, failure to achieve the primary outcome was considered to represent persistent 
dysglycaemia, but this could not be further divided into those with partial remission or persistent type 
2 diabetes. 
 
53 (70%) of participants with dysglycaemia at baseline achieved the primary end point at follow up 
(Table 3-44).  For the entire cohort of 76 participants with dysglycaemia at baseline, use of the ADA 
criteria rather than the Schauer criteria resulted in 19 (25%) fewer participants deemed to have 
achieved complete remission at follow up, and instead remaining with dysglycaemia.  In those with 
prediabetes at baseline, 36 (90%) of participants had achieved the primary end point at follow up, whilst 
4 (10%) remained with dysglycaemia.  The criteria were completely concordant with the ADA criteria 
with respect to the 25 (63%) of participants who were considered to have improved to normal glucose 
tolerance.  However, use of the Schauer criteria resulted in a further 11 (28%) participants with 
prediabetes at baseline and normal glucose tolerance at follow up.  In each of these cases, the 
difference was entirely attributable to higher threshold of HbA1c accepted by the Schauer criteria to 
represent normal glucose tolerance.  Three of the four participants with prediabetes at baseline, and 
considered to remain with dysglycaemia at follow up by the Schauer criteria, had achieved partial 
remission according to the ADA criteria, whilst one had progressed to type 2 diabetes by the ADA 
criteria. 
In those with type 2 diabetes at baseline, 17 (47%) of participants would be considered to have achieved 
the primary endpoint at follow up whilst 19 (53%) would be considered to remain with dysglycaemia.  
Again, the criteria were entirely concordant with results using the ADA criteria with respect to the 9 
(25%) of participants who were considered to have improved to normal glucose tolerance by the ADA 
criteria.  6 (17%) additional participants (17 (47%) in total) were deemed to have complete resolution 
of diabetes at follow up by the Schauer criteria and partial resolution only by the ADA criteria.  Given 
that fasting glucose was not included in the definition utilised by Schauer, this discordancy was 
predominantly the result of the differing HbA1c thresholds set by each criteria.  Each of the 6 




participants in this group had an HbA1c at follow up of between 39 and 42 mmol/mol, although one 
participant with an HbA1c of 36 mmol/mol had a fasting glucose of 5.6 mmol/L resulting in a diagnosis 
of prediabetes (partial remission).  The criteria were again concordant with respect to the 10 
participants with type 2 diabetes at baseline considered to remain with type 2 diabetes at follow up by 
the ADA criteria.  Each of these participants did not achieve the primary objective by the Schauer criteria 
and therefore had persistent dysglycaemia 
 
Table 3-44   Diabetes outcomes using definitions as defined by Schauer et al. Glycaemic control = HbA1c ≤ 42 









All participants 76 53 (70) 23 (30) 
Prediabetes before surgery 40 36 (90) 4 (10) 
Type 2 diabetes before 
surgery 
36 17 (47) 19 (53) 
 
 
3.2.4.2.6 Mingrone et al criteria for diabetes outcomes 
The primary outcome in this study was defined as an HbA1c less than 47 mmol/mol, and a fasting 
plasma glucose of less than 5.6 mmol/L, and the absence of glucose lowering medications. The authors 
used the term diabetes remission if the primary endpoint was achieved.  Thresholds for partial 
responses were not defined. As with the analysis of the Schauer definition above, failure to achieve the 
primary outcome was therefore considered to represent persistent dysglycaemia, but could not be 
further divided into those with partial remission or persistent type 2 diabetes. 
 
58 (76%) of participants with dysglycaemia at baseline achieved the primary end point at follow up, 
whilst 18 (24%) remained with dysglycaemia (Table 3-45).  For the entire cohort of 76 participants with 




dysglycaemia at baseline, use of the ADA criteria rather than the Mingrone criteria resulted in 24 (32%) 
fewer participants deemed to have achieved complete remission at follow up, each of these 
participants remaining with dysglycaemia.   
 
In those with prediabetes at baseline, 39 (98%) of participants had achieved the primary end point at 
follow up, whilst only one (2%) remained with dysglycaemia.  All 40 of participants with prediabetes at 
baseline and either complete remission (25 (63%) or partial remission 14 (35%) by the ADA criteria had 
achieved the primary endpoint used by Mingrone and colleagues.  The participant considered to have 
progressed to type 2 diabetes from this group by the ADA criteria was also considered to have persistent 
dysglycaemia by the Mingrone criteria. In each of these cases, the difference was entirely attributable 
to higher threshold of HbA1c accepted by the Mingrone criteria to represent normal glucose tolerance. 
 
 
Table 3-45   Diabetes outcomes using definitions as defined by Mingrone et al.  Diabetes remission = HbA1c < 47 











All participants 76 58 (76) 18 (24) 
Prediabetes before surgery 40 39 (98) 1 (2) 
Type 2 diabetes before 
surgery 
36 19 (53) 17 (47) 
 
 
In those with type 2 diabetes at baseline, 19 (53%) of participants would be considered to have achieved 
the primary endpoint at follow up whilst 17 (47%) would be considered to remain with dysglycaemia.  
All 9 (25%) of participants considered to have achieved complete remission or partial remission by the 
ADA criteria, had achieved the primary objective set by Mingrone and colleagues.  A further 10 (28%) 
of participants, considered to have achieved partial remission by the ADA criteria, had achieved the 
primary objective. Each of the 11 participants in this group had an HbA1c at follow up of between 39 




and 42 mmol/mol, although one additional participant with an HbA1c of 36 mmol/mol had a fasting 
glucose of 5.6 mmol/L resulting in a diagnosis of prediabetes (partial remission). The criteria were 
entirely concordant with respect to the 10 (28%) participants with type 2 diabetes at baseline 
considered to remain with type 2 diabetes at follow up by the ADA criteria.   
 
3.2.4.2.7 Adams et al criteria for diabetes outcomes 
Like Schauer and Mingrone, Adams defined a primary endpoint which was equated to diabetes 
remission.  The primary endpoint was a fasting glucose level of < 126mg/dl (7.0 mmol/L) and/or and 
HbA1c level < 6.5% (47 mmol/mol), in the absence of glucose lowering medications.  The authors 
categorised those participants who failed to achieve the primary endpoint as remaining with type 2 
diabetes. No thresholds for partial remission were defined.   Two additional participants were included 
in this study given the authors acceptance of either an HbA1c or fasting glucose value in isolation to 
decide diabetes status. 
 
Table 3-46  Diabetes outcomes using definitions as defined meta-analysis by Adams et al. Type 2 diabetes 
defined as a fasting glucose ≥ 126mg/dl (7.0 mmol/L) and/or and HbA1c level ≥ 6.5% (47 mmol/mol), or the use 








All participants 78 64 (82) 14 (18) 
Prediabetes before surgery 40 39 (98) 1 (2) 
Type 2 diabetes before 
surgery 




64 (82%) of participants with dysglycaemia at baseline had achieved the primary end point at follow up 
(Table 3-46).  When all 78 participants with dysglycaemia at baseline were considered, use of the ADA 
criteria rather than the Adams criteria resulted in 30 (37%) fewer participants deemed to have achieved 




complete remission at follow up.  In those with prediabetes at baseline, 39 (98%) of participants had 
achieved the primary end point at follow up, whilst only 1 (2%) remained with dysglycaemia.  Thus, all 
25 (63%) of participants who were considered to have improved to normal glucose tolerance by the 
ADA criteria and all 14 (35%) who had achieved partial remission, had achieved the primary endpoint.    
The only participant with prediabetes at baseline deemed not to have achieved the primary end point 
at follow had progressed to type 2 diabetes by the ADA criteria. The maximum fasting glucose level at 
follow up in those with prediabetes at baseline was 5.8 mmol/L, far below the threshold defined by 
Adams for the primary endpoint.  Therefore, the different diabetes status in the 14 (35%) of participants 
with discordant results was explained entirely by different HbA1c thresholds.  
In those with type 2 diabetes at baseline, 25 (66%) of participants would be considered to have achieved 
the primary endpoint if the Adams criteria were applied to this cohort, and 13 (34%) would be 
considered to remain with dysglycaemia.  As with the NZSSD diagnosis criteria and those defined by 
Buchwald, Schauer, and Mingrone, the criteria were entirely concordant with results using the ADA 
criteria with respect to the 9 (25%) of participants who were considered to have improved to normal 
glucose tolerance by the ADA criteria.  16 (41%) additional participants (25 (66%) in total) were deemed 
to have complete resolution of diabetes at follow up by the Adams criteria and partial resolution only 
by the ADA criteria, including both participants unable to be clarified by the ADA criteria. Thus, all of 
the participants with type 2 diabetes at baseline deemed to have achieved either diabetes remission or 
partial remission by the ADA criteria would be considered in diabetes remission if the Adams criteria 
were applied.  The maximum fasting glucose level in this group was 6.2 mmol/L, again far below the 
defined threshold, and thus attributing every discrepant outcome to the differing HbA1c thresholds.  
Each of the 25 participants in this group had an HbA1c at follow up of between 32 and 46 mmol/mol. 
As with other utilised criteria, the Adams criteria were entirely concordant with the ADA criteria with 
respect to the 10 participants with type 2 diabetes at baseline considered to remain with type 2 
diabetes at follow up by the ADA criteria, although, as above the criteria suggested by Adams did not 
allow consideration of partial remission. 
 
3.2.4.2.8 Ikramuddin et al criteria for diabetes outcomes 
Type 2 diabetes was defined as a fasting glucose ≥ 126mg/dl (7.0 mmol/L) and/or and HbA1c level ≥ 
6.5% (47 mmol/mol), or the use of glucose lowering medications.  However, the study authors elected 




to reported a primary composite outcome of HbA1c <7.0% (53 mmol/mol), serum LDL < 100 mg/dl, and 
a systolic blood pressure of < 130 mmHg.  Neither fasting glucose level nor the use of diabetes 
medications was considered for the primary outcome.  They acknowledge that this does not adequately 
define diabetes resolution, but employed the definition as a clinically useful indicator of the efficacy of 
surgery in patients with type 2 diabetes.   For the purposes of this analysis, only the HbA1c value at 
follow up was considered. 
 
Accordingly, a significantly higher percentage of participants achieved the primary endpoint when this 
definition was employed than when any other definition of diabetes outcome included in this analysis 
was used (Table 3-47).  When all 76 included participants were considered, 70 (92%) were considered 
to have achieved the glycaemic primary end point and only 6 (8%) were considered to remain with type 
2 diabetes.  Every participant (40/40) with prediabetes at baseline had achieved the primary endpoint; 
the one participant considered to have progressed to type 2 diabetes by most other included definitions 
was instead defined as having achieved the diabetes endpoint despite an HbA1c at follow up of 50 
mmol/mol.  Thus, this definition defined 15 (37%) further participants with prediabetes at baseline as 
having diabetes resolution at follow up than when the ADA criteria were applied to same cohort.    Given 
that the HbA1c value was the only considered diabetes outcome, each of the 5 (14%) of participants 
with type 2 diabetes at baseline, and considered to have persistent type 2 diabetes at follow up by the 
ADA criteria had an HbA1c in excess of 55 mmol/L.   Two participants with type 2 diabetes at baseline, 
and not considered to remain with type 2 diabetes at follow up, remained on diabetes medications. 
 
Table 3-47    Diabetes outcomes using definitions as defined meta-analysis by Ikramuddin et al. Primary outcome 








All participants 76 70 (92) 6 (8) 
Prediabetes before surgery 40 40 (100) 0 (0) 
Type 2 diabetes before 
surgery 
36 31 (86) 5 (14) 




Table 3-48   Diabetes outcomes using definitions as defined by each included study.  Participants are categorised by diabetes status before surgery (All, prediabetes, or Type 2 




Diabetes status at baseline 
All Prediabetes Type 2 diabetes 
Resolution Partial resolution 
Diabetes status at follow up (%) 
R PR T2DM R PR T2DM R PR T2DM 





HbA1c ≤ 38 mmol/mol, 
and fasting glucose < 5.6 
mmol/L, and the absence 
of glucose lowering 
medications. 
 
HbA1c 39-47 mmol/mol and/or fasting 
glucose 5.7 to 6.9 mmol/L, in the 
absence of glucose lowering 
medications 
45 41 14 63 35 2 25 47 28 
NZZSD criteria for 
the diagnosis of 
type 2 diabetes 
HbA1c ≤ 40 mmol/mol, 
and fasting glucose ≤ 6.0 
mmol/L, and the absence 
of glucose lowering 
medications.± 
HbA1c ≤ 49 mmol/L and/or fasting 
glucose ≤ 6.9 mmol/L (but one or both 
being above the threshold for 
resolution), and the absence of glucose 
lowering medications. ± 
63 26 12 85 13 2 40 40 20 
ADA criteria for 
the diagnosis of 
type 2 diabetes 
HbA1c ≤ 38 mmol/mol, 
and fasting glucose ≤ 5.6 
mmol/L, and the absence 
of glucose lowering 
medications.   
HbA1c ≤ 47 mmol/L and/or fasting 
glucose ≤ 6.9 mmol/L (but one or both 
being above the threshold for 
resolution), and the absence of glucose 
lowering medications. 
46 40 15 63 35 2 28 44 28 
R = Diabetes resolution, PR = Diabetes partial remission, T2DM = Type 2 diabetes mellitus at follow up.   ± Definitions derived from the NZSSD and ADA criteria for the diagnosis of type 2 diabetes use normal 
concentrations as evidence of diabetes resolution, and concentrations diagnostic of prediabetes or prediabetes as evidence of partial resolution







Diabetes status at baseline 
All Prediabetes Type 2 diabetes 
Resolution Partial resolution 
Diabetes status at follow up (%) 
R PR T2DM R PR T2DM R PR T2DM 
Buchwald et al 
HbA1c < 42 mmol/mol, or 
fasting glucose < 5.6 
mmol/L, and the absence of 
glucose lowering 
medications.   
Fasting glucose 5.6 to 6.9 mmol/L, or a 
reduction in dose or number of 
glucose lowering medications (not 
considered in this analysis) 
83 12 5 98 2 0 68 24 8 
Schauer et al 
HbA1c ≤ 42 mmol/mol, with 
or without the use of 
glucose lowering 
medications. 
Not provided 70 30 90 10 47 53 
Mingrone et al 
HbA1c < 47 mmol/mol, and 
fasting glucose < 5.6 
mmol/L, in the absence of 
glucose lowering 
medications 
Not provided 76 24 98 2 53 47 
Adams et al 
HbA1c ≤ 46 mmol/mol and 
fasting glucose ≤ 6.9 
mmol/L, in the absence of 
glucose lowering 
medications 
Not provided 82 18 98 2 66 34 
Ikramuddin et al 
 
HbA1c < 53 mmol/mol  
 
Not provided 92 8 100 0 86 14 
R = Diabetes resolution, PR = Diabetes partial remission, T2DM = Type 2 diabetes mellitus at follow up.   ± Definitions derived from the NZSSD and ADA criteria for the diagnosis of type 2 diabetes use normal 
concentrations as evidence of diabetes resolution, and concentrations diagnostic of prediabetes or prediabetes as evidence of partial resolution





Use of these seven criteria, when compared to those suggested by the ADA for the assessment of 
diabetes outcomes after surgery, produced significant variability.  The definition associated with the 
best outcomes following surgery was that used by Ikramuddin with complete remission seen in 92% of 
participants with dysglycaemia at baseline, and 86% of participants with type 2 diabetes at baseline in 
the bariatric follow up study had this definition been used.  The definition associated with the poorest 
outcomes following bariatric surgery was by some distance the criteria suggested by the ADA for the 
assessment of diabetes outcomes following bariatric surgery.  This was true for each status of glucose 
tolerance at baseline.  The number of participants with dysglycaemia at baseline who would be 
considered to have achieved diabetes resolution at follow up when the criteria defined by Ikramuddin 
were applied was two fold higher than the number when the ADA criteria were applied.  When only 
those with type 2 diabetes at baseline were considered, this difference was even greater with over a 
three fold difference in the numbers achieving diabetes resolution when the Ikramuddin and ADA 
criteria were applied.  Comparisons with the definitions employed by the NSZSSD, Schauer, Mingrone, 
and Buchwald produce similar findings with a 1.4, 1.6, 1.7, and 1.8 fold greater number of all 
participants considered to have achieved diabetes remission respectively, when compared with the 
ADA criteria.   
The variation was not as significant when those with persistent type 2 diabetes at follow up were 
considered, although the differences are still of importance.  Again, the ADA criteria were the most 
stringent in this respect with 28% of participants with type 2 diabetes at baseline remaining with type 
2 diabetes at follow up.   The other definitions that provided thresholds for partial remission as well as 
complete remission produced 1.4 and 3.5 fold fewer patients with persistent type 2 diabetes using the 
NZSSD and Buchwald criteria respectively.  With respect to the Schauer and Mingrone definitions, this 
variability is reduced to some extent by considering the absence of a partial remission category in the 
definitions employed by the authors.  If one assumes that achieving the primary endpoint in these 
studies is equivalent to the combined numbers of complete remission and partial resolution, then the 
relative ratios are instead 1.4 and 1.5 fold fewer participants with type 2 diabetes achieving this 
endpoint with the Mingrone and Schauer criteria respectively than when the ADA criteria are applied.  
If instead one assumes that failure to achieve the primary endpoint is equivalent to the combined 
numbers of partial resolution and persistent type 2 diabetes then the relative ratios are greater at 1.4 




and 1.6 fold fewer participants failing to achieve the primary endpoint with the Schauer and Mingrone 
criteria respectively than when the ADA criteria are applied. 
The provocative paper by Pories et al in 1995 suggested that bariatric surgery may be the most effective 
currently available therapy for inducing remission of type 2 diabetes.404 This suggestion has since been 
proved correct with the publication of large randomised interventional studies comparing diabetes 
outcomes following bariatric surgery against those of optimal lifestyle/medical management. The 
significant improvements in glucose metabolism following bariatric surgery frequently results in 
individuals being able to stop all antidiabetic medications, including many of those who required insulin 
pre-operatively.  However, a closer inspection of this literature suggests that the diabetes related 
outcomes and endpoints are reported in a diverse fashion, such that comparisons of outcomes from 
individual studies involving different surgical procedures may be rendered meaningless.   
Each of these authors of the studies included in this analysis used differing definitions of glycaemic 
outcomes (Table 3-48) although similarities were predictably present.  It is clear that the HbA1c 
threshold is the major determinant of diabetes outcome when each of these definitions is applied. 
Indeed, the criteria employed by Mingrone et al and those proposed by the ADA as definitions for 
diabetes outcomes following bariatric surgery differ only in terms of the HbA1c threshold.  Both criteria 
stipulate that the fasting glucose level should be less than 5.6 mmol/L for diabetes resolution, and both 
require that this is achieved in the absence of glucose lowering medication.  However, whilst the 
Mingrone criteria accept an HbA1c of less than 48 mmol/mol as evidence of diabetes resolution, the 
ADA suggest that an HbA1c of less than 39 mmol/mol should be the threshold.  This single difference 
resulted in a two fold increase in the prevalence of failure to achieve resolution (24% versus 55%) in all 
participants in the study, and over a 50% reduction in the number of participants with type 2 diabetes 
at baseline who achieved diabetes resolution at five years of follow up (53% versus 25%).    In contrast, 
a significant difference in the fasting glucose threshold alone had a much smaller effect on the 
frequency of different diabetes outcomes.  For example, the definitions employed by Mingrone et al 
and Adams et al both required that the HbA1c level should be less than 48 mmol/mol and that the 
participant should not be using glucose lowering medication.  However, Mingrone et al required a 
fasting glucose of less than 5.6 mmol/L whilst Adams et al used a much higher threshold of 6.9 mmol/L.  
Despite this clear difference, the outcomes when both definitions were employed were generally 
similar, and identical in the participants with prediabetes at baseline.    Four percent more participants 
achieved diabetes resolution when the Adams criteria were applied (82% versus 76%), and 30% more 




of those with pre-existing type 2 diabetes failed to achieve diabetes resolution at follow up when the 
Mingrone criteria were applied (47% versus 34%). 
It is accepted that many of the authors of the included studies do not intend to imply that the stipulated 
diabetes outcome equates to resolution or remission, and that they are simply trying to demonstrate 
clinically relevant effects of bariatric surgery.  Nonetheless, an increasing proportion of patients 
undergoing bariatric diabetes will have pre-existing type 2 diabetes, and are likely to place a high 
priority on the question of whether they can expect their diabetes to be ‘cured’.  It is therefore 
suggested that, irrespective of whether other diabetes outcomes are also presented, it is preferable 
that any study reporting on diabetes outcomes following bariatric surgery also include outcomes based 
on standardised criteria defining resolution and partial resolution.   
However, the use of the terms ‘cure’, ‘resolved’ or ‘remission’ in this context is controversial for a 
number of reasons.  Firstly, the diagnosis of diabetes itself is not dichotomous; rather thresholds for 
disease have been defined on the basis of risk of complications (micro and macro vascular disease).  It 
is not known if these thresholds remain true in a post RYGB surgery population, and therefore, it is 
unknown what glycaemic thresholds are acceptable to define as optimal targets post-surgery.  
Secondly, use of the term “cure” for a chronic disease mediated predominantly by lifestyle may not be 
helpful in encouraging longer term compliance to favourable dietary and exercise strategies.  
Furthermore, progressive decline, albeit potentially reversible, in pancreatic beta cell function over 
time is considered characteristic of type 2 diabetes by some and it remains unclear whether bariatric 
surgery alters this process. 
This study had a number of limitations, predominantly with the ability to entirely apply the definitions 
utilised in the included studies.  Firstly, limited information was available on the specifics of glucose 
lowering therapy at follow up in our cohort.  Data only on the class of glucose lowering medication was 
collected, and not data on dose or whether the dose had changed following surgery.  Buchwald et al 
accepted a reduction in the dose or number of glucose lowering medications as evidence for 
improvement post bariatric surgery, and indeed, had this information been available for this analysis, 
it is highly likely that the outcomes would be further improved when applying the Buchwald definitions.  
In addition, many of the studies stipulated that the biochemical criteria required to categorise each 
participant (fasting glucose and HbA1c) should be persistent over a period of 12 months or more.  In 
particular, the studies by Schauer et al and Mingrone et al were of a prospective nature and therefore 
the authors were able to collect data at numerous time points and comment on the persistency of their 




findings.  The follow up data for this study was collected as part of a larger bariatric follow up study 
(chapter 3.1), where each participant was invited to attend for one follow up assessment.  Additional 
data collected on a different day or at a different time to assess persistency was therefore not available 
for this analysis.  Whilst this is certainly a limitation when extrapolating diabetes outcomes in this cohort 
against others in the published literature, it is not likely that it significantly affected the outcomes of 
this particular analysis, as the limitation would of course effect each employed definition.  A further 
similar limitation is that both the NZSSD and ADA criteria for the diagnosis of diabetes require that a 
repeat confirmatory test be performed unless the patient has clear symptoms of hyperglycaemia.  With 
the exception of the small number of participants with type 2 diabetes at the follow up assessment, 
none of the remainder of participants would be expected to have symptoms of hyperglycaemia and 
therefore confirmatory testing would almost certainly be required in a real world setting.  Again, whilst 
this limitation is acknowledged, each definition here would be affected to a similar extent and it is 
therefore unlikely that this limitation would have a significant effect on the analysis. 
 
  






RYGB has emerged as the preferred bariatric procedure for the treatment of obesity related type 2 
diabetes (chapter 1.3).  Further research is required into the long term effects of this procedure on 
glycaemic, metabolic and nutritional outcomes before the exact role of surgery in the management of 
type 2 diabetes can be clarified.  This needs to include greater understanding of the exact mechanisms 
by which RYGB improves glucose metabolism, focusing on specific effects in the pancreatic beta cell, 
liver, gut and adipose tissue.  The present analysis highlights the need for the use of one consistent set 
of definitions of glycaemic outcomes following bariatric surgery to allow comparisons between studies, 
and facilitate research into post bariatric surgery micro and macro vascular outcomes.  Failure to 
conform to one set of definitions is likely to result in striking differences in reported diabetes outcomes 
in published studies.  Accurate data on diabetes outcomes is vital to allow appropriate pre-operative 
patient counselling on expected benefits of bariatric surgery for those with established type 2 diabetes.  
Nonetheless, further long term data are required before the term diabetes resolution can be 
confidently applied, as it remains unclear whether a period of protracted hyperglycaemia, even if 
corrected by bariatric surgery, leaves the patient with a residual increased long term risk of diabetes 
related complications.  Until that data is available, it would seem prudent to continue micro and macro 
vascular complication surveillance in those with pre-existing type 2 diabetes even after restoration of 
normal glucose homeostasis by bariatric surgery.  












4 Chapter four:    Mechanistic studies 




4.1.   The perioperative stress response to RYGB 
4.2.   Fasting gut peptides following gastric bypass surgery and weight outcomes 
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Bariatric surgery results in improvements in glucose homeostasis in a high proportion of those with 
pre-operative type 2 diabetes.  As discussed in chapter 1.4.4, improvements are observed rapidly 
following surgery, with numerous studies documenting improvements in both beta cell function and 
insulin sensitivity within two to seven days.608,617,685,686  Improvements in insulin sensitivity, related 
particularly to reduced hepatic insulin resistance, are evident within a similar timeframe after non-
surgical caloric restriction.  However, most studies reporting the physiological effects of non-surgical 
very low caloric restriction have shown later improvements in beta cell function improvement after 
four to eight weeks. 
It is therefore of great interest to clarify the physiological changes engendered by bariatric surgery, 
and in particular, how these changes may relate to the early and specific improvements in glucose 
homeostasis observed following surgery.  However, studies addressing this question may be 
inherently flawed if the surgery itself results in transient changes that affect the adequacy of tools 
used to measure markers of glucose homeostasis.  For example, when reporting on early physiological 
changes after bariatric surgery, one would need to account for the temporary effects of post-surgery 
inflammation which may have both positive and negative effects on glucose homeostasis. 
Surgery of any nature is known to induce a stress response, although the degree and characteristics 
of this response are dependent on both nature of the surgery and characteristics of the person 
undergoing surgery.849  This stress response involves both hormonal and metabolic components, and 
is induced by a number of factors that are beyond the scope of this work but discussed 
elsewhere. 850 , 851   Increased secretion of a number of anterior pituitary hormones underlies a 
significant proportion of this response.  Adrenocorticotropin (ACTH) concentrations rise rapidly after 
incision, remain elevated for hours after surgery, and are less responsive to usual negative cortisol 
feedback than in the physiological state.852,853 Consequently, plasma cortisol concentrations rise, often 
greater than four fold above those observed in healthy individuals.854,855  Growth hormone (GH) and 
prolactin concentrations rise in response to surgery under general anaesthesia, although the increase 
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in GH occurs later after incision than observed with ACTH.852,856,857   The peak prolactin level after 
surgery is reduced under epidural rather than general anaesthesia, and is also related to the 
invasiveness of the procedure.856,857   In addition to the anterior pituitary response to surgery, 
increased secretion of a number of other hormones contributes to the stress response to surgery.  
Aldosterone, the major mineralocorticoid and regulator of resting blood pressure, increases markedly 
after surgery as a result of both an increase in renin concentrations and a response to elevated ACTH 
concentrations. 858 , 859   Adrenaline concentrations are also increased early after surgical incision, 
although noradrenaline levels have been reported to be unchanged in some studies.855,860  Along with 
the invasiveness of the surgery, anaesthetic management has been associated with the degree to 
which each of these hormones changes in the perioperative period.853  Most studies have shown a 
return to baseline values within 24 hours of uncomplicated surgery.853,855   
The net consequence of the hormonal response is an increase in catabolism of stored carbohydrate, 
fat, and protein; it has been postulated that this response evolved to allow survival without feeding, 
allowing injured animals to recuperate.850   Increased concentrations of cortisol, catecholamines, and 
GH stimulate enhanced lipolysis, converting stored triglycerides to glycerol and fatty acids, whilst also 
stimulating hepatic glycogenolysis and gluconeogenesis.861   In addition, these hormones increase 
peripheral insulin resistance so that insulin-stimulated glucose uptake in skeletal muscle and other 
tissues is reduced.862,863  Furthermore, insulin secretion appears to be impaired in the perioperative 
state as a result of both the adrenergic response to surgery and the effect of general 
anaesthesia.864,865,866  Thus, a rise in glucose in the perioperative period is to some extent predicted, 
and is dependent on the invasiveness of the surgery. 
This pilot study was therefore designed to assess the effect of open RYGB surgery on concentrations 
of a number of hormonal and metabolic markers of the stress responses to surgery, and to provoke 
further work on whether these changes are likely to affect the integrity of tests used to assess early 
changes in glucose homeostasis. 
 




To characterise hormonal and related metabolic stress responses of obese patients to RYGB surgery. 
 
 
4.1.3 Participants and methods 
 
4.1.3.1 Study overview and design 
This was a non-experimental prospective cohort study of obese patients after open RYGB surgery.  
Blood and urine samples were taken immediately before surgery and then daily for six days after 
surgery to assess hormonal and related stress responses. 
 
 
4.1.3.2 Study participants 
A convenience sample of eight participants, accepted as suitable for RYGB surgery after consultation 
with a bariatric surgeon, gave independent consent for this study. 
 
Inclusion Criteria 
 Assessed as suitable for RYGB surgery 
 BMI >35 kg/m2 before surgery 
 
Exclusion criteria 
 Medication use which could potentially interfere with the assessment of cortisol, 
catecholamine or prolactin concentrations 
 




All participants gave written informed consent to participate in the study.  A New Zealand National 
Health and Disability Ethics Committee (HDEC) screening questionnaire was completed, and confirmed 
that the observational nature of this study meant that a full ethics review was not required.  The HCEC 




Participants were assessed for a total of six days, from the day before surgery and then daily for a 
further five days after operation. Fasting blood and urine samples were collected daily for the 
measurements described below. 
 
1. 24 hour urine collections were obtained as described in chapter 2.3.6 (page 129). On the day 
before surgery (Day = -1) participants collected all urine passed after voiding and discarding 
urine at 0800hours.   Participants arrived at the surgical hospital at 1400. At this time all 
collected urine volume was measured and then divided into 2 equal volume aliquots.  One 
aliquot was then placed into a bottle containing an acidified solution, and the other aliquot into 
an empty bottle (see biochemistry analysis below for rationale).  Urine collections were then 
continued over the next 18 hours to complete a 24 hour collection with equal aliquots placed 
in each container. 
 
2. Participants remained seated from 1400 until 1430 at which point venepuncture was 
performed and baseline blood samples acquired.  Seating before venepuncture is 
recommended for optimal measurement of aldosterone and prolactin concentrations as per 
local laboratory guidelines.  Seated blood pressure and heart rate measurements were then 
obtained as described in chapter 2.2.2 (page 124). 
  
3. RYGB was performed on day 0 as described in chapter 2.1 (page 120).  The second daily urine 
collection was commenced as the procedure began and was continued until 0800 on the first 
post-operative day (day=1). As surgery would commence between 0800 and 1100, the urine 
collection for day varied from a 21 to a 24 hour collection.  As discussed in chapter 2.3.6 (page 
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129), this variation was accounted for by the use of measures of concentration rather than 
absolute urinary hormone concentrations.  A blood sample (day=0) was taken from a central 
venous line placed as per routine care during surgery within 30 minutes of completion of 
surgery 
  
4. Thereafter, from the first post-operative day until the fifth post-operative day, 24 hour urine 
collections were started and stopped at 0800, and a blood sample was taken from the central 
venous line at 0800 with the patient fasted. 
 
5. After the fifth post-operative day the central line was removed and the participant was 
discharged. 
 
All participants received routine postoperative care. The only additional component was a 24 hour urine 
collection at baseline and daily collection over the five days, and the aspiration of an extra 20mls blood 
each day for research rather than clinical purposes. 
 
 
4.1.3.5 Biochemical and clinical observations 
Blood and urine sampling was performed and analysed as per methods discussed in chapter 2.3 (page 
125).  Blood pressure and heart rate measurements were obtained on daily basis as described in 
chapter 2.2.2 (page 124). 
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4.1.3.6 Sample size 
There are no published data on the stress hormone response to open RYGB surgery to use as estimates 
of the variance of these measurements in this particular group of patients.   Data from this study will 
provide these estimates to allow sample size calculations for future research.  The number of potential 
participants was also limited by the number of patients undergoing gastric bypass at Wakefield hospital 
within the six month study period and all such patients were invited to participate in this study.  Two 
people declined to participate in the study. 
 
4.1.3.7 Statistical analysis 
Hormone and other blood derived measurements are summarised by simple data descriptors including 
mean, standard deviation, and quartiles, as well as plots. Comparisons use paired t-tests of the 
difference of each reading from the baseline reading with associated estimates of the mean difference 
and appropriate confidence intervals. 
 
Box-plots representing median, 25% and 75% quartiles, and maximum/minimum values are used to 
illustrate change in each measured variable over the study period. Outliers greater than 1.5 times the 
interquartile range are indicated by a circle, whilst those greater than 3.0 times the interquartile range 
are indicated by an asterisk. 




The characteristics of the eight participants are shown in Table 4-1.  Three of the participants had type 
2 diabetes; one of these participants used insulin therapy pre-operatively, one used oral hypoglycaemic 
agents, and the third used dietary methods only to control diabetes.  Five participants used anti-
hypertensive agents prior to surgery.  All diabetes and blood pressure medications were stopped at 
surgery as per clinical protocols.  No participant used medication that precluded participation in the 
study. 
 
Table 4-1   Demographic and biochemical indices of the eight participants assessed on day=-1   
N=8 unless specified Mean (SD) IQR Min/Max 
Age (years) 48.0 (13.9) 21.8 24/66 
BMI (kg/m2) 50.7 (6.4) 12.5 42.6/59.8 
Heart rate (bpm) 79.0 (11.1) 21 66/96 
Systolic blood pressure (mmHg) 132.5 (17.2) 33 110/158 
Diastolic blood pressure (mmHg) 81.9 (11.4) 23 66/96 
Mean arterial blood pressure (mmHg) 98.8 (11.7) 21.2 86.0/113.3 
Urinary noradrenaline (nmol/mmolUCr/24hr) 35.4 (30.7) 26.7 8.3/105.2 
Urinary adrenaline (nmol/mmolUCr/24hr) 2.7 (2.5) 2.1 0.7/8.6 
Urinary dopamine (nmol/mmolUCr/24hr) 194.1 (114.0) 112.1 93.4/448.6 
Urinary normetadrenaline (μmol/mmolUCr/24hr) 0.25 (0.23) 0.2 0.07/0.8 
Urinary metadrenaline (μmol/mmolUCr/24hr) 0.04 (0.03) 0.09 0.03/0.3 
Urinary free cortisol (nmol/mmolUCr/24hr) 5.14 (3.05) 4.0 2.4/11.5 
Prolactin (U/L) 341.3 (186.2) 237.3 183.0/741.0 
Serum Aldosterone (pmol/L) (N=7) 108.9 (31.8) 45.0 49.0/140.0 
Insulin (U/L) (N=6) 329.7 (151.3) 160.0 230.0/630.0 
Plasma glucose (mmol/L) 7.7 (3.2) 5.4 3.8/13.3 
CRP (U/L) (N=6) 6.2 (2.6) 5.3 4.0/10.0 
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4.1.4.1 Heart rate and blood pressure 
Mean heart rate fell early following surgery (Figure 4-1 and Table 4-2). The nadir was a mean (SD) of 
67.3 (10.9) bpm on day 2. The estimated difference (95% CI) from baseline was 11.8 (1.3 to 22.3), 
P=0.03. From day 3 to day 6 the mean heart rate was similar to that at baseline (day -1).  
 
Mean arterial pressure fell at day 1 at mean (SD) 83.9 (5.9) mmHg (Figure 4-2 and Table 4-2).  The 
estimated difference (95% CI) from baseline was 14.8 (7.1 to 22.5) mmHg, P=0.03.  From day 2 to day 
6 mean arterial pressure was similar to that at baseline (day -1). The decline in mean arterial pressure 
at day 1 was the result of a fall both in systolic blood pressure, baseline mean (SD) 132.5 (17.2) 
compared to day 1 116.1 (7.4) and diastolic blood pressure, baseline mean (SD) 81.9 (11.4) mmHg 
compared to day 1, 67.9 (8.0) (Table 4-2). The estimated systolic and diastolic difference (95% CI) from 
baseline was 16.4 (3.6 to 29.1) mmHg, P=0.02, and 14.0 (5.7-22.3) mmHg, P=0.005 respectively. From 
day 2 to day 6 both systolic and diastolic blood pressures increased to concentrations similar to or 
above those measured at baseline, although participants were no longer on anti-hypertensive 
treatment. 
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Table 4-2   Mean (standard deviations) of the daily measurements of heart rate (bpm), systolic blood pressure 
(mmHg), diastolic blood pressure (mmHg), and mean arterial pressure (mmHg) 
N=8 Mean (SD) 
Day of Study -1 0 1 2 3 4 5 6 
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4.1.4.2 Urinary catecholamine studies (Figure 4-3 and Table 4-3) 
Urinary adrenaline excretion increased immediately after surgery when compared with baseline 
concentrations (Baseline mean (SD) 2.69 (2.53) nmol/mmolUCr/24hr, day 0, 5.65 (2.61) 
nmol/mmolUCr/24hr; estimated difference (95% CI) 2.96 (-0.19 to 5.94), nmol/mmolUCr/24 hr, 
P=0.051).  Consequently there was also an increase in urinary metadrenaline, baseline mean (SD) 0.04 
(0.027) umol/mmolUCr/24hr, day 0 mean (SD) 0.082 (0.08) umol/mmolUCr/24hr; estimated difference 
(95% CI) 0.042 (-0.03 to 0.12), P=0.23.  Thereafter, adrenaline and metadrenaline concentrations were 
not significantly different from baseline studies.  Urinary noradrenaline, normetadrenaline and 
dopamine concentrations were not significantly different from baseline throughout the study period.  
 
 Figure 4-3  Box-plots for daily measurements of a) urinary noradrenaline (nmol/mmolUCr/24hr), b) urinary 
normetadrenaline (umol/mmolUCr/24hr), c) urinary adrenaline (nmol/mmolUCr/24hr), d) urinary 
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4.1.4.3 Urinary steroid studies (Figure 4-4 and Table 4-3) 
Urinary free cortisol excretion increased immediately after surgery when compared with baseline (day 
-1 mean (SD) 5.14 (3.05) nmol/mmolUCr/24hr, day 0 mean (SD) 23.26 (13.6) nmol/mmolUCr/24hr; 
estimated difference (95% CI) 18.2 (6.2 to 30.1), nmol/mmolUCr/24 hr, P=0.009).  Thereafter, urinary 
free cortisol concentrations were not significantly different from baseline. 
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Table 4-3  Mean (standard deviations) of the daily measurements of 24 hour urine collections 
 
N=8 Mean (SD) 



































































































4.1.4.4 Prolactin and aldosterone  
Prolactin markedly rose on the day of operation (day -1 mean (SD) 341.3 (186.2) mU/L, day 0 mean (SD) 
1801.2 (779.0) mU/L; estimated difference (95% CI) 1460.1 (883.6 to 2036.6) mU/L, P=0.001).  The 
prolactin level remained different from baseline until the 3rd post-operative day (day 3 mean (SD) 714.4 
(510.3) mU/L; estimated difference (95% CI) to day -1, 373.1 (90.3-836.5) mU/L, p=0.10.  Thereafter, 
prolactin was not significantly different from baseline values.  
 
Table 4-4   Mean (standard deviations) of the daily measurements of Prolactin and Aldosterone 
 
 Mean (SD) 
Day of Study -1 0 1 2 3 4 5 6 
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Serum Aldosterone increased on the day of operation when compared with baseline (day -1 mean (SD) 
108.9 (31.8) pmol/L, day 0 mean (SD) 532.2 (349.2) pmol/L; estimated difference (95% CI) 509.8 (143.6 
to 876.0) pmol/L, P=0.02) but was thereafter similar to baseline concentrations. 
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4.1.4.5 C-reactive protein (Figure 4-6 and Table 4-5) 
CRP increased from baseline concentrations on day 1 (day -1 mean (SD) 6.2 (2.6) mg/L, day 1 mean 
(SD) 70.3 (29.8) mg/L; estimated difference (95% CI) 64.2 (33.6 to 94.7) mg/L, P=0.003).  Thereafter, 
concentrations remained elevated when compared to baseline from study day 1 through to study 
day 6 (Table 4-5).   
 

















Table 4-5  Mean (standard deviations) of the daily measurement of CRP (mg/L).  Point estimates and confidence 
intervals are against baseline (day -1) measurements 
 


































Estimated difference N/A 0.6 64.2 74.6 55.2 31.5 24.2 18.2 















P value N/A 0.78 0.003 0.02 0.03 0.017 0.02 0.06 
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4.1.4.6 Markers of glucose homeostasis ( 
4.1.4.7  
4.1.4.8 Figure 4-7 and Table 4-6) 
One participants plasma insulin result at baseline was excluded from analysis as an unexpected outlier 
(participant 5, fasting insulin 1625 pmol/L, not on exogenous insulin treatment), on the basis that an 
analysis of pre-operative fasting insulin concentrations in 94 participants in a separate study undergoing 
gastric bypass showed a mean of 159.3 pmol/L (standard deviation 89.6), and a maximum value of 
482.0 pmol/L , suggesting that the participant was not truly fasted. 
Fasting plasma glucose increased significantly on the day of operation (day -1 mean (SD) 7.73 (3.2) 
mmol/L, day 0 mean (SD) 11.1 (3.4) mmol/L; estimated difference (95% CI) 3.39 (1.89 to 4.88) mmol/L, 
P=0.001).  A daily fall in glucose concentrations was evident thereafter, such that fasting plasma glucose 
was significantly less than baseline concentrations by day 5 (mean (SD) 4.93 (1.8) mmol/L; estimated 
difference (95% CI) from baseline = -2.78 (-4.9 to 0.6), p=0.020).  
Unfortunately, only four participants had insulin concentrations measured on day 0 samples.  A 
comparison between day -1 and day 0 insulin concenrations was therefore not performed.   Thereafter, 
fasting insulin concentrations were not different from baseline on days one and two. From day three 
insulin remained significantly lower than baseline concentrations (day 3 mean (SD) 145.7 (42.4) units/L; 
estimated difference (95% CI compared with baseline, N=6) -184.0 (-326.4 to -41.6) units/L, p=0.021).   
HOMA-IR (see chapter Error! Reference source not found.) declined following surgery, such that a 
statistically significant reduction from baseline was evident by day 3 (N=5, day -1 mean (SD) 4.98 (1.0), 
day 3 mean (SD) 2.57 (0.6); estimated difference (95% CI) -2.41 (-4.3 to -0.5), p=0.02).  Thereafter, 
HOMA-IR remained significantly reduced from baseline on each study day (estimated difference -3.2 to 
4.0, p<0.02). Indeed, HOMA-IR fell below the generally accepted threshold indicating clinically 
significant insulin resistance (2.0) on day 5 and day 6 (mean (SD) 1.32 (1.0) and 1.6 (0.8) respectively, 
N=7 for both study days).  The improvements in HOMA-IR were predominantly the result of a trend 
towards increased insulin sensitivity (HOMA-%S) as opposed to beta cell function (HOMA-%B), with 
HOMA-%S different from baseline by day 4 (N=5, day -1 mean (SD) 20.7 (3.7), day 4 mean (SD) 56.7 
(11.8); estimated difference (95% CI) 36.0 (22.3 to 49.7), p=0.002).   
   
 




Figure 4-7   Box-plots for daily measurements of a) glucose (mmol/L), and b) Insulin (mU/L), and calculations of 








































































































































Table 4-6   Mean (standard deviations) of the daily measurements of glucose (mmol/L) and insulin (units/L), and 
related calculations of HOMA-%S, HOMA-%B, and HOMA-IR. 
 
  
 Mean (SD) 
Day of Study 
-1 0 1 2 3 4 5 6 
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   Figure 4-8   Hormonal concentrations on each study day expressed as a ratio against baseline values (i.e. study day 1 urinary noradrenaline ratio = study day 1 mean urinary 


























RYGB results in early improvements in glucose homeostasis in participants with and without 
dysglycaemia, as measured by venous glucose concentrations, HOMA-IR, insulin secretion, the frequent 
sampled intravenous glucose tolerance test, and an oral meal test (see chapter 1.4.4, page 
106).617,619,633,683,685,686  In contrast, insulin sensitivity is not improved within four weeks of surgery when 
assessed using the hyperinsulinaemic euglycaemic clamp technique.688,690,691,707  Understanding the 
mechanisms underlying these early favourable changes are fundamental to understanding both the 
mechanisms driving dysglycaemia in this population, and considering other non-surgical approaches 
that target similar mechanisms.   
 
Glucose homeostasis in this early post-operative period may be influenced by transient physiological 
effects of the surgery itself, and therefore techniques employed to assess glucose homeostasis at this 
time may provide misleading results.  As discussed in chapter 1.4 and 1.5, the current accepted model 
is that significant caloric restriction engendered by surgery is the primary driver of early favourable 
changes in glucose homeostasis.  Definitive studies to test this hypothesis remain to be conducted, and 
would best be performed by comparing early changes in glucose homeostasis in matched participants 
undergoing RYGB or matched caloric restriction.  However, such a study would be inherently flawed if 
results obtained from techniques employed to assess glucose homeostasis were not comparable 
between the groups because of specific and transient effects of surgery.  This study was therefore 
designed to report the perioperative hormonal and metabolic response to open RYGB surgery, and thus 
allow consideration of these responses when assessing glucose homeostasis. 
 
4.1.5.1 Aldosterone and prolactin 
Aldosterone and prolactin concentrations rose significantly on the day of operation.  Aldosterone 
concentrations were not significantly different from baseline on day one, whilst prolactin 
concentrations remained significantly higher than baseline values from day zero until day three. 
 
Major surgery results in sodium retention, a phenomenon recognised over 70 years ago.867  On the 
basis that sodium retention may be a physiological response to hypovolaemia, independent of blood 
loss and instead the consequence of the redistribution of extracellular fluid, the post-operative 
administration of isotonic saline in large volumes was standard practice for many years. 868   The 
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availability of a reliable technique for measuring aldosterone concentrations in the 1970s lead to 
research exploring whether increased aldosterone secretion in response to surgery may explain the 
observed sodium retention.  However, whilst aldosterone secretion increases rapidly following surgery, 
the resultant venous concentration has been shown to be directly related to dietary salt intake in the 
early post-operative period, thereby indicating a physiological rather than autonomous response.869  
Furthermore, sodium retention occurred in participants even after aldosterone concentrations had 
returned to baseline, indicating that aldosterone was not the primary driver of this phenomenon.  
Nonetheless, an increase in aldosterone concentrations has been demonstrated following many other 
surgical procedures in numerous studies.869, 870 , 871 , 872  There is little published longitudinal data on 
aldosterone concentrations beyond the first few post-operative hours.  However, as in this study, other 
studies have also suggested that the rise in aldosterone concentrations is brief, with normal 
concentrations observed within 24 hours of surgery.869,873,874 
 
It is well established that prolactin concentrations rise in response to surgery, and that levels may be 
five fold greater than those observed at baseline.875,876  The mechanism underlying this rise may be 
multifactorial; the administration of dopamine antagonists enhances the rise in prolactin during 
apprehensive stress, but blunts the post-operative rise suggesting that additional mechanisms other 
than dopamine release regulate prolactin secretion in this context.877  As with aldosterone, there is little 
published data on the duration of prolactin rise following surgery.  In one study, prolactin levels had 
returned to preoperative concentrations or below by 24 hours in the majority of 79 patients with 
resectable colon cancer, having risen by between 167% and 379% within the first two post-operative 
hours. 878   A second study reporting perioperative prolactin concentrations in otherwise healthy 
individuals undergoing cholecystectomy, demonstrated that the peak prolactin concentration was 
measured 30 minutes after incision.879  Thus, the significant rise and degree of elevation in prolactin 
concentrations observed immediately after surgery in this study is consistent with the published 
literature.  However, in contrast to aldosterone concentrations, prolactin concentrations remained 
significantly greater than baseline until the third post-operative day, albeit within or only slightly above 
the published reference ranges.  A number of confounding factors may explain this apparent 
discrepancy.  Firstly, the act of venepuncture or apprehension around this procedure frequently results 
in a small rise in prolactin concentrations in healthy individuals, and can be marked in some patients.  
Whilst venous blood was taken from a centrally placed venous catheter during this study and did 
therefore not cause pain, participant anxiety during this procedure cannot be excluded. In contrast to 
the studies reported above, the collection of blood samples beyond the first 24 hours after surgery may 
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be more susceptible to this phenomenon than those collected during the early recovery phase when 
patients may be partially sedated due to residual effects of anaesthesia.     
 
Secondly, pain and discomfort, is a stimulant for prolactin release and it is possible therefore that the 
mildly elevated prolactin concentrations observed on days one to three may result in part from residual 
surgical discomfort.  Further longitudinal data on prolactin concentrations beyond the first 24 hour 
post-operative period in other surgical settings would be required to test this hypothesis.  Furthermore, 
it is likely that one or more pharmaceutical agents used in the peri-operative period (anaesthesia, 
analgesia, etc.) may have affected the production of prolactin. Opiate based analgesic agents have 
diffuse inhibitory effects on anterior pituitary output, reducing the secretion of growth hormone, 
adrenocorticotrophin, thyroid stimulating hormone, and the gonadotrophins, but are also associated 
with hyperprolactinaemia.880  It is likely that this is mediated by antagonistic activity at the dopamine 
receptor.881  Dopamine antagonists are commonly co-administered with opiate analgesia due to their 
anti-emetic properties, and further stimulate prolactin release.  All participants in this study received 
appropriate post-operative analgesia care, with regular and as required opiate based treatment.  Anti-
nausea medication was provided as required. 
 
In contrast to above potential confounders, starvation has been shown to produce no change or a fall 
in prolactin concentrations in humans and rats in most studies.882,883,884  Participants caloric intake fell 
significantly following RYGB, and whilst pre-operative caloric intake was not formally measured in this 
study, from previous analysis in those undergoing the same procedure, it is likely that daily caloric intake 
in the early post-operative period would have equated to as little as 10% of that consumed daily prior 
to surgery.706,707  Thus, there are a number of factors not related to surgical trauma itself that may have 
increased or decreased prolactin concentrations in the early post-operative period.  
 
4.1.5.2 Urinary Catecholamines and cortisol 
Urinary free cortisol concentrations were significantly increased on the day of surgery when compared 
to baseline measurements, but were also not significantly different thereafter during the study period.   
 
An acute rise in catecholamine concentrations however has been documented following numerous 
surgical procedures including endoscopic sinus surgery,885 hysterectomy,886 abdominal aortic aneurysm 
surgery,887,888 and upper abdominal surgery.889 In this study, Urinary adrenaline concentrations were 
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significantly elevated on the day of surgery, when compared with baseline concentrations.  
Consequently, the major metabolite of adrenaline, urinary metadrenaline, was also elevated on day 0 
although this was not statistically significant.  Urinary noradrenaline, normetadrenaline, and dopamine 
levels did not significantly change during the study period.  Peak urinary adrenaline concentrations were 
similar to those observed in other studies, although the absence of a rise in urinary noradrenaline 
concentrations is not. 890   However, there were no clear differences between any of the urinary 
concentrations from day one onwards when compared with baseline. 
 
A number of studies have reported on changes in cortisol concentrations and physiology in the 
perioperative period.  Free cortisol concentrations increase during surgery or immediately after 
surgery, although total serum cortisol concentrations may not be elevated until the first few hours after 
surgery.891,892  This phenomenon may be explained by the effect of anaesthesia on cortisol physiology, 
as the capacity of albumin to bind cortisol is significantly reduced by systemic anaesthetic agents.893  
Thus, general anaesthesia appears to result in higher perioperative cortisol rises than local anaesthesia, 
even when the same procedure is performed.875,894  In this study, an expected transient rise in urinary 
free cortisol excretion was evident on day 0 with a 4 fold elevation in cortisol concentrations when 
compared to baseline.  Whilst urinary free cortisol levels remained higher than baseline on day one, 
this finding was not statistically significant and may be explained by one outlying result.  After exclusion 
of this outlying result on post-operative day 1 (urinary free cortisol = 41.11 nmol/mmolUCr, the mean 
of remainder of day 1 results = 5.78 nmol/mmolUCr), the mean urinary free cortisol concentration on 
day 1 was not clearly different from baseline (5.78 ± 4.41 nmol/mmolUCr vs. 5.14 ± 2.12 
nmol/mmolUCr, P=0.84).  Nonetheless, a conservative conclusion is that urinary free cortisol excretion 
returned to baseline concentrations by day 2 following open RYGB surgery. 
 
4.1.5.3 C-reactive protein 
C-reactive protein (CRP) is produced by hepatocytes in response to circulating interleukin-6, and binds 
to damaged or apoptotic cells to facilitate immune clearance.895  Consequently, the measurement of 
CRP concentrations is used widely in clinical practice as a surrogate marker of inflammation or 
infection.896  A large amount of published data supports a longer term reduction in CRP concentrations 
following bariatric surgery, with the change in CRP at follow up associated with the degree of weight 
loss. 897 , 898 , 899 , 900   There is far less published data reporting change in CRP concentrations in the 
immediate post-operative period, and even less data to investigate any difference in procedural 
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technique.  Open gastrectomy does appear to be associated with a greater post-operative rise in CRP 
concentrations than observed after laparoscopic gastrectomy in the context of gastric cancer, but this 
procedure does not involve the additional surgical manipulations performed during RYGB.901 , 902   A 
literature review identified only one published study specifically reporting early changes in CRP 
following bariatric surgery, although the primary aim of the study was to explore relationships between 
CRP concentrations and post-operative complications.903   410 participants undergoing RYGB were 
included in the study if CRP concentrations had been measured at least once between the day prior to 
surgery and the seventh post-operative day.  The mean CRP concentration pre surgery was 7 (4-12) 
mg/L in both those participants who developed post-operative complications and those who did not, 
whilst the peak mean CRP concentration (129 (80-199) mg/L) was noted on day two.  Concentrations 
in both groups fell thereafter but remained higher at day seven (mean 61 (35-105) mg/L) than at 
baseline.  A CRP concentration of >229 mg/L was found to be 53% sensitive and 91% specific for any of 
a number of specified post-operative complications, and 100% sensitive for intestinal anastomotic 
leaks. 
In this study, CRP concentrations at baseline were similar (mean (SD) 6.2 (2.6) to those observed in the 
earlier study, with a similar trend in changes in CRP thereafter, albeit with lower mean concentrations 
at each time point.  Specifically, the peak mean (SD) CRP concentration was 78.4 (48.2) mg/L observed 
on the second post-operative day, whilst the mean concentration on post-operative day 6 was 29.4 
(17.4) mg/L. 
 
4.1.5.4 Glucose homeostasis and Insulin 
As noted in a large number of other studies exploring early changes in glucose homeostasis after 
bariatric surgery (see chapter 1.3.3.1, page 54), improvements in glucose homeostasis were evident in 
participants by the sixth post-operative day.  Furthermore, fasting insulin concentrations were 
significantly lower than pre-surgery levels by the third post-operative day, whilst the mean fasting 
glucose concentration had fallen from the impaired fasting glucose level to normal glucose tolerance 
by day three, with fasting glucose concentrations significantly lower than pre surgery measurements 
from day five onwards.  Consequently, and acknowledging the limitations of the HOMA assessment in 
this acute context, insulin sensitivity (HOMA-%S) had returned to population mean levels (106%) by the 
fifth post-operative day in comparison to clearly reduced insulin sensitivity (20% of population mean) 
at the pre surgery assessment. 
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4.1.5.5 Direct effects of measured hormonal/metabolic markers on glucose homeostasis 
As presented in chapter 1.4.4 (page 106), caloric restriction is likely to explain a significant proportion 
of the early improvements in glucose homeostasis observed after bariatric surgery, as similar 
improvements are observed after non-surgical caloric restriction.  Furthermore, the data supports that 
this improvement can be mostly explained by an improvement in hepatic insulin sensitivity which is 
evident within days of bariatric surgery, with peripheral insulin resistance improving only after weight 
loss.  This conclusion draws on data from a large number of studies utilising a number of techniques to 
estimate parameters of glucose homeostasis within the first few post-operative days.  However, as 
discussed above, a number of hormonal and metabolic responses to surgery appear evident after RYGB, 
and whilst these responses are transient, it is important to consider the direct impact these changes 
may have on assessments of glucose homeostasis performed within the first few days. 
The renin-angiotensin-aldosterone system appears to influence a number of aspects of glucose 
homeostasis, although the overall effect is modest.904  Angiotensin II increases insulin resistance in 
tissues by interfering with post receptor insulin signalling. 905  Consequently, the clinical use of 
angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARB) results in 
improved peripheral glucose disposal. 906 , 907   Furthermore, it is likely that both angiotensin and 
aldosterone directly impair insulin release.904  To support these findings, two recent large randomized 
studies showed an increased likelihood of improvement to normal glucose tolerance in participants 
with impaired glucose tolerance treated with either ACE or ARB therapy.908 , 909  However, with the 
exception of the day of surgery, aldosterone concentrations were not clearly different after surgery 
when compared to pre-operative measurements in this study.  Thus, this potential confounder would 
need consideration only in the context of assessments on the day of surgery itself.  Furthermore, the 
physiological effects described above may not appear with such short lived exposure to aldosterone. 
Cortisol induces whole body insulin resistance at supraphysiological concentrations.910,911  Furthermore, 
hypercortisolaemia impairs glucose effectiveness, a physiological mechanism whereby hyperglycaemia 
itself suppressed further endogenous glucose release and improves glucose uptake.912   This is not 
surprising as both endogenous and exogenously derived hypercortisolaemia results in dysglycaemia in 
clinical settings.  Both insulin resistance and reduced glucose effectiveness are evident during acute 
hypercortisolaemia in healthy individuals suggesting these effects are rapid in onset.912  Thus, the 
transient elevation in cortisol concentrations, measured as urinary free cortisol, observed early after 
RYGB in this study may potentially impact on the accuracy of assessments of glucose homeostasis 
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during this period.  Furthermore, non-surgical severe caloric restriction results in a gradual reduction 
in plasma and urinary cortisol concentrations in obese individuals, attributed to a reduction in cortisol 
binding globulin production and normalisation of hepatic handling of cortisol. 913 , 914 , 915   It would 
therefore be important to consider this potential confounder in a study comparing surgical and non-
surgical matched caloric restriction on glucose homeostasis, particularly within the first two days after 
surgery. 
The association between glucose homeostasis and inflammation is complex.  Hyperglycaemia is evident 
in previously healthy individuals during acute inflammatory responses, for example during infection, 
primarily as a result of increased hepatic gluconeogenesis.916  This effect is mediated by activation of 
the adrenergic system, counter regulatory hormonal responses, and cytokine production, and 
augmented by the increased supply of gluconeogenic substrates related to the infection response.916,917  
Furthermore, inflammation markedly increases insulin peripheral resistance, despite promoting insulin 
independent glucose uptake, an effect which appears to be mediated by several cytokines including 
TNF-α.918 Whilst interleukin-6, the primary regulator of CRP production, has also been implicated in this 
process, the data is contradictory. 919,920  The observation that interleukin-6 concentrations rise rapidly 
during exercise in healthy individuals is counterintuitive to the concept of this cytokine primarily 
exerting an insulin resistance effect.921  Indeed, studies in humans, as opposed to mice, have suggested 
that interleukin-6 has no measurable effect on hepatic, and actually decreases circulating insulin 
concentrations in humans with type 2 diabetes.920  Circulating interleukin-6 has been shown to either 
have no effect on peripheral glucose uptake or increase glucose uptake in adipocytes in other 
studies.922,923   
It is clear that the relationship between glucose homeostasis and inflammation remains to be fully 
elucidated, but is quite plausible that glucose homeostasis in the very early post-operative period is 
affected in both a positive and negative fashion by surgical inflammation.  As CRP concentrations appear 
to remain elevated until at least the sixth or seventh post-operative day, this should be borne in mind 
when assessing glucose homeostasis early after bariatric surgery.  Of particular relevance may be 
assessments of peripheral insulin resistance using the euglycaemic hyperinsulinaemic clamp.  In 
general, studies reporting changes in insulin resistance following RYGB/SG using the EHC technique, 
have noted improvements only after 6-12 months and not within four weeks.687,688,689,690,691  Further 
longitudinal research is therefore required to ensure that this apparent phenomenon, integral to the 
current understanding of the mechanisms underlying the early improvements in glucose homeostasis 
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following bariatric surgery, is not simply related to the confounding effect of a persistent post-operative 
inflammatory response. 
 
4.1.5.6 Study limitations 
This pilot study provides early data on the expected hormonal and metabolic response to open RYGB 
surgery.  There are however a number of limitations to consider.  Firstly, the number of participants in 
the study was low, and limited by the availability of people meeting the inclusion criteria during the 
study period.  The range of each measured parameter and standard deviations of the calculated mean 
were wide.  In addition, the study is more susceptible to error introduced by outliers, all of which 
increase the likelihood that the conclusions drawn from this data may be revised with a larger dataset.  
Ideally, a further study would be performed to confirm these findings, with the number of participants 
selected based on power calculations using this data.   
Secondly, the conclusions from this study can be applied only to open RYGB surgery.  Bariatric surgery 
is a frequently used over-riding term in clinical and research areas, and may reference one of a number 
of different surgical techniques.  Furthermore, it is likely that the stress response may differ between 
open and laparoscopic surgery as observed in gastrectomy performed for gastric cancer.901,902  To the 
best of my knowledge, no study has yet compared the early stress response to open versus laparoscopic 
bariatric surgery.  Indeed, even when a surgical technique used by two differing surgeons appears to 
be similar in name, it is expected that there may still be intersurgeon variation with respect to time of 
procedure, anaesthesia regimen, etc.  It would be reasonable to suggest that other research groups 
wishing to assess accurately changes in glucose homeostasis early after a bariatric surgical procedure, 
compared against non-surgical caloric restriction, should initially study the stress response expected 
immediately after that particular procedure.   
Failure to document a clear catecholamine response following RYGB may be a limitation of the 
methodology of this study.  To better reflect the overall excretion of catecholamines we elected to use 
urinary collection measurements rather than plasma measurements.  Plasma catecholamine 
measurements are not routinely used in clinical practice due to the significant fluctuations seen in 
normal physiological states; plasma metadrenaline studies are preferred as this reflects an average 
excretion of catecholamines via their metabolites over a period of time.  Urinary studies, whilst 
cumbersome to perform, have the advantage of also reflecting average excretion over a period of 24 
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hours and are therefore less susceptible to error in most clinical scenarios.  Had we elected to measure 
plasma catecholamines in this study, it is plausible that we may have documented shorter duration 
transient elevations in plasma adrenaline, noradrenaline, or dopamine which have not been detected 
by means of a method that reflects a longer period of excretion.  However, this limitation does not 
detract from the conclusion that can be made from this study; the average excretion of catecholamines 
and metanephrines does not appear to differ from baseline from the first post-operative day following 
RYGB surgery, and therefore will not interfere with interpretation of measurements of glucose 
metabolism and insulin sensitivity. 
In this study, CRP was measured as a surrogate of the inflammatory response, which in reality involves 
a multitude of physiological peptides including cytokines.  As discussed above, it is likely that each of 
these cytokines has a direct role within this inflammatory response, and therefore it may have been of 
interest to additionally measure changes in the concentrations of these cytokines.  As noted above, 
both Interleukin-6 and TNF-α play a clear role in the inflammatory and may have direct influence over 
glucose homeostasis.  Whilst not possible with this small dataset, a larger study population may allow 
the estimation of the relative contribution of inflammatory markers to early changes in glucose 
homeostasis following bariatric surgery.  
 
 




Open RYGB surgery results in a transient elevation in concentrations of prolactin, aldosterone, urinary 
adrenaline and metadrenaline, and urinary free cortisol that appear to return to baseline 
concentrations by post-operative day 3.  Conversely, CRP, as a surrogate of inflammation, remains 
elevated for at least the first 6 days following RYGB surgery.  This study supports the assumption that 
studies assessing glucose homeostasis performed on or after day 4 following RYGB, are not likely to be 
affected by stress response hormones but may be influenced by an on-going inflammatory response.  
This finding will need consideration in future studies comparing early changes in glucose homeostasis 
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Caloric restriction, such that energy expenditure exceeds intake, results in weight loss whether this is 
achieved by surgical or non-surgical mechanisms.324,327  However, the durability of this effect differs 
significantly between these two interventions.  Bariatric surgery tends to result in rapid weight loss with 
maximal weight loss observed within 24 months.394,396,397,402  Longer term follow up studies have 
suggested that many of those who have undergone bariatric surgery experience some weight regain 
thereafter, but  this is usually minimal with significant reductions maintained (see chapter 3.1).427,428  In 
contrast, weight regain after non-surgical caloric restriction is common, 924,925 although there is some 
evidence to suggest this is less likely after very low calorie interventions or following rapid  early weight 
loss. 926  Indeed, successful weight loss maintenance, defined as 10% initial body weight loss maintained 
for 12 months, was achieved by only 21% of participants in one highly intensive interventional study.927 
How then can we explain these differing longer term outcomes if the primary effect of each intervention 
is caloric restriction?  Recently the concept that regulatory physiological mechanisms may “defend 
against weight loss” after dietary caloric restriction has received much attention, in recognition of the 
observation that energy homeostasis may actually favour weight gain in humans. 928 , 929 , 930   Whilst 
detailed research is required to clarify this phenomenon, it is likely that it involves interactions between 
persistent adipocyte hyperplasia,931 adipose tissue cytokines, adipocyte and gut hormones,928 appetite 
regulation,932,933 and changes in energy expenditure.934,935 Furthermore, this combination of factors 
appear to be initiated rapidly after the commencement of caloric restriction, prior to weight loss, and 
are independent of actual body energy stores.928  Weight loss induced changes in adipocyte and gut 
peptides favour weight regain, and appear to persist after the period of initial weight loss.601,936 
As discussed in chapter 1.4.1 and 1.4.2, bariatric surgery appears to induce a durable reduction in 
caloric intake which is related to reduced food intake, changes in digestive tract transit, altered food 
behaviour, and  favourable alterations in gut peptides involved in energy homeostasis.  However, most 
of the evidence to support these potential mechanisms is derived from either short term studies in 
animal models, or from early follow up in clinical studies in humans undergoing bariatric surgery.  This 
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study was designed as an initial exploration of whether differences in adipocyte and gut hormones at 
long term follow up after RYGB correlate with weight outcomes, and therefore whether differences in 
the longer term hormonal adaptation to surgical and non-surgical weight loss may explain discrepancies 
in weight regain between these two interventions. 
 
4.2.2 Aims 
To assess fasting gut peptide concentrations during long term follow up after gastric bypass surgery, 
and describe any associations with weight outcomes 
 
4.2.3 Participants and methods 
 
4.2.3.1 Study overview and design 
This was a retrospective non-experimental cohort study of fasting gut peptides in 25 participants who 
had undergone gastric bypass at least five years before their latest measurements.  Fasting gut peptide 
concentrations were measured on blood samples taken immediately prior to surgery, at six days after 
surgery, and at a follow-up at least five years after surgery.  As historical stored samples were used in 
this study, with only fasting plasma samples available, an assessment of  post prandial changes in the 
concentrations of measured gut peptides was not possible. 
 
4.2.3.2 Study Participants 
Study participants were 25 patients who had gastric bypass surgery at least five years previously, and 
had participated in the bariatric follow up study described elsewhere (Chapter 3.1), and were selected 
from this larger cohort because of the availability of historical blood samples for analysis.  
  
 




 RYGB performed at least five years before assessment  
 BMI ≥30kg/m2 at baseline 




 Further bariatric surgery (either revision or repair) performed since original 
procedure 




This study used data previously collected for the pre-operation time point, and collected prospective 
data as part of the bariatric follow up study discussed elsewhere (chapter 3.1, pages 134-243).  In 
addition, data collected at 1 and 2 years following surgery for each participant as part of a separate 
study were used.937  The participant characteristics were recorded as part of the admission for gastric 
bypass surgery and obtained by review of the clinical records for that admission. These data were: 
Weight, height and BMI, and blood markers of glucose homeostasis (fasting glucose, fasting insulin, and 
HbA1c).  Most participants had a standard oral glucose tolerance test (75g OGTT) performed prior to 
their operation as this was the accepted contemporary practice for the assessment of diabetes.  These 
measurements were repeated one and two years after surgery, and these data were obtained from a 
review of the participant’s clinical records, and from a database maintained by Wakefield Obesity Clinic.  
In addition to the routine blood samples taken for the pre-operative and post-operative assessments, 
further fasting blood samples were collected into EDTA collection tubes before surgery, six days after 
surgery and at the follow up assessment at least five years after surgery.  Samples were immediately 
centrifuged (3000 revolutions per minute, for 10 minutes at room temperature) and plasma then 
extracted.  Aliquots of 200 microlitres were then stored in a freezer at -80 degrees Celsius until analysis.  
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4.2.3.4 Biochemical analysis 
Glucose and Insulin concentrations and HbA1c were measured at the biochemistry Laboratory at 
Wellington Regional Hospital, Wellington, NZ (chapter 2.3, page 125).  Inter-assay CV was <5% for 
glucose, 2% for insulin values < 50 pmol/L and 4% for those > 50 pmol/L.   
As discussed in chapter 2.3.4 (page 128) fasting gut peptides (ghrelin, leptin, polypeptide YY, and 
amylin) were measured using a multiplex kit (Product HGT-68K, Merck Millipore, Billerica, 
Massachusetts, USA) in the Department of Nutrition laboratory, University of Otago, Dunedin.  Fasting 
ghrelin (coefficient of variance % = 7.4 and 9.6%), fasting leptin (CV% = 1.6 and 6.7), fasting amylin (CV% 
= 5.0 and 15.9), and fasting PYY (CV% = 8.0 and 16.2) were measured and expressed as pg/mL. 
 
 
4.2.3.5 Statistical analysis  
Simple data descriptions are used for the anthropometric measurements and expressed as mean and 
standard deviation (SD) or other appropriate summaries. The data distributions of the peptide 
concentrations, including change from baseline, were examined with plots (histograms and box-plots), 
and by formal tests to assess whether they were normally distributed. A logarithm transformation was 
also examined to assess whether skew data could be better analysed on that scale of measurement. 
Wilcoxon signed rank test was used to assess variables where normality assumptions for analyses were 
poorly met.  Pearson’s correlation coefficient was used to assess the strength of linear association 








The mean (SD) age of those included in this analysis was 45.1 (12.5) and 52.2 (12.8) years at baseline 
and follow up respectively (Table 4-7).  Nineteen (76%) of the participants were female, and the mean 
(SD) duration of follow up after gastric bypass was 7.0 (1.3) years.  
 
   

















The distribution of data for weight, BMI, fasting glucose, HbA1c, fasting insulin, and HOMA-IR at 
baseline and follow up was right skewed as demonstrated by inspection of histograms (Figure v-1 (403) 
and Figure v-3 (405)).  Box plots to show BMI at baseline and during follow up are presented in Figure 
4-9, and illustrate outlying results.  With the exception of HOMA-IR data, logarithmic transformation of 
all the data resulted in a better approximation of normal distribution allowing parametric analysis 
(Figure v-1 (403) and Figure v-3 (405)). 
N=25 unless specified Mean (SD) IQR Min/Max 
Age at operation (years) 45.1 (12.5) 18.4 24.5/68.1 
Age at follow up (years) 52.2 (12.8) 16.0 30.2/77.4 
Duration of follow up (years) 7.0 (1.3) 2.1 5.1/9.3 
 N/25(%) 
Female 19 (76) 
Ethnicity 
     European 
     Maori 
     Cook Island Maori 
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4.2.4.1 Body weight change 
Every participant in the study lost weight following gastric bypass surgery.  The mean (SD) BMI at 
baseline was 45.4 (7.8) kg/m2, and the minimum BMI at one to two years of follow up was 29.0 (6.5) 
kg/m2. The mean (SD) BMI after at least five years of follow was 33.1 (8.5) kg/m2 (figure 4-1 and table 
4-2).  This translates into relative body weight loss from baseline of 26.9% at latest follow up.   The 
change in BMI from baseline to minimum, and from minimum to the final follow up was normally 
distributed (Figure v-2 (404)). 
 
 
Figure 4-9   Box plot showing body mass index (BMI, kg/m2) at surgery, at one to two years (minimum), and at 
the greater than 5 year follow up assessment 
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4.2.4.2 Diabetes at baseline and outcomes 
Twenty four (96%) participants had sufficient data available to define glycaemic status (ADA criteria) at 
baseline and final follow up (Table 4-8).  Nineteen (76%) participants had abnormal glucose homeostasis 
at baseline.  Of these, thirteen participants had prediabetes, whilst the remaining six had overt type 2 
diabetes.  Three participants used insulin to control diabetes, one used oral glucose lowering agents, 
and two used dietary and lifestyle methods only.  At assessment at greater than five years, three 
participants remained with type 2 diabetes, and a further participant had prediabetes.  Each of the 
participants with residual type 2 diabetes had required insulin treatment before surgery; two of these 
participants managed their diabetes through lifestyle and dietary means only at follow up, whilst one 
participant required oral glucose lowering medication.  The one participant with residual prediabetes 
had type 2 diabetes before surgery and used oral glucose lowering therapy.  All participants with either 
prediabetes or diet/lifestyle controlled type 2 diabetes before surgery, had normal glucose assessments 
at the greater than five year follow up visit.  No participant progressed to either abnormal glucose 
tolerance or type 2 diabetes during the study period. 
 
Table 4-8   Cross tabulation to show glycaemic status at baseline against glycaemic status at the final follow up 
assessment.  The ADA criteria for the diagnosis of diabetes, and the assessment of diabetes following bariatric 
surgery are applied. 
 
N=24 
ADA criteria at final follow up 
Total 
NGT Prediabetes Type 2 DM 
ADA criteria at 
baseline 
NGT 3 3 0 6 
Prediabetes 4 9 0 13 
Type 2 DM 1 1 3 5 
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4.2.4.3 Fasting gut peptide concentrations 
Full data descriptions for fasting gut peptide concentrations prior to surgery, on day six after surgery, 
and at the greater than five year follow up assessment are reported below in Table 4-9 to Table 4-12.  
Results of each hormone studied are discussed below.  Histograms were used to assess data 
distributions (Figure v-4 (408) to Figure v-7 (411)). With the exception of baseline leptin and amylin 
concentrations, and PYY measured at greater than five years, the remaining data had right skew 
distributions which were more symmetric after a natural logarithm transformation (Table v-1 (407)). 
 
 
Table 4-9 Descriptive statistics for fasting leptin concentrations before surgery, at day six after surgery, and at 
the greater than five year assessment 
 
  Baseline Day 6 >5 years 
Leptin (pg/ml) 
Mean 29,943.8 9,936.0 10,608.3 
Standard error of the mean 3,357.3 1,593.2 1,626.5 
95% CI (upper) 36,888.8 13,224.4 13,965.1 
95% CI (lower) 22,998.7 6,647.6 7,251.4 
Median 27,322.1 7,120.4 9,405.3 
Standard Deviation 16,447.2 7,966.5 8,132.3 
Minimum 5,247.2 1,755.6 1,040.6 
Maximum 79,680.9 34,999.7 29,174.5 
Range 74,433.6 33,244.1 28,133.9 
Interquartile range 16,252.9 9,782.0 12,168.6 
 
 
Table 4-10 Descriptive statistics for fasting ghrelin concentrations before surgery, at day six after surgery, and 
at the greater than five year assessment 
 
  Baseline Day 6 >5 years 
Ghrelin (pg/ml) 
Mean 20.64 21.24 18.54 
Standard error of the mean 0.97 0.98 0.61 
95% CI (upper) 22.65 23.23 19.81 
95% CI (lower) 18.64 19.21 17.28 
Median 19.90 18.96 18.10 
Standard Deviation 4.86 4.92 3.06 
Minimum 13.90 16.12 14.77 
Maximum 33.59 32.68 25.42 
Range 19.69 16.56 10.65 
Interquartile range 4.41 7.36 4.94 
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Table 4-11  Descriptive statistics for fasting PYY concentrations before surgery, at day six after surgery, and at 
the greater than five year assessment 
  Baseline Day 6 >5 years 
PYY (pg/ml) 
Mean 242.5 213.1 181.5 
Standard error of the mean 41.1 32.9 14.0 
95% CI (upper) 335.4 284.8 210.9 
95% CI (lower) 149.6 141.4 152.1 
Median 200.9 168.4 164.8 
Standard Deviation 129.9 118.6 60.9 
Minimum 102.5 116.22 97.7 
Maximum 545.1 576.7 341.6 
Range 442.6 460.5 243.9 
Interquartile range 151.9 92.8 80.8 
 
Table 4-12  Descriptive statistics for fasting Amylin concentrations before surgery, at day six after surgery, and 
at the greater than five year assessment 
  Baseline Day 6 >5 years 
Amylin (pg/ml) 
Mean 40.22 34.68 37.01 
Standard error of the mean 0.97 0.98 1.15 
95% CI (upper) 42.23 36.70 39.37 
95% CI (lower) 38.22 32.65 34.64 
Median 39.16 34.13 36.1 
Standard Deviation 4.86 4.91 5.74 
Minimum 30.32 28.91 29.99 
Maximum 55.89 47.47 61.63 
Range 25.57 18.56 31.64 
Interquartile range 5.79 6.70 4.59 
 
 
Table 4-13   Mean and standard error of each measured fasting gut peptide at each study time point.  P values 
illustrate comparison with baseline data  
Gut peptide 
Study time point 
Baseline Day 6 Final follow up 
Mean (SE) Mean (SE) P value Mean (SE) P value 
Leptin (pg/ml)  29,943.8 (3,357.3) 9,936.0 (1,593.2) <0.001 10,608.3 (1,626.5) <0.001 
Ghrelin (pg/ml) 20.64 (0.97) 21.24 (0.98) 0.5 18.54 (0.61) 0.04 
PYY (pg/ml) 242.5 (41.1) 213.1 (32.9) 0.3 181.5 (14.0) 0.4 
Amylin (pg/ml) 40.2 (0.97) 34.7 (0.98) <0.001 37.0 (1.15) <0.001 




Leptin values decreased from the sixth day after surgery.   As shown in Table 4-9 and Figure 4-10 fasting 
leptin decreased from 29,943.8 to 9,936.0 pg/ml after six days, estimated difference after logarithmic 
transformation (n=24): -1.23 (95% CI -0.9 to -1.6, p<0.001), equivalent to a mean ratio of -0.29 (95% CI 
0.41 to 0.2). The mean fasting leptin after five years follow up was 10,608.3 pg/ml, estimated difference 
after logarithmic transformation from baseline -1.28 (95% CI -0.9 to -1.7, P<0.001), equivalent to a 
mean ratio of 0.28 (95% CI 0.41 to 0.18), and from day 6, 0.01 (95% CI -0.3 to 0.3, P=0.9) equivalent to 
a mean ratio of 1.01 (95% CI 0.74 to 1.35).  
4.2.4.5 Ghrelin 
Ghrelin concentrations were not clearly different from baseline at the day 6 assessment, but there was 
a significant further reduction in ghrelin concentrations at the final follow up assessment (Table 4-10 
and Figure 4-10). Baseline and day six mean fasting ghrelin was 20.64 (4.86) and 21.24 (4.92) pg/ml 
respectively (estimated difference after logarithmic transformation (95% CI) 0.03 (-0.1 to 0.06) pg/ml, 
P=0.5), equivalent to a mean ratio of 1.03 (95% CI -1.11 to 1.06).  The mean fasting ghrelin after five 
years follow up was 18.54 (3.06) pg/ml, (estimated difference after logarithmic transformation from 
baseline (95% CI) -0.1 (-0.01 to 0.2) pg/ml, P=0.04), equivalent to a mean ratio of -1.11 (95% CI 1.01 to 
1.22). 
 
4.2.4.6 PYY    
PYY concentrations were not clearly different from baseline at either follow up assessment (Table 4-11 
and Figure 4-10).  Baseline and day six mean fasting PYY was 242.5 (129.9) and 213.1 (118.6) pg/ml 
respectively (estimated difference after logarithmic transformation (95% CI) -0.08 (-0.07 to 0.2) pg/ml, 
P=0.3, N=9), equivalent to a mean ratio of -1.08 (95% CI -0.93 to 1.22).  The mean fasting PYY after five 
years follow up was 181.5 (60.9) pg/ml, (estimated difference (95% CI) -0.14 (-0.2 to 0.4) pg/ml, P=0.4, 
N=10), equivalent to a mean ratio of -1.15 (95% CI -1.22 to 1.49). 
 




Amylin values decreased from the sixth day after surgery (Table 4-12 and Figure 4-10). Baseline mean 
fasting amylin decreased from 40.22 (4.86) to 34.68 (4.91) pg/ml after six days, estimated difference 
after logarithmic transformation (n=25): 0.15 (95% CI 0.09 to 0.21, p=<0.001), equivalent to a mean 
ratio of 1.16 (95% CI 1.09 to 1.23). The mean fasting amylin after five years of follow up remained lower 
than baseline concentrations  at 37.01 (5.74) pg/ml (estimated difference after logarithmic 
transformation from baseline (n=25) -0.09 (95% CI -0.14 to -0.03), p=<0.01, equivalent to a mean ratio 
of -1.09 95% CI -1.15 to -1.03), but were increased in comparison to concentrations at day six  
(estimated difference after logarithmic transformation (n=25): 0.06 (95% CI 0.01 to 0.12), p=0.02, 
equivalent to a mean ratio of 1.06 (95% CI 1.01 to 1.13). 
  
 
Figure 4-10    Box plots showing fasting concentrations of a) leptin (pg/ml), b) ghrelin (pg/ml), c) PYY (pg/ml), 
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4.2.4.8 Regression analysis  
To explore relationships between concentrations of fasting gut peptides and BMI, regression analysis 
was performed.  Absolute concentrations and change in level of each gut peptide were employed as 
independent variables, whilst absolute BMI at each study point and the change in BMI between study 
points were employed as dependent variables.  
 
4.2.4.8.1 Leptin 
Neither fasting leptin at baseline (n=25, r=0.26, f=1.6, p=0.2) or final follow up (n=25, r=0.35, f=3.1, 
p=0.09) predicted BMI at that time point (Table 4-14).  However, fasting leptin concentrations at day 6 
predicted both the minimum BMI at one to two years (n=25, r=0.44, f(1,23)=5.5, p=0.03) and the BMI 
at the final follow up assessment (n=25, r=0.5, f(1,23)=7.7, p=0.01), accounting for 16% and 22% of the 
total variation respectively (Figure 4-11).  Examination of residuals supported the validity of this model.  
Cook’s distance was <1 in all cases, the leverage statistic was 0.04 (expected 0.08), and DFBeta for the 
constant and each independent variable was <1.  5% of cases had studentised residuals > 1.96 but 
<2.58. Standardised residuals were all within 2. The regression equations were: 
 
                    
   Ln(x) Minimum BMI (kg/m2)  = 2.32 + (0.12 * Ln(x) fasting leptin (pg/ml) on day 6) 
 
            Ln(x) BMI (kg/m2) at final assessment = 2.01 + (0.16 * Ln(x) fasting leptin (pg/ml) on day 6) 
 
 
These models remained significant when adjusting for baseline BMI.  Fasting leptin at baseline (r=0.004, 
f<0.01, p=0.99) and day 6 (r=0.23, f=1.3, p=0.3) did not predict the subsequent change in BMI over the 
study period.  Furthermore, the change in leptin from baseline to day 6 did not clearly predict either 
the minimum BMI (r=0.35, f=3.0, p=0.1) or final BMI (r=0.4, f=3.8, p=0.06), and did not predict the 
change in BMI from baseline to minimum (r=0.08, f=0.2, p=0.7), minimum to final follow up (r=0.2, 
f=0.9, p=0.4), or over the entire study period (r=0.24, f=1.3, p=0.3). 
 
Table 4-14   Univariate regression analyses outcomes for fasting leptin on day 6 against BMI at baseline and 
follow up.  Outcomes are following logarithmic transformation of both leptin and BMI data. 
















(pg/ml) on day 6 
2.32 0.12 0.03 2.01 0.16 0.01 
 
 
Figure 4-11   Regression variable plots to show a) day 6 fasting leptin against the minimum BMI at one to two 
years, and b) day 6 fasting leptin against the BMI at final follow up  
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4.2.4.8.2 Ghrelin  
Fasting ghrelin at each time point, or the change in fasting ghrelin between time points did not predict 
BMI outcome or change in this study.  Fasting ghrelin at baseline (n=25, r=0.01, f<0.01, p=0.98) and 
final follow up (n=25, r=0.04, f=0.32, p=0.9) did not predict BMI at that time point.  Furthermore, fasting 
ghrelin concentrations at day 6 did not predict either the minimum BMI at one to two years (n=25, 
r=0.1, f=0.2, p=0.7) or the BMI at the final follow up assessment (n=25, r=0.03, f=0.2, p=0.9). Fasting 
ghrelin at baseline (n=25, r=0.1, f=0.4, p=0.5) and day 6 (n=25, r=0.1, f=4.3, p=0.5) did not predict the 
subsequent change in BMI over the study period.  Furthermore, the change in ghrelin from baseline to 
day 6 did not predict either the minimum BMI (n=25, r=0.05, f=0.04, p=0.9) or final BMI (n=25, r=0.05, 
f=0.6, p=0.8), and did not predict the change in BMI from baseline to minimum (n=25, r=0.2, f=0.9, 
p=0.3), minimum to final follow up (n=25, r=0.2, f=0.9, p=0.4), or over the entire study period (n=25, 




Fasting PYY at baseline (n=10, r=0.1, f=0.1, p=0.8) did not predict baseline BMI (kg/m2).  However, 
fasting PYY at final follow up predicted the BMI at that assessment (n=19, r=0.5, f=4.6, p=0.046) and 
accounted for 17% of the total variation observed (Table 4-15 and  
 
Figure 4-12).  Examination of residuals supported the validity of the model.  Cook’s distance was <1 in 
all cases, the leverage statistic was 0.05 (expected 0.11), and DFBeta for the constant and each 
independent variable was <1.  5% of cases had studentised residuals > 1.96 but <2.58.  Standardised 
residuals were all within 2. The regression equation was: 
 
 
    Ln(x) BMI (kg/m2) at final assessment   = 5.35 + (-0.37 * Ln(x) fasting PYY (pg/ml) on day 6 
 
 
Fasting PYY concentrations at day 6 did not predict the minimum BMI at one to two years (n=9, r=0.1, 
f=0.1, p=0.8) or the BMI at the final follow up assessment (n=9, r=0.05, f=0.03, p=0.9).  Furthermore, 
fasting PYY at baseline (n=10, r=0.3, f=0.8, p=0.4) and day 6 (n=10, r=0.2, f=0.4, p=0.6) did not predict 
the subsequent change in BMI over the study period. 
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The change in PYY from baseline to day 6 predicted both the minimum BMI at one to two years (n=9, 
r=0.68, f=6.1, p=0.04) and the BMI at the >5 year assessment (n=9, r=0.8, f=10.1, p=0.01), and 
accounted for 40% and 53% of the total variation at each time point (Table 4-15 and 
Figure 4-13).  Furthermore, the change in PYY from baseline to day 6 predicted subsequent change in 






Table 4-15   Univariate regression analyses outcomes for fasting PYY (absolute concentrations and change) 













PYY (pg/ml) * 4.0 -0.04 0.8 5.3 -0.4 0.046 
Change in fasting 
PYY (pg/ml) from 
baseline to day 6 
BMI (kg/m2) 
One to two year minimum BMI 
(kg/m2) 








3.42 -0.9 0.042 3.53 -1.27 0.02 
Change in BMI (kg/m2) 








0.36 0.4 0.16 0.26 0.73 0.02 
 
* paired with baseline or follow up BMI 
 
 

















Examination of residuals supported the validity of these models.  Cook’s distance was <1 in all cases, 
the leverage statistic was 0.11 (expected 0.22), and DFBeta for the constant and each independent 
variable was <1.  The standardised and studentised residuals all had values of less than  2.  The 
regression equations were: 
 
Ln(x) minimum BMI (kg/m2)   
= 3.42 + (-0.9 * change in Ln(x) fasting PYY (pg/ml) from baseline to day 6) 
 
Ln(x) minimum BMI (kg/m2)   
= 3.53 + (-1.27 * change in Ln(x) fasting PYY (pg/ml) from baseline to day 6) 
 
Change in Ln(x) BMI (kg/m2) from baseline to final follow up 











Figure 4-13    Regression variable plot to show Ln(x) PYY (pg/ml) on day 6 against a) Ln(x) minimum BMI 
(kg/m2), b) Ln(x) BMI (kg/m2) at final follow up, and c) change in Ln(x) BMI (kg/m2) from baseline to final follow 
up  
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Fasting amylin at each time point, or the change in fasting amylin between time points did not predict 
BMI outcome or change in this study. Neither fasting amylin at baseline (r=0.04, f=0.4, p=0.8) or final 
follow up (r=0.1, f=0.3, p=0.6) predicted BMI at that time point.  Furthermore, fasting amylin 
concentrations at day 6 did not predict either minimum BMI at one to two years (r<0.01, f(<0.01, 
p=0.96) or the BMI at the final follow up assessment (r=0.04, f=0.04, p=0.9).  Fasting amylin at baseline 
(r=0.3, f=2.7, p=0.1) and day 6 (r=0.28, f=2.0, p=0.2) did not predict the subsequent change in BMI over 
the study period.  Furthermore, the change in amylin from baseline to day 6 did not predict either the 
minimum BMI (r=0.17, f=0.7, p=0.4) or final BMI (r=0.18, f=0.81, p=0.4), and did not predict the change 
in BMI from baseline to minimum (r=0.07, f=0.1, p=0.7), minimum to final follow up (r=0.1, f=0.2, 









RYGB results in significant weight loss in most who undergo the procedure, which is associated with 
improvements in glucose homeostasis (chapters 1.3.2 and 1.3.3).  Furthermore, these effects appear 
to be durable in the majority of people (chapter 3.1).  In contrast, whilst caloric restriction by any 
method will result in weight loss if energy intake is decreased below energy expenditure, non-surgical 
methods are associated with a high rate of weight regain.  Therefore, whilst the underlying mechanism 
may be similar (primarily caloric restriction), there appears to be additional factors subsequent to 
surgical  rather than non-surgical methods that result in these different long term outcomes.   
Alterations in the function of hormones that play a role in energy homeostasis must be considered as 
possible contenders to explain or partially explain this difference.  As discussed in chapter 1.1.2.3 (page 
11), a large number of hormones secreted by the adipocyte or throughout the gastrointestinal tract are 
integral in the regulation of appetite and satiety, and matching energy intake to requirements.  
Furthermore, bariatric surgery is known to effect the secretion and function of these hormones 
(chapter 1.4.2 (pages 99-104)).  This study was therefore designed to initially explore whether 
alterations in adipocyte or gastrointestinal hormones induced by bariatric surgery, may underlie the 




Fasting leptin concentrations fell after RYGB, with an increased reduction by day 6 appearing to predict 
a lower BMI at early and late follow up.  However, surprisingly, fasting leptin concentrations did not 
predict concurrent BMI at any time point in this study.     
Leptin circulates in proportion to the number of adipocytes.40  As BMI is also strongly associated with 
adipocyte volume, 938 , 939  leptin concentrations are closely related to BMI. 940 , 941 , 942   However, 
concentrations fall rapidly at the onset of severe caloric restriction, prior to any change in adiposity, 
and help to initiate the physiological response to starvation.943  Thus, the significant decrease in leptin 
concentrations by day 6 after RYGB in this study is a predictable response to reduced energy intake.  
Furthermore, this early reduction is consistent with most,605,606,619 but not all published studies of 
RYGB.608 Whilst a number of published studies have reported on the leptin trajectory after surgery, it is 
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perhaps not appropriate to conduct such an analysis here, as it is impossible to conclude how much of 
this early reduction, resulting in leptin concentrations comparable to those seen at >5 years of follow 
up, can be attributed simply to the acute response to starvation.  However, the fasting leptin 
concentration at day 6 positively predicted the BMI at both the 1-2 years and >5 years follow up, such 
that a greater fasting leptin at day 6 was associated with a higher BMI at each follow up assessment.  In 
contrast, the change in leptin concentrations from baseline to day 6 did not predict weight outcomes.   
This data therefore suggests that the reduction in leptin concentrations by day 6 predicts weight 
outcomes thereafter.  However, there are clear concerns with this conclusion.  Firstly, the absence of 
any association between BMI and serum leptin concentrations at baseline in this study is in contrast to 
the published literature, and raises concerns as to the validity of other conclusions.  It is possible this 
lack of association relates simply to the small sample size; certainly the relationship between fasting 
leptin concentration and BMI at the >5 year assessment approached statistical significance (p=0.09), 
but the magnitude of this relationship (r=0.35) was far less than observed in other studies.940,941,942  
Furthermore, the reduction in fasting leptin concentrations with starvation is considered an adaptive 
mechanism that partially initiates the response to sudden reduced energy availability.  Assuming this 
to remain the case in this context, the apparent greater weight loss with lower leptin levels would be 
somewhat paradoxical.  Furthermore, whilst it is tempting to suggest that a greater reduction in leptin 
concentrations early after surgery may indicate that the intervention has resulted in greater reductions 
in caloric availability, in reality the energy intake of each person is closely regulated up until day 6 after 
surgery, and therefore any possible differences in procedure effectiveness (e.g. pouch size, tract transit 
time) would not be expected to be evident as yet.  However, as discussed above, this apparent 
relationship between fasting leptin at day 6 and future BMI may simply reflect the well established 
relationship between fasting leptin and BMI in humans, despite this not being observed at baseline in 
this study.  
Nonetheless, if the fasting leptin concentration at day 6 was truly predictive of subsequent weight loss, 
we should expect the change in leptin concentrations from baseline to day 6 to also positively predict 
subsequent weight loss, as baseline values, albeit not in this study, should associate with BMI at that 
point.  Whilst not observed in this study, the prediction of final BMI by the change in leptin 
concentrations by day 6 did approach statistical significance, however, with a p value of 0.06.  Further 
study is therefore justified to test whether any such relationship exists. 
 




Ghrelin concentrations had fallen significantly at the >5 year assessment when compared with baseline.  
However, the absolute ghrelin concentration or change in ghrelin concentrations between time points 
did not predict weight outcomes. 
Ghrelin is an appetite initiating hormone that therefore circulates at the highest concentrations when 
fasting.94  Obesity is associated with reduced ghrelin levels, although the normal suppressive effect of 
food on ghrelin secretion is blunted.97,98  As discussed in chapter 1.1.2.3.1 (page 11), circulating ghrelin 
exists in acylated and des-acylated isoforms, with acylated ghrelin accounting for approximately 10% 
of total ghrelin concentrations.944  As only active (acylated) ghrelin was measured in this study, the 
circulating concentrations at baseline appear similar to those in other studies reporting active or total 
ghrelin concentrations immediately prior to bariatric surgery.610,619   
Studies reporting the effect of RYGB on circulating ghrelin concentrations have produced contrasting 
results with both no change,608,610,616 and reduced concentrations reported.619,621,622,629,630  In this study, 
acylated ghrelin concentrations had not changed at 6 days but were significantly lower at the >5 year 
follow up assessment. It is possible that this apparent discordancy relates to both the timing of post 
operative assessments, and the reporting of total versus acylated ghrelin.  As in our study, the only two 
other studies reporting changes in acylated ghrelin levels demonstrated a reduction after RYGB, with 
the earliest time point at which the hormone was measured being 6 weeks after surgery.629,630   To my 
knowledge, this is the first study to report acylated ghrelin concentrations within 6 weeks of surgery 
and it is therefore not possible to compare the day 6 result against published data.  With the exception 
of one study,621 no other study reported significant changes in total ghrelin concentrations within 12 
months of surgery.  It should be noted that, whilst Korner et al reported a trend to reducing total ghrelin 
concentrations prior to this time, the concentrations were not statistically different from baseline 
within the 12 month post-operative period.  It is therefore possible, that reductions in total ghrelin are 
not evident for some time after RYGB, which is perhaps counterintuitive to the concept that the 
reduced ghrelin concentrations relate directly to gastric anatomical changes at surgery as clearly seen 
after SG (chapter 1.4.2.2, page 100).  If this were the case, the apparent reduction in acylated ghrelin 
may be compensated by an increase in circulating des-acylated ghrelin, as demonstrated in some 
studies, and accounting for the early stable total ghrelin concentrations.627  
Irrespective of whether absolute ghrelin concentrations were altered by RYGB, the change in ghrelin 
concentrations between time points over the study period did not predict weight outcomes in this 
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study.  This study therefore supports the conclusions drawn from ghrelin knockout mice models that 
ghrelin plays little role in weight loss after RYGB.628 
 
4.2.5.3 Amylin 
Fasting amylin concentrations were significantly lower at day six in comparison to baseline, and 
remained lower at the >5 year follow up.  However, fasting amylin concentrations did not predict either 
the BMI at any time point, or the change in weight over the study period. 
As discussed in chapter 1.1.2.3.3 (page 14), amylin is secreted by pancreatic beta cells in response to a 
carbohydrate load; therefore, amylin secretion changes alongside changes in insulin 
concentrations.117,119  Fasting amylin concentrations increase with weight gain, with a greater post 
prandial rise in the context of obesity associated with insulin resistance.120  Increased post prandial 
amylin concentrations appear to reduce food intake during a meal, decrease gastric motility and 
emptying, and inhibit glucagon secretion.117,119,125  Furthermore, amylin appears to augment leptin and 
PYY signalling, thereby increasing satiation.945,946 
Fewer studies have reported changes in amylin concentrations after bariatric surgery than changes in 
other hormone concentrations. 947   Whilst some studies have shown no change in fasting amylin 
concentrations after RYGB,634,651,948 others have shown reduced fasting concentrations and reduced 
post-prandial area under the curves in humans.665,949  One study reported no change in fasting amylin 
concentrations at 15 days, but a significant reduction when assessed at 12 months.717  In contrast, a 
study using a rat model reported no change in fasting amylin concentrations and a marked increase in 
post prandial elevations.950  This discrepancy does not appear to relate to the timing of assessment as 
a reduction in fasting amylin concentrations was evident at 6 days in this study and one month in two 
others,665,949 but was not evident within 1 month in other studies.634,651,717,948   Furthermore, it appears 
unlikely that this discordancy can be attributed to the glycaemic status of patients at baseline.  As amylin 
is secreted by the beta cell alongside insulin, amylin concentrations are expected to fall in parallel with 
progressive beta cell failure observed in longstanding type 2 diabetes.120 Thus, if a change in fasting 
amylin was induced bariatric surgery, this may be less apparent in those with longstanding type 2 
diabetes where hyperinsulinaemia is less likely to be present at baseline.  However, two of the studies 
reporting no early change in fasting amylin concentrations included only obese participants with normal 
glucose tolerance at baseline,634,948 whilst the mean pre-surgical duration of type 2 diabetes was 
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relatively short (approximately 5-8 years) in participants in the two studies that enrolled participants 
with established dysglycaemia.651,717 
Irrespective of the above literature, amylin does not appear to play a significant role in weight loss 
following RYGB, consistent with the finding in this study that fasting amylin did not predict weight 
outcomes.  Whilst this study and a few others have reported reduced fasting amylin concentrations, 
this is likely simply to relate to reduced beta cell output with weight loss associated improved insulin 
sensitivity.  Furthermore, given amylin’s apparent satiating effect in humans, reduced concentrations 
induced by surgery would not be favourable to weight loss or weight loss maintenance.     
 
4.2.5.4 PYY 
Fasting PYY concentrations were similar at baseline, day six, and at the >5 year follow up assessment.  
However, fasting PYY concentrations at the >5 year follow up assessment predicted BMI at that time 
point, such that the BMI decreased with an increasing fasting PYY concentration.  Perhaps in contrast 
to this finding, the change in PYY concentrations between baseline and day 6 predicted the BMI at 1-2 
and >5 years of follow up, and the change in BMI over the study period, such that a greater reduction 
in PYY concentrations from baseline to day 6 predicted a lower BMI at each subsequent time point and 
a greater reduction in BMI over the study period. 
PYY is an anorexigenic hormone produced widely throughout the lower digestive tract in response to a 
meal (see chapter 1.1.2.3.2 (page 13).110  PYY concentrations are elevated 30-60 minutes after the 
commencement of a meal, with satiating effect evident through studies reporting a clear reduction in 
food intake when PYY is infused throughout a meal.115  Obesity is associated with both a reduced fasting 
PYY concentration and a blunted response to meal ingestion.116  It is therefore possible that the 
relationship between fasting PYY and BMI at the >5 year assessment reflects simply the established 
negative relationship between PYY and weight in non-surgical populations. 
The literature reveals discordant results with respect to the effect of RYGB on fasting PYY 
concentrations with some studies demonstrating a clear reduction,610,617 others reporting a clear 
increase,619,657,667 and other studies including our study reporting no change in fasting PYY 
concentrations.660,665  However, there was a trend to reducing PYY concentrations from baseline 
through to the >5 year assessment in our study, with the mean fasting PYY concentration at >5 years 
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being 25% lower than the mean fasting PYY at baseline.  Whilst 19 samples were available at the >5 
year follow up assessment, only nine of these participants had comparable samples at baseline.  Both 
of the other listed studies that reported no change in fasting PYY concentrations after RYGB were also 
limited by small sample sizes of six and eleven participants.660,665  Indeed, one of these studies reported 
a fasting PYY at 12 months that was 21% lower than baseline values, although this was not statistically 
significant.665  It is therefore quite possible that the failure to demonstrate any change in circulating 
fasting PYY concentrations in our study and others is a limitation of the sample size, although it should 
be acknowledged that the sample size in all listed studies was relatively small. 
All studies reporting the PYY response to a meal reported a significantly increased area under the curve 
after RYGB.610,617,619,657,658,659,660,663,665  Furthermore, the increase in post prandial PYY concentrations by 
day six predicted subsequent weight loss by 52 weeks after surgery in one study,658 and poor and good 
weight loss after RYGB could be discriminated by the PYY response to a meal at 2 years after surgery.659  
In contrast, no correlation between PYY concentrations in the fasting or fed state and weight loss at 52 
weeks was observed in one study.619 In our study, fasting PYY concentrations at the >5 year follow up 
assessment predicted BMI at that time point, a finding supported by one other study after both RYGB 
and BPD, albeit in the context of an increase in PYY concentrations.667  Neither study listed above that 
observed a relationship between post meal PYY responses and weight loss after RYGB reported fasting 
PYY concentrations, and therefore did not consider whether this relationship was persistent for fasting 
samples.  As noted above, it should also be acknowledged that increasing BMI is associated with 
decreasing fasting PYY concentrations in non-surgical populations, although the PYY response to a meal 
is also blunted in this group and may be restored by RYGB.  To further support a significant role of PYY 
in longer term weight outcomes after RYGB, le Roux and colleagues recruited 13 participants who had 
undergone RYGB and inhibited PYY secretion with octreotide treatment. 659  A significant increase in 
food intake was evident in comparison to when saline was instead infused, and this was associated with 
a clear reduction in satiety scores during an observed meal. 
The perhaps counterintuitive finding that a greater reduction in fasting PYY early after surgery predicts 
greater longer term weight loss should be interpreted with caution given the small sample size of nine 
participants.  However, as the majority of interest in the physiological role of PYY thus far has been in 
the fed state.  Whilst this study found no statistical difference between PYY concentrations at baseline 
and >5 years after RYGB, there was a trend to a reduction.  If a fall in fasting PYY concentrations truly is 
observed after RYGB, this possible relationship should be re-examined, and the function of PYY in the 
fasting state should be re-explored. 
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4.2.5.5 Comparison with hormonal responses to non-surgical weight loss 
This study and others have therefore demonstrated that severe caloric restriction through RYGB results 
in a reduction in the concentrations of leptin, ghrelin, CCK, and amylin, whilst the changes in fasting PYY 
concentrations are less clear.  It is of interest to consider hormonal responses to non-surgical caloric 
restriction, and whether any differences may explain the more durable nature of surgically induced 
weight loss. 
Leptin,601,936,951,952 PYY,601,610,953 cholecystokinin,601 ,954 and amylin601,955 concentrations fall in response 
to non-surgical caloric restriction, whilst circulating concentrations of ghrelin601, 956 , 957  and GIP601 
increase.601  Furthermore, this response appears to be persist for many months or years after the initial 
period of weight loss.601,936  In combination with decreases in total, resting, and physical energy 
expenditure, these adaptive responses to caloric restriction favour weight regain.958,959,960 
Therefore, the apparent difference between the gut peptide responses to surgical and non-surgical 
caloric restriction include opposite changes in fasting and post-prandial ghrelin, CCK, and PYY 
concentrations.  Whilst the increased ghrelin and reduced CCK and PYY observed after non-surgical 
weight loss favour weight regain, the decreased ghrelin and increased post prandial CCK and PYY 
observed after RYGB favour weight loss maintenance.  This study supports that reductions in fasting 
ghrelin and PYY concentrations are observed after RYGB. 
 
4.2.5.6 Study limitations 
As noted above, the sample size in this study was small given the retrospective nature of the study and 
the limited number of suitable participants.  However, data from this study will be used to adequately 
power future studies in this field. 
Because of the retrospective nature of this study we were unable to assess all hormones of interest in 
weight loss outcomes following bariatric surgery.  Ideally the incretin hormones, GLP-1 and GIP, would 
be assessed and certainly show promise as additional components in the mechanism of improved 
glucose homeostasis following surgery (chapter 1.4.4.3).  However, the incretin hormones have a short 
half-life in plasma as a result of rapid deactivation by dipeptidyl peptidase (DPP) enzymes; analysis of 
incretin concentrations therefore requires that a DPP inhibitor is added to the sample at collection 
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which did not occur at baseline or day 6 in this study.  Further work planned given the outcomes of this 
study will be prospective in nature and will thus allow the inclusion of additional hormones of interest. 
Furthermore, we were unable to assess the response of each of these hormones to meal ingestion, as 
appropriate studies were not conducted at the historical time points.  This is clearly of importance when 
considering the function of PYY and ghrelin and will be included in future studies. 
 
  




Non-surgical weight loss results in decreased circulating concentrations of leptin, PYY, CCK, and amylin, 
with increased concentrations of ghrelin.    This study supports other data demonstrating reduced 
fasting concentrations of leptin, amylin, and ghrelin following RYGB surgery, with no clear changes in 
fasting PYY observed.    Furthermore, weight outcomes were predicted by the early change in PYY 
following surgery, although this finding requires further study given the small study sample.  The 
adaptive gut hormone response to surgical caloric restriction differs from that observed after non-
surgical caloric restriction in that favourable effects on ghrelin, PYY, and CCK, all promoting weight loss 
maintenance, are observed after surgery but not after non-surgical interventions.  Further research is 
required to clarify the mechanisms by which these hormonal changes occur, and whether differences 
in weight outcomes after RYGB may relate to differing effects on gut peptide physiology.  Furthermore, 
as the early favourable metabolic consequences of RYGB appear to be mostly reproducible through 
matched non-surgical caloric restriction, further research to clarify whether the additional longer term 
effects can be mimicked through pharmaceutical manipulation of these gut peptides would be of 
significant interest. 
 












5 Chapter Five:  Summary 
 
 
5.1.   Summary 
5.2.   Proposed further research 
  




The body of work presented in this thesis was conceived and initiated in 2012.  At that time, whilst 
bariatric surgery was in widespread use for the management of obesity and to a lesser extent type 2 
diabetes, high quality evidence to support this intervention was lacking.  Since then a number of high 
quality randomised controlled trials have been undertaken and published that support the 
effectiveness of bariatric surgery in this clinical context.  Consequently, a number of national and 
international organisations now advocate the use of bariatric surgery in obese patients with type 2 
diabetes, and furthermore, suggest that it may be provided at an earlier stage than previously 
considered.405,961 
The undertaking of a study designed to report the longer term outcomes after bariatric surgery is 
therefore timely, as, in light of these recent policy changes, a greater number of patients will 
undoubtedly undergo surgery, and many will be young enough to reasonably expect several decades 
of post-surgery life expectancy.  In the long term follow up study (chapter 3.1, pages  134-242) I have 
shown that RYGB surgery is an effective treatment for obesity and type 2 diabetes and furthermore, 
that it is durable over a 10 year follow up period.  Specifically, this study demonstrated a mean weight 
loss of 29.6% (38.5kg) and that weight regain over the study period was not associated with the 
duration of follow up.  No patient with normal glucose tolerance prior to surgery progressed to type 2 
diabetes at follow up, whilst 86% of those with pre-operative dysglycaemia (prediabetes or type 2 
diabetes) had either normal glucose tolerance or significantly improved glucose tolerance (partial 
remission by criteria) at follow up.  28% of participants with pre-operative type 2 diabetes remained 
with type 2 diabetes at follow up, a figure that compares favourably to reported outcomes in other  
similar studies (chapter 3.2, page 243).  Significant improvements in blood pressure and lipid levels 
were observed, along with a reduction in the frequency of depression, gout, and sleep apnoea following 
surgery.  No clear effects on cardiovascular endpoints was observed, but this study was not designed 
to adequately explore this.  Contrary to popular opinion, vitamin B12 deficiency was not clearly more 
common after surgery than expected in this population based on baseline features, whilst copper 
deficiency was not observed.  Zinc deficiency does however appear to be common (49% of participants); 
further research will be required to explore the best method with which to prevent morbidity as a result 
of this after surgery.  Equally as important as the above findings, quality of life was improved in this 
population to matched non-surgical controls, and almost all participants were positive about their 
decision to have undergone surgery. 
Chapter 5: Summary 
333 
 
This study therefore supports the contemporary view that RYGB is a highly effective treatment for 
established obesity and type 2 diabetes when compared against existing non-surgical strategies, and 
furthermore that bariatric surgery should considered at an earlier stage in appropriate patients.  In 
chapter 3.2, however, I have highlighted one of the methodological issues that pervades throughout 
the literature in this field, which collectively still hamper efforts to definitively place bariatric surgery in 
the treatment paradigm for obesity associated with type 2 diabetes.  A number of definitions for the 
diagnosis of states of glucose tolerance both before and after bariatric surgery are employed, and 
frequently are different enough to render comparative analysis of studies reporting outcomes after 
bariatric surgery meaningless.  This study supports the widespread enforcement of one standardised 
set of definitions in this context, with those proposed by the American Diabetes Association seemingly 
the most reasonable.848 
However, as effective as bariatric surgery is, it does not address the root of the problem which is a rapid 
increase in the prevalence of obesity in most societies.  As discussed in chapter 1.1.1(page 2), obesity 
and type 2 diabetes are now reaching epidemic proportions with no convincing evidence to suggest 
that this increase in prevalence is slowing.  The major focus of research in the field of obesity and type 
2 diabetes should therefore be in preventing these conditions developing in the first place.  Bariatric 
surgery provides an intriguing insight into the pathophysiology of both of these conditions.  In chapter 
4 I have reported outcomes from two studies designed to further explore the mechanisms by which 
bariatric surgery is effective.  Whilst studies of this nature may help to optimise outcomes following 
bariatric surgery, they may also provide important insights into these two conditions that will guide 
preventative interventions.  Of particular relevance here is the clear difference between longer term 
weight outcomes in those people who initially lose weight by surgical or non-surgical means.  Whilst 
weight regain is observed in the majority of those who lose a significant proportion of body weight 
through non-surgical caloric restriction, it does not occur in the majority of those who achieve weight 
through surgical means.  Our present understanding of the mechanisms underlying bariatric surgery 
does not sufficiently explain this discordancy.  In chapter 4 I have reported outcomes from two small 
studies that exploring these mechanisms in further detail.  Firstly, I have shown that, whilst hormonal 
changes induced acutely as part of a stress response to RYGB surgery normalise rapidly, inflammation 
is likely to persist, and does therefore need consideration when performing studies to explore the 
mechanism by which bariatric surgery induced early dramatic improvements in glucose homeostasis.  
Secondly, I have performed an initial study exploring whether differences in the circulating 
concentrations of gut peptides in the fasting state may underlie differences in weight outcomes after 
RYGB.  As discussed below, this research question will be developed further in the coming years. 
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I intend to continue the lines of research established in this thesis over the coming years.  Of primary 
interest will be further work exploring the mechanisms underlying sustained weight loss maintenance 
or conversely weight regain following bariatric surgery, and comparing these mechanisms to those that 
drive weight regain commonly after dietary interventions.  I believe there is further work to be done to 
fully describe the role of alterations in gut peptide physiology in this context.  In particular, work 
presented in this thesis and elsewhere supports a favourable role of PYY, ghrelin, and leptin along with 
GLP-1, GIP, and CCK.  I plan to study in further detail the physiology of these peptides following bariatric 
surgery in those who have achieved differing weight outcomes, and complement this with work to 
explore the contribution any differences may make to the overall picture.  Furthermore, our research 
group has an interest in energy expenditure, and have recently developed techniques to study this in 
greater detail.  I plan to further quantify any changes in energy expenditure that bariatric surgery may 
induce, above and beyond those predicted by weight loss.  From a clinical perspective, I am to further 
contribute to the longer term literature around sleeve gastrectomy which is now performed in greater 
numbers in my institution.  As discussed in chapter 1, the evidence underlying the mechanisms and 
outcomes after sleeve gastrectomy is less established than for LAGB or gastric bypass.  It is plausible 
that sleeve gastrectomy may become the preferred bariatric surgery in obese patients with type 2 
diabetes, due to lower costs and reduced complication rates when compared with RYGB.  Clearly 
therefore, longer term outcomes and clinical aspects of surgery follow up require further clarification. 
In conclusion, the work presented in this thesis supports that RYGB is an effective and durable 
treatment for obesity and type 2 diabetes, and is not associated with a high long term risk of 
complications.  RYGB, and other forms of bariatric surgery with an equally compelling evidence, should 
be employed more frequently in the management of established obesity and type 2 diabetes.  Further 
research into the mechanisms underlying this therapeutic effect is required both to optimise outcomes 
following surgery, and, perhaps more importantly, to fully clarify the pathophysiology of these two 
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Appendix i-2  Response from research advisory group Maori 
 
Research Advisory Group – Māori 
Māori Partnership Board, Capital & Coast DHB 
 
RESEARCH ADVISORY GROUP MAORI (RAG-M) 
 
 
6 May 2011 
 
Dr Jeremy Krebs 
Level 5 
Grace Neil Block 
Wellington Hospital 
 
Tena koe Dr Krebs 
 
 
RAG-M 2011/129 - Letter of Endorsement 
 
On behalf of the Research Advisory Group Māori I write in relation to your study 
titled Long term follow up on metabolic characteristics and nutritional aspects 
following gastric bypass surgery compared with a non surgical group. 
 
You have supplied a RAG-M coversheet, an ethics application to the Multi-Region Ethics 
Committee, patient information sheet, interview questionnaire and consent forms. 
 
Our reading of your proposal characterises the research as:  
 A case control study, with cases defined as having had Roux-en-Y Gastric Bypass 
(RYGB) surgery compared with a group not undergoing Bypass surgery. 
 Participants will be recruited from the Wakefield Obesity Clinic database ( ~800 
cases, 150 controls) of these about 5% are expected to be Māori. 
 Eligible patients will be invited by letter to participate and once consented they will 
undergo an interview, physical assessment and blood & urine tests. 
 
We note that:  










Given that this topic is of high significance to Māori we highly recommend and encourage that 
there be active recruitment of Māori participants.  We would expect that: 
 you would ensure that any Māori who participate are well informed and supported, 
including their whanau as appropriate; 
 you would recognise any cultural expectations and seek to meet these expectations 
responsively; 
 you treat any blood and tissue samples taken consistently with the CCDHB policy on 
human samples which is endorsed by this Committee. 
 as the disposal of blood and specimens may be an issue for Māori participants you 
are advised this should be carefully discussed at the consent stage and written 
consent obtained. 
 
We note there is no evidence of Māori consultation either in the design of this project, or plans 
for any formal ongoing involvement of Māori advisors/researchers. Given the significance of 
this issue we would strongly recommend, you seek Māori advice prior to the commencement 
of the study and again prior to the dissemination of the study results. 
 
Whānau Care Services WCS:  We also note you have not obtained a support agreement 
with Whanau Care Services. You will be aware that WCS operate within the Wellington 
Regional Hospital.  WCS have a responsibility to both patients of the hospital and staff.  Given 
that this research may operate within the hospital campus, or involve CCDHB staff, we would 
expect that you: a) advise WCS of the operation of this research project b) negotiate with WCS 
the nature of their support, and c) notify us of the arrangements which are in place.  Please 
email wcs@ccdhb.org.nz 
 
We would be interested in receiving a copy of the final report of your study (March 2015. We 
would also like a report sent to us detailing the total number of Māori patients recruited to this 
study. 
 
On confirmation that the expectations specified above are understood and accepted by you 
we will be happy to endorse your research proposal. Please confirm these details with the 
RAG-M secretary, Ms Vanessa Mill by email to ragm@ccdhb.org.nz . 
 


















Appendix i-3  Response to research advisory group Maori 
 
May 21st 2011 
To Jack Rikihana, Chair RAG-M 
Re: RAG-M 2011/129 
In response to your recommendations and concerns 
The participants for this study are defined by those who have either had gastric bypass surgery or 
were referred and seen for consideration of gastric bypass surgery by Prof Stubbs.  We will be 
actively recruiting those Māori participants who are within these parameters to take part in this 
follow up study as we too feel that this project has high significance to Māori. 
We will ensure that any Māori who participate are well informed and supported including their 
whanau as appropriate.  We have the support of Whanau Care Services at CCDHB (letter attached). 
We encourage all participants to have their support networks and whanau present for any 
discussions, interviews or assessments if requested. 
We would seek to recognize and meet any cultural expectations. All our research nurses have had 
training in cultural responsibility and interacting with in the context of Maoritanga and the principles 
of the Treaty of Waitangi. 
We treat any blood or tissue samples taken consistent with the CCDHB policy on human samples. All 
samples will be processed within commercial laboratories that all have robust policies regarding 
blood and tissue sampling handling, storage and disposal 
All Māori will have the opportunity as part of the consent process to discuss the disposal of blood 
and specimens. Again all samples will be sent to accredited commercial laboratories who all have 
robust specimen disposal policies 
Maori consultation and support has been obtained for various projects performed at Wakefield 
Obesity Clinic and for collaborative projects between Wakefield Obesity Clinic and the Wellington 
hospital Diabetes centre. Consultation has taken place in the past with Te Kaunihera Kaumatua in 
respect of the Wakefield Diabetes research programme, which resulted in their support for the 
programme being given. They have not been involved in the conception and design of individual 
studies.  
Your endorsement of our project is appreciated 
 



























Appendix i-6   Participant information sheet and consent form 
 
 





Long term follow up on metabolic characteristics and nutritional 




Dr Jeremy Krebs, Clinical leader, Endocrine, Diabetes and Research Centre, 
Wellington Hospital, Wellington. 
 
Co-Investigators 
Dr John Wilson, Research Fellow, Endocrine, Diabetes and Research Centre, 
Wellington Hospital, Wellington;  
Dr Amber Parry-Strong, Dietician, Endocrine, Diabetes and Research Centre, 
Wellington Hospital, Wellington;  
Dr Richard Carroll, Research Fellow, Endocrine, Diabetes and Research Centre, 
Wellington Hospital, Wellington; 
Professor Richard Stubbs, Wakefield Clinic, Wakefield Hospital Wellington;  
Professor Mark Weatherall, Statistician, University of Otago, Wellington;  




You are invited to take part in the above study. Your participation is entirely 
voluntary (your choice). You do not have to take part in this study, and if you 
choose not to take part this will not affect any future care or treatment. If you do 
agree to take part in the study, you are free to withdraw from the study at any 
time, without having to give a reason, and this will in no way affect your future 









About the study 
 
You have been selected either because you have had a gastric bypass at 
Wakefield Hospital between 1990 and 2007 or you have had a referral made to 
Mr Richard Stubbs at Wakefield Hospital, Wellington or its affiliates in 
Christchurch for consideration of gastric bypass surgery. 
 
The aims of the study are to look at the long term follow up of subjects with 
obesity that have had or not had gastric bypass surgery. The principal factors we 
will be looking at are metabolic and cardiovascular risk factors such as weight, 
blood pressure, glucose control or diabetes, lipids (fat and cholesterol) and 
nutritional aspects such as dietary intake, nutritional supplementation and 
micronutrient deficiency. We wish to compare the surgical group to the non 
surgical group. 
 
There is increasing interest in New Zealand regarding the use of gastric bypass 
(a type of bariatric surgery) in regards to the management of obesity and other 
related co morbidities. Most bariatric surgery in New Zealand has been done in 
the private sector with only small numbers being done in the public system. The 
Associate Minister of Health, Tariana Turia, has recently announced increased 
funding for bariatric surgery over the next 2-4 years. Already it is known that 
bariatric surgery is the only long term effective method for weight loss in obese 
subjects. In the USA over 400,000 bariatric surgery operations are being done 
currently every year. 
 
There is a wealth of information on bariatric surgery and its effects on 
improvements in blood pressure, diabetes, lipids, and weight over the short term 
of 1-2 years. Long term data is however lacking.  
 
Two major studies show decreased mortality at 10 years post surgery but they 
largely used data from operations not routinely performed today. Follow up data 
from the largest of these studies also suggests type 2 diabetes is resolved in 80% 
of subjects at 2 years but only in about 30 % at 10 years. 
 
Nutritional data at longer term follow up is also lacking. This is also important 
as the gastric bypass operation is a malabsorptive procedure (i.e. it inhibits the 
absorption of some nutrients). Some micronutrients are stored in the body and it 






For this study we wish to assess the long term effect of gastric bypass surgery 
versus not having a gastric bypass (or other form of bariatric surgery eg 
banding, sleeve, gastroplasty). 
 
What will happen during the study 
 
To do this we require one interview where we ask some demographic details, 
perform a Quality of Life assessment, obtain a medical history, medication 
history and a basic examination. You do not have to answer all the questions, 
and you may stop the interview at any time. These will be performed at the 
Endocrine, Diabetes and Research Centre at Wellington Hospital, Wellington 
(or other approved sites as per your location). This should take about 2 hours. 
You will also be asked to perform some fasting blood tests and some urine tests 
at your local laboratory and to complete a 4 day food diary at home. We plan to 
run this study over a period of 3 years for the data collection. The results of 
these will be collated and direct comparisons made between the 2 study groups. 
 
 
Benefits, Risks and Safety 
 
The major benefit of this study is to further our knowledge on the long term 
aspects of gastric bypass surgery of which data greater than 5 years is lacking. 
Direct benefits to participants are mainly assessment of nutritional and 
metabolic status. Your GP will be informed of your participation and results of 
the investigations will be forwarded onto your GP for any action. 
 
There is little risk to taking part in the study. We require some of your time and 
the inconvenience of a blood and urine test. Any adverse outcome should be 
covered by ACC compensation provisions. 
 
This study is a non-therapeutic study. There will be no additional treatments or 
medications given. 
 
There will be no direct cost to you for taking part in the study. We expect to be 
able to cover parking but there is no payment for taking part in the study. 
 
If you require additional information on the trial you can contact Dr Jeremy 
Krebs or Dr Richard Carroll at the Endocrine, Diabetes and Research Centre, 







If required an interpreter can be provided. 
If you have any queries regarding your rights as a participant in this study, you 
may wish to contact an independent health and disability advocate: 
Free phone: 0800 555 050 





In the unlikely event of a physical injury as a result of your participation in this 
study, you may be covered by ACC under the Injury Prevention, Rehabilitation, 
and Compensation Act 2001.  ACC cover is not automatic, and your case will 
need to be assessed by ACC according to the provisions of the Injury 
Prevention, Rehabilitation, and Compensation Act 2001.  If your claim is 
accepted by ACC, you still might not get any compensation.  This depends on a 
number of factors, such as whether you are an earner or non-earner.  ACC 
usually provides only partial reimbursement of costs and expenses, and there 
may be no lump sum compensation payable.  There is no cover for mental 
injury unless it is a result of physical injury.  If you have ACC cover, generally 
this will affect your right to sue the investigators. 
 
If you have any questions about ACC, contact your nearest ACC office or the 
investigator. 
 
You are also advised to check whether participation in this study would affect 
any indemnity cover you have or are considering, such as medical insurance, 




All details will be kept in a confidential way as per Capital and Coast DHB 
policy. All subjects will be given a unique identifying code and only this will be 
used as a marker for analysis. No material that could personally identify you 
will be used in any reports on this study will be used in any of the final reports. 
 
We expect publication of results in international journals and presentations at 
national or international conferences. Participants are able to get copies of 
reports and presentations if they wish. There will be a delay between data 






This study has received ethical approval from the Multi-region Ethics 
Committee, which reviews national and multi regional studies.  The ethics 




Please fill out the attached acceptance form and post back in 
the enclosed envelope. 
 
Please feel free to contact the researchers if you have any questions about this 
study on (04) 806 2458. 
 
 
Signed THE INVESTIGATORS 
 
Dr Jeremy Krebs 
Dr John Wilson 
Dr Amber Parry-Strong 
Dr Richard Carroll 
Professor Richard Stubbs 
Professor Mark Weatherall 











Long term follow up on metabolic characteristics and nutritional aspects 
following gastric bypass surgery compared with a non surgical group . 
 
Principal investigator- 




Dr John Wilson, Research Fellow, Endocrine, Diabetes and Research Centre, Wellington 
Hospital, Wellington;  
Dr Amber Parry-Strong, Dietician, Endocrine, Diabetes and Research Centre, Wellington 
Hospital, Wellington 
Dr Richard Carroll, Research Fellow, Endocrine, Diabetes and Research Centre, Wellington 
Hospital, Wellington 
Professor Richard Stubbs, Wakefield Clinic, Wakefield Hospital Wellington;  
Professor Mark Weatherall, Statistician, University of Otago, Wellington;  
Professor Jim Mann, University of Otago, Dunedin 
 
Request for interpreter (to be included on all consent forms) 
English I wish to have an interpreter Yes No 
Deaf I wish to have a NZ sign language interpreter Yes No 





Ka inangaro au i tetai tangata uri reo Ae Kar
e 
Fijian Au gadreva me dua e vakadewa vosa vei au Io Sega 
Niuean Fia manako au ke fakaaoga e taha tagata fakahokohoko 
kupu 
E Nakai 
Sāmoan Ou te mana’o ia i ai se fa’amatala upu Ioe Leai 
Tokelaun Ko au e fofou ki he tino ke fakaliliu te gagana Peletania ki 
na gagana o na motu o te Pahefika 
Ioe Leai 





I have read and I understand the information sheet dated 24/06/13 for 
volunteers taking part in the study designed to assess long term follow 
results of gastric bypass surgery. I have had the opportunity to discuss 
this study.  I am satisfied with the answers I have been given. 
Y N 
I have had the opportunity to use whānau support or a friend to help me 
ask questions and understand the study. 
Y N 
I understand that taking part in this study is voluntary (my choice), and 
that I may withdraw from the study at any time, and this will in no way 
affect my future health care or continuing healthcare. 
Y N 
I have had this project explained to me by ____________________ 
Y N 
I understand that my participation in this study is confidential and that 
no material that could identify me will be used in any reports on this 
study. 
Y N 
I understand the compensation provisions for this study. 
Y N 
I have had time to consider whether to take part in the study. 
Y N 
I know who to contact if I have any questions about the study in 
general. 
Y N 
I agree to an approved auditor appointed by either the ethics committee 
or the regulatory authority or their approved representative and 
approved by the Multi-region  ethics committee reviewing my relevant 
medical records for the sole purpose of checking the accuracy of the 
information recorded for the study.  
Y N 
I consent to the researchers storing a specimen of my blood (or other 
tissue) for its later use as a part of this study or other research  
Y N 
I wish to receive a copy of the results. Participants should be advised 
that a significant delay may occur between data collection and 
publication of the results.   
Y N 
I agree to my GP or other current provider being informed of my 
participation in this study/the results of my participation in this study. 
Y N 
I consent to my GP being contacted for additional details regarding my 
medical history 
Y N 
I consent to us contacting additional laboratories and hospitals for 






I consent to sending samples overseas if required. (this will require 
additional approval by ethics committee) 
 
Y N 





5. I ___________________________hereby consent to take part in this study.   
 
Date:       
  




Project explained by:       
  
Project role:       
  
Signature:       
  
Date:       
 
Notes: 
1. A copy of the consent form is to be retained by each participant and (in the case of 






Appendix i-7   Interview datasheet 
 





CODE NUMBER   __ __ __ __ __ __ 
 
 




NHI:  __________________________ 
DOB:  __________________________ 
Gender: Male  □ Female   □ 
Address:      _________________________________________ 
                      _________________________________________ 
                      _________________________________________        
Ph Home:     ________________ 
Ph Mobile:    ________________ 
Email:       @sdfsddfdsdsdsdfsdfsdfsdsdf                                                          
    
GP Name: _________________________________________ 
GP Address: _________________________________________                      
_________________________________________ 
_________________________________________ 








QOL Questionnaire   
 
 
4 Day Food Diary  
 
 






1. Bypass Group  
 
If subject has not undergone bypass surgery proceed to Q3 
 
 
1.1. When was your operation? (DD/MON/YYYY) 
 
__ __ / __ __ __ / __ __ __ __ 
 
2. Have you had subsequent bariatric surgery (e.g. Banding, revision bypass, 
gastroplasty, gastric sleeve)? 
 
 
YES / NO 
 
 
If subject has undergone proceed to question 4 
 
 
3. Non Bypass Group 
 
3.1. Have you ever had Bariatric Surgery (e.g. Banding, gastric bypass, 
gastroplasty, gastric sleeve)?  
 








1                     2                     3                     4                     5 








5. Which of the following ethnic groups do you belong to? 
 
   New Zealand European          Niuean   
   Maori      Chinese  
   Samoan     Indian  
   Cook Island Maori    Other ____________ 
   Tongan    
 
Please fill in the following boxes for each of your grandparents.  If you do not know their origin please 
indicate this with a question mark.  Tick as many circles as you need within each box. 
 
               Paternal Grandfather                                  Paternal Grandmother 
 
             Maternal Grandfather                              Maternal Grandmother  
 





Social / diet / exercise information 
 
7. Smoker?               Yes   □     No   □     Ex-smoker   □ 
 
7.1    If Yes/Ex, How many pack years?_______________________ 
 
One pack year is 20 cigarettes per day for 1 year. (i.e. 10 cigarettes/day for 20 years 
would be 10 pack/years) 
 
 
8. Alcohol                  Yes   □     No   □     Ex   □ 
 
8.1    If yes, how much alcohol did you drink in the last 7 days (units)? 
 
 a. Beer    







8.2    Is this an average intake for you? If no, how many standard   





9. Are you currently working?         Yes   □     No   □ 
 
9.1    If Yes, How many hours per week? __________ 
 
9.2     At this time are you: (Please tick all that apply) 
 In paid employment? 
 Self-employed? 
 Working full time? 
 Working part time? 
 In physical/manual employment? 
 In non-physical employment? 
 Retired?  
 A home-maker?  
 A student?  
 Unemployed?  





 Other ____________________________________ 
 
10.    How many years of education have you completed?  
 
 
      2  3  4  5  6  7  8  9  10  11 (5th form)  12  13 (7th form)  14  15  16  17  18  19  20 
Please circle the number of years at school, college, university etc 
 
11.    Exercise habits (tick one) 
 Sedentary   
 Moderate (minor strenuous exercise at least 4hrs/wk e.g. walking/cycling)  
 Regular strenuous exercise (at least 3hrs/wk e.g. sports) 
 Regular hard physical training (e.g. for competition) 
 
12. How many sugar-sweetened drinks (including fruit juice), but not including diet 
drinks, do you normally drink per day? 
 
Can or large glass: (Please circle the number that applies)  
0 1 2 3 4 5 more than 5 
 
13. How many pieces of whole fresh fruit do you usually eat per day: (please 
circle the number that applies) 
     
0 1 2 3 4 5 more than 5 
 
14.     How many times do you normally eat seafood in a week? ___________ 
 
 
15.     Approximately at what age do you recall developing problems with  







15.   Hypertension  Yes   □     No   □ 
 
Year of diagnosis 




  YES / NO 
 
 
16.   High Cholesterol  Yes   □     No   □ 
 
Year of diagnosis 




  YES / NO 
 
 
17.    Heart problems   
   a. Angina?    Yes   □     No   □ 
   b. Heart failure?    Yes   □     No   □  
   c. Pacemaker/stent/bypass?  Yes   □     No   □  
   d. Heart attack?   Yes   □     No   □  
   e. Stroke?    Yes   □     No   □  
  
A positive answer at least one of 17a – 17d constitutes a positive cardiac  
history for the purposes of bariatric follow up study 
 
 
18. Do you have/have previously had gout? 
 
   Yes   □     No   □ 
 
 
19.    Associated medical problems 
    
Condition Code 
Sleep apnoea  
Arthritis  
Gallbladder surgery  
Osteoporotic fracture  
Fatty liver disease  
 
0 = Never,  1 = Before surgery, resolved,  





















21.    Please list all relevant over the counter medications, Herbal or   









22.     How often do you take Multivitamins? 
 
 
              1                        2                        3                         4                    5 
 
          Every Day             3-4/week          1-2/week            Not regular      Never 
 
 










24.    Do you suffer from symptoms of low blood sugar?        Yes   □     No   □ 
 
If yes, please describe time of day, characteristics, use of  











25.    Do you suffer from dumping syndrome?           Yes   □     No   □ 
 
If yes, please describe time of day, characteristics,  







26.    How would you describe you enjoyment of food? 
 
Before the operation  
Since the operation  
 
 
   1 = Always enjoy my food,  2 = Occasionally don’t enjoy my food,  
3 = Always do not enjoy my food 
 
 
27.    Have you developed any of the following negative symptoms since   
surgery? 
 
  a.      Frequent vomiting   Yes   □     No   □ 
  b.      Indigestion              Yes   □     No   □ 
  c.      Change in bowel habit  Yes   □     No   □ 
 
28.    Do you feel any benefits you have received from the surgery outweigh  
negative symptoms? 







29.     Do you have diabetes?    Yes   □     No   □ 
 
Year of diagnosis 




  YES / NO 
 
   Confirm type 2 diabetes if positive answer to above 
 






 YES / NO 
 
 
30.    Diabetes related medical problems 





Peripheral vascular disease  
Depression  
 
0 = Never,  1 = Before surgery, resolved,  
2 = Before surgery, not resolved, 3 = After surgery only 
 











     
     
     
     
 
 Therapy compliance score; Always taken=1;  






2. Age at first gout attack        ____________Years 
3. Number of gout attacks in the past year    
 _________________ 
4. Is there tophus as evidenced by clinical examination?  
Yes   □     No   □ 
5. Has the participant ever had diuretic treatment?   
6. Yes   □     No   □ 
If so, did this induce gout?     YES/NO 
 
7. What treatment has the participant had for gout in the past? 
Allopurinol   YES / NO 
Steroid    YES / NO 
Anti-inflammatories  YES / NO 
Probenecid   YES / NO 
Colchicine   YES / NO 
Other    YES / NO 
 
8. Were there any side effects from these treatments? (specify drug)   
 
______________________________________________________ 
9. Do certain foods/drink trigger your gout?    YES / NO 
 




10. Does seafood trigger your gout?     YES / NO 
 
11. Does alcohol trigger your gout?     YES / NO 
 











Weight (kg)    __ __ __ 
 
Height (cm)                __ __ __ 
 
Waist (cm)   __ __ __ 
 
Hip (cm)                    __ __ __ 
 
Pulse (beats/minute) on 3 occasion’s    __ __ __    
 
      __ __ __   
 
       __ __ __   
  
BP     (3 occasions)            __ __ __ / __ __ __ 
 
      __ __ __ / __ __ __ 
 
      __ __ __ / __ __ __ 
 
O2 Saturations (%)      __ __ % 
 



































ii. Appendix B 
Table ii-1   Baseline characteristics of study participants based on bariatric procedure 
 Mean (SD) 95% CI Minimum Maximum 
Transected RYGB (N=99) 
Age at operation (years) 48.1 (10.9) 46.0 to 50.3 23.5 68.5 
Age at follow up (years) 55.9 (11.2) 53.7 to 58.1 30.1 77.4 
Duration of follow up (years) 7.8 (2.5) 7.3 to 8.2 5.1 14.0 
Pre-operative weight (kg) 129.4 (26.7) 124.1 to 134.7 83.0 202.0 
Pre-operative BMI (kg/m2) 46.4 (8.6) 44.6 to 48.1 33.0 73.6 
Silastic ring RYGB (N=13) 
Age at operation (years) 47.0 (9.0) 41.6 to 52.4 23.4 60.2 
Age at follow up (years) 65.4 (9.9) 59.4 to 71.4 40.5 78.1 
Duration of follow up (years) 18.4 (2.9) 16.7 to 20.1 14.6 22.9 
Pre-operative weight (kg) 126.1 (32.5) 106.4 to 145.7 89.0 192.0 
Pre-operative BMI (kg/m2) 47.3 (10.6) 40.9 to 53.7 34.8 74.9 
Vertical banded gastroplasty (N=1) 
Age at operation (years) 33.1 (N/A) N/A N/A N/A 
Age at follow up (years) 57.3 (N/A) N/A N/A N/A 
Duration of follow up (years) 24.2 (N/A) N/A N/A N/A 
Pre-operative weight (kg) 124.0 (N/A) N/A N/A N/A 
Pre-operative BMI (kg/m2) 44.5 (N/A) N/A N/A N/A 
Gastric bypass (N=5) 
Age at operation (years) 37.5 (5.0) 31.3 to 43.7 30.9 42.6 
Age at follow up (years) 66.5 (6.15) 58.9 to 74.2 59.5 72.5 
Duration of follow up (years) 29.0 (1.8) 26.8 to 31.3 25.9 30.6 
Pre-operative weight (kg) 125.3 (18.2) 102.7 to 147.9 104.0 144.0 
Pre-operative BMI (kg/m2) 50.0 (5.1) 41.9 to 58.0 43.3 54.5 
Revision (N=2) 
Age at operation (years) 41.6 (N/A) N/A 38.6 44.5 
Age at follow up (years) 64.2 (N/A) N/A 23.5 68.5 
Duration of follow up (years) 22.7 (N/A) N/A 22.2 23.1 
Pre-operative weight (kg) 99.0 (N/A) N/A 68.0 130.0 





Table ii-2   Smoking status, alcohol use, and employment history at follow up by type of bariatric procedure 





Transected RYGB (N=99) 
Smoking 
Never 56 (57) Pack years 
Ex 36 (36) 20.8 (26.1) 11.2 to 30.3 1.0 120.0 
Current 7 (7) 17.3 (9.1) 7.8 to 26.9 5.0 32.0 
Alcohol 
Never 32 (32) Units per week 
Ex 33 (33) 9.2 (12.8) 4.6 to 13.8 1.0 60.0 




 Hours per week 
Employed at 
follow up 
67 (67) 36.0 (17.4) 31.8 to 40.0 2.5 80.0 
Silastic ring RYGB (N=13) 
Smoking 
Never 10 (77) Pack years 
Ex 2 (15) 7.5 (N/A) N/A 5.0 10.0 
Current 1 (8) 40.0 N/A N/A N/A 
Alcohol 
Never 6 (46) Units per week 
Ex 5 (38) 11.4 (10.4) -1.5 to 24.3 6.0 30.0 




 Hours per week 
Employed at 
follow up 
9 (69) 38.9 (17.6) 25.3 to 52.4 2.5 50.0 
Other (n=8) 
Smoking 
Never 3 (37) Pack years 
Ex 5 (63) 31.2 (22.1) 3.7 to 59.7 1.0 50.0 
Current 0 (0) N/A N/A N/A N/A 
Alcohol 
Never 4 (50) Units per week 
Ex 2 (25) 22.0 (28.3) -232 to 276 2.0 42.0 




 Hours per week 
Employed at 
follow up 






Figure ii-1   Frequency histograms showing (left hand column) a) weight (kg) and b) BMI (kg/m2) at baseline.  














Table ii-3   Shapiro-Wilk test of normality results for non-transformed and logarithmic transformed weight at 
(kg), and BMI (kg/m2) at baseline.  The null hypothesis is accepted (i.e. data is not clearly not normally 
distributed) if p>0.05.  
N=118 Non-transformed Logarithmic transformed 
 Statistic P value Statistic P value 
Weight (kg) 0.96 0.02 0.99 0.31 






Figure ii-2    Frequency histograms showing (left hand column) a) weight (kg) and b) BMI (kg/m2) at follow up.  














Table ii-4  Shapiro-Wilk test of normality results for non-transformed and logarithmic transformed weight (kg) 
and BMI (kg/m2) at follow up.  The null hypothesis is accepted (i.e. data is not clearly not normally distributed) 
if p>0.05.  
N=118 Non-transformed Logarithmic transformed 
 Statistic P value Statistic P value 
Weight (kg) 0.96 0.001 0.99 0.5 





Figure ii-3   Frequency histograms to show distribution of a) change in weight, b) change in BMI, and c) body 






















Table ii-5   Baseline and follow up characteristics of participants stratified by obesity classification at baseline.  Paired T tests results are shown. 
 
N=118 
Baseline Follow up 
Paired T test for 
equality of means 
Mean (SD) IQR Min/Max Mean (SD) IQR Min/Max 
Estimated 
difference 
95% CI P value 
Class 1 obesity (n=8) 
Age (years) 52.2 (9.4) 17.7 38.6/65.4 61.1 (10.5) 18.5 45.2/75.9 9.0 4.2 to 13.7 0.003 
Duration of follow up (years) N/A N/A N/A 9.0 (5.7) 4.2 5.4/22.4 N/A N/A N/A 
Weight (kg) 95.5 (12.6) 21.3 83.0/83.0 71.5 (1.9) 28.2 47.9/102.7 24.1 14.4 to 33.7 0.001 
BMI (kg/m2) 34.1 (0.7) 1.3 33.0/34.8 25.3 (4.51) 12.8 19.4/32.3 8.8 4.9 to 12.7 0.001 
Body weight loss (%) N/A N/A N/A 25.6 (13.4) 26.9 7.1/42.6 N/A N/A N/A 
Class 2 obesity (n=18) 
Age (years) 50.3 (8.1) 7.5 25.1/65.2 60.3 (10.0) 13.0 30.2/73.2 10.0 9.9 to 12.1 <0.001 
Duration of follow up (years) N/A N/A N/A 9.9 (4.3) 7.4 5.1/20.6 N/A N/A N/A 
Weight (kg) 100.9 (7.3) 10.2 91.0/119.0 74.0 (11.2) 15.3 61.3/103.4 26.9 21.8 to 32.0 <0.001 
BMI (kg/m2) 37.8 (1.1) 1.6 35.7/39.6 27.8 (3.88) 4.9 22.9/37.1 10.1 8.3 to 77.9 <0.001 
Body weight loss (%) N/A N/A N/A 26.7 (9.6) 14.9 6.3/39.7 N/A N/A N/A 




 Baseline Follow up Paired T test for equality of means 
 Mean (SD) IQR Min/Max Mean (SD) IQR Min/Max 
Estimated 
difference 
95% CI P value 
Class 3 obesity (n=56) 
Age (years) 47.0 (11.0) 18.5 23.5/68.1 57.1 (11.8) 16.5 30.1/78.1 10.1 8.5 to 11.8 <0.001 
Duration of follow up (years) N/A N/A N/A 10.1 (6.3) 7.1 5.1/29.5 N/A N/A N/A 
Weight (kg) 124.7 (14.8) 20.5 100.9/162.0 87.2 (15.4) 24.3 61.3/123.2 37.4 33.9 to 40.9 <0.001 
BMI (kg/m2) 44.5 (2.88) 4.8 40.0/49.9 31.2 (4.8) 4.9 22.0/47.4 13.3 12.1 to 14.6 <0.001 
Body weight loss (%) N/A N/A N/A 29.9 (9.8) 10.8 3.0/50.4 N/A N/A N/A 
Class 4 obesity (n=36) 
Age (years) 45.7 (11.2) 15.0 23.4/68.5 55.6 (11.5) 18.0 32.6/74.4 9.9 7.8 to 11.9 <0.001 
Duration of follow up (years) N/A N/A N/A 9.9 (6.1) 4.7 5.5/30.6 N/A N/A N/A 
Weight (kg) 156.7 (22.6) 34.0 117.0/202.0 108.0 (22.4) 30.4 69.0/171.0 48.7 41.6 to 55.9 <0.001 
BMI (kg/m2) 57.0 (6.5) 6.4 50.0/74.9 39.2 (6.8) 9.7 24.5/51.5 17.8 15.1 to 20.4 <0.001 





Table ii-6  Univariate regression analyses outcomes for baseline variables (independent) against change in BMI 







Age (years) 11.80 0.05 0.41 
Gender 13.89 0.30 0.83 
Weight (kg) -1.03 0.12 <0.001 
BMI (kg/m2) -6.23 0.43 <0.001 
Diabetes status 12.2 1.72 0.02 
Fasting glucose (mmol/L) 12.2 0.27 0.33 
HbA1c (mmol/mol) 11.5 0.06 0.16 
Fasting insulin (pmol/L) 12.8 0.01 0.23 
HOMA-IR 11.0 0.97 0.04 
Total cholesterol (mmol/L) 21.3 -1.29 0.05 
HDL (mmol/L) 15.5 -0.9 0.65 
LDL (mmol/L) 17.3 -0.88 0.21 
Triglycerides (mmol/L) 15.9 -0.91 0.15 
Hypertension  10.7 4.0 0.02 
Systolic blood pressure (mmHg) 7.73 0.05 0.13 





Table ii-7   Descriptive data for all participants, stratified by duration of follow up (years) 
 
n=118 
Duration of follow up Independent T test for  
equality of means <10.0 years (n=81) ≥10 years (n=37) 
Mean (SD) IQR Min/Max Mean (SD) IQR Min/Max Mean 95% CI P value 
Age at operation (years) 48.1 (11.2) 17.7 23.5/68.5 46.3 (8.9) 13.1 23.4/60.3 1.72 -2.4 to 5.9 0.4 
Age at follow up (years) 54.9 (11.3) 17.6 30.1/77.4 63.6 (8.2) 8.6 40.5/78.1 8.7 4.6 to 12.8 <0.001 
Duration of follow up 
(years) 
6.9 (1.4) 2.3 5.1/9.9 17.3 (6.1) 9.4 10.0/30.6 10.4 9.0 to 11.8 <0.001 
Weight at baseline (kg) 132.1 (25.9) 39.5 83.0/202.0 121.6 (28.2) 33.0 83.5/192.0 10.5 0.1 to 20.9 0.05 
Weight at follow up (kg) 91.3 (22.4) 33.2 49.4/171.0 88.1 (19.7) 27.9 47.9/140.2 3.2 -5.3 to 11.7 0.5 
Weight loss (kg) 40.8 (16.9) 22.0 3.4/93.1 33.6 (17.5) 15.3 3.3/84.0 7.3 0.6 to 14.0 0.03 
BMI at baseline (kg/m2) 47.3 (8.8) 12.2 33.0/73.6 45.2 (8.1) 10.8 33.9/74.9 2.0 -1.4 to 5.4 0.24 
BMI at follow up (kg/m2) 32.6 (7.4) 9.5 19.6/51.5 32.9 (6.4) 8.5 19.4/47.4 0.3 -3.1 to 2.5 0.8 
Change in BMI (kg/m2) 14.7 (6.3) 7.1 1.3/36.6 12.3 (6.0) 5.9 1.45/31.5 2.3 -0.1 to 4.8 0.06 





Figure ii-4   Frequency histograms to show distributions of a) fasting glucose, b) HbA1c, c) fasting insulin, and d) 











































Table ii-8   Shapiro-Wilk test of normality results for diabetes variables at baseline and follow up. 
N=118 Baseline Follow up 
 Statistic P value Statistic P value 
Fasting glucose (mmol/L) 0.75 <0.001 0.61 <0.001 
HbA1c (mmol/mol) 0.83 <0.001 0.80 <0.001 
Fasting insulin (pmol/L) 0.92 <0.001 0.88 <0.001 






















Figure ii-5   Frequency histograms to show distributions of a) Ln(x) fasting glucose, b) Ln(x) HbA1c, c) Ln(x) 










































Figure ii-6   Frequency histograms to show the distribution of the change in a) fasting glucose (mmol/L) b) 
HbA1c (mmol/mol), c)  fasting insulin (pmol/L) and d) HOMA-IR  from baseline to follow up (left column) and 
following logarithmic transformation (right column) 












































Figure ii-7   Frequency histograms to show distributions of a) systolic blood pressure at baseline (left column) 





















Table ii-9   Shapiro-Wilk test of normality results for systolic and diastolic blood pressure at baseline and follow 
up. 
N=118 Baseline Follow up 
 Statistic P value Statistic P value 
Systolic blood pressure 0.98 0.09 0.96 0.01 







Figure ii-8   Frequency histograms to show the distribution of the change in a) systolic blood pressure (mmHg), 































Table ii-10  Univariate regression analyses outcomes for baseline variables (independent) against change in systolic, diastolic, and mean arterial blood pressure at the 
follow up assessment (dependent variables) 
 
Independent variable 





P value Constant 
Independent 
variable 




Blood pressure status -3.7 -9.0 0.1 1.7 -5.7 0.1 -0.1 -6.8 0.07 
SBP (mmHg) 48.4 -0.4 <0.001 29.0 -0.2 <0.001 35.4 -0.3 <0.001 
DBP (mmHg) 29.4 -0.5 0.003 54.4 -0.7 <0.001 46.1 -0.6 <0.001 
MAP (mmHg) 45.7 -0.6 <0.001 49.9 -0.5 <0.001 48.5 -0.5 <0.001 
Number of BP medications -12.5 1.9 0.5 -4.1 1.6 0.4 -6.9 1.7 0.3 
Duration of HTN (years) -10.3 0.2 0.6 -1.4 -0.03 0.9 -4.3 0.03 0.9 
Duration of treated HTN (years) -6.8 -0.06 0.9 2.1 -0.2 0.4 -0.8 -0.2 0.6 
BMI at baseline(kg/m2) -9.9 -0.03 0.9 -3.4 -0.005 1.0 -5.2 -0.02 0.9 
BMI at follow up (kg/m2) -16.3 0.15 0.6 -9.3 0.2 0.3 -11.5 0.17 0.4 
BMI (kg/m2) change -7.5 -0.28 0.4 0.6 -0.3 0.2 -1.9 -0.3 0.2 





Figure ii-9   Frequency histograms to show distributions of a) total cholesterol, b) HDL, c) LDL, d) Triglycerides 































Table ii-11   Shapiro-Wilk test of normality results for total cholesterol, HDL, LDL, and triglyceride 
concentrations at baseline and follow up.  The null hypothesis is accepted (i.e. data is not clearly not normally 
distributed) if p>0.05.  
 
Baseline Follow up 
Statistic P value Statistic P value 
Total cholesterol 0.99 0.40 0.99 0.36 
HDL 0.95 0.001 0.98 0.05 
LDL 0.98 0.29 0.99 0.34 
Triglycerides 0.77 <0.001 0.91 <0.001 
 
 
Figure ii-10   Frequency histograms to show logarithmic transformed distributions of a) HDL, and b) 



















Table ii-12   Shapiro-Wilk test of normality results for logarithmic transformed HDL and triglyceride 
concentrations at baseline and follow up.  The null hypothesis is accepted (i.e. data is not clearly not normally 
distributed) if p≥0.05. 
 
Baseline Follow up 
Statistic P value Statistic P value 
Ln(X) HDL 0.99 0.63 0.98 0.22 
Ln(X) Triglycerides 0.97 0.05 0.99 0.26 
 
 
Figure ii-11   Frequency histograms to show the distribution of the change in a) total cholesterol (mmol/L), b) 
HDL (mmol/L), c) LDL (mmol/L), and d) triglycerides (mmol/L) from baseline to follow up 





















Table ii-13   Estimated differences for lipid concentrations at baseline and follow up in participants not using a 







Paired T test for 
Estimated difference * 
Estimated 
difference 
95% CI P value 
Total cholesterol (mmol/L) 5.48 (0.94) 5.39 (0.84) -0.09 -0.31 to 0.13  0.40 
HDL (mmol/L) 1.37 (0.35) 1.97 (0.53) 0.36 0.30 to 0.41 <0.001 
LDL (mmol/L) 3.37 (0.83) 2.93 (0.75) -0.44 -0.65 to -0.22  <0.001 
Triglycerides (mmol/L) 1.60 (0.62) 1.06 (0.33) -0.39 -0.49 to -0.29 <0.001 
 





Table ii-14  Univariate regression analyses outcomes for baseline variables (independent) against the change in LDL, HDL, and triglyceride concentrations from baseline to 
the follow up assessment (dependent variables) 
 
Independent variable 





P value Constant 
Independent 
variable 




Follow up measurements 
LDL at baseline (mmol/L) -1.89 0.71 <0.001 0.3 0.08 0.11 1.42 -0.23 0.03 
HDL at baseline (mmol/L) -0.09 0.39 0.21 0.6 -0.02 0.87 1.93 -0.93 0.001 
Triglycerides at baseline (mmol/L) 0.66 -0.1 0.23 0.74 -0.09 0.04 -0.71 0.77 <0.001 
BMI at baseline 0.22 0.005 0.73 0.91 -0.007 0.18 1.26 -0.01 0.26 
BMI at follow up 0.79 -0.01 0.49 1.19 -0.02 0.003 0.94 -0.008 0.57 
Change in BMI (kg/m2) 0.07 0.03 0.17 0.41 0.01 0.15 0.91 -0.02 0.33 
% Body weight loss -0.1 0.02 0.1 0.22 0.01 0.01 0.85 -0.006 0.56 




Table ii-15   Descriptive lipid data for participants at baseline and follow up, stratified by duration of 
dyslipidaemia prior to surgery.   Results of an independent T test are shown.  
n=29 








Independent T test for  
Estimated difference * 
Mean 
(SD) 
95% CI Mean 
(SD) 
95% CI Mean 95% CI P value 









1.7 -5.3 to 8.7 0.6 









1.6 -5.7 to 8.9 0.7 




6.6 to 8.7 
7.6 
(3.1) 
5.8 to 9.3 0.1 -1.9 to 2.1 0.9 









0.05 -0.1 to 0.2 0.5 


























Number of lipid lowering 







0.4 to 1.0 0.4 0.1 to 0.8  0.02 
Number of lipid lowering 
medications at follow up 
0.1 
(0.4) 
0 to 0.3 
0.4 
(0.5) 


















































Figure ii-13   Histogram to show the distribution of a) zinc concentrations, and b) logarithmic transformed zinc 
concentrations in all participants at follow up 
 






































Table ii-16   IWQOL-lite answers provided by participants to each question 
 
Physical function (n=118) 
Chosen answer %  
1 2 3 4 5 N/A Mean (SD) 
Because of my weight I have trouble 
picking up objects 
64 21 11 0 1 3 1.5 (0.8) 
Because of my weight I have trouble tying 
my shoes 
75 11 9 3 0 3 1.4 (0.8) 
Because of my weight I have difficulty 
getting up from chairs 
69 17 9 2 1 3 1.5 (0.8) 
Because of my weight I have trouble using 
stairs 
63 14 14 5 2 3 1.7 (1.0) 
Because of my weight I have difficulty 
putting on or taking off my clothing 
83 10 3 1 0 3 1.2 (0.5) 
Because of my weight I have trouble with 
mobility 
66 14 15 2 0 3 1.5 (0.8) 
Because of my weight I have trouble 
crossing my legs 
72 9 8 5 4 3 1.6 (1.1) 
I feel short of breath with only mild exertion 54 16 21 3 3 3 1.8 (1.1) 
I am troubled by painful or stiff joints 36 14 23 11 13 4 2.5 (1.4) 
My ankles and lower legs are swollen at 
the end of the day 
53 21 12 6 5 3 1.9 (1.2) 
I am worried about my health 2 28 26 9 7 3 2.4 (1.2) 
Self-esteem (n=118) 
Chosen answer %  
1 2 3 4 5 N/A Mean (SD) 
Because of my weight I am self-conscious 35 22 19 9 13 3 2.4 (1.4) 
Because of my weight my self-esteem is not 
what it could be 
40 25 18 9 5 3 2.1 (1.2) 
Because of my weight I feel unsure of myself 48 25 13 6 4 3 1.9 (1.1) 
Because of my weight I don’t like myself 54 17 15 7 4 3 1.9 (1.1) 
Because of my weight I am afraid of being 
rejected 
57 14 14 6 7 3 1.9 (1.2) 
Because of my weight I avoid looking in 
mirrors or seeing myself in photographs 
53 17 11 12 4 3 1.9 (1.2) 
Because of my weight I am embarrassed to 
be seen in public places 




Sexual life (n=118) 
Chosen answer %  
1 2 3 4 5 N/A Mean (SD) 
Because of my weight I do not enjoy sexual 
activity 
53 20 9 2 3 14 1.6 (1.0) 
Because of my weight I have little or no 
sexual desire 
52 21 9 3 2 14 1.6 (0.9) 
Because of my weight I have difficulty with 
sexual performance 
55 21 5 2 3 14 1.5 (0.9) 
Because of my weight I avoid sexual 
encounters whenever possible 
59 18 4 2 3 14 1.5 (1.0) 
Public distress (n=118) 
Chosen answer %  
1 2 3 4 5 N/A Mean (SD) 
Because of my weight I experience ridicule, 
teasing, or unwanted attention 
64 19 9 1 0 8 1.4 (0.7) 
Because of my weight I worry about fitting 
into seats in public places (e.g. theaters, 
restaurants, cars, or airplanes) 
63 15 8 3 3 8 1.6 (1.0) 
Because of my weight I worry about fitting 
through aisles or turnstiles 
67 16 5 2 3 8 1.4 (0.9) 
Because of my weight I worry about finding 
chairs that are strong enough to hold my 
weight 
66 15 6 2 3 9 1.5 (0.9) 
Because of my weight I experience 
discrimination by others 
64 14 11 0 3 9 1.5 (1.0) 
Work (n=118) 
Chosen answer %  
1 2 3 4 5 N/A Mean (SD) 
Because of my weight I have trouble getting 
things accomplished or meeting my 
responsibilities 
70 14 4 2 1 9 1.3 (0.7) 
Because of my weight I am less productive 
than I could be 
65 13 10 2 1 9 1.5 (0.8) 
Because of my weight I don’t receive 
appropriate raises, promotions or 
recognition at work 
77 8 3 0 0 12 1.2 (0.5)  
Because of my weight I am afraid to go on job 
interviews 










Bariatric follow up study (n=119) 
IWQOL-lite reference data 
(n=11,640) 
Unpaired T test 
n Mean SD n Mean SD Est. diff. 95% CI P value 
Physical 
function 
18.0 to 24.9 14 90.4 12.9 338 94.5 8.5 -4.1 -8.8 to 0.6 0.09 
25.0 to 29.9 31 90.2 8.9 1199 84.4 14.1 5.8 0.8 to 10.8 0.02 
30.0 to 34.9 35 82.5 18.0 3283 73.6 18.8 8.9 2.6 to 15.2 0.005 
35.0 to 39.9 15 79.5 13.8 3022 63.4 21.8 16.1 5.0 to 27.2 0.004 
>40.0 19 65.6 20.1 3794 44.5 24.9 21.1 1.0 to 41.2 0.04 
Self 
esteem 
18.0 to 24.9 14 91.3 20.6 338 88.2 18.8 3.1 -7.0 to 13.2 0.5 
25.0 to 29.9 31 91.8 11.0 1198 73.4 25.4 18.4 9.4 to 27.4 <0.001 
30.0 to 34.9 36 77.2 26.7 3282 61.8 26.8 15.4 6.6 to 24.2 <0.001 
35.0 to 39.9 14 65.6 20.6 3022 54.4 27.3 11.2 -3.2 to 25.6 0.1 
>40.0 18 49.6 24.0 3798 43.1 27.8 6.5 -6.4 to 19.4 0.3 
Sexual life 
18.0 to 24.9 14 91.7 14.6 334 95.4 13.5 -3.7 -11.0 to 3.6 0.3 
25.0 to 29.9 29 94.2 9.6 1174 84.5 22.5 9.7 1.5 to 19.9 0.02 
30.0 to 34.9 30 82.1 20.8 3189 75.7 26.1 6.4 -3.0 to 15.8 0.2 
35.0 to 39.9 13 84.6 27.3 2941 70.9 27.8 13.7 -1.5 to 28.9 0.08 







Bariatric follow up study (n=119) 
IWQOL-lite reference data 
(n=11,640) 
Unpaired T test 
n Mean SD n Mean SD Est. diff. 95% CI P value 
Public 
distress 
18.0 to 24.9 14 95.0 10.9 338 97.7 9.0 -2.7 -7.6 to 2.2 0.3 
25.0 to 29.9 31 99.7 1.2 1199 95.8 9.2 3.9 0.7 to 7.1 0.02 
30.0 to 34.9 32 88.6 18.5 3282 90.4 14.1 -1.8 -6.7 to 3.1 0.5 
35.0 to 39.9 14 80.0 19.1 3021 79.9 20.4 0.1 -10.6 to 10.8 1.0 
>40.0 17 63.8 25.5 3795 52.8 27.8 11.0 -2.3 to 24.3 0.1 
Work 
18.0 to 24.9 14 97.8 8.4 328 97.4 8.7 0.4 -4.3 to 5.1 0.9 
25.0 to 29.9 31 99.0 3.3 1183 90.7 9.3 8.3 5.0 to 11.6 <0.001 
30.0 to 34.9 30 92.3 13.2 3256 85.4 17.9 6.9 -0.3 to 14.1 0.06 
35.0 to 39.9 14 86.6 16.6 2980 79.1 21.6 7.5 -3.9 to 18.9 0.2 
>40.0 16 82.0 16.9 3731 64.6 28.0 17.4 3.6 to 31.2 0.01 
Total 
18.0 to 24.9 14 92.5 12.8 338 94.0 9.2 -1.5 -6.5 to 3.5 0.6 
25.0 to 29.9 29 93.8 5.0 1199 84.6 13.3 9.2 4.3 to 14.1 <0.001 
30.0 to 34.9 27 84.1 16.8 3284 75.4 16.5 8.7 0.02 to 17.4 0.05 
35.0 to 39.9 14 75.5 12.3 3023 67.0 18.9 8.5 -1.4 to 18.4 0.09 





Figure ii-15  Bivariate correlation using Pearson’s correlation coefficient for a) physical function, b) self-esteem, 
c) sexual function, d) public distress, e) work, and f) total % scores against BMI (kg/m2) at follow up 
 


















Table ii-18   Baseline characteristics of the recruited participants (n=118) and non-recruited persons (n=1114).  Results of an independent T test are shown 
 
Recruited population (n=118) Non-recruited population (n=1114) Independent T test 
n (%) Mean (SD) IQR Min/Max n (%) Mean (SD) IQR Min/Max Est. diff 95% CI P value 
Age (years) 118 (100) 47.5 (10.5) 14.9 23.4/68.5 1099 (99) 43.8 (10.9) 15.0 18.0/83.0 3.7 1.7 to 5.8 <0.001 
Weight (kg) 118 (100) 128.8 (26.8) 36.0 83.0/202.0 1046 (94) 132.0 (30.1) 35.6 66.0/360.0 3.1 -2.6 to 8.8 0.28 
BMI (kg/m2) 118 (100) 46.6 (8.6) 11.8 33.0/74.9 1046 (94) 49.9 (9.1) 11.2 22.8/99.3 0.28 -1.4 to 1.9 0.75 
Fasting glucose 
(mmol/L) 
105 (89) 6.16 (2.08) 1.75 3.90/13.90 937 (84) 6.09 (2.41) 1.30 3.10/21.90 0.07 -0.55 to 0.40 0.77 
HbA1c 
(mmol/mol) 
92 (78) 47.1 (14.7) 16.0 28/99 722 (65) 44.9 (14.8) 9.0 26/117 2.3 -1.0 to 5.5 0.17 
Systolic blood 
pressure (mmHg) 
99 (84) 141.9 (20.7) 30.0 100.0/200.0 648 (58) 139.3 (20.2) 30.0 95.0/200.0 2.6 -1.7 to 6.9 0.24 
Diastolic blood 
pressure (mmHg) 




98 (83) 101.9 (13.9) 15.3 66.7/133.3 643 (58) 101.7 (14.1) 17.3 66.7/153.3 0.16 -2.8 to 3.2 0.92 
Total cholesterol 
(mmol/L) 





Table ii-19   One and two year follow up data for recruited participants (n=118) and non-recruited persons (n=684).  Results of an independent T test are shown 
 
 
Recruited population (n=118) Non-recruited population (n=684) Independent T test 
n (%) Mean (SD) IQR Min/Max n (%) Mean (SD) IQR Min/Max Est. diff 95% CI 
P 
value 
One year data 
Weight (kg)  92 (78) 84.2 (20.3) 26.6 46.6/139.0 92 (674) 85.8 (21.1) 27.6 45.5/180.0 1.7 -2.9 to 6.3 0.5 
BMI (kg/m2) 92 (78) 29.7 (6.3) 5.8 17.5/54.0 92 (78) 30.6 (8.5) 8.5 17.8/61.0 0.9 -0.6 to 2.4 0.9 
Fasting glucose 
(mmol/L) 
88 (75) 4.87 (0.85) 0.65 3.70/9.10 628 (92) 4.86 (0.96) 0.60 2.90/16.30 0.01 -0.2 to 0.2 0.93 
HbA1c 
(mmol/mol) 
88 (75) 35.8 (5.6) 7.0 23/54 624 (91) 36.3 (8.1) 6.0 20/128 0.9 -1.2 to 2.3 0.5 
Systolic blood 
pressure (mmHg) 
92 (78) 119.1 (17.3) 20.0 80.0/166.0 647 (95) 117.9 (16.7) 24.0 80.0/120.0 1.2 -2.5 to 5.0 0.5 
Diastolic blood 
pressure (mmHg) 




92 (78) 87.8 (12.5) 16.0 53.3/120.0 646 (94) 87.8 (12.0) 16.0 53.3/140.0 0.02 -2.7 to 2.6 0.99 
Total cholesterol 
(mmol/L) 





Recruited population (n=118) Non-recruited population (n=684) Independent T test 
N (%) Mean (SD) IQR Min/Max n (%) Mean (SD) IQR Min/Max Est. diff 95% CI 
P 
value 
Two year data 
Weight (kg)  92 (78) 83.1 (20.6) 28.2 49.8/148.2 92 (78) 83.6 (20.0) 26.1 46.5/162.9 0.5 -3.9 to 4.8 0.8 
BMI (kg/m2) 92 (78) 29.4 (6.3) 6.7 18.7/54.0 92 (78) 29.9 (6.5) 7.7 18.2/61.0 0.5 -0.9 to 1.9 0.5 
Fasting glucose 
(mmol/L) 
92 (78) 4.88 (0.73) 0.5 4.00/9.20 640 (94) 4.91 (0.60) 0.60 2.90/25.0 0.04 -0.2 to 0.3 0.8 
HbA1c 
(mmol/mol) 
89 (75 37.0 (7.0) 7.0 28/58 636 (93) 36.5 (8.0) 5.8 20/128 0.5 -1.2 to 2.2 0.6 
Systolic blood 
pressure (mmHg) 
92 (78) 121.1 (16.0) 22.0 80.0/160.0 657 (96) 118.9 (17.2) 20.0 90.0/200.0 2.2 -1.5 to 6.0 0.3 
Diastolic blood 
pressure (mmHg) 




92 (78) 89.3 (11.7) 12.0 53.3/120.0 656 (96) 88.7 (12.5) 16.5 53.3/143.3 0.7 -2.1 to 3.4 0.6 
Total cholesterol 
(mmol/L) 




iii. Appendix C 
Figure iii-1   Frequency histograms showing the distribution of a) fasting glucose (mmol/L), b) HbA1c 






























Table iii-1   Shapiro-Wilk test of normality results for glycaemic markers at baseline and follow up. 
 
Baseline Follow up 
Statistic P value Statistic P value 
Fasting glucose 0.78 <0.01 0.59 <0.01 
HbA1c 0.83 <0.01 0.79 <0.01 
Fasting insulin 0.93 <0.01 0.89 <0.01 
HOMA-IR 0.97 0.2 0.88 <0.01 
 
Figure iii-2   Frequency histograms showing the distribution of a) fasting glucose (mmol/L), b) HbA1c 
(mmol/mol), c) insulin (pmol/L), and d) HOMA-IR, at baseline (left column) and follow up up (right column) after 


















































v. Appendix E 
Figure v-1   Frequency histograms to show distributions of a) BMI at baseline, b) minimum BMI, c) BMI at final 

































Figure v-2   Frequency histograms to show the distribution of a) change in BMI from baseline to minimum BMI, 
b) change in BMI from baseline to final follow up assessment, and c) change in BMI from minimum BMI to final 
follow up assessment. 






























Figure v-3   Frequency histograms to show distributions of a) fasting glucose at baseline, b) fasting glucose at 
follow up, c) HbA1c at baseline, d) HbA1c at follow up, e) fasting insulin at baseline, f) fasting insulin at follow 
up, g) HOMA-IR at baseline, and h) HOMA-IR at follow up before (left colum) and after logarithmic 




















































































Table v-1  Mean (Standard deviations) and 95% confidence intervals for ln(x) leptin (pmol/L), ln(x) ghrelin 
(pmol/L), ln(x) PYY (pmol/L), and ln(x) amylin (pmol/L) measured on the day before gastric bypass surgery , on 
day six following surgery, and at follow up greater than five years following surgery. 

















































































Figure v-4   Frequency histograms showing (left hand column) fasting concentrations of Leptin (pg/dl) before 
surgery, on day six following surgery, and at greater than five years.  Histograms of transformed (ln(x)) data are 






























Figure v-5   Frequency histograms showing (left hand column) fasting concentrations of Ghrelin (pg/ml) before 
surgery, on day six following surgery, and at greater than five years.  Histograms of transformed (ln(x)) data are 



































Figure v-6   Frequency histograms showing (left hand column) fasting concentrations of PYY (pg/ml) before 
surgery, on day six following surgery, and at greater than five years.  Histograms of transformed (ln(x)) data are 



































Figure v-7   Frequency histograms showing (left hand column) fasting concentrations of amylin (pg/ml) before 
surgery, on day six following surgery, and at greater than five years.  Histograms of transformed (ln(x)) data are 
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334 Sa ̈mann A, Mu ḧlhauser I, Bender R, Kloos Ch, Mu ̈ller UA. Glycaemic control and severe hypoglycaemia following training in flexible, 
intensive insulin therapy to enable dietary freedom in people with type 1 diabetes: a pro- spective implementation study. 
Diabetologia 2005;48:1965–1970  
335 Natali, A., & Ferrannini, E. (2006). Effects of metformin and thiazolidinediones on suppression of hepatic glucose production and 
stimulation of glucose uptake in type 2 diabetes: a systematic review. Diabetologia, 49(3), 434-441. 
336 Zimmerman BR. Sulfonylureas. Endocrinol Metab Clin North Am. 1997;26:511-521. 
337 Inzucchi, S. E. (2002). Oral antihyperglycemic therapy for type 2 diabetes: scientific review. Jama, 287(3), 360-372. 
338 UK Prospective Diabetes Study (UKPDS) Group. In- tensive blood-glucose control with sulphonylureas or insulin compared with 
conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837-853  
339 Johansen K. Efficacy of metformin in the treatment of NIDDM: meta-analysis. Diabetes Care. 1999; 22:33-37. 
340 Bailey CJ, Turner RC. Metformin. N Engl J Med. 1996;334:574-579. 
341 Salpeter, S. R., Greyber, E., Pasternak, G. A., & Salpeter, E. E. (2003). Risk of fatal and nonfatal lactic acidosis with metformin use in 
type 2 diabetes mellitus: systematic review and meta-analysis. Archives of internal medicine, 163(21), 2594-2602. 
342 Misbin RI, Green L, Stadel BV, Gueriguian JL, Gubbi A, Fleming GA. Lactic acidosis in patients with diabetes treated with metformin. N 
Engl J Med. 1998; 338:265-266. 
343 Cariou, B., Charbonnel, B., & Staels, B. (2012). Thiazolidinediones and PPARγ agonists: time for a reassessment. Trends in 
Endocrinology & Metabolism, 23(5), 205-215. 
344 Yki-Järvinen, H. (2004). Thiazolidinediones. New England Journal of Medicine, 351(11), 1106-1118. 
345 Bilezikian, J. P., Josse, R. G., Eastell, R., Lewiecki, E. M., Miller, C. G., Wooddell, M., ... & Fitzpatrick, L. A. (2013). Rosiglitazone 
decreases bone mineral density and increases bone turnover in postmenopausal women with type 2 diabetes mellitus. The Journal of 
Clinical Endocrinology & Metabolism, 98(4), 1519-1528. 
346 Colhoun, H. M., Livingstone, S. J., Looker, H. C., Morris, A. D., Wild, S. H., Lindsay, R. S., ... & Scottish Diabetes Research Network 
Epidemiology Group. (2012). Hospitalised hip fracture risk with rosiglitazone and pioglitazone use compared with other glucose-
lowering drugs. Diabetologia, 55(11), 2929-2937. 
347 Loke YK, Singh S & Furberg CD. Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis. CMAJ: Canadian 
Medical Association Journal200918032–39. 
348 Lewis, J. D., Ferrara, A., Peng, T., Hedderson, M., Bilker, W. B., Quesenberry, C. P., & Strom, B. L. (2011). Risk of bladder cancer among 
diabetic patients treated with pioglitazone interim report of a longitudinal cohort study. Diabetes care, 34(4), 916-922. 
349 Lewis, J. D., Habel, L. A., Quesenberry, C. P., Strom, B. L., Peng, T., Hedderson, M. M., ... & Ferrara, A. (2015). Pioglitazone use and risk 




                                                                                                                                                                                    
350 Kuo HW, Tiao MM, Ho SC, Yang CY. Pioglitazone use and the risk of bladder cancer. Kaoh- siung J Med Sci 2014;30:94–97 
351 Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., ... & Matthews, D. R. (2015). Management of 
hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes 
Association and the European Association for the Study of Diabetes. Diabetes Care, 38(1), 140-149. 
352 Lebowitz HE. �-Glucosidase inhibitors as agents in the treatment of diabetes. Diabetes Rev. 1998;6: 132-145 
353 Brunetti, L., & DeSantis, E. H. (2015). Patient Tolerance and Acceptance of Colesevelam Hydrochloride: Focus on Type-2 Diabetes 
Mellitus. Pharmacy and Therapeutics, 40(1), 62. 
354 Beysen, C., Murphy, E. J., Deines, K., Chan, M., Tsang, E., Glass, A., ... & Hellerstein, M. K. (2012). Effect of bile acid sequestrants on 
glucose metabolism, hepatic de novo lipogenesis, and cholesterol and bile acid kinetics in type 2 diabetes: a randomised controlled 
study. Diabetologia, 55(2), 432-442. 
355 Ryan, G. J., Jobe, L. J., & Martin, R. (2005). Pramlintide in the treatment of type 1 and type 2 diabetes mellitus. Clinical therapeutics, 
27(10), 1500-1512. 
356 Hollander, P. A., Levy, P., Fineman, M. S., Maggs, D. G., Shen, L. Z., Strobel, S. A., ... & Kolterman, O. G. (2003). Pramlintide as an 
Adjunct to Insulin Therapy Improves Long-Term Glycemic and Weight Control in Patients With Type 2 Diabetes A 1-year randomized 
controlled trial. Diabetes care, 26(3), 784-790. 
357 Singh-Franco, D., Robles, G., & Gazze, D. (2007). Pramlintide acetate injection for the treatment of type 1 and type 2 diabetes mellitus. 
Clinical therapeutics, 29(4), 535-562. 
358 Ferrannini, E., & Solini, A. (2012). SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects. Nature Reviews Endocrinology, 
8(8), 495-502. 
359 Vasilakou D, Karagiannis T, Athanasiadou E, et al. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review 
and meta- analysis. Ann Intern Med 2013;159:262–274 
360 Nauck MA, Del Prato S, Meier JJ, et al. Da- pagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have 
inade- quate glycemic control with metformin: a random- ized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes 
Care 2011;34:2015– 2022 
361 Erondu, N., Desai, M., Ways, K., & Meininger, G. (2015). Diabetic ketoacidosis and related events in the canagliflozin type 2 diabetes 
clinical program. Diabetes care, dc151251. 
362 Rosenstock, J., & Ferrannini, E. (2015). Euglycemic diabetic ketoacidosis: a predictable, detectable, and preventable safety concern 
with SGLT2 inhibitors. Diabetes care, 38(9), 1638-1642. 
363 Bolinder J, Ljunggren, Johansson L, et al. Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 
years in patients with type 2 diabetes mellitus inadequately controlled on metformin. Diabetes Obes Metab. 2014;16:159 –69 
364 FDA briefing document. Invokana (canagli- flozin) tablets. [NDA 204042], U.S. Food and Drug Administration, 2013 
365 Deacon, C. F. (2011). Dipeptidyl peptidase‐4 inhibitors in the treatment of type 2 diabetes: a comparative review. Diabetes, Obesity 
and Metabolism, 13(1), 7-18. 
366 Karagiannis, T., Paschos, P., Paletas, K., Matthews, D. R., & Tsapas, A. (2012). Dipeptidyl peptidase-4 inhibitors for treatment of type 2 
diabetes mellitus in the clinical setting: systematic review and meta-analysis. Bmj, 344. 
367 Liu, S. C., Tu, Y. K., Chien, M. N., & Chien, K. L. (2012). Effect of antidiabetic agents added to metformin on glycaemic control, 
hypoglycaemia and weight change in patients with type 2 diabetes: a network meta‐analysis. Diabetes, Obesity and Metabolism, 
14(9), 810-820. 
368 Green, J. B., Bethel, M. A., Armstrong, P. W., Buse, J. B., Engel, S. S., Garg, J., ... & Holman, R. R. (2015). Effect of sitagliptin on 




                                                                                                                                                                                    
369 Wu, S., Hopper, I., Skiba, M., & Krum, H. (2014). Dipeptidyl Peptidase‐4 Inhibitors and Cardiovascular Outcomes: Meta‐Analysis of 
Randomized Clinical Trials with 55,141 Participants. Cardiovascular therapeutics, 32(4), 147-158. 
370 Meier, J. J. (2012). GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nature Reviews Endocrinology, 
8(12), 728-742. 
371 Cho, Y. M., Wideman, R. D., & Kieffer, T. J. (2013). Clinical application of glucagon-like peptide 1 receptor agonists for the treatment of 
type 2 diabetes mellitus. Endocrinology and Metabolism, 28(4), 262-274. 
372 Li, L., Shen, J., Bala, M. M., Busse, J. W., Ebrahim, S., Vandvik, P. O., ... & Sun, X. (2014). Incretin treatment and risk of pancreatitis in 
patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studies. BmJ, 348, 
g2366. 
373 Eng, C., Kramer, C. K., Zinman, B., & Retnakaran, R. (2015). Glucagon-like peptide-1 receptor agonist and basal insulin combination 
treatment for the management of type 2 diabetes: a systematic review and meta-analysis. The Lancet, 384(9961), 2228-2234. 
374 Diamant M, Nauck MA, Shaginian R, et al.; 4B Study Group. Glucagon-like peptide 1 recep- tor agonist or bolus insulin with optimized 
basal insulin in type 2 diabetes. Diabetes Care 2014; 37:2763–2773 
375 Holman RR, Thorne KI, Farmer AJ, et al.; 4-T Study Group. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 
diabetes. N Engl J Med 2007;357:1716–1730  
376 Rodgers S, Burnet R, Goss A, et al. Jaw wiring in treat- ment of obesity. Lancet 1977; 1(8024):1221–1222  
377 Kremen AJ, Linner JH, Nelson CH. An experi- mental evaluation of the nutritional importance of proximal and distal small intestine. 
Ann Surg 1954; 140:439–448 
378 Payne JH, DeWind LT, Commons RR. Metabolic observations in patients with jejunocolic shunts. Am J Surg 1963; 106:273–289  
379 Shibata HR, MacKenzie JR, Long RC. Metabolic effects of controlled jejunocolic bypass. Arch Surg 1967; 95:413–428 
380 Jorgensen S, Olesen M, Gudman-Hoyer E. A review of 20 years of jejunoileal bypass. ScandJGastroenterol. 1997;32:334- 339. 
381 Mason, E. E., & Ito, C. (1967). Gastric bypass in obesity. The Surgical clinics of North America, 47(6), 1345-1351. 
382 Rubino, F., Schauer, P. R., Kaplan, L. M. & Cummings, D. E. Metabolic Surgery to Treat Type 2 Diabetes : Clinical Outcomes and 
Mechanisms of Action. Annu. Rev. Med. 61, 393 (2012).  
383 Alden JF. Gastric and jejuno-ileal bypass: a com- parison in treatment of morbid obesity. Arch Surg 1977; 112:799  
384 Fobi, M. A. L. (2004). Surgical treatment of obesity: a review. Journal of the National Medical Association, 96(1), 61. 
385 Fobi, M. A. L., Lee, H., & Flemming, A. (1989). The surgical technique of the banded Roux-en-Y gastric bypass. J Obesity Weight Reg, 
8(2), 99-102. 
386 Scopinaro N, Gianetta E, Civalleri D, et al. Bilio- pancreatic bypass for obesity. Part II. Initial expe- rience in man. Br J Surg 1979; 
66:618–620  
387 Molina M. Gastric banding, an experience with more than 500 cases. Presented at symposium on surgical treatment of 
obesity,LosAngeles,CA, 1984. 
388 Chakravarty, P. D., McLaughlin, E., Whittaker, D., Byrne, E., Cowan, E., Xu, K., ... & Ford, J. A. (2012). Comparison of laparoscopic 
adjustable gastric banding (LAGB) with other bariatric procedures; a systematic review of the randomised controlled trials. the 
surgeon, 10(3), 172-182. 
389 O'Brien, P. E., MacDonald, L., Anderson, M., Brennan, L., & Brown, W. A. (2013). Long-term outcomes after bariatric surgery: fifteen-





                                                                                                                                                                                    
390 Brethauer, S. A., Hammel, J. P., & Schauer, P. R. (2009). Systematic review of sleeve gastrectomy as staging and primary bariatric 
procedure. Surgery for Obesity and Related Diseases, 5(4), 469-475. 
391 Melissas, J., Koukouraki, S., Askoxylakis, J., Stathaki, M., Daskalakis, M., Perisinakis, K., & Karkavitsas, N. (2007). Sleeve gastrectomy—a 
restrictive procedure?. Obesity surgery, 17(1), 57-62. 
392 Dixon, J. B., le Roux, C. W., Rubino, F., & Zimmet, P. (2012). Bariatric surgery for type 2 diabetes. The Lancet, 379(9833), 2300-2311. 
393 Montero PN, Stefanidis D, Horton HJ, Gersin K, Kuwada T. (2011) Reported excess weight loss afterbariatric surgery could vary  
significantly depending on calculation method: a plea for standardization. Surg Obes Relat Dis 7(4), 531-534 
394 Mingrone G, Greco AV, Giancaterini A, Scarfone A, Castagneto M, Pugeat M. Sex hormone-binding globulin concentrations and 
cardiovascular risk factors in morbidly obese subjects 39 before and after weight reduction induced by diet or malabsorptive surgery. 
Atherosclerosis 2002;161:455-62.  
395 O’Brien PE, Sawyer SM, Laurie C, Brown WA, Skinner S, Veit F, et al. Laparoscopic 44 adjustable gastric banding in severely o bese 
adolescents: A randomized trial. JAMA 2010;303:519-26.  
396 Mingrone G, Panunzi S, De Gaetano A, Guidone C, Iaconelli A, Leccesi L, et al. Bariatric surgery versus conventional medical therapy for 
type 2 diabetes. N Engl J Med 2012;366:1577-85.  
397 Dixon JB, Schachter LM, O’Brien PE, Jones K, Grima M, Lambert G, et al. Surgical vs conventional therapy for weight loss treatment of 
obstructive sleep apnea: a randomized controlled trial. JAMA 2012;308:1142-9.  
398 O’Brien PE, Dixon JB, Laurie C, Skinner S, Proietto J, McNeil J, et al. Treatment of mild to moderate obesity with laparoscop ic 
adjustable gastric banding or an intensive medical program: a randomized trial. Ann Intern Med 2006;144:625-33.  
399 Dixon JB, O’Brien PE, Playfair J, Chapman L, Schachter LM, Skinner S, et al. Adjustable gastric banding and conventional therapy for type 
2 diabetes: a randomized controlled trial. Obstet Gynecol Survey 2008;63:372-3. 
400 Ikramuddin S, Korner J, Lee WJ, Connett JE, Inabnet WB, Billington CJ, et al. Roux-en-Y 41 gastric bypass vs intensive medical 
management for the control of type 2 diabetes, hypertension, and hyperlipidemia: the Diabetes Surgery Study randomized clinical 
trial. 42 JAMA 2013;309:2240-9.  
401 Liang Z, et al.  (2013)  Effect of laparoscopic Roux-en-Y gastric bypass surgery on type 2 diabetes mellitus with hypertension: A 
randomized controlled trial.  Diabetes research and clinical practice 101; 50-56 
402 Schauer PR et al (2014)  Bariatric surgery versus intensive medical therapy for diabetes – 3 year outcomes. N Engl J Med 2014;370:2002-
13. 
403 Courcoulas AP et al.  (2015) Three year outcomes of bariatric surgery vs lifestyle intervention for type 2 diabetes mellitus treatment.  A 
randomized clinical trial.  JAMA Surg 150(10); 931-940 
404 Pories, W. J., Swanson, M. S., MacDonald, K. G., Long, S. B., Morris, P. G., Brown, B. M., & Barakat, H. A. (1995). Who would  have 
thought it? An operation proves to be the most effective therapy for adult-onset diabetes mellitus. Annals of surgery, 222(3), 339. 
405 Zimmet P, Alberti KGMM, Rubino F, Dixon JB. IDF’s view of bariatric surgery in type 2 diabetes. Lancet. 2011;378(9786):108–10.  
406 Ihnat M, Thorpe JE, et al. Hypothesis: the “metabolic memory”, the new challenge of diabetes. Diabet Med. 2007;24(6):582–6. 
407 Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW. 10-Year Follow-Up of Intensive Glucose Control in Type 2 Diabetes. N Engl J 
Med. 2008;359(15):1577–89.. 
408 Buse JB, Caprio S, Cefalu WT et al. How do we define cure of diabetes? Diabetes care. 2009;32(11):2133-2135 
409 ACCORD Study Group. Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 
2008;358:2545–59 
410 Currie, C. J., Peters, J. R., Tynan, A., Evans, M., Heine, R. J., Bracco, O. L., ... & Poole, C. D. (2010). Survival as a function of HbA 1c in 




                                                                                                                                                                                    
411 Hofsø D, Nordstrand N, Johnson LK, et al. Obesity-related cardiovascular risk factors after weight loss: a clinical trial comparing gastric 
bypass surgery and intensive lifestyle intervention. Eur J Endocrinol. 2010;163(5):735–45.  
412 Ikramuddin S, Korner J, Lee W-J, et al. Roux-en-Y Gastric Bypass vs Intensive Medical Management for the Control of Type 2 Diabetes, 
hypertension, and hyperlipidaemia. JAMA. 2013;309(21):2240–2249.. 
413 Serrot FJ, Dorman RB, Miller CJ, et al. Comparative effectiveness of bariatric surgery and nonsurgical therapy in adults with  type 2 
diabetes mellitus and body mass index <35 kg/m2. Surgery. 2011;150(4):684–91. 
414 Lee W-J, Chong K, Ser K-H, et al. Gastric Bypass vs Sleeve Gastrectomy for Type 2 Diabetes Mellitus. Arch Surg. 2011;146(2):143–148. 
415 Schauer PR, Kashyap SR, Wolski K, et al. Bariatric Surgery versus Intensive Medical Therapy in Obese Patients with Diabetes. N Engl J 
Med. 2012:1–10. 
416 Vidal J, et al. Type 2 Diabetes Mellitus and the Metabolic Syndrome Following Sleeve Gastrectomy in Severely Obese Subjects. Obes 
Surg. 2008;18(9):1077-1082 
417 Scopinaro N, Adami GF, Papadia FS, et al. Effects of biliopanceratic diversion on type 2 diabetes in patients with BMI 25 to 35. Ann 
Surg. 2011;253(4):699–703. 
418 Leslie DP, et al.  Efficacy of the Roux-en-Y Gastric Bypass Compared to Medically Managed Controls in Meeting the American Diabetes 
Association Composite End Point Goals for Management of Type 2 Diabetes Mellitus.  Obes Surg. 2012;22(3):367-374 
419 Dixon JB, O’Brien PE, Playfair J, et al. Adjustable gastric banding and conventional therapy for type 2 diabetes: a randomized 
controlled trial. JAMA. 2008;299(3):316–23.. 
420 Kashyap SR, Bhatt DL, Wolski K, et al. Metabolic Effects of Bariatric Surgery. Diabetes care. 2013;36:2175–2182.  
421 Mingrone G, Panunzi S, Gaetano A De, et al. Bariatric Surgery versus Conventional Medical Therapy for Type 2 Diabetes. N Engl J Med. 
2012:1–9. 
422 Adams TD, Davidson LE, Litwin SE, et al. Health Benefits of Gastric Bypass Surgery After 6 Years. JAMA. 2012;308(11). 
423 Pontiroli A, Folli F, Paganelli M, et al. Laparoscopic Gastric Banding Prevents Type 2 Diabetes and Arterial Hypertension and  Induces 
Their Remission in Morbid Obesity. Diabetes Care. 2005;28(11):2703–2709. 
424 Iaconelli A, Panunzi S, De Gaetano A, et al. Effects of bilio-pancreatic diversion on diabetic complications: a 10-year follow-up. 
Diabetes Care. 2011;34(3):561–7.. 
425 Pinheiro JS, et al. Long-long limb Roux-en-Y gastric bypass is more efficacious in treatment of type 2 diabetes and lipid disorders in 
super-obese patients.  Surg Obes Relat Dis. 2008, 4(4), 521-525 
426 Pournaras DJ, Osborne A, Hawkins SC, Royce P. Remission of Type 2 Diabetes After Gastric Bypass and Banding. Ann Surg. 
2010;252(6):1–6. 
427 Schauer PR, Bhatt DL, Kirwan JP, et al. Bariatric Surgery versus Intensive Medical Therapy for Diabetes - 3-Year Outcomes. N Engl J 
Med. 2014:1–12.  
428 Sjöström L, Lindroos A, Peltonen M. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med. 
2004;351(26):2683–2693.  
429 Li J-F, Lai D-D, Ni B, et al. Comparison of laparoscopic Roux-en-Y gastric bypass with laparoscopic sleeve gastrectomy for morbid 
obesity or type 2 diabetes mellitus : a meta-analysis of randomized controlled trials. J Can Chir. 2013;56(6):158–164. 
430 Maggard-gibbons M, Maglione M, Livhits M, Ewing B, Maher AR. Bariatric Surgery for Weight Loss and Glycemic Control in 
Nonmorbidly Obese Adults with Diabetes. JAMA. 2013;309(21):2250–2261. 





                                                                                                                                                                                    
432 Parikh M, Issa R, Vieira D, et al. Role of bariatric surgery as treatment for type 2 diabetes in patients who do not meet current NIH 
criteria: a systematic review and meta-analysis. J Am Coll Surg. 2013;217(3):527–32.  
433 Buchwald H, Estok R, Fahrbach K, Banel D, et al. Weight and Type 2 Diabetes after Bariatric Surgery : Systematic Review and Meta-
analysis. AJM. 2009;122(3):248–256. 
434 Buchwald H, Avidor Y, Braunwald E, et al. Bariatric Surgery: A Systematic Review and Meta-analysis. JAMA. 2004;292(14):1724–1737. 
435 Yip S, Plank L, Murphy R.  Gastric bypass and sleeve gastrectomy for type 2 diabetes: a systematic review and meta-analysis of 
outcomes.  Obes Surg 2013:23(12), 1994-2003 
436 Still, C. D., Wood, G. C., Benotti, P., Petrick, A. T., Gabrielsen, J., Strodel, W. E., ... & Argyropoulos, G. (2014). Preoperative prediction of 
type 2 diabetes remission after Roux-en-Y gastric bypass surgery: a retrospective cohort study. The Lancet Diabetes & Endocrinology, 
2(1), 38-45 
437 Hamza N, Abbas MH, Darwish A, Shafeek Z, New J, Ammori BJ. Predictors of remission of type 2 diabetes mellitus after laparoscopic 
gastric banding and bypass. Surgery for obesity and related diseases: official journal of the American Society for Bariatric Surgery. 2011; 
7(6):691–6. 
438 Schauer PR, Burguera B, Ikramuddin S, et al. Effect of laparoscopic Roux-en Y gastric bypass on type 2 diabetes mellitus. Ann Surg. 
2003;238(4):467–84  
439 Steven, S., Carey, P. E., Small, P. K., & Taylor, R. (2015). Reversal of Type 2 diabetes after bariatric surgery is determined by the degree 
of achieved weight loss in both short‐and long‐duration diabetes. Diabetic Medicine, 32(1), 47-53. 
440 Dixon JB, Chuang LM, Chong K, et al. Predicting the glycemic response to gastric bypass surgery in patients with type 2 diabetes. Diabetes 
Care. 2013;36(1):20–6. PMCID: 3526207. 
441 Deitel M. Update: Why diabetes does not resolve in some patients after bariatric surgery. Obesity surgery. 2011; 21(6):794–6.  
442 Lee WJ, Hur KY, Lakadawala M, et al. Gastrointestinal metabolic surgery for the treatment of diabetic patients: a multi -institutional 
international study. J Gastrointest Surg. 2012;16(1):45–51.   
443 Bhasker, A. G., Remedios, C., Batra, P., Sood, A., Shaikh, S., & Lakdawala, M. (2014). Predictors of Remission of T2DM and Metabolic 
Effects after Laparoscopic Roux-en-y Gastric Bypass in Obese Indian Diabetics—a 5-Year Study. Obesity surgery, 1-7. 
444 Panunzi, S., De Gaetano, A., Carnicelli, A., & Mingrone, G. (2015). Predictors of remission of diabetes mellitus in severely obese 
individuals undergoing bariatric surgery: do BMI or procedure choice matter? A meta-analysis. Annals of surgery, 261(3), 459-467. 
445 Zenti, M. G., Rubbo, I., Ceradini, G., Rinaldi, E., Nadalini, L., Battistoni, M., ... & Zoppini, G. (2015). Clinical factors that predict remission 
of diabetes after different bariatric surgical procedures: interdisciplinary group of bariatric surgery of Verona (GICOV). Acta 
diabetologica, 1-6. 
446 Wang, G. F., Yan, Y. X., Xu, N., Yin, D., Hui, Y., Zhang, J. P., ... & Yang, T. (2015). Predictive factors of type 2 diabetes  mellitus remission 
following bariatric surgery: a meta-analysis. Obesity surgery, 25(2), 199-208. 
447 Chikunguwo SM, Wolfe LG, Dodson P, et al. Analysis of factors associated with durable remission of diabetes after Roux -en-Y gastric 
bypass. Surgery for obesity and related diseases: official journal of the American Society for Bariatric Surgery. 2010; 6(3):254–9. 
448 Hall, T. C., Pellen, M. G., Sedman, P. C., & Jain, P. K. (2010). Preoperative factors predicting remission of type 2 diabetes mellitus after 
Roux-en-Y gastric bypass surgery for obesity. Obesity surgery, 20(9), 1245-1250. 
449 Yu, H., Di, J., Bao, Y., Zhang, P., Zhang, L., Tu, Y., ... & Jia, W. (2015). Visceral fat area as a new predictor of short-term diabetes remission 
after Roux-en-Y gastric bypass surgery in Chinese patients with a body mass index less than 35 kg/m 2. Surgery for Obesity and Related 
Diseases, 11(1), 6-11. 
450 Hayes MT, Hunt LA, Foo J, et al. A model for predicting the resolution of type 2 diabetes in severely obese subjects followin g Roux-en Y 




                                                                                                                                                                                    
451 Still CD, Wood GC, Chu X, Manney C, Strodel W, Petrick A, et al. Clinical factors associated with weight loss outcomes after Roux -en- Y 
gastric bypass surgery. Obesity (Silver Spring). 2013 
452 Lee, W. J., Chong, K., Ser, K. H., Chen, J. C., Lee, Y. C., Chen, S. C., ...  & Tsai, M. H. (2012). C-peptide predicts the remission of type 2 
diabetes after bariatric surgery. Obesity surgery, 22(2), 293-298. 
453 Dahl-Jørgensen, K., Brinchmann-Hansen, O., Hanssen, K. F., Sandvik, L., & Aagenaes, O. (1985). Rapid tightening of blood glucose control 
leads to transient deterioration of retinopathy in insulin dependent diabetes mellitus: the Oslo study. BMJ, 290(6471), 811-815. 
454 van Ballegooie  EHooymans  JMTimmerman  Z  et al.  Rapid deterioration of diabetic retinopathy during treatment with continuous 
subcutaneous insulin infusion. Diabetes Care. 1984;7236- 242 
455 Dandona  PBolger  JPBoag  FFonesca  VAbrams  JD Rapid development and progression of proliferative retinopathy after strict diabetic 
control. Br Med J (Clin Res Ed). 1985;290895- 896 
456 Diabetes Control and Complications Trial Research Group. (1998). Early worsening of diabetic retinopathy in the Diabetes Control and 
Complications Trial. Archives of Ophthalmology, 116(7), 874. 
457 Mohamed, Q., Gillies, M. C., & Wong, T. Y. (2007). Management of diabetic retinopathy: a systematic review. Jama, 298(8), 902-916. 
458 Silva, R. A., Morton, J. M., & Moshfeghi, D. M. (2013). Severe worsening of diabetic retinopathy following bariatric surgery. Ophthalmic 
surgery, lasers & imaging retina, 44(6), E11. 
459 Sjöström, L., Peltonen, M., Jacobson, P., Ahlin, S., Andersson-Assarsson, J., Anveden, Å., ... & Carlsson, L. M. (2014). Association of 
bariatric surgery with long-term remission of type 2 diabetes and with microvascular and macrovascular complications. JAMA, 311(22), 
2297-2304. 
460 Singh, R. P., Gans, R., Kashyap, S. R., Bedi, R., Wolski, K., Brethauer, S. A., ... & Schauer, P. (2015). Effect of Bariatric Surgery Versus 
Intensive Medical Management on Diabetic Ophthalmic Outcomes. Diabetes care, 38(3), e32-e33. 
461 Miras, A. D., Chuah, L. L., Lascaratos, G., Faruq, S., Mohite, A. A., Shah, P. R., ... & le Roux, C. W. (2012). Bariatric surgery does not 
exacerbate and may be beneficial for the microvascular complications of type 2 diabetes. Diabetes Care, 35(12), e81-e81. 
462 Amin, A. M., Wharton, H., Clarke, M., Syed, A., Dodson, P., & Tahrani, A. A. (2015). The impact of bariatric surgery on retinopathy in 
patients with type 2 diabetes: a retrospective cohort study. Surgery for Obesity and Related Diseases. 
463 Cheung, D., Switzer, N. J., Ehmann, D., Rudnisky, C., Shi, X., & Karmali, S. (2014). The impact of bariatric surgery on diabetic retinopathy: 
a systematic review and meta-analysis. Obesity surgery, 1-6. 
464 Amor, A., Jiménez, A., Moizé, V., Ibarzabal, A., Flores, L., Lacy, A. M., & Vidal, J. (2013). Weight loss independently predicts urinary 
albumin excretion normalization in morbidly obese type 2 diabetic patients undergoing bariatric surgery. Surgical endoscopy, 27(6), 
2046-2051. 
465 Heneghan, H. M., Cetin, D., Navaneethan, S. D., Orzech, N., Brethauer, S. A., & Schauer, P. R. (2013). Effects of bariatric  surgery on 
diabetic nephropathy after 5 years of follow-up. Surgery for Obesity and Related Diseases, 9(1), 7-14. 
466 Rao, B. B., Bhattacharya, A., & Agrawal, V. (2014). Renal outcomes of bariatric surgery in obese adults with diabetic kidney disease. 
Journal of nephrology, 27(4), 361-370. 
467 Friedman, A. N., & Wolfe, B. (2015). Is Bariatric Surgery an Effective Treatment for Type II Diabetic Kidney Disease?. Clinical Journal of 
the American Society of Nephrology, CJN-07670715. 
468 Müller-Stich, B. P., Fischer, L., Kenngott, H. G., Gondan, M., Senft, J., Clemens, G., ... & Büchler, M. W. (2013). Gastric bypass leads to 
improvement of diabetic neuropathy independent of glucose normalization—results of a prospective cohort study (DiaSurg 1 study). 
Annals of surgery, 258(5), 760-766. 
469 Miras, A. D., Chuah, L. L., Khalil, N., Nicotra, A., Vusirikala, A., Baqai, N., ... & le Roux, C. W. (2015). Type 2 diabetes mellitus and 




                                                                                                                                                                                    
470 Kwok, C. S., Pradhan, A., Khan, M. A., Anderson, S. G., Keavney, B. D., Myint, P. K., ... & Loke, Y. K. (2014). Bariatric surgery and its impact 
on cardiovascular disease and mortality: a systematic review and meta-analysis. International journal of cardiology, 173(1), 20-28. 
471 Pontiroli, A. E., & Morabito, A. (2011). Long-term prevention of mortality in morbid obesity through bariatric surgery. a systematic 
review and meta-analysis of trials performed with gastric banding and gastric bypass. Annals of surgery, 253(3), 484-487. 
472 Sjöström, L., Peltonen, M., Jacobson, P., Sjöström, C. D., Karason, K., Wedel, H., ... & Carlsson, L. M. (2012). Bariatric su rgery and long-
term cardiovascular events. Jama, 307(1), 56-65. 
473 Adams TD, Gress RE, Smith SC, et al. Long-term mortality after gastric bypass surgery. N Engl J Med 2007;357:753-61. 
474 Miranda W. Long-term mortality in patients undergoing bariatric surgery compared to patients managed non-operatively for morbid 
obesity. Eur Heart J 2012;33.  
475 Klop, B., Elte, J. W. F., & Cabezas, M. C. (2013). Dyslipidemia in obesity: mechanisms and potential targets. Nutrients, 5(4) , 1218-1240. 
476 Mooradian, A. D. (2009). Dyslipidemia in type 2 diabetes mellitus. Nature clinical practice endocrinology & metabolism, 5(3), 150-159. 
477 Krauss RM and Siri PW (2004)  Dyslipidemia in type 2 diabetes. Med Clin North Am 88: 897–909 
478 Buchwald H, Avidor Y, Braunwald E. Bariatric Surgery: A Systematic Review and Meta-analysis. JAMA. 2004;292(14):1724–1737. 
doi:10.1001/jama.292.14.1724. 
479 Dixon, J. B., O’Brien, P. E., Playfair, J., Chapman, L., Schachter, L. M., Skinner, S., ... & Anderson, M. (2008). Adjustable  gastric banding 
and conventional therapy for type 2 diabetes: a randomized controlled trial. Jama, 299(3), 316-323. 
480 Corradini, S. G., Eramo, A., Lubrano, C., Spera, G., Cornoldi, A., Grossi, A., ... & Badiali, M. (2005). Comparison of changes in lipid profile 
after bilio-intestinal bypass and gastric banding in patients with morbid obesity. Obesity surgery, 15(3), 367-377. 
481 Busetto, L., Pisent, C., Rinaldi, D., De Marchi, F., Segato, G., Lise, M., ... & Favretti, F. (2000). Variation in lipid concentrations in 
morbidly obese patients operated with the lap-Band® adjustable gastric banding system: effects of different concentrations of weight 
loss. Obesity surgery, 10(6), 569-577. 
482 Pontiroli, A. E., Pizzocri, P., Librenti, M. C., Vedani, P., Marchi, M., Cucchi, E., ... & Folli, F. (2002). Laparoscopic adjustable gastric 
banding for the treatment of morbid (grade 3) obesity and its metabolic complications: a three-year study. The Journal of Clinical 
Endocrinology & Metabolism, 87(8), 3555-3561. 
483 Benaiges, D., Flores-Le-Roux, J. A., Pedro-Botet, J., Ramon, J. M., Parri, A., Villatoro, M., ... & Goday, A. (2012). Impact of restrictive 
(sleeve gastrectomy) vs hybrid bariatric surgery (Roux-en-Y gastric bypass) on lipid profile. Obesity surgery, 22(8), 1268-1275. 
484 Zhang, F., Strain, G. W., Lei, W., Dakin, G. F., Gagner, M., & Pomp, A. (2011). Changes in lipid profiles in morbidly obese patients after 
laparoscopic sleeve gastrectomy (LSG). Obesity surgery, 21(3), 305-309. 
485 Schauer PR, Kashyap SR, Wolski K, et al. Bariatric Surgery versus Intensive Medical Therapy in Obese Patients with Diabetes. N Engl J 
Med. 2012:1–10. 
486 Hady, H. R., Dadan, J., Gołaszewski, P., & Safiejko, K. (2012). Impact of laparoscopic sleeve gastrectomy on body mass index,  ghrelin, 
insulin and lipid concentrations in 100 obese patients. Videosurgery and Other Miniinvasive Techniques. 
487 Mingrone G, Panunzi S, Gaetano A De, et al. Bariatric Surgery versus Conventional Medical Therapy for Type 2 Diabetes. N Engl J Med. 
2012:1–9. 
488 Nguyen, N. T., Varela, E., Sabio, A., Tran, C. L., Stamos, M., & Wilson, S. E. (2006). Resolution of hyperlipidemia after laparoscopic 
Roux-en-Y gastric bypass. Journal of the American College of Surgeons, 203(1), 24-29. 
489 Woodard, G. A., Peraza, J., Bravo, S., Toplosky, L., Hernandez-Boussard, T., & Morton, J. M. (2010). One year improvements in 





                                                                                                                                                                                    
490 Våge, V., Nilsen, R. M., Berstad, A., Behme, J., Sletteskog, N., Gåsdal, R., ... & Mellgren, G. (2013). Predictors for remiss ion of major 
components of the metabolic syndrome after biliopancreatic diversion with duodenal switch (BPDDS). Obesity surgery, 23(1), 80-86. 
491 Rubino F, Schauer PR, Kaplan LM, Cummings DE. Metabolic Surgery to Treat Type 2 Diabetes : Clinical Outcomes and Mechanisms of 
Action. Annu Rev Med. 2012;61:393.  
492 Stefater M a, Wilson-Pérez HE, Chambers AP, Sandoval D a, Seeley RJ. All bariatric surgeries are not created equal: insights from 
mechanistic comparisons. Endocr Rev. 2012;33(4):595–622.  
493 Olbers, T., Björkman, S., Lindroos, A. K., Maleckas, A., Lönn, L., Sjöström, L., & Lönroth, H. (2006). Body composition, dietary intake, and 
energy expenditure after laparoscopic Roux-en-Y gastric bypass and laparoscopic vertical banded gastroplasty: a randomized clinical 
trial. Annals of surgery, 244(5), 715. 
494 Brolin, R. L., Robertson, L. B., Kenler, H. A., & Cody, R. P. (1994). Weight loss and dietary intake after vertical banded ga stroplasty and 
Roux-en-Y gastric bypass. Annals of surgery, 220(6), 782. 
495 Wardé-Kamar, J., Rogers, M., Flancbaum, L., & Laferrère, B. (2004). Calorie intake and meal patterns up to 4 years after Roux-en-Y gastric 
bypass surgery. Obesity surgery, 14(8), 1070-1079. 
496 Chambers, A. P., Jessen, L., Ryan, K. K., et al (2011). Weight-independent changes in blood glucose homeostasis after gastric bypass or 
vertical sleeve gastrectomy in rats. Gastroenterology, 141(3), 950-958. 
497 Stefater, M. A., Sandoval, D. A., Chambers, A. P., et al (2011). Sleeve gastrectomy in rats improves postprandial lipid clearance by 
reducing intestinal triglyceride secretion. Gastroenterology, 141(3), 939-949. 
498 StefaterMA,Pe´rez-Tilve D, Chambers AP, Wilson-Pe´rez HE,SandovalDA,Berger J, ToureM,Tscho¨pM,Woods SC, Seeley RJ 2010 Sleeve 
gastrectomy induces loss of weight and fat mass in obese rats, but does not affect leptin sensitivity. Gastroenterology 138:2426–2436, 
2436.e1–3 
499 Stylopoulos, N., Hoppin, A. G., & Kaplan, L. M. (2009). Roux‐en‐Y Gastric Bypass Enhances Energy Expenditure and Extends Lifespan in 
Diet‐induced Obese Rats. Obesity, 17(10), 1839-1847. 
500 le Roux, C. W., Aylwin, S. J., Batterham, R. L, et al. (2006). Gut hormone profiles following bariatric surgery favor an anorectic state, 
facilitate weight loss, and improve metabolic parameters. Annals of surgery, 243(1), 108. 
501 Powley TL, Phillips RJ. Gastric satiation is volumetric, intestinal satiation is nutritive. Physiol Behav 2004; 82: 69-74. 
502 Jones KL, Doran SM, Hveem K, Bartholomeusz FD, Morley JE, Sun WM, Chatterton BE, Horowitz M. Relation between postprandial 
satiation and antral area in normal subjects. Am J Clin Nutr 1997; 66: 127-132. 
503 Favretti, F., Cadiere, G. B., Segato, G., Himpens, J., De Luca, M., Busetto, L., ... & Enzi, G. (2002). Laparoscopic banding:  selection and 
technique in 830 patients. Obesity surgery, 12(3), 385-390. 
504 Suter, M., Calmes, J. M., Paroz, A., & Giusti, V. (2006). A 10-year experience with laparoscopic gastric banding for morbid obesity: high 
long-term complication and failure rates. Obesity surgery, 16(7), 829-835. 
505 Mittermair, R. P., Obermüller, S., Perathoner, A., Sieb, M., Aigner, F., & Margreiter, R. (2009). Results and complications after Swedish 
adjustable gastric banding—10 years experience. Obesity surgery, 19(12), 1636-1641. 
506 Busetto, L., Segato, G., De Marchi, F., Foletto, M., De Luca, M., Caniato, D., ... & Enzi, G. (2002). Outcome predictors in morbidly obese 
recipients of an adjustable gastric band. Obesity surgery, 12(1), 83-92. 
507 Braghetto, I., Korn, O., Valladares, H., Gutiérrez, L., Csendes, A., Debandi, A., ... & Brunet, L. (2007). Laparoscopic sleeve gastrectomy: 
surgical technique, indications and clinical results. Obesity surgery, 17(11), 1442-1450. 
508 Langer, F. B., Bohdjalian, A., Felberbauer, F. X., Fleischmann, E., Hoda, M. A. R., Ludvik, B., ... & Prager, G. (2006). Does gastric 
dilatation limit the success of sleeve gastrectomy as a sole operation for morbid obesity?. Obesity surgery, 16(2), 166-171. 
509 Weiner, R. A., Weiner, S., Pomhoff, I., Jacobi, C., Makarewicz, W., & Weigand, G. (2007). Laparoscopic sleeve gastrectomy—influence 




                                                                                                                                                                                    
510 Frezza, E. E., Chiriva-Internati, M., & Wachtel, M. S. (2008). Analysis of the results of sleeve gastrectomy for morbid obesity and the 
role of ghrelin. Surgery today, 38(6), 481-483. 
511 Perugini, R. A., Mason, R., Czerniach, D. R., Novitsky, Y. W., Baker, S., Litwin, D. E., & Kelly, J. J. (2003). Predictors of complication and 
suboptimal weight loss after laparoscopic Roux-en-Y gastric bypass: a series of 188 patients. Archives of surgery, 138(5), 541-546. 
512 Nguyen NT, Goldman C, Rosenquist CJ, et al. Laparoscopic versus open gastric bypass: a randomized study of outcomes, quality of life , 
and costs. Ann Surg 2001;234:279–289. 
513 Schauer, P. R., Ikramuddin, S., Gourash, W., Ramanathan, R., & Luketich, J. (2000). Outcomes after laparoscopic Roux-en-Y gastric 
bypass for morbid obesity. Annals of surgery, 232(4), 515. 
514 Schauer, P. R. (2003). Open and laparoscopic surgical modalities for the management of obesity. Journal of gastrointestinal s urgery, 
7(4), 468-475. 
515 Topart, P., Becouarn, G., & Ritz, P. (2011). Pouch size after gastric bypass does not correlate with weight loss outcome. Obesity  
surgery, 21(9), 1350-1354. 
516 Heneghan, H. M., Yimcharoen, P., Brethauer, S. A., Kroh, M., & Chand, B. (2012). Influence of pouch and stoma size on weight loss 
after gastric bypass. Surgery for Obesity and Related Diseases, 8(4), 408-415. 
517 Iannelli, A., Schneck, A. S., Hébuterne, X., & Gugenheim, J. (2013). Gastric pouch resizing for Roux-en-Y gastric bypass failure in 
patients with a dilated pouch. Surgery for Obesity and Related Diseases, 9(2), 260-267. 
518 Hamdi, A., Julien, C., Brown, P., Woods, I., Hamdi, A., Ortega, G., ... & Tran, D. (2014). Midterm Outcomes of Revisional Surgery for 
Gastric Pouch and Gastrojejunal Anastomotic Enlargement in Patients with Weight Regain After Gastric Bypass for Morbid Obesity. 
Obesity surgery, 1-5. 
519 Horner, K. M., Byrne, N. M., Cleghorn, G. J., Näslund, E. and King, N. A. (2011), The effects of weight loss strategies on gastric emptying 
and appetite control. Obesity Reviews. doi: 10.1111/j.1467- 789X.2011.00901.x 
520 Horowitz M, Cook DJ, Collings PJ, et al.  Measurement of gastric emptying after gastric bypass surgery using radionuclides.  British 
Journal of Surgery 69;11, 655-657, 1982 
521 Horowitz M, Collins PJ, Harding PE, Shearman DJ 1986 Gastric emptying after gastric bypass. Int J Obes 10:117– 121 
522 Naslund I, Beckman K-W. (1987) Gastric emptying rate after gastric bypass and gastroplasty.  Scandinavian journal of 
gastroenterology.  22;2, 193-201 
523 Wang G, Agenor K, Pizot J et al.  Accelerated gastric emptying but no carbohydrate malabsorption 1 year after gastric bypass surgery 
(GBP).  Obes Surg 22;8, 1263-1267 (2013) 
524 Suzuki S, Ramos EJB, Goncalves CG et al.  Changes in GI hormones and their effect on gastric emptying and transit times after Roux-en-
Y gastric bypass in rat model.  Surgery 138;2, 283-290, 2005. 
525 Guijarro A, Suzuki S, Chen C, et al. Characterization of weight loss and weight regain mechanisms after Roux-en-Y gastric bypass in rats 
Characterization of weight loss and weight regain mechanisms after Roux-en-Y gastric bypass in rats. Am J Physiol. 2012.  
526 Morinigo R, Moize V, Musri M, Lacy AM, Navarro S, Marin JL, Delgado S, Casamitjana R, Vidal J. Glucagon-like peptide-1, peptide YY, 
hunger, and satiety after gastric bypass surgery in morbidly obese subjects. J Clin Endocrinol Metab 2006; 91: 1735-1740 
527 Falkén Y, Hellström PM, Holst JJ, et al. Changes in Glucose Homeostasis after Roux-en-Y Gastric Bypass Surgery for Obesity at Day 
Three , Two Months , and One Year after Surgery : Role of Gut. J Clin Endocrinol Metab. 2011;96(July):2227–2235.  
528 Dirksen C, Damgaard M, Bojsen-Moller KN, et al.  Fast pouch emptying, delayed small intestinal transit, and exaggerated gut hormone 
responses after Roux-en-Y gastric bypass.  Neurogastroenterology and motility 25;4, 346-e255 (2013) 
529 Bernstine, H., Tzioni-Yehoshua, R., Groshar, D., Beglaibter, N., Shikora, S., Rosenthal, R. J., & Rubin, M. (2009). Gastric emptying is not 
affected by sleeve gastrectomy—scintigraphic evaluation of gastric emptying after sleeve gastrectomy without removal of the gastric 




                                                                                                                                                                                    
530 Melissas J, Koukouraki S, Askoxylakis J, Stathaki M, Daskalakis M, Perisinakis K, Karkavitsas N 2007 Sleeve gastrectomy: a restrictive 
procedure? Obes Surg 17:57–62 
531 Melissas, J., Daskalakis, M., Koukouraki, S., Askoxylakis, I., Metaxari, M., Dimitriadis, E., ... & Papadakis, J. A. (2008). Sleeve 
gastrectomy—a “food limiting” operation. Obesity surgery, 18(10), 1251-1256. 
532 Braghetto I,DavanzoC,KornO,Csendes A, ValladaresH, Herrera E, Gonzalez P, Papapietro K 2009 Scintigraphic evaluation of gastr ic 
emptying in obese patients submitted to sleeve gastrectomy compared to normal subjects. Obes Surg 19:1515–1521 
533 Shah S, Shah P, Todkar J, GagnerM,Sonar S, Solav S 2010 Prospective controlled study of effect of laparoscopic sleeve gastrectomy on 
small bowel transit time and gastric emptying half-time in morbidly obese patients with type 2 diabetes mellitus. Surg Obes Relat Dis 
6:152–157 
534Pilone V,  Tramontano S,  Di Micco R et al. Gastric emptying after sleeve gastrectomy: statistical evidence of a controlled p rospective 
study with gastric scintigraphy.  Minerva Chirurgica [2013, 68(4):385-392] 
535 Baumann, T., Kuesters, S., Grueneberger, J., Marjanovic, G., Zimmermann, L., Schaefer, A. O., ... & Karcz, W. K. (2011). Time-resolved 
MRI after ingestion of liquids reveals motility changes after laparoscopic sleeve gastrectomy—preliminary results. Obesity surgery, 
21(1), 95-101. 
536 de Jong JR, van Ramshorst B, Gooszen HG, Smout AJ, Tiel-Van Buul MM. Weight loss after laparoscopic adjustable gastric banding is 
not caused by altered gastric emptying. Obes Surg 2009; 19: 287-292. 
537 Burton PR, Yap K, Brown WA, Laurie C, O'Donnell M, Hebbard G, Kalff V, O'Brien PE. Effects of adjustable gastric bands on gas tric 
emptying, supra- and infraband transit and satiety: A randomized double-blind crossover trial using a new technique of band 
visualization. Obes Surg 2010; 20: 1690-1697. 
538 Usinger L, Hansen KB, Kristiansen VB, Larsen S, Holst JJ, Knop FK. Gastric emptying of orally administered glucose solutions and 
incretin hormone responses are unaffected by laparoscopic adjustable gastric banding. Obes Surg 2011; 21: 625-632. 
539 Kritas, S., Khurana, S., Chisholm, J., Couper, R. T., Kow, L., & Omari, T. (2013). 304 Effect of Gastric Banding on Esophagea l Function, 
Gastroesophageal Reflux and Gastric Emptying in Morbidly Obese Adolescents. Gastroenterology, 144(5), S-63. 
540 Bray, G. A., Blackburn, G. L., Ferguson, J. M., Greenway, F. L., Jain, A. K., Mendel, C. M., ... & Seaton, T. B. (1999). Sibutramine produces 
dose‐related weight loss. Obesity Research, 7(2), 189-198. 
541 James, W. P. T., Caterson, I. D., Coutinho, W., Finer, N., Van Gaal, L. F., Maggioni, A. P., ... & Renz, C. L. (2010). Effect of sibutramine on 
cardiovascular outcomes in overweight and obese subjects. New England Journal of Medicine, 363(10), 905-917. 
542 Vazquez Roque MI, Camilleri M, Clark MM, Tepoel DA, Jensen MD, Graszer KM, Kalsy SA, Burton DD, Baxter KL, Zinsmeister AR. 
Alteration of gastric functions and candidate genes associated with weight reduction in response to sibutramine. Clin Gastroenterol 
Hepatol 2007; 5: 829-837 
543 Torra, S., Ilzarbe, L., Malagelada, J. R., Negre, M., Mestre-Fusco, A., Aguadé-Bruix, S., ... & Delgado-Aros, S. (2010). Meal size can be 
decreased in obese subjects through pharmacological acceleration of gastric emptying (The OBERYTH trial). International journal of 
obesity, 35(6), 829-837. 
544 Odstrcil, E. A., Martinez, J. G., Santa Ana, C. A., Xue, B., Schneider, R. E., Steffer, K. J., ... & Fordtran, J. S. (2010). The contribution of 
malabsorption to the reduction in net energy absorption after long-limb Roux-en-Y gastric bypass. The American journal of clinical 
nutrition, 92(4), 704-713. 
545 Wang, G., Agenor, K., Pizot, J., Kotler, D. P., Harel, Y., Van Der Schueren, B. J., ... & Laferrère, B. (2012). Accelerated gastric emptying but 
no carbohydrate malabsorption 1 year after gastric bypass surgery (GBP). Obesity surgery, 22(8), 1263-1267. 
546 Nguyen, N. Q., Debreceni, T. L., Bambrick, J. E., Chia, B., Deane, A. M., Wittert, G., ... & Young, R. L. (2014). Upregulatio n of intestinal 
glucose transporters after Roux‐en‐Y gastric bypass to prevent carbohydrate malabsorption. Obesity, 22(10), 2164-2171. 
547 Ceneviva, R., Júnior, W. S., & Marchini, J. S. (2015). A new revisional surgery for severe protein-calorie malnutrition after Roux-en-Y 




                                                                                                                                                                                    
548 Faintuch J, Matsuda M, Cruz ME et al (2004)  Severe protein-calorie malnutrition after bariatric procedures.  Obes Surg 14, 175-181 
549 Scopinaro, N., Marinari, G. M., Camerini, G., Pretolesi, F., Papadia, F., Murelli, F., ... & Adami, G. F. (2000). Energy and nitrogen absorption 
after biliopancreatic diversion. Obesity surgery, 10(5), 436-441. 
550 Scopinaro, N. (2006). Biliopancreatic diversion: mechanisms of action and long-term results. Obesity surgery, 16(6), 683-689. 
551 Bal, B. S., Finelli, F. C., Shope, T. R., & Koch, T. R. (2012). Nutritional deficiencies after bariatric surgery. Nature Reviews Endocrinology, 
8(9), 544-556. 
552 Zheng, H., Shin, A. C., Lenard, N. R., Townsend, R. L., Patterson, L. M., Sigalet, D. L., & Berthoud, H. R. (2009). Meal patterns, satiety, 
and food choice in a rat model of Roux-en-Y gastric bypass surgery. American Journal of Physiology-Regulatory, Integrative and 
Comparative Physiology, 297(5), R1273-R1282. 
553 Le Roux, C. W., Bueter, M., Theis, N., Werling, M., Ashrafian, H., Löwenstein, C., ... & Lutz, T. A. (2011). Gastric bypass reduces fat 
intake and preference. American Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 301(4), R1057-R1066. 
554 Brolin, R. L., Robertson, L. B., Kenler, H. A., & Cody, R. P. (1994). Weight loss and dietary intake after vertical banded gastroplasty and 
Roux-en-Y gastric bypass. Annals of surgery, 220(6), 782. 
555 Olbers T, Bjo¨rkman S, Lindroos A, Maleckas A, Lo¨nn L, Sjo¨stro¨mL, Lo¨nrothH2006 Body composition, dietary in - take, and energy 
expenditure after laparoscopic Roux-en-Y gastric bypassandlaparoscopic vertical banded gastroplasty: a randomized clinical trial. Ann 
Surg 244:715–722 
556 Lindroos AK, Lissner L, Sjostrom L. Weight change in relation to intake of sugar and sweet foods before and after weight reducing 
gastric surgery. Int J Obes Relat Metab Disord. 1996;20:634–643. 
557 Suter M, Calmes JM, Paroz A, Giusti V 2007 A new ques- tionnaire for quick assessment of food tolerance after bari- atric surgery. 
Obes Surg 17:2–8 
558 Schweiger C, Weiss R, Keidar A 2010 Effect of different bariatric operations on food tolerance and quality of eat- ing. Obes Surg 
20:1393–1399 
559 Tack J, Arts J, Caenepeel P, De Wulf D, BisschopsR2009 Pathophysiology, diagnosis and management of postoper- ative dumping 
syndrome. Nat Rev Gastroenterol Hepatol 6:583–590 
560 Didden P, Penning C, Masclee AA 2006 Octreotide therapy in dumping syndrome: analysis of long-term results. Aliment Pharmacol 
Ther 24:1367–1375 
561 Heber AD, Greenway FL, Kaplan LM, Livingston E, Salvador J. Guidelines Endocrine and Nutritional Management of the Post-Bariatric 
Surgery Patient : An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2010;95(11):4823–4823. 
562 MalloryGN,MacgregorAM,RandCS1996Theinfluence of dumping on weight loss after gastric restrictive surgery for morbid obesity. 
Obes Surg 6:474–478 
563 Iannelli A, Dainese R, Piche T, Facchiano E, Gugenheim J 2008 Laparoscopic sleeve gastrectomy for morbid obesity. World J 
Gastroenterol 14:821–827 
564 Fuks D, Verhaeghe P, Brehant O, Sabbagh C, Dumont F, RiboulotM,DelcenserieR,RegimbeauJM2009Results of laparoscopic sleeve 
gastrectomy: a prospective study in 135 patients with morbid obesity. Surgery 145:106–113 
565 Tichansky DS, Boughter Jr JD, Madan AK 2006 Taste change after laparoscopic Roux-en-Y gastric bypass and laparoscopic adjustable 
gastric banding. Surg Obes Relat Dis 2:440–444 
566 Scruggs DM, Buffington C, Cowan Jr GS 1994 Taste acu- ity of the morbidly obese before and after gastric bypass surgery. Obes Surg 
4:24–28 




                                                                                                                                                                                    
568 Shin AC, Berthoud H-R.  Food reward functions as affected by obesity and bariatric surgery.  International Journal of Obesity 35, S40-
S44, 2011 
569 Hajnal A, Kovacs P, Ahmed T, Meirelles K, Lynch CJ, CooneyRN2010 Gastric bypass surgery alters behavioral and neural taste functions 
for sweet taste in obese rats. Am J Physiol Gastrointest Liver Physiol 299:G967–G979 
570 Tichansky DS, Glatt AR, Madan AK, Harper J, Tokita K, Boughter JD 2011 Decrease in sweet taste in rats after gastric bypass surgery. 
Surg Endosc 25:1176–1181 
571 Schultes B, Ernst B, Wilms B et al.  Hedonic hunger is increased in severely obese patients and is reduced after gastric bypass surgery.  
Am J Clin Nutr August 2010   vol. 92  no. 2  277-283 
572 Ochner CN, Kwok Y, Conceic ¸a˜o E, Pantazatos SP, Puma LM, Carnell S, Teixeira J, Hirsch J, Geliebter A 2011 Selective reduction in 
neural responses to high calorie foods following gastric bypass surgery. Ann Surg 253:502–507 
573 Bretault, M., Boillot, A., Muzard, L., Poitou, C., Oppert, J. M., Barsamian, C., ... & Czernichow, S. (2013). Bariatric surgery following 
treatment for craniopharyngioma: a systematic review and individual-level data meta-analysis. The Journal of Clinical Endocrinology & 
Metabolism, 98(6), 2239-2246. 
574 Scheimann A. O., Butler M. G., Gourash L., Cuffari C., Klish W. (2008). Critical analysis of bariatric procedures in Prader-Willi syndrome. 
J. Pediatr. Gastroenterol. Nutr. 46, 80–83 
575 Grayson, B. E., Hakala-Finch, A. P., Kekulawala, M., Laub, H., Egan, A. E., Ressler, I. B., ... & Ulrich-Lai, Y. M. (2014). Weight loss by calorie 
restriction versus bariatric surgery differentially regulates the hypothalamo-pituitary-adrenocortical axis in male rats. Stress, 17(6), 484-
493. 
576 Aslan, I. R., Ranadive, S. A., Ersoy, B. A., Rogers, S. J., Lustig, R. H., & Vaisse, C. (2011). Bariatric surgery in a patient with complete MC4R 
deficiency. International Journal of Obesity, 35(3), 457-461. 
577 Frank, S., Wilms, B., Veit, R., Ernst, B., Thurnheer, M., Kullmann, S., ... & Schultes, B. (2014). Altered brain activity in severely obese 
women may recover after Roux-en Y gastric bypass surgery. International Journal of Obesity, 38(3), 341-348. 
578 Stefater, M. A., Pérez–Tilve, D., Chambers, A. P., Wilson–Pérez, H. E., Sandoval, D. A., Berger, J., ... & Seeley, R. J. (2010). Sleeve 
gastrectomy induces loss of weight and fat mass in obese rats, but does not affect leptin sensitivity. Gastroenterology, 138(7), 2426-
2436. 
579  de Lima-Júnior, J. C., Velloso, L. A., & Geloneze, B. (2015). The Obese Brain—Effects of Bariatric Surgery on Energy Balance 
Neurocircuitry. Current atherosclerosis reports, 17(10), 1-8. 
580 Leibel, R. L., Rosenbaum, M., & Hirsch, J. (1995). Changes in energy expenditure resulting from altered body weight. New England Journal 
of Medicine, 332(10), 621-628. 
581 Keesey RE, Corbett SW. Metabolic defense of the body weight set-point. In: Stunkard AJ, Stellar E, eds. Eating and its disorders. Vol. 62 
of Research publications: association for research in nervous and mental disease. New York: Raven Press, 1984:87-96 
582 Schwartz, A., & Doucet, E. (2010). Relative changes in resting energy expenditure during weight loss: a systematic review. Obesity 
reviews, 11(7), 531-547. 
583 Acheson, K. J., Campbell, I. T., Edholm, O. G., Miller, D. S., & Stock, M. J. (1980). The measurement of daily energy expendi ture--an 
evaluation of some techniques. The American journal of clinical nutrition, 33(5), 1155-1164. 
584 Kaiyala KJ, Schwartz MW 2011 Toward a more complete (and less controversial) understanding of energy expendi- ture and its role in 
obesity pathogenesis. Diabetes 60: 17–23 
585 Benzinger, T. H., & Kitzinger, C. (1949). Direct calorimetry by means of the gradient principle. Review of Scientific Instruments, 20(12), 
849-860. 




                                                                                                                                                                                    
587 Roza AM, Shizgal HM. The Harris Benedict equation reevaluated: resting energy requirements and the body cell mass. Am J Clin Nutr. 
1984;40(1):168–182. 
588 Mifin MD, St Jeor ST, Hill LA, Scott BJ, Daugherty SA, Koh YO. A new predictive equation for resting energy expenditure in he althy 
individuals. Am J Clin Nutr. 1990;51(2):241–247. 
589  Alfonzo-González, G., Doucet, E., Alméras, N., Bouchard, C., & Tremblay, A. (2004). Estimation of daily energy needs with the 
FAO/WHO/UNU 1985 procedures in adults: comparison to whole-body indirect calorimetry measurements. European journal of clinical 
nutrition, 58(8), 1125-1131. 
590 Benedetti G, Mingrone G, Marcoccia S, Benedetti M, Gi- ancaterini A, Greco AV, Castagneto M, Gasbarrini G 2000 Body composition and 
energy expenditure after weight loss following bariatric surgery. J Am Coll Nutr 19:270 – 274 
591 Coupaye M, Bouillot JL, Coussieu C, Guy-Grand B, Bas- devant A, Oppert JM 2005 One-year changes in energy expenditure and serum 
leptin following adjustable gastric banding in obese women. Obes Surg 15:827– 833 
592 Das SK, Roberts SB, McCrory MA, Hsu LK, Shikora SA, Kehayias JJ, Dallal GE, Saltzman E 2003 Long-term changes in energy expenditure 
and body composition after massive weight loss induced by gastric bypass surgery. Am J Clin Nutr 78:22–30 
593 Bueter M, Lowenstein C, Olbers T, Wang M, Cluny NL, et al. (2010) Gastric bypass increases energy expenditure in rats. Gastroenterology 
138: 1845–1853. doi: 10.1053/j.gastro.2009.11.012 
594 Stylopoulos N, Hoppin AG, Kaplan LM (2009) Roux-en-Y gastric bypass enhances energy expenditure and extends lifespan in diet-induced 
obese rats. Obesity (Silver Spring) 17: 1839–1847. doi: 10.1038/oby.2009.207 
595 Saeidi N, Nestoridi E, et al (2012)  Sleeve gastrectomy and Roux-en-Y gastric bypass exhibit differential effects on food preferences, 
nutrient absorption, and energy expenditure in obese rate.  International journal of obesity 36, 1396-1402 
596 Nestoridi, E., Kvas, S., Kucharczyk, J., & Stylopoulos, N. (2012). Resting energy expenditure and energetic cost of feeding are augmented 
after Roux-en-Y gastric bypass in obese mice. Endocrinology, 153(5), 2234-2244. 
597 Iesari, S., le Roux, C. W., De Gaetano, A., Manco, M., Nanni, G., & Mingrone, G. (2013). Twenty-four hour energy expenditure and skeletal 
muscle gene expression changes after bariatric surgery. The Journal of Clinical Endocrinology & Metabolism. 
598 Werling, M., Fändriks, L., Olbers, T., Bueter, M., Sjöström, L., Lönroth, H., ... & le Roux, C. W. (2015). Roux-en-Y Gastric Bypass Surgery 
Increases Respiratory Quotient and Energy Expenditure during Food Intake. PloS one, 10(6), e0129784. 
599 Werling, M., Olbers, T., Fandriks, L., Bueter, M., Lonroth, H., & Stenlof, K. (2013). Increased postprandial energy expenditure may explain 
superior long term weight loss after Roux-en-Y gastric bypass compared to vertical banded gastroplasty. PLoS One, 8(4), e60280. 
600 Dirksen C, Jorgensen NB, Bojsen-Moller KN et al. (2013) Gut hormones, early dumping, and resting energy expenditure in patients with 
good and poor weight loss response after Roux-en-Y gastric bypass.  International journal of obesity 37, 1452-1459 
601 Sumithran, P., Prendergast, L. A., Delbridge, E., Purcell, K., Shulkes, A., Kriketos, A., & Proietto, J. (2011). Long-term persistence of 
hormonal adaptations to weight loss. New England Journal of Medicine, 365(17), 1597-1604. 
602 Korner J, Inabnet W, Conwell IM, et al. Diff erential eff ects of gastric bypass and banding on circulating gut hormone and leptin 
concentrations. Obesity (Silver Spring) 2006; 14: 1553–61. 
603 Riedl, M., Vila, G., Maier, C., Handisurya, A., Shakeri-Manesch, S., Prager, G., ... & Luger, A. (2008). Plasma osteopontin increases after 
bariatric surgery and correlates with markers of bone turnover but not with insulin resistance. The Journal of Clinical Endocrinology & 
Metabolism, 93(6), 2307-2312. 
604 Bradley, D., Conte, C., Mittendorfer, B., Eagon, J. C., Varela, J. E., Fabbrini, E., ... & Klein, S. (2012). Gastric bypass a nd banding equally 
improve insulin sensitivity and β cell function. The Journal of clinical investigation, 122(12), 4667. 
605 Ramón, J. M., Salvans, S., Crous, X., Puig, S., Goday, A., Benaiges, D., ... & Grande, L. (2012). Effect of Roux-en-Y gastric bypass vs sleeve 




                                                                                                                                                                                    
606 Woelnerhanssen, B., Peterli, R., Steinert, R. E., Peters, T., Borbély, Y., & Beglinger, C. (2011). Effects of postbariatric surgery weight loss 
on adipokines and metabolic parameters: comparison of laparoscopic Roux-en-Y gastric bypass and laparoscopic sleeve gastrectomy—
a prospective randomized trial. Surgery for Obesity and Related Diseases, 7(5), 561-568. 
607 Kotidis, E. V., Koliakos, G., Papavramidis, T. S., & Papavramidis, S. T. (2006). The effect of biliopancreatic diversion with pylorus-
preserving sleeve gastrectomy and duodenal switch on fasting serum ghrelin, leptin and adiponectin concentrations: is there a  hormonal 
contribution to the weight-reducing effect of this procedure?. Obesity surgery, 16(5), 554-559. 
608 Falkén, Y., Hellström, P. M., Holst, J. J., & Näslund, E. (2011). Changes in glucose homeostasis after Roux-en-Y gastric bypass surgery for 
obesity at day three, two months, and one year after surgery: role of gut peptides. The Journal of Clinical Endocrinology & Metabolism, 
96(7), 2227-2235. 
609 Faraj, M., Havel, P. J., Phélis, S., Blank, D., Sniderman, A. D., & Cianflone, K. (2003). Plasma acylation-stimulating protein, adiponectin, 
leptin, and ghrelin before and after weight loss induced by gastric bypass surgery in morbidly obese subjects. The Journal of Clinical 
Endocrinology & Metabolism, 88(4), 1594-1602. 
610 Oliván, B., Teixeira, J., Bose, M., Bawa, B., Chang, T., Summe, H., ... & Laferrère, B. (2009). Effect of weight loss by diet or gastric bypass 
surgery on peptide YY3–36 concentrations. Annals of surgery, 249(6), 948. 
611 Kotidis, E. V., Koliakos, G., Papavramidis, T. S., & Papavramidis, S. T. (2006). The effect of biliopancreatic diversion with pylorus-
preserving sleeve gastrectomy and duodenal switch on fasting serum ghrelin, leptin and adiponectin concentrations: is there a  hormonal 
contribution to the weight-reducing effect of this procedure?. Obesity surgery, 16(5), 554-559. 
612 Stefater, M. A., Pérez–Tilve, D., Chambers, A. P., Wilson–Pérez, H. E., Sandoval, D. A., Berger, J., ... & Seeley, R. J. (2010). Sleeve 
gastrectomy induces loss of weight and fat mass in obese rats, but does not affect leptin sensitivity. Gastroenterology, 138(7), 2426-
2436. 
613 Terra, X., Auguet, T., Guiu-Jurado, E., Berlanga, A., Orellana-Gavaldà, J. M., Hernández, M., ... & Richart, C. (2013). Long-term changes in 
leptin, chemerin and ghrelin concentrations following different bariatric surgery procedures: Roux-en-Y gastric bypass and sleeve 
gastrectomy. Obesity surgery, 23(11), 1790-1798. 
614 Michalakis, K., & Le Roux, C. (2012). Gut hormones and leptin: impact on energy control and changes after bariatric surgery—what the 
future holds. Obesity surgery, 22(10), 1648-1657. 
615 Langer, F. B., MA Reza Hoda, A. Bohdjalian, F. X. Felberbauer, J. Zacherl, E. Wenzl, K. Schindler, A. Luger, B. Ludvik, and G. Prager. "Sleeve 
gastrectomy and gastric banding: effects on plasma ghrelin concentrations." Obesity surgery 15, no. 7 (2005): 1024-1029. 
616 Karamanakos, Stavros N., Konstantinos Vagenas, Fotis Kalfarentzos, and Theodore K. Alexandrides. "Weight loss, appetite suppr ession, 
and changes in fasting and postprandial ghrelin and peptide-YY concentrations after Roux-en-Y gastric bypass and sleeve gastrectomy: 
a prospective, double blind study." Annals of surgery 247, no. 3 (2008): 401-407. 
617 Peterli, R., Wölnerhanssen, B., Peters, T., Devaux, N., Kern, B., Christoffel-Courtin, C., ... & Beglinger, C. (2009). Improvement in glucose 
metabolism after bariatric surgery: comparison of laparoscopic Roux-en-Y gastric bypass and laparoscopic sleeve gastrectomy: a 
prospective randomized trial. Annals of surgery, 250(2), 234-241. 
618 Basso N, Capoccia D, Rizzello M, Abbatini F, Mariani P, Maglio C, Coccia F, Borgonuovo G, De Luca ML, Asprino R, Alessandri G, Casella 
G, Leonetti F 2011 First-phase insulin secretion, insulin sensitivity, ghrelin, GLP-1, and PYY changes 72 h after sleeve gastrectomy in 
obese dia- betic patients: the gastric hypothesis. Surg Endosc 25: 3540 –3550 
619 Korner, Judith, William Inabnet, Gerardo Febres, Irene M. Conwell, Donald J. McMahon, Rocio Salas, Carmen Taveras, Beth Schro pe, 
and Marc Bessler. "Prospective study of gut hormone and metabolic changes after adjustable gastric banding and Roux -en-Y gastric 
bypass." International Journal of Obesity 33, no. 7 (2009): 786-795. 
620 Busetto L, Segato G, De Luca M, Foletto M, Pigozzo S, Favretti F, Enzi G 2006 High ghrelin concentration is not a predictor of less weight 
loss in morbidly obese women treated with laparoscopic adjustable gastric banding. Obes Surg 16:1068 –1074 
621 Frühbeck, G., Rotellar, F., Hernández-Lizoain, J. L., Gil, M. J., Gómez-Ambrosi, J., Salvador, J., & Cienfuegos, J. A. (2004). Fasting plasma 





                                                                                                                                                                                    
622 Cummings, David E., David S. Weigle, R. Scott Frayo, Patricia A. Breen, Marina K. Ma, E. Patchen Dellinger, and Jonathan Q. Purnell. 
"Plasma ghrelin concentrations after diet-induced weight loss or gastric bypass surgery." New England Journal of Medicine 346, no. 21 
(2002): 1623-1630. 
623 Carrasco, F., Rojas, P., Csendes, A., Codoceo, J., Inostroza, J., Basfi-fer, K., ... & Ruz, M. (2012). Changes in ghrelin concentrations one 
year after resective and non-resective gastric bypass: associations with weight loss and energy and macronutrient intakes. Nutrition, 
28(7), 757-761. 
624 Tymitz, K., Engel, A., McDonough, S., Hendy, M. P., & Kerlakian, G. (2011). Changes in ghrelin concentrations following bariatric surgery: 
review of the literature. Obesity surgery, 21(1), 125-130. 
625 Lopez PP, Nicholson SE, Burkhardt GE, Johnson RA, Johnson FK 2009 Development of a sleeve gastrectomy weight loss model in obese 
Zucker rats. J Surg Res 157: 243–250 
626 Patrikakos P, Toutouzas KG, Gazouli M, Perrea D, Me- nenakos E, Papadopoulos S, Zografos G Long-term plasma ghrelin and leptin 
modulation after sleeve gastrec- tomy in Wistar rats in comparison with gastric tissue ghre- lin expression. Obes Surg 21:1432–1437  
627 Whitson BA, Leslie DB, Kellogg TA, Maddaus MA, Bu- chwald H, Billington CJ, Ikramuddin S 2007 Entero-en- docrine changes after 
gastric bypass in diabetic and non- diabetic patients: a preliminary study. J Surg Res 141: 31–39 
628 Chambers, A. P., Kirchner, H., Wilson–Perez, H. E., Willency, J. A., Hale, J. E., Gaylinn, B. D., ... & Sandoval, D. A. (2013). The effects of 
vertical sleeve gastrectomy in rodents are ghrelin independent. Gastroenterology, 144(1), 50-52. 
629 Yousseif, A., Emmanuel, J., Karra, E., Millet, Q., Elkalaawy, M., Jenkinson, A. D., ... & Withers, D. J. (2014). Differential effects of 
laparoscopic sleeve gastrectomy and laparoscopic gastric bypass on appetite, circulating acyl-ghrelin, peptide YY3-36 and active GLP-1 
concentrations in non-diabetic humans. Obesity surgery, 24(2), 241-252. 
630 Malin, S. K., Samat, A., Wolski, K., Abood, B., Pothier, C. E., Bhatt, D. L., ... & Kashyap, S. R. (2014). Improved acylated ghrelin suppression 
at 2 years in obese patients with type 2 diabetes: effects of bariatric surgery vs standard medical therapy. International Journal of 
Obesity, 38(3), 364-370. 
631 Foschi, D., Corsi, F., Pisoni, L., Vago, T., Bevilacqua, M., Asti, E., ... & Trabucchi, E. (2004). Plasma cholecystokinin concentrations after 
vertical banded gastroplasty: effects of an acidified meal. Obesity surgery, 14(5), 644-647. 
632 Näslund, E., Grybäck, P., Hellström, P. M., Jacobsson, H., Holst, J. J., Theodorsson, E., & Backman, L. (1997). Gastrointestinal hormones 
and gastric emptying 20 years after jejunoileal bypass for massive obesity. International journal of obesity and related metabolic 
disorders: journal of the International Association for the Study of Obesity, 21(5), 387-392. 
633 Peterli, R., Steinert, R. E., Woelnerhanssen, B., Peters, T., Christoffel-Courtin, C., Gass, M., ... & Beglinger, C. (2012). Metabolic and 
hormonal changes after laparoscopic Roux-en-Y gastric bypass and sleeve gastrectomy: a randomized, prospective trial. Obesity surgery, 
22(5), 740-748. 
634 Jacobsen, S. H., Olesen, S. C., Dirksen, C., Jørgensen, N. B., Bojsen-Møller, K. N., Kielgast, U., ... & Madsbad, S. (2012). Changes in 
gastrointestinal hormone responses, insulin sensitivity, and beta-cell function within 2 weeks after gastric bypass in non-diabetic 
subjects. Obesity surgery, 22(7), 1084-1096. 
635 Mumphrey, M. B., Patterson, L. M., Zheng, H., & Berthoud, H. R. (2013). Roux ‐en‐Y gastric bypass surgery increases number but not 
density of CCK‐, GLP‐1‐, 5‐HT‐, and neurotensin‐expressing enteroendocrine cells in rats. Neurogastroenterology & Motility, 25(1), e70-
e79. 
636 Morínigo, R., Moizé, V., Musri, M., Lacy, A. M., Navarro, S., Marín, J. L., ... & Vidal, J. (2006). Glucagon-like peptide-1, peptide YY, hunger, 
and satiety after gastric bypass surgery in morbidly obese subjects. The Journal of Clinical Endocrinology & Metabolism, 91(5), 1735-
1740. 
637 Vidal, J., Nicolau, J., Romero, F., Casamitjana, R., Momblan, D., Conget, I., ... & Lacy, A. M. (2009). Long-term effects of Roux-en-Y gastric 
bypass surgery on plasma glucagon-like peptide-1 and islet function in morbidly obese subjects. The Journal of Clinical Endocrinology & 
Metabolism, 94(3), 884-891. 
638 Romero, F., Nicolau, J., Flores, L., Casamitjana, R., Ibarzabal, A., Lacy, A., & Vidal, J. (2012). Comparable early changes in gastrointestinal 
hormones after sleeve gastrectomy and Roux-En-Y gastric bypass surgery for morbidly obese type 2 diabetic subjects. Surgical 




                                                                                                                                                                                    
639 Novaes, F. S., Vasques, A. C., Pareja, J. C., Knop, F. K., Tura, A., Chaim, É. A., & Geloneze, B. (2015). Recovery of the Incretin Effect in Type 
2 Diabetic Patients After Biliopancreatic Diversion. The Journal of Clinical Endocrinology & Metabolism. 
640 Plourde, C. É., Grenier‐Larouche, T., Caron‐Dorval, D., Biron, S., Marceau, S., Lebel, S., ... & Carpentier, A. C. (2014). Biliopancreatic 
diversion with duodenal switch improves insulin sensitivity and secretion through caloric restriction. Obesity, 22(8), 1838-1846. 
641 Shak, J. R., Roper, J., Perez-Perez, G. I., Tseng, C. H., Francois, F., Gamagaris, Z., ... & Blaser, M. J. (2008). The effect of laparoscopic gastric 
banding surgery on plasma concentrations of appetite-control, insulinotropic, and digestive hormones. Obesity surgery, 18(9), 1089-
1096. 
642 Dirksen C, Damgaard M, Bojsen-Moller KN, Jorgensen NB, Kielgast U, Jacobsen SH, Naver LS, Worm D, Holst JJ, Mads- bad S, Hansen DL, 
Madsen JL. Fast pouch emptying, delayed small intestinal transit, and exaggerated gut hormone re- sponses after Roux-en-Y gastric 
bypass. Neurogastroenterol Motil 25: 346 –355, 2013.  
643 Trung VN, Yamamoto H, Furukawa A, Yamaguchi T, Murata S, Yoshimura M, Murakami Y, Sato S, Otani H, Ugi S, Morino K, Maegawa H , 
Tani T. Enhanced intestinal motility during oral glucose tolerance test after laparoscopic sleeve gastrec- tomy: preliminary results using 
cine magnetic resonance imaging. PLos One 8: e65739, 2013. 
644 Dirksen, C., Hansen, D. L., Madsbad, S., Hvolris, L. E., Naver, L. S., Holst, J. J., & Worm, D. (2010). Postprandial Diabetic Glucose Tolerance 
Is Normalized by Gastric Bypass Feeding as Opposed to Gastric Feeding and Is Associated With Exaggerated GLP-1 Secretion A case 
report. Diabetes care, 33(2), 375-377. 
645 McLaughlin, T., Peck, M., Holst, J., & Deacon, C. (2010). Reversible hyperinsulinemic hypoglycemia after gastric bypass: a consequence 
of altered nutrient delivery. The Journal of Clinical Endocrinology & Metabolism, 95(4), 1851-1855. 
646 Habegger, K. M., Kirchner, H., Yi, C. X., Heppner, K. M., Sweeney, D., Ottaway, N., ... & Müller, T. D. (2013). GLP-1R agonism enhances 
adjustable gastric banding in diet-induced obese rats. Diabetes, 62(9), 3261-3267. 
647 Ye J, Hao Z, Mumphrey MB et al. (2014) GLP-1 receptor signalling is not required for reduced body weight after RYGB in rodents.  Am J 
Physiol Regul Integr Comp Physiol. 306(5), R352-R362 
648 Wilson-Perez HE, Chambers AP, Ryan KK, Li B, Sandoval DA, Stoffers D, Drucker DJ, Perez-Tilve D, Seeley RJ. Vertical sleeve gastrectomy 
is effective in two genetic mouse models of glucagon-like peptide-1 receptor deficiency. Diabetes 62: 2380–2385, 2013 
649 Korner J, Bessler M, Inabnet W, Taveras C, Holst JJ. Exaggerated glucagon-like peptide-1 and blunted glucose-dependent insulinotropic 
peptide secretion are associated with Roux-en-Y gastric bypass but not adjustable gastric banding. Surg Obes Relat Dis 2007; 3: 597–
601. 
650 Laferrère, B., Teixeira, J., McGinty, J., Tran, H., Egger, J. R., Colarusso, A., ... & Olivan, B. (2008). Effect of weight loss by gastric bypass 
surgery versus hypocaloric diet on glucose and incretin concentrations in patients with type 2 diabetes. The Journal of Clinical 
Endocrinology & Metabolism, 93(7), 2479-2485. 
651 Kashyap SR, Daud S, Kelly KR, et al. Acute eff ects of gastric bypass versus gastric restrictive surgery on β-cell function and 
insulinotropic hormones in severely obese patients with type 2 diabetes. Int J Obes (Lond) 2010; 34: 462–71. 
652 Rao, R. S., & Kini, S. (2011). GIP and bariatric surgery. Obesity surgery, 21(2), 244-252. 
653 Clements, R. H., Gonzalez, Q. H., Long, C. I., Wittert, G., & Laws, H. L. (2004). Hormonal Changes After Roux -en Y Gastric Bypass For 
Morbid Obesity and the Control of Type-II Diabetes Mellitus. The American surgeon, 70(1), 1. 
654 Circadian rhythms of GIP and GLP1 in glucose-tolerant and in type 2 diabetic patients after biliopancreatic diversion Diabetologia, 52 
(5) (2009), pp. 873–881 
655 Laferr.re B, Heshka S, Wang K, et al. Incretin concentrations and effect are markedly enhanced 1 month after Roux‑en‑Y gastric bypass 
surgery in obese patients with type 2 diabetes. Diabetes Care. 2007;30:1709-1716. 
656 Goldfine, A. B., Mun, E. C., Devine, E., Bernier, R., Baz-Hecht, M., Jones, D. B., ... & Patti, M. E. (2013). Patients with neuroglycopenia 
after gastric bypass surgery have exaggerated incretin and insulin secretory responses to a mixed meal. The Journal of Clinical 




                                                                                                                                                                                    
657 Rodieux, F., Giusti, V., D'alessio, D. A., Suter, M., & Tappy, L. (2008). Effects of gastric bypass and gastric banding on glucose kinetics and 
gut hormone release. Obesity, 16(2), 298-305. 
658 Morínigo, R., Vidal, J., Lacy, A. M., Delgado, S., Casamitjana, R., & Gomis, R. (2008). Circulating peptide YY, weight los s, and glucose 
homeostasis after gastric bypass surgery in morbidly obese subjects. Annals of surgery, 247(2), 270-275. 
659 le Roux, C. W., Welbourn, R., Werling, M., Osborne, A., Kokkinos, A., Laurenius, A., ... & Olbers, T. (2007). Gut hormones as  mediators of 
appetite and weight loss after Roux-en-Y gastric bypass. Annals of surgery, 246(5), 780-785. 
660 Borg, C. M., Le Roux, C. W., Ghatei, M. A., Bloom, S. R., Patel, A. G., & Aylwin, S. J. B. (2006). Progressive rise in gut hormone 
concentrations after Roux‐en‐Y gastric bypass suggests gut adaptation and explains altered satiety. British Journal of Surgery, 93(2), 
210-215. 
661 Valderas, J. P., Irribarra, V., Boza, C., de la Cruz, R., Liberona, Y., Acosta, A. M., ... & Maiz, A. (2013). Medical and surgical treatments for 
obesity have opposite effects on peptide YY and appetite: a prospective study controlled for weight loss. The Journal of Clinical 
Endocrinology & Metabolism. 
662 Basso, N., Capoccia, D., Rizzello, M., Abbatini, F., Mariani, P., Maglio, C., ... & Alessandri, G. (2011). First-phase insulin secretion, insulin 
sensitivity, ghrelin, GLP-1, and PYY changes 72 h after sleeve gastrectomy in obese diabetic patients: the gastric hypothesis. Surgical 
endoscopy, 25(11), 3540-3550. 
663 Tsoli, M., Chronaiou, A., Kehagias, I., Kalfarentzos, F., & Alexandrides, T. K. (2013). Hormone changes and diabetes resolution after 
biliopancreatic diversion and laparoscopic sleeve gastrectomy: a comparative prospective study. Surgery for Obesity and Related 
Diseases, 9(5), 667-677. 
664 Korner J, Inabnet W, Conwell IM, et al (2006)  Differential effects of gastric bypass and banding on circulatin gut hormone a nd leptin 
concentrations.  Obesity 14(9), 1553-1561  
665 Bose M, Machineni S, Olivan B et al (2010) Superior appetite hormone profile after equiavelent weight loss by gastric bypass compared 
to gastric banding.  Obesity 18(6); 1085-1091 
666 Hedberg, J., Hedenström, H., Karlsson, F. A., Edén-Engström, B., & Sundbom, M. (2011). Gastric emptying and postprandial PYY response 
after biliopancreatic diversion with duodenal switch. Obesity surgery, 21(5), 609-615. 
667 Garcia-Fuentes, E., Garrido-Sanchez, L., Garcia-Almeida, J. M., Garcia-Arnes, J., Gallego-Perales, J. L., Rivas-Marin, J., ... & Soriguer, F. 
(2008). Different effect of laparoscopic Roux-en-Y gastric bypass and open biliopancreatic diversion of Scopinaro on serum PYY and 
ghrelin concentrations. Obesity surgery, 18(11), 1424-1429. 
668 Rhee, N. A., Wahlgren, C. D., Pedersen, J., Mortensen, B., Langholz, E., Wandall, E. P., ... & Jelsing, J. (2015). Effect of Roux-en-Y gastric 
bypass on the distribution and hormone expression of small-intestinal enteroendocrine cells in obese patients with type 2 diabetes. 
Diabetologia, 58(10), 2254-2258. 
669 Meguid, M. M., Glade, M. J., & Middleton, F. A. (2008). Weight regain after Roux-en-Y: a significant 20% complication related to PYY. 
Nutrition, 24(9), 832-842. 
670 Chandarana, K., Gelegen, C., Karra, E., Choudhury, A. I., Drew, M. E., Fauveau, V., ... & Batterham, R. L. (2011). Diet and Gastrointestinal 
Bypass–Induced Weight Loss The Roles of Ghrelin and Peptide YY. Diabetes, 60(3), 810-818. 
671 Suau A, Bonnet R, Sutren M, et al. Direct analysis of genes encoding 16S rRNA from complex communities reveals many novel molecular 
species within the human gut. Appl Environ Microbiol. 1999; 65(11):4799–4807. 
672  Human Microbiome Project Consortium. Structure, function and diversity of the healthy human microbiome. Nature. 2012; 
486(7402):207–214.  
673 Ley RE, Turnbaugh PJ, Klein S, Gordon JI. Microbial ecology: human gut microbes associated with obesity. Nature. 2006; 444(7122):1022–
1023.  
674 Armougom F, Henry M, Vialettes B, Raccah D, Raoult D. Monitoring bacterial community of human gut microbiota reveals an increase 




                                                                                                                                                                                    
675 Balamurugan R, George G, Kabeerdoss J, Hepsiba J, Chandragunasekaran AM, Ramakrishna BS. Quantitative differences in intestin al 
Faecalibacterium prausnitzii in obese Indian children. Br J Nutr. 2010; 103(3):335–338.  
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